The isolation, characterisation and investigation into the In vitro behaviour of human ocular vascular endothelial cells by Browning, Andrew C.
Browning, Andrew C. (2013) The isolation, 
characterisation and investigation into the In vitro 
behaviour of human ocular vascular endothelial cells. 
PhD thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/13119/1/ACB_Thesis_Final_Version.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
  
 
 
 
THE ISOLATION, CHARACTERISATION AND 
INVESTIGATION INTO THE IN VITRO 
BEHAVIOUR OF HUMAN OCULAR 
VASCULAR ENDOTHELIAL CELLS 
 
 
 
 
 
ANDREW C BROWNING, BSc 
 
 
Thesis submitted to the University of Nottingham 
for the degree of Doctor of Philosophy 
 
JULY  2013 
 
 
 ii 
 
 
 
 
Aknowledgements 
 
I would like to thank my supervisor, Mr Winfried Amoaku, Reader in 
Ophthalmology at the University of Nottingham for his support and 
guidance over the years it has taken for me to undertake this work and 
prepare this thesis. I would also like to thank my wife, Alison for 
enduring many hardships over the years and her help in the preparation 
of this thesis.  
 
7KDQNVDOVRJRWR'U(XJHQH+DOOLJDQDQG5RVDPXQG'RYHDW.LQJ¶V
College, London for their help and guidance in undertaking the 
microarray and real time PCR experiments and to Dr Daniel Swan at 
the University of Newcastle for his guidance in analysing the microarray 
data. Finally, I would also like to thank the trustees of Nottingham 
University hospitals, the Kelner Foundation and the British Eye 
Research Fund (previously the Iris Fund) for their financial support so 
that I could undertake this work.
 Contents 
ACKNOWLEDGEMENTS«««««««««««««««««««««« II 
FIGURES & TABLES«««««««««««««««««««««« VII 
APPENDICES«««««««««««««««««««««««« XVI 
ABBREVIATIONS««««««««««««««««««««««« XVII 
RATIONALE AND AIMS««««««««««««««««««««« XIX 
CHAPTER: 1 INTRODUCTION  
SECTION 1: VASCULAR BIOLOGY  
Haemovasculogenesis«««««««««««««««««««« 3 
Vasculogenesis««««««««««««««««««««««« 4 
Angiogenesis««««««««««««««««««««««« 6 
Abnormal or pathological angiogenesis«««««««««««« 10 
Endothelial Cells«««««««««««««««««««««« 11 
Endothelial cell surface markers«««««««««««««« 12 
Role of endothelial cells«««««««««««««««««« 15 
Ultrastructure of endothelial cells«««««««««««««« 24 
Caveolae««««««««««««««««««««««« 24 
Fenestrations««««««««««««««««««««« 25 
Weibel-Palade Bodies««««««««««««««««« 27 
Endothelial cell junctional complexes««««««««««« 27 
Effect of growth factors on endothelial cells««««««««« 32 
VEGF«««««««««««««««««««««««« 34 
VEGF isoforms««««««««««««««««««« 37 
VEGF Receptors««««««««««««««««««« 39 
VEGFR2«««««««««««««««««««««« 39 
VEGFR1«««««««««««««««««««««« 41 
Fibroblast Growth Factors«««««««««««««««« 43 
Insulin like growth Factor 1 (IGF-1)«««««««««««« 46 
Placental Growth Factor (PlGF)««««««««««««« 47 
Angiogenesis modifying factors«««««««««««««« 48 
Platelet Derived Growth Factor (PDGF)««««««««« 48 
Angiopoietin/Tie system««««««««««««««««« 49 
Anti-angiogenic factors«««««««««««««««««« 52 
Pigment Epithelial Derived Factor (PEDF)««««««««« 52 
Neurotrophic/protective functions««««««««««« 53 
Antiangiogenic function««««««««««««««« 53 
Thrombospondin 1««««««««««««««««««« 55 
Endothelial cell heterogeneity«««««««««««««««. 55 
Inter-organ differences««««««««««««««««« 59 
Intra-organ differences««««««««««««««««« 62 
Interspecies differences««««««««««««««««« 63 
Adult Vascular structure«««««««««««««««««« 64 
Arteries««««««««««««««««««««««««« 64 
 iv 
Arterioles«««««««««««««««««««««««« 64 
Capillaries««««««««««««««««««««««« 65 
Venules««««««««««««««««««««««««« 65 
Veins«««««««««««««««««««««««««« 66 
Arteries and veins«««««««««««««««««««« 66 
SECTION 2: HUMAN OCULAR VASCULAR STRUCTURES  
The human eye«««««««««««««««««««««« 67 
The structure of the retina«««««««««««««««««« 69 
The macula«««««««««««««««««««««««« 71 
Retinal vascular structure«««««««««««««««««« 73 
Retinal vascular development«««««««««««««««« 74 
Choroidal vascular structure««««««««««««««««« 77 
Iris vasculature structure«««««««««««««««««« 83 
Regulation of ocular blood flow««««««««««««««« 83 
SECTION 3: ANGIOGENIC DISEASES AFFECTING THE EYE  
Wet age related macular degeneration«««««««««««« 85 
Epidemiology««««««««««««««««««««««.. 88 
Clinical features««««««««««««««««««««« 89 
Pathophysiological mechanisms«««««««««««««« 92 
The role of growth factors in choroidal neovascularisation««« 94 
Animal Models«««««««««««««««««««««« 95 
Genetic mouse models of AMD««««««««««««« 95 
Laser photocoagulation models of wet AMD««««««««« 97 
Treatment«««««««««««««««««««««««« 98 
In vitro study of endothelial cells with relevance to AMD««« 100 
In vitro experiments using human choroidal endothelial cells« 101 
Diabetic retinopathy«««««««««««««««««««« 103 
Retinopathy of prematurity««««««««««««««««« 107 
Iris neovascularisation««««««««««««««««««« 110 
Conclusion«««««««««««««««««««««««« 111 
References««««««««««««««««««««««««113 
CHAPTER 2: THE ISOLATION OF OCULAR MICROVASCULAR 
ENDOTHELIAL CELLS  
 
Introduction««««««««««««««««««««««« 174 
Methods««««««««««««««««««««««««« 174 
Isolation of human choroidal endothelial cells«««««««« 175 
Isolation of human iris endothelial cells«««««««««« 176 
Human umbilical vein endothelial cells (HUVEC)«««««« 177 
Endothelial cell characterisation«««««««««««««« 177 
Results««««««««««««««««««««««««« 179 
Discussion«««««««««««««««««««««««« 186 
References««««««««««««««««««««««« 187 
 v 
CHAPTER 3: COMPARATIVE GENE EXPRESSION PROFILING OF 
HUVEC AND OCULAR VASCULAR ENDOTHELIAL CELLS  
 
Introduction««««««««««««««««««««««« 190 
Methods««««««««««««««««««««««««« 194 
RNA extraction««««««««««««««««««««« 194 
Microarray analysis««««««««««««««««««« 195 
First strand cDNA synthesis««««««««««««««« 197 
Second strand cDNA synthesis«««««««««««««« 197 
Double stranded cDNA purification«««««««««««« 197 
cDNA amplification by PCR««««««««««««««« 199 
Synthesis of cRNA««««««««««««««««««« 199 
Microarray hybridisation««««««««««««««««« 199 
Data Analysis««««««««««««««««««««««200 
Real time PCR««««««««««««««««««««« 201 
Results««««««««««««««««««««««««« 204 
Confirmation of human endothelial cell identity««««««« 204 
Overview of gene expression patterns««««««««««« 204 
Gene expression patterns of proliferating HUVEC vs ocular 
microvascular endothelial cells«««««««««««««« 204 
Proliferating human choroidal versus retinal vascular       
endothelial cells«««««««««««««««««««««214 
Proliferating human choroidal versus retinal vascular       
endothelial cells«««««««««««««««««««««215 
Proliferating human choroidal versus iris vascular            
endothelial cells«««««««««««««««««««« 230 
Proliferating human retinal versus iris vascular endothelial cells 237 
Real time PCR««««««««««««««««««««« 249 
Discussion«««««««««««««««««««««««« 257 
References««««««««««««««««««««««« 271 
CHAPTER 4: THE ISOLATION AND CHARACTERISATION OF 
MACULAR INNER CHOROIDAL ENDOTHELIAL CELLS  
 
Introduction««««««««««««««««««««««« 283 
Methods««««««««««««««««««««««««« 289 
Vibratome sectioning«««««««««««««««««« 289 
Manual dissection«««««««««««««««««««« 290 
Human inner choroidal endothelial cell characterisation««« 291 
Immunohistochemistry««««««««««««««««« 291 
Transmission electron microscopy«««««««««««« 293 
Results««««««««««««««««««««««««« 295 
Toludine blue staining of sections of human choroid««««« 295 
Immunohistochemistry«««««««««««««««««« 296 
Matrigel tube formation««««««««««««««««« 297 
Fenestrations«««««««««««««««««««««« 297 
Discussion«««««««««««««««««««««««« 308 
References««««««««««««««««««««««« 313 
 vi 
CHAPTER 5: COMPARATIVE GENE EXPRESSION PROFILING OF 
HUMAN MACULAR AND PERIPHERAL INNER CHOROIDAL 
ENDOTHELIAL CELLS AND MACULAR OUTER CHOROIDAL 
ENDOTHELIAL CELLS  
Introduction««««««««««««««««««««««« 317 
Methods««««««««««««««««««««««««« 321 
Confirmation of EC purity«««««««««««««««« 321 
RNA extraction««««««««««««««««««««« 322 
Microarray analysis««««««««««««««««««« 322 
Data Analysis««««««««««««««««««««««322 
QPCR««««««««««««««««««««««««« 323 
Results««««««««««««««««««««««««« 324 
Overview of gene expression patterns««««««««««« 324 
Proliferating human macular inner choroidal endothelial cells  
(ECs) versus peripheral inner choroidal ECs«««««««« 325 
Proliferating human macular inner choroidal ECs versus      
macular outer choroidal ECs««««««««««««««« 328 
Real time PCR««««««««««««««««««««« 340 
Discussion«««««««««««««««««««««««« 344 
References««««««««««««««««««««««« 354 
CHAPTER 6: THE EFFECTS OF GROWTH FACTORS ON THE 
PROLIFERATION AND IN VITRO ANGIOGENESIS OF HUMAN 
MACULAR INNER CHOROIDAL CELLS  
 
Introduction««««««««««««««««««««««« 362 
Methods««««««««««««««««««««««««« 365 
Isolation of human macular inner choroidal endothelial cells« 365 
Cell Proliferation assays««««««««««««««««« 365 
Manual Cell counting««««««««««««««««« 365 
WST-1 assay««««««««««««««««««««« 366 
In vitro Angiogenesis Assay««««««««««««««« 367 
Statistics««««««««««««««««««««««««« 369 
Results««««««««««««««««««««««««« 370 
Human macular ICEC Proliferation«««««««««««« 370 
Manual Cell Counting«««««««««««««««««« 371 
WST-1 assay«««««««««««««««««««««« 373 
In vitro Angiogenesis Assay«««««««««««««« 375 
'LVFXVVLRQ«««««««««««««««««««««««« 376 
References««««««««««««««««««««««« 385 
CHAPTER 7: FINAL CONCLUSIONS 395 
 
References««««««««««««««««««««««« 409 
 Figures & Tables  
 
Fig. 1.1  Electron micrograph of vascular endothelial cell  
demonstrating a Weibel-Palade body.................................................. 15 
 
Fig. 1.2  Diagram of an endothelial cell membrane and its adjacent 
extracellular matrix.............................................................................. 21 
 
Fig. 1.3  Electron micrograph of an endothelial cell demonstrating 
numerous caveloae............................................................................. 25 
  
Fig. 1.4  Electron micrograph of an endothelial cell membrane 
demonstrating diaphragmed fenestrations............................................26 
 
Fig. 1.5  A diagram demonstrating different types of endothelial cell  
junctions (zonula occludens and zonula adherens.............................. 29 
 
Fig. 1.6  A simplified representation of the HIF transcription factor  
pathway............................................................................................... 36 
 
Fig. 1.7  A schematic outline of the actions of VEGF on binding to  
9(*)5«««««««««««««««««««««««««« 41 
 
Fig. 1.8  A schematic outline of the actions of FGF2 on binding to  
FGFR1................................................................................................. 45 
 
Fig. 1.9  A schematic outline of the actions of ANG1 on binding 
to Tie 2................................................................................................ 50 
 
Fig. 1.10  A cross section of a human eye showing its basic 
structural components.......................................................................... 67 
 
Fig. 1.11  The basic histological structure of the human retina............ 70 
 
Fig. 1.12  A diagram of the outer retina, %UXFK¶VPHPEUDQHDQG 
choroid.................................................................................................. 71 
 
Fig. 1.13  A diagram of the ultra structure of the human macula 
and fovea.............................................................................................. 72 
 
Fig. 1.14  An Optical Coherence Tomography (OCT) scan through 
the human macula................................................................................ 72 
 
Fig. 1.15  A colour photograph of a human retina demonstrating the 
retinal arterioles and venules................................................................ 74 
 
Fig. 1.16  A diagram of the arterial supply of the globe........................ 76 
 
Fig. 1.17  A diagram of the venous drainage of the globe.................. 77 
 viii 
 
Fig. 1.18  A haematoxylin/eosin histlogical section of human 
sub-macular choroids........................................................................... 78 
 
Fig. 1.19  A diagram demonstrating pattern of blood supply of 
choriocapillaris lobules......................................................................... 79 
 
Fig. 1.20  A scanning electron micrograph of a cast of the human 
choroidal vasculature viewed from the retinal aspect.......................... 80 
 
Fig. 1.21  A scanning electron micrograph of a cast of the human 
choriocapillaris viewed from the scleral aspect................................... 80 
  
Fig. 1.22  A diagram of the underlying steps involved in choroidal 
neovascularisation................................................................................ 86 
 
Fig. 1.23  $FRORXUIXQGDOSKRWRJUDSKRIDSDWLHQW¶V right eye 
demonstrating drusen.......................................................................... 89 
 
Fig. 1.24  A colour fundal photograph of the left eye of a patient 
with wet AMD....................................................................................... 90 
 
Fig. 1.25  A Fundus fOXRUHVFHLQDQJLRJUDPRIDSDWLHQW¶VULJKt eye 
demonstrating a choroidal neovascular membrane............................ 91 
  
Fig. 1.26  Fundal photographs of proliferative diabetic retinopathy... 104 
 
Fig. 1.27  A fundus photograph of active retinopathy of prematurity.. 108 
 
Fig. 2.1  A phase contrast photomicrograph of primary cultures of  
human umbilical cells (HUVEC)........................................................ 179 
 
Fig. 2.2  A phase contrast photomicrograph of primary cultures of  
human choroidal endothelial cells.......................................................180 
 
Fig. 2.3  A phase contrast photomicrograph of primary cultures of 
human retinal endothelial cells........................................................... 180 
 
Fig. 2.4  A phase contrast photomicrograph of primary cultures of 
human iris endothelial cells................................................................ 181 
 
Fig. 2.5a  An immunofluorescent photomicrograph of human 
retinal and choroidal endothelial cells stained for CD31..................... 181 
 
Fig. 2.5b  An immunofluorescent photomicrograph of human 
iris and umbilical vein endothelial cells stained for CD31.................. 182 
 ix 
Fig. 2.6a  An immunofluorescent photomicrograph of human 
retinal and choroidal endothelial cells stained with a non-specific 
anti-rat epitope murine IgG1 antibody (negative control for the 
anti-CD31 primary antibody............................................................... 182 
 
Fig. 2.6b  An immunofluorescent photomicrograph of human iris and 
umbilical vein endothelial cells stained with a non-specific anti-rat 
epitope murine IgG1 antibody (negative control for the anti-CD31 
primary antibody................................................................................. 183 
 
Fig. 2.7  An immunofluorescent photomicrograph of human retinal  
and choroidal endothelial cells stained with anti-CD31 with the 
secondary antibody replaced with PBS.............................................. 183 
 
Fig. 2.8a  An immunofluorescent photomicrograph of human 
retinal and choroidal endothelial cells stained for vWf........................ 184 
 
Fig. 2.8b  An immunofluorescent photomicrograph of human 
iris and umbilical vein endothelial cells stained for vWf........ ............. 184 
 
Fig. 2.9a  An immunofluorescent photomicrograph of human retinal 
and choroidal endothelial cells stained with a FITC labelled non- 
specific swine anti-rabbit immunoglobulin fraction (negative control 
for the anti-vWf primary antibody......................................................  185 
 
Fig. 2.9b  An immunofluorescent photomicrograph of human 
iris endothelial cells and HUVECs stained with a FITC labelled 
non-specific swine anti-rabbit immunoglobulin fraction (negative 
control for the anti-vWf primary antibody............................................ 185 
 
Fig. 3.1  A heatmap of the differential probeset expression reaching 
statistical significance with  reference to HUVEC and different 
human ocular microvascular endothelial cells................................... 206 
 
Table 3.1  One hundred most highly expressed probesets in 
HUVECs compared with ocular microvascular endothelial cells....... 207 
. 
Table 3.2  One hundred most highly expressed probesets in 
ocular microvascular endothelial cells compared with HUVE cells... 210 
 
Fig. 3.2a  A pie chart of significantly up-regulated genes grouped 
by biological processes in proliferating HUVECs compared with 
proliferating ocular microvascular endothelial cells............................ 213 
 
Fig. 3.2b  A pie chart of significantly upregulated genes grouped by 
biological processes in proliferating ocular microvascular 
endothelial cells compared with proliferating HUVECs.....................  214 
 x 
Table 3.3  Differential expression of selected probe sets involved 
In cell signalling between matched human choroidal and retinal  
endothelial cells.................................................................................  216 
 
Fig. 3.3  A heatmap of differential probeset expression reaching 
statistical significance with  reference to human retinal and 
choroidal microvascular endothelial cells..........................................  221 
 
Fig. 3.4a  A pie chart of significantly up-regulated genes grouped 
by biological processes in  proliferating human choroidal 
endothelial cells compared with proliferating human retinal 
endothelial cells................................................................................. 222 
 
Fig. 3.4b  A pie chart of significantly upregulated genes grouped 
by biological processes in  proliferating human retinal endothelial 
cells compared with proliferating human  choroidal endothelial 
cells.................................................................................................... 223 
 
Table 3.4  One hundred most highly expressed probesets in human 
choroidal microvascular endothelial cells compared with human 
retinal endothelial cells...................................................................... 224 
 
Table 3.5  One hundred most highly expressed probesets in human 
retinal microvascular endothelial cells compared with human 
choroidal endothelial cells.................................................................. 227 
 
Fig. 3.5  A heatmap of differential probeset expression reaching 
statistical significance with  reference to human iris and choroidal 
microvascular endothelial cells.......................................................... 231 
  
Fig. 3.6a  A pie chart of significantly up-regulated genes grouped by 
biological processes in proliferating human iris endothelial cells 
compared with proliferating human choroidal endothelial cells......... 232 
 
Fig. 3.6b  A pie chart of significantly up-regulated genes grouped by 
biological processes in proliferating human choroidal endothelial 
cells compared with proliferating human iris endothelial cells........... 233 
 
Table 3.6  A table of the probesets reaching differential expression 
of 2.0 or greater in human  choroidal microvascular endothelial 
cells compared with human iris endothelial cells................................ 234 
 
Table 3.7  A table of the probesets reaching diiferential expression 
of 2.0 or greater in human iris microvascular endothelial cells 
compared with human choroidal endothelial cells.............................. 236 
 
Table 3.8  A table of the differential expression of selected probe 
sets involved in cell signalling between matched human iris and 
retinal endothelial cells....................................................................... 239 
 
 xi 
Fig. 3.7  A heatmap of differential probeset expression reaching 
statistical significance with  reference to human retinal and iris 
microvascular endothelial cells........................................................... 240 
 
Fig. 3.8a  A pie chart of significantly up-regulated genes grouped 
by biological processes in proliferating human iris endothelial cells 
compared with proliferating human retinal endothelial cells............... 241 
 
Fig. 3.8b  A pie chart of significantly up-regulated genes grouped 
by biological processes in proliferating human retinal endothelial 
cells compared with proliferating human iris  ndothelial cells............. 242 
 
Table 3.9  A table of the one hundred most highly expressed 
probesets in human retinal microvascular endothelial cells 
compared with human iris endothelial cells........................................ 243 
 
Table 3.10  A table of the one hundred most highly expressed 
probesets in human iris microvascular endothelial cells compared 
with human retinal endothelial cells.................................................... 246 
 
Fig. 3.9  The real time PCR dissociation curves of selected 
probesets in HUVEC and ocular endothelial cells.............................. 250 
 
Fig. 3.9a  The dissociation curves for a series of 10 fold dilutions 
for an Angiopoietin 2 reference sample.............................................. 250 
 
Fig. 3.9b  Shows the calculated standard curve derived from 
fig.3.9a ............................................................................................... 250 
 
Fig. 3.9c  Demonstration of the QPCR dissociation curves for 
angiopoietin 2 expression in HUVEC and human choroidal 
endothelial cells.................................................................................. 251 
 
Fig. 3.9d  Demonstration of the QPCR dissociation curves for 
Keratin 18 expression in HUVEC and human retinal endothelial 
cells.................................................................................................... 252 
 
Fig. 3.9e  Demonstration of the QPCR dissociation curves for 
CD44 expression in HUVEC retinal and iris human endothelial 
cells.................................................................................................... 253 
 
Table 3.11  A table showing an example of the output of the 
ABI PRISM 7000 sequence detection system for Angiopoietin 2 
QPCR for human iris, retinal, choroidal ECs and HUVECs................ 254 
 
Table 3.12  A table showing the differences in probe set expression 
of selected genes for HUVEC, iris, choroidal and retinal endothelial 
cells comparing microarray and real time PCR.................................. 256 
 xii 
Fig. 4.1  A haematoxylin and eosin stained section of human 
choroid and RPE ............................................................................... 283 
 
Fig. 4.2  A scanning electron micrograph of a cast of human 
choroidal vasculature viewed from the scleral side............................ 284 
 
Fig. 4.3  A scanning electron micrograph of a cast of human 
choroidal vasculature viewed in cross section.................................... 285 
 
Fig. 4.4  An electron micrograph of a renal glomerular endothelial 
cell membrane demonstrating diaphragmed fenestrations................  286 
 
Table 4.1  A table of the primary antibodies used in the study of 
human inner choroidal endothelial cells............................................. 292 
 
Fig. 4.5a  A histological section of human sub-macular choroids 
stained with toluidine blue before removal of the outer choroidal 
vessels .............................................................................................. 295 
 
Fig. 4.5b  A histological section of human sub-macular choroids 
stained with toluidine after  removal of the outer choroidal vessels.....296  
  
Fig. 4.6 An immunofluorescent photomicrograph of macular inner 
choroidal endothelial cells  stained for vWf..........................................298  
 
Fig. 4.7  An immunofluorescent photomicrograph of macular inner 
choroidal endothelial cells stained with rabbit Ig fraction (negative 
control) (primary antibody and secondary antibody ± swine 
anti-UDEELW)DE¶IUagment FITC conjugate...................................... 299 
 
Fig. 4.8  An immunofluorescent photomicrograph of macular inner 
choroidal endothelial cells stained for CD31......................................  299 
 
Fig. 4.9  An immunofluorescent photomicrograph of human RPE 
cells stained for CD31 (negative control)............................................ 300 
 
Fig. 4.10  An immunofluorescent photomicrograph of macular inner 
choroidal endothelial cells stained for VEGF receptor 1..................... 300 
 
Fig. 4.11  An immunofluorescent photomicrograph of human RPE 
cells stained for VEGF R1 (negative control).....................................  301 
 
Fig. 4.12  An immunofluorescent photomicrograph of macular 
inner choroidal endothelial cells stained for VEGF receptor 2  
(VEGFR2)........................................................................................... 301 
 
Fig. 4.13  An immunofluorescent photomicrograph of human RPE 
cells stained for VEGF R2 (negative control)...................................... 301 
 xiii 
Fig. 4.14  An immunofluorescent photomicrograph of macular inner 
choroidal endothelial cells stained for E-Selectin (unstimulated)....... 302 
 
Fig. 4.15  An immunofluorescent photomicrograph of macular inner 
choroidal endothelial cells  stained for E-Selectin (1 hour post 
TNF-ĮVWLPXODWLRQ.............................................................................. 303 
 
Fig. 4.16  An immunofluorescent photomicrograph of human RPE 
cells stained for E-Selectin (1 hour post TNF-ĮVWLPXODWLRQ).............. 303 
 
Fig. 4.17  An immunofluorescent photomicrograph of macular inner 
choroidal endothelial cells  stained with mouse anti-rat isotype 
(negative control) .............................................................................. 304 
 
Fig. 4.18  An immunofluorescent photomicrograph of macular inner 
choroidal endothelial cells stained for alpha-smooth muscle actin 
Į-SMA) .............................................................................................. 304 
 
Fig. 4.19  An immunofluorescent photomicrograph of human RPE 
FHOOVWDLQHGIRUĮ-smooth muscle actin (positive control).................... 305 
 
Fig. 4.20  An immunofluorescent photomicrograph of macular inner 
choroidal endothelial cells stained for Fibroblast surface protein....... 305 
 
Fig. 4.21  An immunofluorescent photomicrograph of human 
7HQRQ¶VFDSVXOHILEUREODVWVVWDLQHG for fibroblast surface protein  
(positive control)................................................................................. 306 
 
Fig. 4.22  A photomicrograph of macular inner choroidal 
endothelial cells seeded onto Matrigel forming capillary-like 
structures within 3 hours of seeding................................................... 306 
 
Fig. 4.23  A transmission electron micrograph of a macular inner 
choroidal endothelial cells tube-like structure demonstrating a 
lumen, and cell junctional complexes................................................. 307 
 
Fig. 4.24  A transmission electron micrograph of macular inner 
choroidal endothelial cell fenestrations............................................... 307 
 
Table 5.1  A table of all probesets reaching differential expression 
of 2.0 or greater in human  macular inner choroidal endothelial 
cells compared with matching peripheral inner choroidal ECs........... 326 
 
Table 5.2  A table of all probesets reaching differential expression 
of 2.0 or greater in human peripheral inner choroidal endothelial 
cells compared with macular inner  choroidal ECs............................. 327 
 
Table 5.3  A table of all probesets reaching differential expression 
of 2.0 or greater in human macular inner choroidal ECs compared 
with macular outer choroidal ECs....................................................... 329 
 xiv 
Table 5.4  A table of the top one hundred probesets reaching 
differential expression of 2.0 or greater in human macular outer 
choroidal ECs compared with macular inner choroidal ECs............... 332 
 
Fig. 5.1a  A pie chart of significantly up-regulated genes grouped by 
biological processes in proliferating human macular inner choroidal 
endothelial cells compared with proliferating human macular outer 
endothelial cells.................................................................................. 335 
 
Fig. 5.1b  A pie chart of significantly up-regulated genes grouped by 
biological processes in proliferating human retinal endothelial 
cells compared with proliferating human iris endothelial cells............ 336 
 
Fig. 5.2  A heatmap of the differential probeset expression reaching 
statistical significance with  reference to human macular inner and 
outer choroidal microvascular endothelial cells.................................  337 
 
Table 5.5  A comparison table of selected probesets up-regulated 
in human macular inner and outer choroidal endothelial cells............ 338 
 
Fig. 5.3  Examples of the real time PCR dissociation curves for 
Keratin 19 in peripheral inner choroidal ECs, macular inner and 
macular outer choroidal ECs.............................................................. 341 
 
Fig. 5.3a  Real time PCR dissociation curves for a series of 
10 fold dilutions for a keratin 19 reference sample............................. 341 
 
Fig. 5.3b  The real time PCR calculated standard curve derived 
for keratin 19 reference sample......................................................... 341 
 
Fig. 5.3c  The real time PCR dissociation curves for keratin 19 
expression in peripheral inner choroidal ECs, macular inner and 
macular outer choroidal ECs.............................................................. 342 
 
Table 5.6  A table demonstrating the differences in gene expression 
for selected genes for proliferating human macular inner and outer 
choroidal endothelial cells comparing the microarray and Real 
time-PCR results................................................................................ 343 
 
Table 5.7  A table demonstrating the differences in gene 
Expression  of a selected gene for proliferating human macular 
inner and peripheral inner choroidal endothelial cells comparing 
microarray and Real time-PCR results............................................... 343 
 
Fig. 6.1  A phase contrast micrograph demonstrating the invasion 
of preformed macular inner choroidal EC microvessels into the 
secondary Matrigel layer.................................................................... 369 
 xv 
Fig. 6.2  A graph of the mean proliferation of macular inner 
choroidal endothelial cells measured using cell counting in the 
presence of different concentrations of heat inactivated foetal 
calf serum........................................................................................... 370 
 
Fig. 6.3  A graph of the mean proliferation of human macular inner 
choroidal endothelial cells  measured by manual cell counting in 
the presence of various growth factorsat 300 pmol/l.......................... 372 
 
Fig. 6.4  A graph of the mean proliferation of human macular inner 
choroidal endothelial cells  measured by manual cell counting in 
the presence of various growth factors at 900 pmol/l......................... 373 
 
Fig. 6.5  A graph of the growth curves for human macular inner 
choroidal endothelial cells measured using the WST-1 assay in 
the presence of different growth factors.............................................. 374 
 
Fig. 6.6  A graph of the mean increase in human macular inner 
choroidal endothelial tube formation compared with control as a 
measurement of angiogenesis using 3D double layer Matrigel 
assay for various growth factors......................................................... 375 
 
Fig. 6.7  A diagram demonstrating an overview of FGFR-1 
signalling............................................................................................. 379 
 
Fig. 6.8  A diagram demonstrating an overview of VEGFR-1 and 
VEGFR-2 signalling............................................................................ 380 
 
 Appendices  
 
Publications from this thesis 
 
Browning AC, Gray T, Amoaku WM. Isolation, culture, and 
characterisation of human macular inner choroidal microvascular 
endothelial cells. Br J Ophthalmol 2005:89:1343-1347. 
 
Browning AC, Dua HS, Amoaku WM. The effects of growth factors on 
the proliferation and in vitro angiogenesis of human macular inner 
choroidal endothelial cells. Br J Ophthalmol 2008:92:1003-1008. 
 
Browning AC, Halligan EP, Stewart EA, Swan DC, Dove R, 
Samaranayake GJ, Amoaku WM. Comparative gene expression 
profiling of human umbilical vein endothelial cells and ocular vascular 
endothelial cells. Br J Ophthalmol 2011:96:128-132. 
 
Stewart EA, Samaranayake GJ, Browning AC, Hopkinson A, Amoaku 
WM. Comparison of choroidal and retinal endothelial cells: 
Characteristics and response to VEGF isoforms and anti-VEGF 
treatments. Exp Eye Research 2011: 93:761-766  
 Abbreviations 
 
ADP  Adenosine diphosphate 
AGES  Advanced glycation end products 
Akt Acutely transforming retrovirus AKT8 in rodent T cell 
lymphoma 
AMD  Age related macular degeneration 
Apo   Apolipoprotein  
BSA  Bovine serum albumin 
CD  Cluster differentiation 
CFH   Complement factor H 
CNV  Choroidal neovascularisation 
DABCO 1-4 diazabicyclo[2,2,2] octane  
DAG  Diacylglycerol 
EC  Endothelial cell 
ECM  Extracellular matrix 
EDTA  Ethylene diamino tetra acetic acid 
ERK  Extra cellular signal regulated kinase 
FGF  Fibroblast growth factor 
FGFR  Fibroblast growth factor receptor 
FITC  Fluorescein isothiocyanate 
FLK  Foetal liver kinase 
FLT  FMS like tyrosine kinase 
GTP  Guanosine triphosphate 
hCEC  Human choroidal endothelial cell 
HEPES 4-(2-hydroxyethyl)-1-piperazineethansulphonic acid 
HGF  Hepatocyte growth factor 
HUVEC Human umbilical vein endothelial cell 
ICAM  Intercellular adhesion molecule 
ICEC  Inner choroidal endothelial cell 
IGF  Insulin-like growth factor 
IL  Interleukin 
kDa  kilo Dalton 
KDR  Kinase insert domain receptor 
 xviii 
LDL  Low density lipoprotein 
MAPK  Mitogen-activated protein kinase pathway 
MEM  Minimum Essential Medium 
MHC  Major Histocompatibility complex  
MMP  Matrix metalloproteinases 
mRNA messenger RNA 
NGF  Nerve growth factor 
NO  Nitric oxide 
NOS  Nitric oxide synthetase 
PDGF  Platelet derived growth factor 
PDT  Photodynamic therapy 
PECAM  Platelet endothelial cell adhesion molecule 
PBS  Phosphate buffered saline 
PEDF  Pigment Epithelial Derived Factor  
PI  Phosphoinositide 
PKC  Protein kinase C 
PLGF  Placental growth factor 
PDR  Proliferative diabetic retinopathy 
RAS  Rat sarcoma 
RCS  Royal College of Surgeons 
ROP  Retinopathy of prematurity 
RPE  Retinal pigment epithelium 
SDF  Stromal derived factor 
 Rationale and Aims  
 
Intraocular angiogenesis is associated with a number of common 
blinding conditions including wet age-related macular degeneration, 
proliferative diabetic retinopathy, retinopathy of prematurity and rubeotic 
glaucoma. The pathogenesis of these disorders is centred on the 
choroidal, retinal and iris microvascular endothelial cells respectively.  
 
Investigators have attempted to increase the understanding of these 
disorders by studying vascular endothelial cells in vitro. Due to their 
availability in large numbers and relative ease of culture, many studies 
have used ocular cells from non-human sources, or non-ocular human 
endothelial cells derived from sites such as the umbilical vein (HUVEC).  
 
Workers have therefore inferred and applied conclusions from in vitro 
studies of macro- and microvascular endothelial cells derived from 
different species or organs to human eye diseases. It is now widely 
accepted that endothelial cells derived from different species, vascular 
organs and from within different vascular beds within those organs 
display different phenotypical, biochemical and genetic heterogeneity. It 
follows that the extrapolation of results from these non-human ocular or 
HUVEC cells may not provide reliable data applicable to human eye 
disease. Any meaningful insight  into the pathogenesis and selective 
treatment of the diseases mentioned previously would therefore 
probably only be gained by conducting in vitro studies using 
microvascular endothelial cells derived from the particular site(s) 
affected by the disease, i.e. endothelial cells derived from the human 
retina, choroid and the iris. Within the ocular vascular beds themselves, 
many diseases appear site specific, such as diabetes predominantly 
affecting the retinal vasculature and age related macular degeneration 
affecting the choroidal circulation. 
 xx 
One disease in particular that is the leading cause of blindness in those 
over 65 is wet age related macular degeneration. The underlying 
pathophysiological mechanisms responsible for disease progression 
remain largely unknown. Current opinion suggests an angiogenic 
response by inner choroidal endothelial cells to a local adverse stimulus 
driven by a range of cytokines and growth factors. Because of the 
impact of wet AMD on the quality of life of a large proportion of the 
elderly population, it was decided to focus attention during the latter 
part of this research project on the cells thought to be central to the 
disorder ± the inner choroidal endothelial cell. Until now, these critical 
cells have not been successfully isolated and subjected to in vitro 
examination.  
 xxi 
The aims of this project are therefore: 
 
1) To successfully isolate and culture matched human retinal, choroidal 
and iris endothelial cells. 
 
2) To acquire and culture unpassaged human umbilical vein 
endothelial cells (HUVEC). 
 
3) To compare the gene expression profiles of proliferating 
unpassaged HUVEC and ocular microvascular endothelial cells to 
determine if HUVEC cells are representative cells to use in ocular 
angiogenic research. 
 
4) To compare the gene expression profiles of matched, unpassaged 
human retinal, choroidal and iris endothelial cells to determine 
whether any differences in gene expression provide insight into the 
site specificity of ocular vascular disorders and to determine whether 
any differences would provide potential targets for future anti-
angiogenic therapies. 
 
5) To develop a technique for the successful isolation of human 
macular inner choroidal endothelial cells and to propagate them in 
culture. 
 
6) To characterise the isolated cells in terms of the surface expression 
of a range of purported endothelial cell markers. 
 
7) To compare the gene expression profiles of matched unpassaged 
human macular inner and outer choroidal endothelial cells to 
determine whether inner choroidal endothelial cells possess any 
gene expression characteristics that make them susceptible to 
growth during wet AMD. 
 
 xxii 
8) To compare the gene expression profiles of matched unpassaged 
human macular and peripheral inner choroidal endothelial cells to 
determine whether macular inner choroidal endothelial cells possess 
any gene expression characteristics that make them susceptible to 
growth during wet AMD. 
 
9) To determine the effect of a range of growth factors on the 
proliferation and vascular tube formation of human macular inner 
choroidal endothelial cells. 
 
Overall, the realisation of these objectives will provide an insight as to 
whether HUVEC cells provide a useful alternative to ocular cells in 
research into ocular angiogenic diseases given their widespread 
availability and ease of culture. The comparison of the gene expression 
profile of ocular endothelial cells will also provide an insight into 
endothelial cell heterogeneity within the eye and may provide clues as 
to the reasons for ocular vascular bed disease susceptibility and 
potential future selective anti-angiogenic treatments. 
 
The in vitro characterisation and gene expression profiling of human 
inner choroidal endothelial cells will provide an extremely powerful and 
unique model for the laboratory investigation of the mechanisms 
underlying age related macular degeneration and may provide an 
insight into selective treatment of this disease. 
  
 
 
Chapter 1 
 
 
 
 
Introduction 
 2 
Section 1: Vascular Biology 
 
Oxygen is one of the essential requirements for life. The cells of some 
simple organisms receive oxygen by simple diffusion from the air, while 
larger organisms such as the fruit fly have developed a system of air 
filled tubes within cell layers. Because the diffusion limit of oxygen 
through tissue is 100 to 200µm, vertebrates have developed complex 
cardiovascular systems lined by endothelium. These systems efficiently 
maintain oxygen homeostasis in all cells and at the same time facilitate 
bi-directional exchange of solutes and carbon dioxide; waste product 
removal; recruitment and diapedesis of leukocytes; antigen 
presentation; lipoprotein metabolism and temperature regulation.  The 
idea of a vascular system was first proposed by Harvey in 1628 when 
he suggested that blood circulates around the body. Soon afterwards, 
Malphigi described the separation of blood and tissues and for the first 
time visualised blood flow in capillaries. It was not until the nineteenth 
century (1860) that von Recklinghausen suggested that blood flowed 
along vessels lined with endothelial cells. Since then, Simionescu has 
described the interaction of the endothelium with leukocytes and 
endothelial cell junctions (Simionescu et al, 1976) and many others 
KDYHVXEVHTXHQWO\GHVFULEHGWKHQXPHURXV³DFWLYH´IXQFWLRQVRIWKH
endothelium.  
 
The cardiovascular system is the first organ system to develop in an 
embryo, the failure of which is universally lethal in early embryogenesis 
(Risau W, 1995; Risau W, 1997). It evolves by three different, distinct 
mechanisms: haemovasculogenesis, vasculogenesis and 
angiogenesis. 
 3 
Haemovasculogenesis 
 
While it is widely accepted that embryonic haemopoiesis occurs at early 
stages within the liver before moving to the bone marrow, as long as 
100 years ago, it was noted that there was a link between the 
production of blood cells (erythrocyte precursors) and endothelial cells 
at the earliest stages of development within the blood islands of the 
chick yolk sac (Sabin, 1917).  Similar findings have subsequently been 
found in the aorta and umbilical artery (Jaffredo et al, 1998: Hirai et al, 
2002). With modern methods of examination, it is now thought that this 
budding of erythroblasts from endothelial cells is a common event in the 
embryo and is found to occur in the kidney, brain and skin. The 
existence of a common precursor for both endothelial and 
haematopoietic cells (Murray, 1932: Ogawa et al, 2002) led to the term 
³KDHPR-YDVFXORJHQHVLV´. This is defined as the formation of blood 
vessels within the embryo during which new blood vessels 
(vasculogenesis) and blood cells (haematopoiesis) develop 
simultaneously within the embryo from a common precursor (the 
haemangioblast) (Sequira-Lopez et al, 2003). Histologically, 
erythroblasts develop within aggregates of endothelial cell precursors. 
As the lumen of a vessel forms, the erythroblasts bud from the lining 
endothelial cells to fill the lumen (Sequira-Lopez et al, 2003). The 
common precursor cells express ȕOglobin and this has been used as a 
marker of haemovasculogenesis (Sequira-Lopez et al, 2003). What is 
not known for certain is the earliest marker of this pluripotent 
haemangioblast. Various elegant experiments by Yamashita in 2000 
and Nishikawa in 1998 using embryonic stem cells show that cells 
positive for Flk-1 (VEGF receptor 2), which is thought to be an early 
haemangioblast marker, can develop into either endothelial or 
haematopoietic cells (and also possibly mural cells) (Yamashita et al, 
2000; Nishikawa et al, 1998). The expression of VE-cadherin or not, is 
an important determinant as to which path the progenitor cell then 
follows (Nishikawa et al, 1998). Ogawa has subsequently shown that 
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progenitor cells following haematopoietic lineage then go on to express 
Į-integrin. It is suspected that growth factors such as VEGF may be 
important in determining the route of differentiation taken by the original 
cells but this is an area where further research is needed. It has now 
been proposed that the choriocapillaris (part of the choroidal 
vasculature within the eye) originates via haemovasculogenesis 
because precursor cells are positive for epsilon globin (an erythroblast 
marker) and VEGF receptor 2. These cells were seen to aggregate and 
then differentiate into separate endothelial cells and erythroblasts. 
(Hasegawa et al, 2007). 
 
Vasculogenesis 
 
Vasculogenesis describes the formation of blood vessels in which 
endothelial cells differentiate and proliferate in situ within a previously 
avascular tissue. This primary network includes some of the major 
vessels such as the aorta and major veins (Yancopoulos et al, 2000; 
Risau & Flamme, 1995). Vascular progenitor cells either migrate or 
differentiate locally at sites of vascularisation and coalesce to form a 
vascular plexus (Hristov M et al, 2003; Ribatti et al, 2009). This process 
leads to the formation of the major intra-embryonic blood vessels such 
as the aorta and the primary vascular plexus in the yolk sac. Later, the 
vascular networks of organs such as the lungs, the myocardium and the 
liver also form via vasculogenesis (Pardanaud et al, 1989). This initial 
process appears to be pre-programmed and is independent of the local 
oxygen concentration. In the yolk sac, the blood islands are composed 
of haemangioblasts, the precursors of both endothelial and 
haematopoietic cells. In the peripheral areas of the islands, 
haemangioblasts differentiate into angioblasts (CD39 or ADPase 
positive) which later aggregate into vascular networks within the yolk 
sac and the embryo proper (McLeod et al, 2006). During early in vitro 
vasculogenesis, fibroblast growth factor 2 (FGF-2) appears to be 
important for angioblast differentiation (Krail et al 1994; Flamme and 
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Risau 1992; Cox & Pool, 2000). However, in vivo, the vasculature of 
FGF-2 knockout mice models appeared to develop normally (Zhou et 
al, 1998). Although the reason for this discrepancy is uncertain, it may 
be due to a high degree of redundancy in the FGF growth 
factor/receptor system. It is known that at present, there are at least 4 
different FGF receptors, 3 of which have 3 subtypes. Each receptor can 
also bind a number of the 22 structurally related members of the FGF 
growth factor family. Any knock out model of a particular subtype of 
FGF molecule would most likely be easily bypassed, thereby 
suggesting an important role of FGF in embryogenesis. Conversely, 
vascular endothelial growth factor (VEGF) and VEGF receptor 2 
knockout mice die early with vascular maldevelopment suggesting a 
pivotal role for VEGF and its main receptor in early vasculogenesis 
(Carmeliet et al, 1996; Shalaby et al, 1995). Other endothelial 
cytokines/receptors such as the angiopoietins, Tie 1 and 2 and 
neuropilin are thought to play a more minor role in early 
vasculogenesis, with animals undergoing normal vessel development 
but dying of cardiac defects. Once formed, tubes of endothelial cells 
begin to secrete laminin and collagen IV which in turn forms the 
basement membrane. 
 
Until recently it was thought that vasculogenesis only occurred in the 
ePEU\R,WLVQRZNQRZQWKDW³SRVW-QDWDOYDVFXORJHQHVLV´RFFXUVYLD
bone marrow-derived endothelial stem and progenitor cells (Hristov M 
et al, 2003; Asahara et al, 1999; Käßmeyer et al, 2009). Asahara et al 
isolated mononuclear cells from the blood of patients who had the 
antigenic characteristics of angioblasts and, after inducing ischaemia in 
limbs, found bone marrow endothelial progenitor cells within the vessels 
of the limbs after restoration of blood flow. They state that this is 
consistent with post natal vasculogenesis. Within the eye, it is thought 
that the retinal vasculature develops by the process of vasculogenesis 
(see later) and this is a well studied model of vascular development 
because of the ease with which it can be studied (McLeod et al, 2006; 
Saint-*HQLH]	'¶$PRUH 
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Angiogenesis 
 
Angiogenesis is the term applied to the formation of capillaries from 
pre-existing vessels. In the embryo it is responsible for expansion of the 
primary network formed by vasculogenesis. In contrast to 
vasculogenesis, it appears to be less pre-programmed and is more 
dependent on tissue hypoxia for its stimulation and regulation (Pugh & 
Ratcliffe, 2003; Carmeliet, 2003; Semenza, 2007). It occurs by a series 
of well defined steps which include: 
 
1. Endothelial cell (EC) activation by growth factors such as VEGF and 
FGF-2 via VEGF receptor 2 and FGF receptors respectively. These 
receptors are membrane bound tyrosine kinases that lead to the 
activation of multiple intra-cellular signalling cascades. The principle 
drive for growth factor up-regulation, especially for VEGF, is tissue 
hypoxia. There is debate as to whether FGF exerts its pro-
angiogenenic effect on endothelial cells by a direct effect on the 
cellular proliferative mechanism via FGF receptors and intracellular 
signalling cascades or via up-regulation of the effect of VEGF. 
Evidence exists for both hypotheses as it is known that specific pro-
angiogenic pathways are activated when FGF binds to its receptor 
(FGFR1) (Cross and Claesson-Welsh), and FGF has also been 
shown to up-regulate VEGF and VEGF receptor expression on ECs 
(Murakami and Simons, 2008; Murakami et al 2011; Seghezzi et al, 
1998). 
 
2. Degradation of endothelial basement membranes by proteases such 
as matrix metalloproteinases (MMPs), urokinase plasminogen 
activator (uPA), heparinases, trypases and cathepsins (Kalluri, 
2003; Steen et al, 1998). Matrix metalloproteinases are a family of at 
least 20 different zinc-dependent endopeptidases that are capable 
of degrading various components of the extracellular matrix (ECM). 
Under basal conditions, MMPs are capable of remodelling tissue. 
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However, during periods of angiogenesis, they are able to modify 
the ECM ahead of proliferating endothelial cells, aiding their 
passage through tissue. Their activity is regulated by natural 
inhibitors called Tissue inhibitors of metalloproteinases (TIMPs). 
MMPs are known to be secreted by proliferating endothelial cells, 
and in wet AMD, the most important types appear to be MMP2 and 
MMP9 (gelatinase a and b respectively) (Bandyopadhyay and 
Rohrer, 2012). They are able to degrade various components of 
Bruchs membrane such as collagen IV, V and fibronectin (Sethi et 
al, 2000). Proteinases also play a role in angiogenesis by liberating 
extra cellular matrix-bound growth factors such as FGF-2, thereby 
liberating free growth factor which can therefore take part in the 
angiogenic process. 
 
3. Formation of vascular sprouts and migration of activated endothelial 
cells through the adjacent extracellular matrix towards the 
angiogenic stimulus. The tips of the sprouts are formed by 
specialised endothelial tip cells. Tip cells extend numerous filopodia 
to sense their microenvironment and lead the direction of the 
growing sprout. Behind the tip cells, other cells form the stalk of the 
new vessel. Selection of endothelial cells to become tip cells is 
affected by Notch expression (Gerhardt et al, 2003; Suchting & 
Eichmann, 2009). A model of tip cell selection has been proposed 
that starts with binding of VEGF by VEGF receptor 2 on an 
endothelial cell which causes the up regulation of the notch ligand 
delta like ligand 4 (Dll4) on the cell surface. This interacts with notch 
receptors on surrounding ECs and this in turn leads to down 
regulation of VEGFR2 on these cells which are thus less sensitive to 
VEGF signalling. The cells expressing Dll4 and VEGF R2 become 
non proliferative tip cells, forming filopodia and extending into the 
surrounding ECM along VEGF gradients (Hellstrom et al, 2007; 
Gerhardt et al, 2003). Cells expressing notch receptors proliferate 
and become stalk cells which extend the newly forming blood vessel 
(Tung et al, 2012). It is not known how specific tip cells are selected 
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or how their numbers are controlled in relation to the number of stalk 
cells, but it may be linked to Dll4-notch 1 interactions. This brings 
about a down regulation of tip cell formation and angiogenesis 
(Hellstrom et al, 2007; Phng and Gerhardt, 2009) and notch-
1/jagged-1 interactions which antagonise the effect of Dll4, leading 
to pro-angiogenenic signals and increased formation of tip cells 
(Bernedito, 2009). It is obvious that the ratio of tip to stalk cells 
needs to be strictly controlled for organised angiogenesis to occur. 
Growth of the new vessel is affected by integrins which are cell 
surface receptors for specific ECM components that enable signals 
from the ECM to be transmitted into the EC (Hynes, 1992). This 
communication between the activated EC and the ECM is thought to 
be critical because blocking of integrins signalling significantly 
inhibits angiogenesis (Umeda et al, 2006; Yasukawa et al, 2004). 
Microarray analysis of tip cells prepared by laser microdissection 
demonstrated enrichment for CXCR4 (stromal derived factor 
receptor) which is a growth factor/receptor combination thought to 
be important in embryonic vascular development. The tip cells also 
appeared to be enriched for apelin, VEGF Receptor 2 and 
angiopoietin 2. The authors conducted a number of elegant 
experiments and showed that inhibition in CXCR4 signalling resulted 
in defects in neonatal mice retinal tip cell morphology and function 
(Strasser et al, 2010). 
 
4. Endothelial cell proliferation.  
 
5. Capillary tube formation. The mechanisms underlying tube formation 
are largely unknown but probably include changes in cell polarity, 
cytoskeletal components and interactions with the ECM via integrins 
(Tung et al, 2012). Two models have been proposed to explain the 
mechanism of tube formation. The first is cell hollowing. This 
involves the coalescence of intracellular vesicles to eventually form 
a lumen. Once the lumen is formed within an individual cell, the 
ends open and link with adjacent cells to form a primitive vessel 
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(Folkman and Haudenschild, 1980). An alternative model is known 
as cord hollowing. In this model, endothelial cells aggregate into a 
long cord and vesicles form between the cells which eventually form 
into a lumen (Lueng et al, 1999). While other models probably also 
exist, the model taking place in an individual setting is probably 
context driven  
 
6. Recruitment of mural cells to surround and stabilise the newly 
formed vascular tube. For larger blood vessels (arteries and veins), 
this involves the recruitment of smooth muscle cells (SMC), while for 
capillaries, arterioles and venules, pericytes are recruited. It is 
thought that SMCs and pericytes are derived from a similar lineage 
and are part of a phenotype continuum. The number of pericytes 
recruited to a vascular structure per endothelial cell varies within 
different beds. Within the retina there is 1 pericyte per EC whereas 
in skeletal muscle there are 100 pericytes per EC (Shepro and 
Morel, 1993). The reason for this difference is uncertain, but 
pericytes may be important for the formation of the inner blood 
retinal barrier or act as receptors for hypoxia or hypoglycaemia; all 
important factors for normal retinal function. For many years the role 
of pericytes was ignored as they were thought to be passive cells 
providing simple mechanical support. It is now known that they are 
critical for the stability and maintenance of the vessel and the 
endothelial cells. Abnormalities in pericyte biology are now thought 
to cause specific diseases in their own right. Proliferating endothelial 
cells secrete platelet derived growth factor (PDGF) B which attracts 
PDGFR-ȕH[SUHVVLQJPXUDOFHOOVWRWhe nascent vessel (Lindblom et 
al, 2003; Lindahl et al, 1997). Mouse knock out models of PDGF-B 
and PDGFR-ȕUHVXOWLQDVLPLODUOHWKDOSKHQRW\SHFDXVHGE\DEVHQW
pericyte recruitment and major vascular abnormalities (Leveen et al, 
1994; Soriano P, 1994). It is thought that localised binding of PDGF-
B to the surrounding endothelial cell ECM aides the orderly 
coverage of the new vessel with pericytes (Armulik et al, 2005). An 
absence of pericytes on pre-formed vessels, either as a result of 
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disease (diabetes) or by pharmacological manipulation by the use of 
PDGF-B antibodies, leads to loss or stripping away of pericytes and 
vascular disorganisation. Another signalling molecule associated 
with pericytes is Angiopoietin 1 (Ang 1). It is thought that Ang1 is 
secreted by pericyte/mural cells and acts in a paracrine fashion on 
endothelial cells via the Tie 2 receptor to stabilise the vessel. Ang 1 
or Tie 2 knockout mice have disorganised basement membranes 
and poor pericyte coverage.(Sato et al, 1995; Suri et al 1996) 
 
Abnormal or pathological angiogenesis  
 
It was recognised over 100 years ago that blood vessels grow around 
tumours and that without these new vessels tumours could not grow 
beyond a certain size or metastasise. In 1968 it was hypothesised that 
tumours secrete a diffusible angiogenic substance (Greenblatt & Shubi, 
1968; Ehrmann & Knoth, 1968) and in 1971 Folkman suggested that 
inhibiting angiogenesis may stop tumour growth (Folkman, 1971a) and 
KHDWWHPSWHGWRLVRODWHWKLV³IDFWRU´)RONPDQE7KHtumour 
vessels studied were structurally and functionally abnormal. The 
vessels were disorganised, dilated and tortuous with excessive 
branching and there were many openings or gaps both within 
IHQHVWUDHDQGEHWZHHQHQGRWKHOLDOFHOOVPDNLQJWKHPYHU\³OHDN\´ 
 
In adult normal, non-neoplastic tissue, the majority of vascular 
endothelial cells are dormant and only approximately 0.01% of 
endothelial cells are undergoing division at any one time (Engerman et 
al, 1967). Diseases in which there is excessive angiogenesis are a 
major cause of disease-related morbidity and mortality. Examples 
include: psoriasis, atherosclerosis, haemangiomas and endometriosis. 
Within the eye, a number of common blinding conditions are caused by 
aberrant angiogenesis including wet age related macular degeneration, 
proliferative diabetic retinopathy, rubeotic glaucoma and retinopathy of 
prematurity.  
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Endothelial Cells 
 
Blood vessels are lined by a monolayer of endothelial cells. The adult 
human contains approximately 1-6x1013 endothelial cells and they 
cover an approximate surface area of 7m2 (Cines et al, 1998; Augustin 
et al, 1994). They are flat, polygonal cells that are elongated in the 
direction of blood flow and, on cursory examination, appear identical in 
different parts of the body; but in reality there is significant heterogenic 
diversity. Their life span is in the region of 100 days (Hobson & 
Denekamp, 1984). In cross section, the cells are 2-3µm thick at the 
nucleus but they can be as thin as 0.2µm in the peripheral parts of the 
cell (Anderson et al, 1995). The thinness of the cell may contribute 
many of their attributes. Endothelial cells express a number of cell 
markers that are used to identify them in experimental studies. 
However, none is entirely endothelial specific, but rather more 
³HQGRWKHOLDOUHVWULFWHG´7KHLQWHQVLW\RIH[SUHVVLRQLVDOVRYDULDEOH
depending on the site of origin of the cells (Langenkamp & Molema, 
2009). Endothelial cell restricted markers include: CD31, CD34 and von 
Willebrand factor (vWf). 
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Endothelial cell surface markers 
 
CD 31, also known as PECAM 1 (platelet endothelial cell adhesion 
molecule) is a 130kDa glycoprotein found on endothelial cells and was 
first cloned in 1990 (Newman et al, 1990). It is also found on platelets 
and some leukocytes. It is a member of the Ig superfamily and consists 
of 6 extracellular Ig folds. Its role is as a cell-cell adhesion molecule 
with its main ligand being other CD31 molecules. Other ligands are 
WKRXJKWWRLQFOXGH&'&'DQGȐYȕLQWHJULQZKLFKDUHIRXQGon 
circulating leukocytes (Deaglio et al, 1998; Sachs et al, 2007). While 
CD31 is responsible in part for the adhesion of adjacent endothelial 
cells, its main role appears to be that of the binding of leukocytes to the 
luminal side of ECs with the specific function of allowing the loosening 
of the binding of adjacent cells, and to facilitate the passage of the 
leukocyte between ECs  into the extra-vascular compartment 
(diapedesis). This phenomenon is commonly seen in states of 
inflammation and allows leukocytes to migrate to sites of trauma and 
infection. While the mechanisms controlling this event are poorly 
understood, it is thought that cell binding or the local release of factors 
by leukocytes leads to activation of the CD31 molecule and the 
subsequent stimulation of an intracellular signalling cascade. It has 
been observed that CD31 binding leads to the intracellular 
phosphorylation of tyrosine and serine/threonine residues on the 
receptor (Newman and Newman, 2003) which, in turn, can alter the 
vigour of cell-cell binding. It is not known if or how CD31 interacts with 
other adhesion molecules important for EC integrity such as ZO-1 and 
occludin. 
 
CD34 is a 105-120kDa trans-membrane glycoprotein expressed by 
bone marrow lymphohaematopoietic stem cells, endothelial cell 
progenitor cells, embryonic fibroblasts and mature vascular endothelial 
cells (especially tip cells). It was discovered in 1984 during the search 
for markers of bone marrow progenitor or stem cells (Civin et al, 1984), 
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labelling approximately 1.5% of bone marrow cells. Despite its wide 
expression on a range of potentially important precursor cells, its role is 
poorly understood. Early studies suggested that its expression on 
endothelial cells plays a role in leukocyte adhesion and homing, 
particularly in lymphoid tissues via L-selectin expressed by circulating 
lymphoid cells (Nielsen and McNagny, 2008). Interestingly, CD34 exists 
as at least two splice variants depending on the maturity of the cells 
(Krause et al, 1996). The smaller splice variant is missing an exon 
responsible for coding part of the intracellular domain, with potential 
sites of phosphorylation which may therefore play a role in intracellular 
signalling, although the importance of this is currently unknown. Both 
forms have the same extracellular domains so are therefore not able to 
be differentiated by antibody labelling of cells.  
 
Another important observation is the loss of vascular endothelial cell 
expression of CD34 after one or two passages or after exposure to 
inflammatory mediators such as TNF alpha (which coincidently up-
regulates expression of ICAM 1) (Delia et al, 1993). These observations 
have led to the theory that CD34 is important in cell±cell adhesion, 
especially during inflammation. Interestingly, CD34 knock out mice 
appear to have normal bone marrow and endothelial cell function 
(Cheng et al, 1996), further increasing the mystery of the role of CD34 
other than being a useful marker of endothelial cells.  
 
von Willebrand factor (vWf) is a circulating protein important in blood 
clotting (haemostasis), an absence of which causes the bleeding 
GLVRUGHUFDOOHGYRQ:LOOLEUDQG¶VGLVHDVH7KHglycoprotein is critical for 
the recruitment of platelets to sites of bleeding, thereby providing part of 
the initial haemostatic plug before the slower activation of blood clotting 
factors. It is also important for the stabilisation of Factor VIII - clotting 
factor (thereby enhancing the clotting cascade). It is synthesised and 
stored within endothelial cells and megakaryocytes (platelet precursors) 
in electron dense Weibel-Palade (WP) bodies. These electron dense 
bodies were first recognised using electron microscopy in 1964 in the 
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cytoplasm of small vessel endothelial cells (Weibel and Palade, 1964). 
They have a diameter of 0.1-ȝP, a length of 1-ȝPDQGthey have 
characteristic longitudinal striations (Valentijn et al, 2008) (see 
illustration below). In cross section they consist of electron dense 
tubules which are thought to give them the characteristic striated 
appearance surrounded by a less dense matrix. For many years, it was 
thought that vWf was the only secreted constituent of WP bodies. It is 
now known that tissue plasminogen activator (t-PA), P-selectin, 
interleukin-8, angiopoietin 2 and endothelin-1 are also stored and 
secreted (Valentijn et al, 2011). This means that WP bodies contain a 
number of mediators important in haemostasis, inflammation, 
angiogenesis and vascular tone. There is a continuous basal secretion 
of vWf into the blood stream which can be quickly enhanced during 
times of localised vascular stress by degranulation of WP bodies near 
sites of vessel (and endothelial) injury by activation of cell surface G 
protein linked receptors by secretagogues such as thrombin and 
histamine (Valentijn et al, 2011). Unlike CD31 and CD34, vWf appears 
to be much more specific for the identification of endothelial cells in vitro 
and in vivo as the only other cell known to synthesise vWf, 
megakaryocytes, are easily identified by their size and morphology and 
are not found outside of the bone marrow except in certain extremely 
rare instances of malignancy or systemic organ failure. There is still 
debate as to whether all endothelial cells process WP bodies and 
therefore vWf. Much of the confusion appears to derive from species 
differences. Examination of the pig vascular tree demonstrated a 
heterogeneous distribution, with vWf being virtually absent in the 
thoracic and abdominal aorta but present in pulmonary arteries and the 
vena cava. Interestingly, abnormal WP bodies were found in all ECs 
(Gebrane-Younes et al, 1991), while Folkman et al in 1979 found that 
human capillary ECs possessed WB bodies whereas bovine ECs did 
not. As part of the work of this thesis, it was found that human retinal, 
choroidal and iris ECs all stained positive for intracellular vWf and 
expressed mRNA coding for vWf, thereby suggesting that human ocular 
ECs express vWf and by association possess some form of WP bodies. 
 15 
 
 
 
 
 
Role of endothelial cells 
 
Endothelial cells act as gate keepers between the vascular lumen and 
the extra-vascular environment. Due predominantly to their cell surface 
receptors and cell-cell junctional molecules they have a range of roles. 
These include: 
 
1. The regulation of substances and cells passing through cell 
junctions and through WKHFHOOV¶F\WRSODVPIURPWKHLQWUDYDVFXODUWR
the extravascular space. This process is thought to be regulated by 
a variety of membrane-bound surface receptors for growth factors 
such as VEGF; pro- and anti-coagulant factors; lipid particles such 
as LDL; and metabolites such as nitric oxide and hormones (Cines 
et al, 1998). 7KHGHJUHHRI³OHDNLQHVV´RIWKHYDVFXODWXUHLV
dependent upon the location of the endothelial cells within the body 
and on its phenotype. The inner choroidal vasculature within the 
human eye is generally regarded to be semi-permeable due to the 
presence of fenestrations. As discussed later, these are small, full 
thickness hole-like structures in endothelial cells, often capped by a 
semi permeable membrane. They allow the passage of small and 
Fig 1.1. Electron micrograph of vascular endothelial cell demonstrating 
a Weibel-Palade body with its characteristicstriations.The inset shows 
a cross sectional view demonstrating the intra-organelle tubules which 
contain vWf. (with permission of Nature publishing) 
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medium sized molecules from the vascular lumen to the extra 
vascular space. Within the choroid of the eye, they allow the support 
of retinal pigment epithelial cells and photoreceptors, both of which 
have very high metabolic demands. Other ECs expressing 
fenestrations include those found in the glomerulus of the kidney 
where high rates of solute exchange are required to take place, and 
in the liver. At the other extreme, some endothelia are resistant to 
the passage of fluid, solutes, macromolecules and cells from the 
intra-vascular to the extravascular compartments. Examples are the 
retinal and brain vasculature. The cells form the inner blood-retinal 
and blood-brain barriers respectively, and are necessary for the 
structural integrity and functioning of the retina and brain. The major 
component of the inner blood-retinal barrier is tight junctions or 
zonula occludans between ECs (Sagaties et al, 1987). Astrocytes, 
present in the retina and brain are thought to be important in the 
formation and maintenance of the retinal and brain endothelial 
barrier functions by the expression of zonula occludens -1 (ZO-1) 
(Gardner et al, 1997). 
 
2. The control of blood coagulation by the secretion of factors such as 
vWf (procoagulant), tissue factor pathway inhibitor (anti-coagulant), 
thrombomodulin (anti-coagulant), protein S (anti-coagulant) and 
tissue factor (procoagulant). The coagulation of blood is a complex 
process. At the site of vascular injury, e.g. a cut, a breach in the 
endothelium exposes collagen and extracellular matrix molecules 
which stimulate the clotting cascade, a process characterised by the 
activation of a large number of circulating intravascular proteins 
starting with factor XII. In the initial phase of injury, release of factors 
such as von Willibrand factor by endothelial cells recruits platelets to 
the site of injury to form the primary haemostatic plug. This is a 
transient response that aims to stabilise blood loss before the 
activated clotting cascade permanently closes the defect. In a 
similar fashion to the control of angiogenesis, blood coagulation is 
tightly controlled to avoid total coagulation within the vascular 
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system and relies on a delicate balance of pro- and anti- coagulation 
factors. Endothelial cells are critical to this balance, secreting factors 
such as thrombomodulin in order to abrogate the effects of other 
factors such as vWf.  
 
3. The secretion of substances important in the control of blood flow 
and pressure such as nitric oxide, prostacyclin and endothelin 1.  
 
Endothelin-1 (ET-1) was discovered in 1988 and has subsequently 
been shown to be the most potent vasoconstrictor known to date 
(Yanagisawa et al, 1988). It also has the capacity to induce vascular 
remodelling, fibrosis, cell proliferation and apoptosis and is thought 
to be involved in a number of vascular diseases (Bourque et al, 
2011). While three isoforms exist (ET-1 to ET-3), ET-1 is the most 
important and best studied. It is synthesised predominantly by 
vascular endothelial cells although it has also been found in 
vascular smooth muscle cells, the spleen, pancreas and lung. 
Expression of ET-1 is up-regulated by mediators such as 
catecholamines, angiotensin II, arginine vasopressin and insulin, 
and by mechanical factors such as shear stress, hypoxia and 
bacterial lipopolysaccharide. Expression is inhibited by factors that 
are important in vasodilatation such as nitric oxide, prostacyclin and 
atrial natriuretic peptide (KhimjiA and Rockey D, 2010). Secreted 
ET-1 is functionally inactive, only becoming activated after cleavage 
by endothelin converting enzymes and matrix metalloproteinases 
(Bourque et al, 2011). The actions of ET-1 are brought about by two 
G-protein coupled receptors, ETA and ETB, predominantly on 
vascular smooth muscle cells (thereby bringing about 
vasoconstriction). The main action of endothelin 1 is 
vasoconstriction and is thought to be important in the medical 
condition systemic hypertension. It is now common practice for a 
range of ETA antagonists to be used as treatment for hypertension.  
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Nitric oxide (NO) is a gas that can act as a signalling molecule. 
One of its main functions on the endothelium is to act as a stimulator 
of vasodilatation. Its existence was suggested by Furchgott and 
Zawadzshi in 1980 but it was not until 1987 that its role in 
vasodilatation was discovered by Rees et al (1991) and confirmed 
by Ignarro (1989) who demonstrated that NO synthase inhibitors 
blocked vasodilatation. As NO is a volatile gas and lipophilic, it is 
freely diffusible across cell membranes and therefore does not need 
a cell surface receptor to bring about its actions. It is synthesised in 
response to factors such as shear stress on vessel walls by the 
action of nitric oxide synthase (NOS) on L-arginine. Within 
endothelial cells, the NOS isoenzyme is known as endothelial NOS 
or eNOS. Within neuronal cells which may be juxtaposed in tissues 
such as the brain and retina, the NOS isoenzyme is neuronal NOS 
or nNOS. Shear stress (i.e. fast and turbulent flow) within a vessel is 
detected by endothelial cells and this leads to an increase in 
intracellular Ca2+ which in turn, binds to and activates the regulatory 
protein calmodulin. Calmodulin in turn activates eNOS, leading to 
the synthesis of NO. Nitric oxide then diffuses out of the endothelial 
cell and into juxtaposed vascular smooth muscle cells to stimulate 
guanylate cyclase. This in turn, inhibits the calcium dependent 
contraction of the vascular smooth muscle cell i.e. vasodilatation.  
 
Because the up-regulation of NO is both rapid and sensitive to 
changes in shear stress, it is thought to be the main vasodilatory 
mechanism maintaining vascular tone. Since its discovery, it has 
also become apparent that NO has other important vasoprotective 
roles including protection against apoptosis and other endothelial 
cell survival functions. In 2001, Brookes et al demonstrated that 
mice deficient in eNOS, either by gene knockout or by the ingestion 
of eNOS inhibitors, were protected against oxygen induced vaso-
obliteration, thereby suggesting that high levels of NO are 
pathogenic (Brooks et al, 2001). NO is also thought to play a role in 
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endothelial cell VEGF signalling and will be discussed in more detail 
later. 
 
Prostacyclin was discovered in 1977 by Moncada et al although it 
was initially called prostaglandin I2.  It is produced in endothelial 
cells by the action of prostacyclin synthase on a derivative of 
arachidonic acid, released from endothelial cell membranes by 
phospholipase. As well as acting in an autocrine fashion within the 
synthesising endothelial cell, it is secreted from the cell and acts in a 
paracrine fashion on local cells possessing prostacyclin (IP) 
receptors. Stimulation of this G protein coupled receptor can lead to 
vasodilatation and the localised inhibition of platelet aggregation. 
The mechanism of vasodilatation is thought to be due to vascular 
smooth muscle cell hyperpolarisation. The role of prostacylin in 
basal vascular tone and systemic hypertension is dubious given the 
fact that systemic administration of drugs such as aspirin and 
indomethacin which inhibit the production of prostacyclin have no 
measureable effect on blood pressure in humans (Parkington et al, 
2004).  
 
4. Endothelial cells are sensitive to stretch and shear stress, thereby 
acting as a measure of blood flow and pressure (Topper et al, 1996, 
Malek & Izumo, 1995; Korff & Augustin, 1999). The mechanisms 
underlying the detection of intravascular flow and shear stress and 
the changes in the cell are poorly understood. Rapid reactions to 
changes in shear stress include the activation of signalling 
mechanisms such as the generation of nitric oxide as described 
previously, the opening of potassium and calcium channels, the 
activation of focal adhesion kinase, MAPK and PKC (Tzima, 2006). 
Slower changes include the up-regulation of cell surface ICAM-1, 
TGF and PDGF, rearrangement of intracellular microfilaments and 
microtubules (Malek and Izumo, 1996) and their elongation along 
the direction of flow (Levesque and Nerem, 1985). The cellular 
mechanisms for sensing flow and stress are poorly understood but 
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are thought to involve cellular mechano-transducers (Tzima E, 
2006). The mechanism is thought to involve the transmission of 
shear stress from the apical surface of the cell through the 
cytoskeleton to points of attachment (Davies P, 1995) both within 
the cell and at its basal surface junction with its basement 
membrane. Four candidate molecules have been suggested as 
being possible mechano-transducers involved in this process: 
surface integrins by virtue of their interactions with the extracellular 
matrix; ion channels; specialised membrane microdomains and G 
proteins (Traub and Berk, 1998). Recently, a fifth mechanism was 
suggested that involves PECAM-1 (CD31) acting via VE-Cadherin 
and VEGFR2, the latter acting as the signal transduction molecule 
(Tzima et al, 2005). 
 
5. The secretion of extracellular matrix components such as 
fibronectin, laminin, collagen and elastin. Endothelial cells do not 
exist in isolation and require a complex micro-environment around 
them for cell stability and function. Part of this microenvironment is 
FRPSRVHGRIWKHH[WUDFHOOXODUPDWUL[ZKLFKLQFOXGHVWKHFHOO¶V
laminin rich basal anchoring basement membrane and a 
surrounding, paracellular fibronectin scaffold. The endothelial cells 
are thought to bind to and interact with the ECM via membrane 
spanning molecules called integrins. A simplified diagram of the 
ECM is shown below (Fig 1.2).  
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Fig 1.2. Diagrammatic representation of endothelial cell membrane 
interaction with extracellular matrix (with permission from Springer 
images) 
 
 
The base materials of the ECM are proteoglycans, including heparin 
sulphate, glycosaminoglycans and water. Heparin sulphate is able 
to bind growth factors such as VEGF and FGF, thereby inactivating 
them and/or making an extracellular store that can be rapidly 
activated by enzymatic digestion of the heparin sulphate. Binding of 
VEGF by the ECM is also thought to be critical in the formation of 
growth factor gradients, important for both angiogenic sprouting and 
guidance of tip cells and during embryonic vasculogenesis.  
 
Fibronectin is a high molecular weight (440kDa) proteoglycan dimer 
within the ECM that binds the extracellular component of integrin 
molecules. Each molecule has four fibronectin binding domains 
allowing a fibronectin scaffold to be built up around cells. Additional 
binding domains allow binding to collagen, fibrin, fibulin 1 and 
heparin sulphate. In vitro studies of isolated vascular endothelial 
cells have shown that fibronectin is one of the ECM components 
required for the satisfactory adhesion of ECs to culture plates and 
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for their subsequent proliferation. This requirement appears 
particularly important for microvascular ECs. 
 
Integrins are a heterogeneous group of trans-membrane receptors 
that are composed of two dissimilar FKDLQVĮDQGȕFKains) .The 
LQWHJULQVPRVWFRPPRQO\DVVRFLDWHGZLWKHQGRWKHOLDOFHOOVDUHĮY
ȕDQGȕTheir roles are to anchor the cell to the ECM and to 
provide a signalling pathway from the ECM to the intracellular 
environment. Matrix-integrin signalling is thought to be critical for 
embryonic development, cell proliferation, survival and migration. 
There are many different types of integrin depending on the different 
FRPELQDWLRQVRIĮDQGȕFKDLQVXVHGTo date, GLIIHUHQWĮFKDLQV
and eight ȕFKDLQVKDYHEHHQFKDUacterised (Hehlgans and Cordes, 
2007). Inside the cell, integrins are attached to microfilaments of the 
cytoskeleton. At sites of ECM ligand-integrin binding, integrin 
clustering occurs and complexes form called focal adhesions. It is at 
these sites that signal transduction is thought to take place. It is 
thought that integrins themselves do not have any tyrosine kinase 
activity, but bring about signal transduction by recruitment of 
accessory molecules such as focal adhesion kinase,(FAK) and 
integrin linked kinase (ILK)to the intracellular portion of the 
molecule, thereby activating signalling cascades such as SRC 
((Hehlgans and Cordes, 2007).  
 
6. The synthesis of growth factors. Conventional thinking suggests that 
endothelial cells are acted upon by growth factors secreted by other 
cells such as retinal pigment epithelial cells and ganglion cells within 
the eye, or by circulating VEGF derived from platelets (Webb et al, 
1998) and neutrophils (Guadry et al, 1997). While the role of growth 
factors such as VEGF and FGF 2 in vascular development and 
pathological angiogenesis are well recognised, it has recently been 
discovered that endothelial cells themselves produce VEGF 
(Maharaj et al, 2006). It has also recently been demonstrated that 
genetic deletion of VEGF in the endothelial cells of adult mice led to 
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progressive endothelial degeneration, microhaemorrhagic events, 
intravascular thrombosis and death (Lee et al, 2007). Interestingly, 
circulating levels of VEGF were unaffected. This suggests that the 
requirement for autocrine VEGF cannot be replaced by circulating or 
paracrine VEGF, confirming the importance of autocrine VEGF as a 
cell survival signal. The authors also demonstrated that the actions 
of autocrine VEGF are mediated via the VEGF Receptor 2. 
Endothelial cells have also been demonstrated to produce fibroblast 
growth factor 2 (FGF2) (Yu et al 1993; Cordon-Cardo et al, 1990). 
However, the role of FGF2 in auto/paracrine signalling is much less 
understood than for VEGF. It has recently been reported that 
increased production of FGF2 by pulmonary endothelial cells 
contributes to pulmonary smooth muscle hyperplasia seen in the 
rare condition of primary pulmonary hypertension, although the 
mechanism has yet to be determined (Tu et al, 2011). As discussed 
previously, endothelial cells are known to secrete PDGF B which 
attracts PDGFR-ȕH[SUHVVLQJPXUDOFHOOVWRWKHQDscent vessel 
(Lindblom et al, 2003; Lindahl et al, 1997). Mouse knock out models 
of PDGF-B and PDGFR-ȕUHVXOWLQDVLPLODUOHWKDOSKHQRW\SH
caused by absent pericyte recruitment and major vascular 
abnormalities (Leveen et al, 1994; Soriano P, 1994). It is thought 
that localised binding of PDGF-B to the surrounding endothelial cell 
ECM aids the orderly coverage of the new vessel with pericytes 
(Armulik et al, 2005). Basal secretion of PDGF by endothelial cells is 
required to maintain the mural cell coverage and the function of the 
vascular structure.  
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Ultrastructure of endothelial cells 
 
Under electron microscopic examination, the luminal surface of 
endothelial cells shows fine projections and a coating of glycocalyx 
(Ryan & Ryan, 1984). The glycocalyx is a mixture of glycoproteins 
which may be involved in the regulation of solute transport and the 
mechanical effects of blood flow on the cell and the inhibition of 
inadvertent activation of the clotting cascade by cell surfaces.  
Caveolae  
 
The luminal surface is covered in pits called caveolae (derived from 
their initial appearance as caves)7KHVHVWUXFWXUHV³EXGRII´IURPWKH
surface to form 50-100µvesicles and are seen to migrate through the 
cytoplasm (transcytosis) and to fuse with the opposite cell surface and 
release their contents into the extracellular space (Palade and Bruns, 
1968). It is thought that caveolae are important for the transcellular 
passage of solutes and macromolecules such as low-density lipoprotein 
(LDL), very low density lipoprotein (VLDL), insulin, caeruloplasmin 
(copper carrying protein), albumin and transferrin (iron carrying protein) 
from the vascular lumen to the subendothelial space, perhaps by 
specific macromolecule receptors within individual caveolae 
(Simionescu and Simionescu, 1991; King and Johnson, 1985).  
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Fig 1.3. The image above is an electron micrograph of an endothelial 
cell demonstrating numerous caveolae, either budding from the luminal 
surface (upper arrow), within the cytoplasm or fused with the basal 
surface of the cell in direct communication with the subcellular space 
(lower arrow). (with permission from Springer images) 
 
A major structural and critical protein found in caveolae is caveolin-1. 
This is a 22kDa protein that forms a major structural component of the 
vesicle membrane and is critical for its function (Rothberg et al, 1992). 
Without caveolin-1, caveolae do not form as demonstrated in the 
caveolin null mouse (Razani et al, 2001; Drab et al, 2001). It appears 
that without caveolae, increased transfer of solutes and 
macromolecules occurs by an up-regulation of paracellular routes, 
stimulated by up-regulation of intracellular eNOS activity and 
subsequent increased NO levels (Schubert et al, 2002). The passage of 
caveolae through the cell is thought to be along microtubules and is an 
$73GHSHQGHQWSURFHVV'¶6RX]DHWDO. 
 
Fenestrations 
 
Fenestrations are round or oval transcellular holes through the thinnest 
parts of the endothelial cell cytoplasm. They are found in areas where a 
high rate of partially selective exchange of components between the 
intra- and extravascular compartments is required. This exchange is 
usually limited to water and small solutes with passage of larger 
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components such as lipids and proteins being inhibited. The 
fenestrations within the choriocapillaris therefore allow the rapid transfer 
RIQXWULHQWVWKURXJK%UXFK¶VPHPEUDQHDQGWKH53(LQWRWKHKLJKO\
metabolically active photoreceptors. To date, three types of 
fenestrations have been described (Satchell and Braet, 2009).  
 
Type 1 fenestrations are 60-70 µm in diameter and are covered by a 
thin diaphragm. The glycoprotein - plasmalemmal vesicle associated 
protein 1 (PLVAP-1) is thought to be a major component of this 
diaphragm. Each fenestration is surrounded by a cytoskeletal lattice. 
Type I fenestrations are found in the endothelia of endocrine glands, 
gastrointestinal mucosa and renal tubular capillaries (Fig 1.4). It is 
thought that the fenestrations found in the human choriocapillaris may 
be type I by virtue of the expression of PLVAP in gene array 
experiments (see later) and the possession of a diaphragm.  
 
 
 
Fig 1.4. Electron micrograph of endothelial cell membrane 
demonstrating diaphragmed (type 1) fenestrations (with permission of 
Nature publishing) 
Extracellular 
compartment 
Fenestrations 
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Type II fenestrations are found in discontinuous endothelia such as 
those found in the spleen, liver and bone marrow. These fenestrations 
are wider (up to 200µm diameter) and do not have diaphragms or 
express PLVAP.  
 
Type III fenestrations are found in the endothelium of renal glomeruli. 
They are of a similar size to type I, but like type II, do not express 
PLVAP or have diaphragms.  
 
Weibel-Palade Bodies 
 
 Within the cell, the usual cellular constituents such as mitochondria, 
endoplasmic reticulum, microfilaments (actin) and intermediate 
filaments (vimentin) are found. Evidence for the apparatus for cellular 
excretion of specific molecules is scanty. The characteristic organelle of 
endothelial cells is the Weibel-Palade body. As previously described, 
these are intracellular organelles that synthesise and store von 
Willebrand factor (Factor VIII) which is a glycoprotein that is important 
in blood clotting and platelet adhesion to extracelluar matrix. The 
density of these intra-cellular organelles varies with the source or site of 
the endothelial cells. 
 
Endothelial cell junctional complexes 
 
In order to maintain the integrity of the vascular lumen, endothelial cells 
adhere to adjacent (endothelial) cells by a range of cell junctional 
complexes. The range and complexity of the junctions gives a clue to 
the importance of these junctions in the function of the endothelial 
barrier in both health and disease. Solutes and macromolecules can 
pass through the endothelial barrier either by a transcellular route, as 
discussed above (caveolae and fenestrations) or by a paracellular 
route, which is controlled by a range of junctional complexes.  
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These include zonula adherens and zonula occludens. Because of the 
heterogeneity and variation in function of the endothelial cells in 
different vascular beds, junctional complexes vary. This has the effect 
of introducing variability to the barrier function of ECs. As mentioned 
previously, endothelial cells form the inner blood retinal and blood brain 
barriers, and these barriers are necessary for the structural integrity and 
functioning of the retina and brain by excluding toxic solutes and 
macromolecules from reaching the tissues. In these instances, 
essential molecules are taken up by active transcellular processes via 
routes such as caveolae. The major component of the inner blood 
retinal and the blood brain barriers are tight junctions or zonula 
occludans between ECs (Sagaties et al, 1987). Astrocytes, present in 
the retina and brain, are thought to be important in the formation and 
maintenance of the retinal and brain endothelial barrier functions by 
modulating the expression of ZO-1 (Gardiner et al, 1997). 
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Fig 1.5. A diagram demonstrating the two major types of cell-cell 
junctions in endothelial cells (zonula occludens (tight junction) and 
zonula adherens (adherens junction). The diagram demonstrates the 
orientation of the major components and their interaction with the 
cytoskeleton of the cells (with permission of Springer images) 
 
 
Zonula Occludens (ZO) consist of an adhesive belt around cells and 
are composed of components such as occludin and claudin. They 
prevent the movement of fluid between cells and are responsible for 
much of the integrity of the vascular lumen, preventing extravasation of 
fluid to the interstitial tissue. They also limit the movement of membrane 
bound proteins from the luminal to the abluminal surface of the cell. The 
first major protein identified was occludin. This is a 60kDa protein 
consisting of four transmembrane and two extracellular domains. Each 
occludin molecule binds to another occludin molecule on an adjacent 
cell, thereby forming a bond. The intracellular tails of the occludin 
molecules are linked to the actin filaments of the cytoskeleton by ZO-1 
(and ZO-2) molecules. The role of occludin in tight junction formation 
and function may be complex as occludin deficient cells still 
demonstrate tight junction structures (Saltou et al, 2000) and 
 30 
occludin-null mice demonstrated widespread abnormalities such as 
brain calcification. These findings suggest that structural redundancy 
exists in tight junction formation and function and that occludin may 
have wider roles in the body than just tight junction formation. It has 
been shown however, that the permeability of an endothelial cell barrier 
is directly related to the expression of occludin (Harhaj et al, 2006). It is 
widely recognised that increased local levels of VEGF, as seen in 
diabetic retinopathy, leads to increased vascular permeability. One of 
the main mechanisms of this increased permeability is the increased 
phosphorylation of occludin (and probable reduced function), stimulated 
by VEGF via up-regulation of intracellular PKC (Harhaj et al, 2006).  
 
Another important component of tight junctions is claudin. This is a 
family of 24 different proteins that have a similar structure to occludin 
i.e. four transmembrane domains and two extracellular domains. 
Despite this similarity, claudins and occludins are structurally different. 
They bind to other claudin molecules of adjacent ECs and are linked to 
the cytoskeleton, like occludin, by ZO-1. Brain endothelial cells 
specifically express claudins 1, 2, 3, 5, 11 and 12 (Huber et al, 2001, 
Sandoval and Witt, 2008). It is thought that claudin 5 is the critical factor 
in the formation of the blood brain barrier (Tam and Watts, 2010). 
Junctional adhesion molecules (JAM) are another separate group of 
proteins involved in the structure of tight junctions. They are members 
of the immunoglobulin superfamily and three types are found in 
endothelial cells, JAM A to C (Ballabh et al, 2004). Like occludin and 
claudins, they attach to the cytoskeleton via ZO-1. 
 
The accessory protein, ZO-1, is a 220kDa phosphoprotein with specific 
binding sites (PDZ sites) for occludin, claudins and JAM, and binding 
sites on its C-terminus for actin molecules. Its role is to link these tight 
junction molecules to the actin cytoskeleton. The molecule also has 
guanylate cyclase activity and plays a role in signal transduction (Bauer 
et al, 2010). The importance of ZO-1 in tight junction function is 
 31 
illustrated by the fact that cells failing to express ZO-1 demonstrate 
complete disruption of tight junctions (Umeda et al, 2006).  
 
Zonula Adherens (ZA) (cell-cell junctions) usually occur in a more 
basal location of the cell membrane than zonula occludens. They can 
take the form of an encircling band around the cell (zonula adherens) or 
as focal points of adhesion (adhesion plaques). The most important and 
abundant transmembrane proteins are the Cadherin family. These 
proteins form homodimers in a calcium dependent manner with other 
cadherin molecules on adjacent cells. One of the roles of zonula 
adherens junctions is thought to be the direct connection of the actin 
filaments of adjacent cells. The intracellular connection of cadherin 
molecules is via p120 protein and alpha and beta catenin molecules. 
The cadherin molecules most commonly associated with endothelial 
cells are VE-Cadherin (Vascular Endothelial), otherwise called cadherin 
5, and N-Cadherin (Neuronal) which is also found on neuronal and 
smooth muscle cells. N-Cadherin appears to be present across the 
endothelial cell membrane and is not localised to adherens junctions. 
The importance of VE-cadherin in vascular integrity is demonstrated by 
the fact that injection of anti-VE-cadherin antibodies in mice leads to a 
marked breakdown in vascular integrity. In contrast, molecules such as 
VEGF and histamine have a much less dramatic effect and are 
reversible (Weis and Cheresh, 2005). It is thought that changes in 
vascular permeability are in part due to effects of molecules such as 
VEGF on adherens junctions and particular VE-cadherin. Activation of 
intracellular pathways (SRC) by VEGF can lead to phosphorylation, 
cleavage and internalisation of VE-cadherin (Esser, 1998). 
 32 
Effect of growth factors on endothelial cells 
 
The existence of growth factors that stimulate the growth of blood 
vessels was postulated after the observation of an angiogenic response 
in transplanted tumours (Folkman et al, 1963, Folkman et al, 1966; 
Folkman, 1972). Over a hundred years ago, Virchow noted, in a 
number of German language publications, that tumour growth is 
accompanied by an increase in vascularity. This was followed in 1927 
by an observation by Lewis who described the variability in the vascular 
structure of tumours in rats and suggested that the tumours were 
having an influence on the characteristics of the blood vessels (Lewis, 
1927). In 1939 Ide used a transparent chamber devised by Sandison, 
inserted into a rabELW¶VHDUWRVWXG\WKHJURZWKRIWKHYDVFXODUVXSSO\LQ
a transplanted carcinoma (Ide et al, 1939). It was observed that tumour 
growth was accompanied by extensive vessel growth, confirming the 
LGHDWKDWYDVFXODULVDWLRQZDVUHTXLUHGWR³QRXULVK´WKHJURZLng tumour. 
The technique was developed further by Algire et al by quantifying 
vessel growth with time (Algive et al, 1945). At this point it was noted 
that vascular growth preceded the rapid growth of the tumour and that 
vessel growth is an important rate limiting step in tumour growth. 
 
It was hypothesised at the time that a chemical substance may be 
involved in this process. Potential candidates at the time included the 
breakdown products of chromatin. However, in 1948, Michaelson 
VXJJHVWHGWKHWHUP³)DFWRU;´0LFKDHOVRQ,QDVHULHVRI
experiments showed that vessel growth was stimulated by tumours 
even if a filter was placed between the tumour and the growing vessels 
(Greenblatt & Shubi, 1968; Ehrmann & Knoth, 1968). This suggested 
that a diffusible substance was responsible. A series of landmark 
experiments starting in 1971 by Judah Folkman reported attempts to 
LVRODWH³WXPRXUDQJLRJHQHVLVIDFWRU´)RONPDQ.ODJVEUXQHWDO
1976; Folkman, 1982). Folkman studied the stimulated growth of 
vessels in chick chorioallantoic membrane by this factor using cultured 
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tumour cells and the corneal pocket model (Kenyon et al, 1996). At this 
time, another pro-angiogenic factor, FGF, was isolated and was thought 
to be the postulated ³WXPRXUDQJLRJHQHVLVIDFWRU´6XEVHTXHQWZRUN
proved that this FGF was not the responsible agent and so the search 
for the factor continued (Dennis & Rifkin, 1990). In 1983, Senger 
reported the partial isolation of a protein that stimulated vascular 
leakage and this was terPHG³YDVFXODUSHUPHDELOLW\IDFWRU´93)
(Senger et al, 1983). Soon after, Ferrara and Henzel (1989) isolated a 
protein from the conditioned medium of bovine pituitary glands which 
led to a profuse growth of blood vessels in an in vivo assay. The fact 
that the mitogen was secreted and appeared specific for endothelial 
cells made it unlikely to be FGF (which lacks a secretory component 
and therefore may act in an autocrine environment). It was therefore 
WHUPHG³YDVFXODUHQGRWKHOLDOJURZWKIDFWRU´9(*))HUrara & Henzel, 
1989). At a similar time, Plouët et al isolated a similar endothelial 
PLWRJHQDQGFDOOHGLW³YDVFXORWURSKLQ´3ORXsWHWDO,WZDVQRW
long before both VPF and VEGF had been cloned and sequenced and 
found to be identical (Leung et al, 1989; Keck et al, 1989)  
 
Ten years later, a large number of growth factors had been isolated 
with pro-angiogenic responses including vascular endothelial growth 
factor (VEGF), acidic and basic fibroblast growth factors (FGF 1 and 2 
respectively), insulin-like growth factor 1 (IGF-1), placental growth 
factor PlGF), hepatocyte growth factor (HGF), tumour necrosis factor 
alpha (TNF- ) (via up-regulation of VEGF) (Yoshida et al, 1997) and 
interleukin-8 (Heidemann et al, 2003). To date, VEGF appears to be the 
most important in bringing about both normal physiological vascular 
development and pathological angiogenesis. In addition, other factors 
such as Transforming Growth Factor (TGF), Angiopoietins 1and 2 and 
Tie 2 are thought to be important in modulating the angiogenic 
response. 
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VEGF 
 
As discussed above, vascular endothelial growth factor was originally 
discovered by Senger, Ferrara and Plouët and was initially called 
vascular permeability factor because its main effect appeared to be to 
increase the permeability of blood vessels. VEGF consists of a family of 
molecules, the most important of which is VEGF A. Other members 
include VEGF B, C, D and placental growth factor (PlGF), (McColl, 
2004). The C and D forms regulate lymphatic angiogenesis. While 
vascular endothelial cells are the principal target for the actions of 
VEGF, other cells such as retinal ganglion cells (Nishijima, 2007; Kilic 
et al, 2006), monocytes (Clauss et al, 1990) and lung alveolar cells 
(Compernolle, 2002) express receptors to VEGF and appear to play a 
role in their physiology.  
 
Actions of VEGF on endothelial cells include: 
 
1. Stimulation of cell proliferation 
 
2. Stimulation of cell migration 
 
3. Enhancement of cell survival by the inhibition of cell apoptosis via a 
PI-3 kinase-Akt pathway and the expression of bcl-2 
 
4. Increasing vascular permeability by alterations in cell-cell adhesion 
molecules such as the phosphorylation of occludin and VE-cadherin 
(discussed previously).  
 
5. Vasodilatation by stimulated release of nitric oxide by activation of 
eNOS.  
 
6. The formation of fenestrae. 
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In 1992 Breier et al showed that VEGF mRNA was temporally and 
spatially correlated with angiogenesis in the developing embryo (Breier 
et al, 1992). The same group later reported that VEGF mRNA was up-
regulated in ischaemic areas of aggressive brain tumours, suggesting 
that it may be stimulated by hypoxia (Plate et al, 1992). It has since 
been discovered that the stimulation of VEGF is principally under the 
control of hypoxia inducible factor 1 (HIF-1) which binds to a binding 
site on the VEGF promoter (Semenza, 2002). In addition, other 
transcription factors such as the ETS family and reactive oxygen 
species affect VEGF expression (Randi et al, 2009). Hypoxia inducible 
factor 1 was discovered in 1992 (Semenza et al, 1992) and is one of 
the cell¶s main mechanisms of reacting to varying levels of tissue 
oxygenation. HIF-1 is a heterodimer protein transcription factor that 
consists of two proteins, HIF-ĮDQG+,)-ȕ+,)-1 activates the 
transcription of at least 60 genes that are involved in angiogenesis 
(VEGF), glucose metabolism, and cell proliferation (Semenza G, 2003). 
Interestingly, the effect of oxygen is not on the synthesis of HIF-1 but on 
its degradation. Hypoxia leads to an inhibition of its breakdown, thereby 
leading to elevated levels. Under conditions of normoxia, HIF-1 
degradation is regulated by O2 dependent prolyl hydroxylation which 
targets the protein for ubiquitination by ubiquitin-protein ligases which 
include the von Hippel-Lindau tumour suppressor (an important protein 
mutated in the ocular disease von Hippel-Lindau syndrome) The HIF-1 
is therefore rapidly degraded and angiogenic growth factors such as 
VEGF are not up-regulated. Under conditions of hypoxia, the O2 
dependent hydroxylation does not occur and therefore the HIF-1 is not 
targeted for degradation. This therefore leads to an up-regulation of 
VEGF expression. 
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 Fig 1.6. A simplified representation of the HIF pathway.  
 
 
In von Hippel Lindau disease, mutations in the VHL protein lead to 
inactivation of the ubiquitinisation process thereby inhibiting HIF-1 
degradation and up-regulation of local VEGF expression. The disease 
is characterised by localised vascular tumours in the retina, cerebellum, 
kidney and pancreas.  
 
)XUWKHUHYLGHQFHRI9(*)¶Vpro-angiogenic role is provided by results 
of the in vivo use of VEGF blocking antibodies which reduced the 
growth of glioblastomas (a type of brain tumour) by 80% in mice (Kim et 
al, 1993) and inhibited iris neovascularisation in a monkey model of 
retinal ischaemia (Adamis et al, 1996). In vitro culture of the 
glioblastoma cells revealed that the antibodies had no direct action on 
tumour cell growth but were acting on the tumour blood supply.  
   HIF-1     HIF-1 
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The anti-tumour effect of anti-VEGF antibodies has subsequently been 
demonstrated for a range of animal tumours and has also been shown 
to have a modest clinical effect in human disease. The humanised anti-
9(*)PRQRFORQDODQWLERG\UHIHUUHGWRDVEHYDFL]XPDE$YDVWLQLV
licensed for the treatment of bowel tumours and has been shown to 
prolong life in clinical trials (Vincenzi et al, 2009). 
 
VEGF isoforms 
 
The gene responsible for VEGF A consists of eight exons and seven 
introns. Alternative splicing of the gene product produces at least four 
different human isoforms: VEGF 121, VEGF165, VEGF189 and VEGF206,, 
consisting of 121, 165, 189 and 206 amino acids respectively. The 
intensely studied mouse isoforms of VEGF each have one less amino 
acid than their human equivalent. The main difference between 
isoforms is the presence of heparin binding domains. While all isoforms 
KDYHDQLGHQWLFDO³DFWLYH´UHJLRQ9(*)121 has no heparin binding 
domain or tail and appears freely diffusible through the extracellular 
matrix (ECM), whereas VEGF 206 and 189 both bind heparin avidly 
and are therefore strongly bound on cell surfaces or within the 
extracellular matrix. VEGF 165 has intermediate heparin binding 
properties. This difference in properties appears to be important in 
vascular development and in the formation of VEGF concentration 
gradients (Ruhrberg et al, 2002). It is known that endothelial cells will 
not form vessels by simply being in a VEGF-rich environment, but need 
a concentration gradient for the endothelial cells to migrate along, 
thereby forming a vasculature (Ruhrberg et al, 2002). It is thought that 
ECM-bound forms of VEGF are released by cleavage by proteases 
such as plasmin, heparinase and matrix metalloproteases.  
 
Mice expressing a null mutation for VEGF A die in utero with an 
extremely disorganised and rudimentary vasculature (Carmeliet et al, 
1996). Ruhrberg et al in 2002 demonstrated that mice solely expressing 
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the VEGF120 isoform, which is devoid of a heparin binding domain and 
is thereby unable to associate with the perivascular ECM, develop a 
vasculature with a marked reduction in branching patterns. They found 
that this reduction in branching was caused by a redistribution of 
endothelial cells from the formation of additional branches to being 
incorporated into the existing vasculature to increase lumen calibre 
instead. They suggest that variations in the ratio or proportions of VEGF 
isoforms around the developing vasculature alter the branching patterns 
by establishing concentration gradients of VEGF along which 
developing blood vessels grow. They hypothesise that VEGF120 will 
rapidly diffuse away from the developing vessel while the VEGF 189 
isoform will remain juxtaposed to the vessel, neither of which will allow 
a sufficient concentration gradient of VEGF to be established. It is 
therefore most likely that a combination of all four isoforms is required 
to establish the required gradient (Ruhrberg et al, 2002). Although 
VEGF A is thought to be the most important member of the VEGF 
family, other members exist such as VEGF B, VEGF C and VEGF D. It 
is known that the C and D forms are involved in lymphangiogenesis. 
Other members include placental growth factor (PLGF) and EG-VEGF 
(endocrine gland VEGF), which is expressed and acts solely on 
endothelial cells within endocrine glands such as the adrenal gland. 
5HFHQWO\RWKHU9(*)³OLNH´PROHFXOHVKDYHEHHQGHVFULEHGLQFOXGLQJ
parapox virus open reading frame (VEGFE) (Ogawa et al, 1998) and 
snake venom derived polypeptide (VEGFF) (Yamazaki et al, 2005). 
Their roles, if any, in human endothelial biology are unknown. An 
additional mammalian splice variant of VEGF A is denoted VEGFAxxxb, 
which binds, but fails to activate VEGF receptors and has therefore 
been described as anti-angiogenic (Harper and Bates, 2008). It has 
been found that in the vitreous fluid of diabetic patients, there is a 
switch from the anti-angiogenic VEGFAxxxb splice variants to the pro-
angiogenenic VEGFAxxx variants with increasing retinal ischaemia and 
neovascularisation (Perrin et al, 2005). This little understood or 
researched VEGF splice variant may therefore be an important part of 
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the anti/pro angiogenic balance within tissues, disruption of which can 
lead to aberrant angiogenesis.  
 
VEGF Receptors 
 
The actions of VEGF on endothelial cells are initiated via two cell-
surface receptors. The first of these was discovered in 1992 in the 
mouse and was termed Flt-1 (de Vries, 1992). Its human equivalent is 
termed VEGFR1. A second mouse VEGF receptor was discovered 
soon afterwards and termed Flk1 or KDR (Terman et al, 1992). Its 
human equivalent was termed VEGFR2. While VEGFR2 is 
predominantly expressed on vascular endothelial cells and their 
embryological precursors, it is also found on pancreatic duct cells, 
retinal progenitor cells and megakaryocytes (Oelrichs et al, 1993), 
although its function in these cells is unknown. These two receptors are 
receptor tyrosine kinases with seven extracellular immunoglobulin-type 
domains, a single transmembrane domain and a single intracellular 
tyrosine kinase domain (Costa et al, 2004; Neufeld et al, 1999; Ferrara 
et al, 2003). 
 
VEGFR2 
 
It is widely accepted that VEGFR2 (Flk 1) is the main receptor involved 
in endothelial proliferation, survival, migration, permeability and 
vascular tube formation. VEGFR2 has a binding affinity for VEGF A, ten 
fold lower than VEGFR1. Binding of VEGF to VEGFR2 leads to 
receptor dimerisation and conformational changes within the 
intracellular domain. These changes lead to exposure of the ATP 
binding site in the kinase domain which in turn leads to 
autophosphorylation of a number of tyrosine residues (Takahashi et al, 
2001). One of the most important residues is Tyr 1175, phosphorylation 
of which leads to activaWLRQRI3/&ȖDQGLQWXUQ,33 diacyl glycerol 
(DAG), PKCĮȕDQGȗ, MER/ERK, phospholipase A2 and RAS (Wu et 
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al, 2000; Yu, 1999, Bullard et al, 2003, Koch et al, 2011). This pathway 
is thought to be important for cell proliferation. Phosphorylation at 
Tyr1214 leads to up-regulation of p38MAPK and this is important for cell 
migration. The activation of PIP2 to PIP3 at the cytosolic surface of the 
cell membrane leads to activation of AKT which is thought to be 
important for cell survival. (Cebe-Suarez et al, 2006). Activation of 
VEGFR2 also appears to have a role of increasing vascular 
permeability via the weakening of cell-cell adhesions. Activation of the 
9(*)UHFHSWRUOHDGVWRH126DFWLYDWLRQYLD3/&ȖZLWKWKHUHVXOWWKDW
intracellular NO is up-regulated. (as discussed previously). A similar 
effect is also seen when other pro-angiogenic growth factors such as 
FGF-2 and TGF beta are added to endothelial cells (Inoue et al, 1995, 
Wu et al, 1996). In addition to its vasodilatory roles, NO is thought to be 
an important intermediary in angiogenesis (Hida et al, 2004). Sodium 
nitroprusside (an exogenous NO donor) stimulates endothelial cell DNA 
synthesis, proliferation and migration (Zheng et al, 2005). It is thought 
that NO exerts its effect by stimulation of cyclic guanosine 
monophosphate (cGMP), a downstream modulator of the VEGF 
signalling pathways (Ziche et al, 1997, Ignarro et al, 1991). Stimulation 
of cGMP leads to activation of MAPK, an important mediator on the 
VEGF signalling pathway. This effect of NO on the up-regulation of 
cGMP can be inhibited by thalidomide, a drug noted for its anti-
angiogenic properties before it was withdrawn from use, by its action on 
guanylate cyclase Majumder et al, 2009) 
 
Lack of VEGFR2 in the Flk-1 null mouse leads to failure of the 
development of blood islands and blood vessels and ultimately causes 
death in utero (Shalaby et al, 1995).  
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Fig 1.7. below is a simplified schematic outline of the actions of VEGF 
on binding to VEGFR2. Note the receptor has formed an activated 
dimer. Many of the reported intermediary steps have been omitted for 
simplicity and clarity.  
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VEGFR1 
 
The role and actions of VEGFR1 are less well understood and still 
subject to debate. It is thought that this may be due to variability in 
receptor function depending on cell type and the developmental stage 
of the animal. Like VEGFR2, VEGFR1 is highly expressed on vascular 
endothelial cells and has a binding affinity for VEGF ten fold higher than 
VEGFR2. It is also expressed on monocytes, macrophages, 
trophoblasts, smooth muscle cells and renal mesangial cells (Koch et 
al, 2001). Like VEGFR2, its expression is up-regulated by hypoxia but 
VEGF binding appears not to stimulate a mitogenic signal. Binding of 
VEGF to VEGFR1 stimulates very weak intracellular tyrosine kinase 
activity with different tyrosine residues being activated depending on 
the ligand i.e. VEGF or placental growth factor (Autiero et al, 2003). 
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Although weak, activation of tyrosine kinase domains on VEGFR1 does 
lead to activation of intracellular phospholipase C (PLC) and the 
generation of inositol 1,4,5 triphosphate (Sawano et al, 1997). One 
hypothesis for the role of VEGFR1 is that it LVD³GHFR\´IRU9(*)5
perhaps mopping up VEGF and thereby limiting its binding and 
consequent stimulatory actions on VEGFR2 (Park et al, 1994). Other 
hypotheses include roles as a VEGF reservoir or actin microtubule 
reorganisation and tube formation (Koch et al, 2011). Recently, actions 
such as the stimulation of matrix metaloproteinase 9 and the 
recruitment of endothelial progenitor cells have been ascribed to the 
receptor (Hristov et al, 2003). Despite the conflicting opinions on the 
role and importance of VEGFR1, it is clear that Flt-1 (VEGFR1) null 
mice die in utero because endothelial cells develop but fail to form 
vascular channels (Fong et al 1995). Interestingly, deletion of just the 
intracellular domain is compatible with normal vascular development 
(Hiratsuki et al, 1998), giving credence to the hypothesis that it acts in 
some way as a reservoir or decoy for VEGF. This underlines the 
important but as yet undefined roles of VEGFR1. 
 
Two other receptors have also been found to bind VEGF. The first is 
neuropilin 1 which is a receptor found on axons and is thought to play a 
role in axon guidance (the pathways of blood vessels and nerves often 
co-exist). It may also augment VEGF binding to VEGFR2 but has no 
mitogenic actions itself when binding VEGF (Ferrara, 2004). The 
second is VEGFR3 (or Flt4 in mice). This VEGF receptor is found on 
lymphatic endothelial cells and is important for lymphangiogenesis and 
tumour metastasis via lymphatics. 
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Fibroblast Growth Factors 
 
Fibroblast growth factors (FGFs) are a group of growth factors that 
have mitogenic actions on a wide range of cells such as fibroblasts and 
endothelial cells and are also important in embryogenesis (Javerzat, 
2002). The mitogenic and migratory action of FGFs on vascular 
endothelial cells pre-dates the discovery of VEGF, and ironically, for 
many years was thought to account for the action of VEGF. To date, at 
least 23 isoforms of FGF have been discovered, acting via 4 tyrosine 
kinase receptors (Cronauer et al, 2003).  
 
The main FGF receptor on ECs is FGF receptor 1 (FGFR1) and this 
binds the two most abundant forms, FGF2 (basic FGF) and FGF1 
(acidic FGF). Activation leads to stimulation of the mitogen-activated 
protein kinase pathway (MAPK) (Zubilewicz et al, 2001) and Ca2+ 
channel activation (Rosenthal et al, 2005). An interesting fact about 
FGF2, the main FGF involved in EC mitogenesis, is that it contains no 
signal motif after synthesis on the Golgi apparatus. In theory, it cannot 
be excreted. Interestingly, mice carrying either a null mutation for the 
FGFR 1 or a transgenic mouse with an inducible defect in ocular FGFR 
1 action both demonstrated poor generalised and ocular vascular 
development (Rousseau et al, 2000; Rousseau et al, 2003). Because of 
its lack of secretary signal motif, the action of FGF on endothelial cells 
may either be autocrine in nature or it may leave the cell by an 
unknown mechanism to produce a paracrine or distant action. Clearly, 
cells would not express FGF receptors if it was not present in the ECM 
of cells. Because of the contradictory evidence for FGF having a 
specific role in angiogenesis (presence of FGF receptors on ECs linked 
to a proliferative intracellular signalling cascade (Cross and Claesson-
Welch, 2001) versus a lack of a secretory signal on the intracellular 
protein (thereby suggesting an absence of a true stimulatory role), 
workers have questioned whether FGF 2 acts via a second growth 
factor such as VEGF (Murakami and Simons, 2008). Masaki et al in 
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2002 showed that the therapeutic effect of FGF 2 on the improvement 
of a mouse hind limb ischaemia model could be eliminated by the 
administration of VEGF neutralising antibodies. This suggested that 
VEGF was required for the action of FGF 2. Potential mechanisms of 
action include the stimulation of VEGF secretion by FGF 2 (Seghezzi et 
al, 1998) or that VEGF is required for FGF receptor function (Pepper 
and Mandriota, 1998). Welti et al in 2001 demonstrated that FGF 2 still 
provided pro-angiogenenic signals and stimulated endothelial cell 
proliferation despite inhibition of the VEGFR2 tyrosine kinase activity 
using a drug called Sunitinib. This finding has implications for the 
treatment of angiogenenic diseases such as neovascular age-related 
macular degeneration or cancer because the endothelial cells may 
circumvent anti-VEGF treatments by utilising FGF pathways The picture 
is further confused by the finding that FGF action in the embryo 
precedes the appearance of VEGF signalling and is also required for 
VEGF receptor function (Murakami et al, 2011).  
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Fig 1.8. The diagram below is a simplified schematic outline of the 
actions of FGF2 on binding to FGFR1. Note that the receptor has 
formed an activated dimer. Many of the reported intermediary steps 
have been omitted for simplicity and clarity. Unlike VEGF, many of the 
roles and pathways of FGF2 action are currently unknown 
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Insulin like growth Factor 1 (IGF-1) 
 
Insulin like growth factor 1 (IGF-1) is a 7.6 KDA protein important in 
childhood growth. Its secretion is stimulated by growth hormone and is 
produced predominantly by the liver and to a lesser extent in a 
paracrine fashion by target organs. IGF 1 circulates in the blood almost 
totally bound to at least 6 different IGF binding proteins (Novosyadlyy et 
al, 2004; Lofqvist et al, 2009), with IGF binding protein 3 being one of 
the most important (Baxter, 2001). Target cells (which include 
endothelial cells) possess two different IGF receptors (I and II). Binding 
of IGF 1 to IGF RI leads to activation of its tyrosine kinase activity which 
in turn leads to activation of several intracellular pathways such as 
TOR, Akt, and MAPK (Hellström et al, 2001; Smith et al, 1999) although 
they are poorly understood. As well as directly stimulating intracellular 
signalling pathways, IGF 1 is also thought to lead to an up-regulation of 
VEGF expression by increasing the expression of HIF-ĮYLD3,-3 and 
MAPK (Fukuda et al, 2002). This would suggest that the effect of IGF-1 
on endothelial cells is brought about by direct actions of the IGF 
receptor and by secondary effects on VEGF. This makes research into 
the effects of IGF-1 on disease mechanisms difficult to elucidate. This 
may be the reason why a number of oncology and anti-angiogenesis 
clinical trials using IGF-1 inhibition have produced disappointing clinical 
results despite promising in vitro experiments.  
 
IGF -1 can also bind to insulin receptors but with much less avidity than 
that of the IGF receptor.  
 
In specific relation to the eye, IGF 1 is thought to be required for retinal 
vascular development in utero, acting in conjunction with VEGF and its 
role in retinopathy of prematurity is currently under investigation (Smith 
et al, 1999; Hellström et al, 2002; Hellström et al, 2001). In adults, it is 
thought to be one of a range of growth factors involved in choroidal 
neovascularisation (Lambooij et al, 2003; Rosenthal et al, 2004) and 
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proliferative diabetic retinopathy (Meyer-Schwickerath et al, 1993; Grant 
et al, 1986). Interestingly, when given as a subcutaneous injection to 
diabetic patients, it was found to worsen diabetic retinopathy and is also 
found in high concentration in the vitreous of eyes with proliferative 
diabetic retinopathy (PDR) (Grant et al, 1986). However, pituitary 
dysfunction or surgical removal of the pituitary, with concomitant 
reduction in IGF-1 levels secondary to low growth hormone levels, can 
prevent or reverse proliferative diabetic retinopathy (Sharp et al, 1987; 
Merimee et al, 1970; Wright et al, 1969). Humans with defects in the 
IGF-1 or IGF-1 receptor gene were found to have reduced retinal 
vascular branching points (Hellström 2002). Taken together, all of these 
observations would suggest a critical role for IGF 1 in ocular 
development and angiogenic diseases. 
Placental Growth Factor (PlGF) 
 
PlGF is a member of the VEGF family and was originally cloned from 
the human placenta as the name suggests, in 1991 (Maglione et al, 
1991). Like VEGF, PlGF occurs in at least 4 different isoforms, with 
isoforms 2 and 4 being strongly bound by heparin. Human PlGF 
displays 42% sequence homology with human VEGFA, although their 
3D structures are almost identical. Despite this similarity in 3D 
structure, PlGF is almost solely bound by VEGFR1 (Park et al, 1994). 
However, it may indirectly stimulate VEGFR2 by displacing VEGF from 
VEGFR1. In addition, PlGF is also to bind to neuropilin 1 and 2. Like 
VEGF, its expression is up-regulated by hypoxia despite it not having a 
hypoxia response element in its promoter sequence. Its angiogenenic 
potential was demonstrated in 1997 (Ziche et al) but knockout models 
failed to demonstrate any abnormalities in vascular development 
(Carmeliet et al, 2001) suggesting that its angiogenenic role may be 
limited to pathological states. While it has been found associated with 
choroidal neovascular membranes, its role in disease pathogenesis 
remains uncertain (Rakic et al, 2003). 
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Angiogenesis modifying factors 
 
Platelet Derived Growth Factor (PDGF) 
 
Platelet Derived Growth Factor is a growth and chemotactic factor for 
fibroblasts, smooth muscle cells and glial-derived cells, being found in 
high concentration as the name suggests, in platelets. It has a dimer 
structure, being composed of an A and a B chain. This gives rise to 
three isoforms, PDGF-AA, -BB and -AB. Originally, it was thought that 
endothelial cells were unresponsive to PDGF but it is now known that 
endothelial cells express PDGF receptors (R  and R ) and that, in 
particular, PDGF-BB has some pro-angiogenic action (Risau et al, 
1992). It is known that the pericytes of developing blood vessels (in 
particular, the stlk cells) express PDGF receptors and require 
endothelial cells to secrete PDGF for their survival (Lindblom et al, 
2003). In a PDGF-B knock mouse model animals were found to lack 
pericytes covering brain microvessels and these tended to form 
microaneurysms and were prone to rupture (Lindahl et al, 1997). 
Sprouting capillaries also appeared to fail to attract pericytes. In a 
mouse model of choroidal neovascularisation; inhibition of both VEGF 
and PDGF-B signalling was more effective in causing actual new vessel 
regression than in those animals targeting VEGF alone (Bergers et al, 
2003; Jo et al, 2006). In a similar experiment in mice induced to 
develop proliferative diabetic retinopathy, injection of an anti-PDGF-B 
aptamer demonstrated significant reduction in disease complications 
such as retinal detachment compared with those given sham aptamer 
(Akiyama et al, 2006).  
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Angiopoietin/Tie system 
 
The human angiopoietin (Ang) / Tie system consists of two Tie tyrosine 
kinase receptors (Tie 1 and Tie 2) and three secreted ligands (Ang1, 
Ang2 and Ang4). Angiopoietin 1 functions as a Tie 2 receptor agonist 
and Ang 2 normally functions as an Ang 1 antagonist (Maisonpierre et 
al, 1997), except when present in very high in vitro concentrations, in 
which case it can act as a weak agonist (Kim et al, 2000). Little is 
known about Ang4 but it has been shown to inhibit HUVEC migration 
towards VEGFA and FGF2 and to also inhibit in vitro angiogenesis 
(Olsen et al, 2006) and so may be important in modulating 
angiogenesis. The receptor Tie2 is expressed on endothelial cells and 
binds all angiopoietin ligands whereas Tie 1 has no known ligand but 
has been shown to bind to Tie 2 and to regulate its activity (Milner et al, 
2009). Binding of Ang 1 to Tie2 leads to receptor dimerisation and the 
resultant auto phosphorylation and activation of intracellular signalling 
pathways. Signalling molecules activated include: eNOS, SH2 domain 
containing phosphatase (SHP2) and PI-3K. Many of the signalling 
components and pathways activated are similar to those seen when 
VEGF binds to VEGFR2 (see below). However, Tie activation on its 
own does not cause cell proliferation. This difference in end response 
may be context driven. It has recently been shown that in quiescent 
endothelial cells linked by cell-cell junctions, Ang1/Tie2 activation leads 
to cell survival signals via AKT. Up-regulated ³TXLHVFHQFHJHQHV´
include kruppel like factor 2 and Dll-4 (Zhang et al, 2011). When 
endothelial cells are isolated or detached from the effects of 
surrounding cells, as they may be in angiogenesis, Tie2 is embedded in 
the cell substratum and Ang1 is associated with ECM, and then the 
signal switches to a pro-angiogenic pathway (Zhang et al, 2011).  
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Fig 1.9. The diagram below is a simplified schematic outline of the 
actions of ANG1 on binding to Tie 2. Note that the receptor has formed 
an activated dimer. 
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In quiescent adult vasculature, Ang1 secreted from mural cells induces 
Tie2 activation in endothelial cells to maintain mature blood vessels by 
enhancing vascular integrity (barrier function) and endothelial survival 
(Brindle et al, 2006). It also plays a role in maintaining an effective 
pericyte covering of vessels. In contrast, the antagonist Ang2 leads to 
breakdown of cell barrier function. The importance of the Tie/Ang 
system is revealed when murine gene knock out models for Tie 2 and 
Ang 1 produce animals with abnormal hearts and abnormal vascular 
walls (Tachibana et al, 2005; Suri, 1996) while mice overexpressing 
Ang2 are lethal in utero (Maisonpierre et al, 1997), presumably due to 
competitive inhibition of Ang1. 
 
The role of Tie1 remains elusive but mouse knock down models using 
siRNA s demonstrate increased Ang1-mediated Tie2 activation, 
suggesting that it is a negative regulator of Tie 2 activity. Angiopoietin 1 
is constitutively expressed in tissues by mural cells and fibroblasts 
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whereas Ang2 is usually only expressed by endothelial cells at sites of 
vascular remodelling. At sites of vascular remodelling, expression of 
Ang2 is up-regulated by VEGF, IGF-1 and PDGF and is stored in 
Weibel-Palade bodies along with von Willebrand factor. While acting as 
an Ang1 antagonist at sites of vascular remodelling, Ang2 stimulates 
the dissociation of pericytes from vessels and increases vascular 
permeability. Both of these factors are thought to be important for an 
angiogenic response and so the up-regulation of Ang 2 at sites of 
angiogenesis may be necessary for vessel growth. Our work shows that 
Ang2 is expressed by proliferating ocular vascular ECs (see later). 
Continued Ang2 activity however, after vascular growth has occurred, 
may prevent appropriate pericyte recruitment and maintenance, thereby 
making the new vessels unstable and liable to breakdown, particularly if 
VEGF is withdrawn. As well as maintaining pericyte stability on new 
vessels, ANG1 also maintains the continuous distribution of CD31 
(PECAM1), ZO-1 and VE-cadherin, all of which are important in 
endothelial cell-cell adhesion (Falcon et al, 2009).  
 
Overall, the data on the Ang/Tie system appears confusing and at times 
contradictory. While today we know far more about the signalling 
pathways and interactions within the system, our thoughts on the role of 
the system in the overall maintenance and evolution of the vasculature 
still comes back to the original views of the system which suggested 
that the Ang/Tie V\VWHPZDVUHVSRQVLEOHIRUYHVVHO³VWDELOLW\´Several 
research teams are looking at the potential of the Ang/Tie system in 
treating angiogenic diseases but at present results are limited. To date, 
the effect of the system on human disease remains limited to a rare 
mutation in Tie 2 which leads to a disease characterised by 
abnormalities of the smooth muscle surrounding small vessels and 
microaneurysms leading to venous malformations (Vikkula et al, 1996).  
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Anti-angiogenic factors 
 
It has been suggested for many years that the control of normal 
(physiological) and pathological angiogenesis is brought about by a fine 
balance between pro- (VEGF, FGF 2 etc) and anti-angiogenic factors. 
Soon after Folkman discovered his new angiogenic factor he began to 
search for a substance that could inhibit it, as this may potentially be 
used as a treatment for cancer-induced angiogenesis (Folkman, 2004). 
The first endogenous substance to be discovered was interferon alpha 
which has been successfully used in the treatment of life threatening 
haemangiomas in the lung, hand and jaw (White et al, 1989; Marler et 
al, 2002). This was followed by the discovery of angiostatin (a fragment 
RISODVPLQRJHQE\2¶5HLOO\HWDOLQDQGHQGRVWDWLQDIUDJPHQWRI
collagen XVIII) (Wen et al, 1999). It had long been recognised that 
SDWLHQWVZLWK'RZQ¶VV\QGURPHKDYHDPDUNHGO\ reduced incidence of 
solid tumours. One explanation for this is the possession of three 
copies of the collagen XVIII gene with subsequently higher levels of the 
endostatin collagen fragment (Zorick et al, 2001).  
 
Pigment Epithelial Derived Factor (PEDF) 
 
An angiogenesis inhibitor with specific relevance to the eye is Pigment 
Epithelial Derived Factor (PEDF). This was first identified in the medium 
of cultured foetal retinal pigment epithelial (RPE) cells and was found to 
stimulate the outgrowth of neurites from retinoblastoma cells (Tombran-
Tink, 1989). It is a 418 amino acid protein and is a member of the 
serine protease inhibitor (serpin) family (Barnstable & Tombran-Tink, 
2004). Expression studies have revealed that PEDF is secreted by RPE 
cells into the inter-photoreceptor matrix (Tombran-Tink et al, 1995) and 
also by cells at the corneal limbus and the ciliary body (Barnstable & 
Tombran-Tink, 2004). Another major site of PEDF expression is in the 
central nervous system where it is found in ependymal cells and motor 
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neurones of the ventral horn (Bilak et al, 1999). Interestingly, PEDF 
appears to have two major functions: neurotrophic/ neuroprotective and 
antiangiogenic (Barnstable & Tombran-Tink, 2004). 
 
Neurotrophic/protective functions 
 
In vitro experiments of cultured neurones treated with PEDF show that 
it stimulates outgrowth from the nerve cells. As it is found in high 
concentrations in the eye from an early stage of foetal development, it 
may play a role in retinal development. Support for this role is confirmed 
by a mouse PEDF knockout that showed abnormal development of the 
retinal architecture (Doll et al, 2003). Injection of PEDF into the vitreous 
of mice with mutations in photoreceptor genes significantly reduced 
photoreceptor degeneration Cayoutte et al, 1999), while injection into 
the vitreous of rats rescued photoreceptors from light damage (Cao et 
al, 2001). From these studies, it is thought that PEDF stimulates 
chemical changes in photoreceptors that make them more resistant to 
toxic insults. It is not known, however, if PEDF acts directly on the 
photoreceptors themselves or stimulates adjacent cells such as Muller 
or RPE cells to produce protective factors.  
 
Antiangiogenic function 
 
It is known that the level of PEDF is reduced in the vitreous of patients 
with proliferative diabetic retinopathy and in RPE cells cultured under 
hypoxic conditions and that the degree of neovascularisation appears to 
be negatively correlated with PEDF levels. PEDF has also been shown 
to inhibit the migration of endothelial cells in a dose dependent manner 
(Duh et al, 2002) and is more potent than other naturally occurring 
angiogenesis inhibitors such as angiostatin, endostatin and 
thrombospondin 1. It is not known if PEDF exerts its anti-angiogenic 
effect directly on VEGF expression, on its receptor, or by an 
intracellular downstream mechanism. However, one action of PEDF on 
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VEGF receptor 1 was recently described which may explain some of its 
effect. Cai et al demonstrated that PEDF brings about cleavage and 
intra cellular translocation of the transmembrane domain of VEGFR1, 
thereby indirectly down regulating the effect of VEGF (Cai et al, 2006). 
Evidence for a dedicated PEDF receptor remains elusive. In vitro, 
PEDF has been found to bind to a specific site on retinoblastoma and 
cerebellar granulosa cells (Alberdi et al, 1999). Purification of the cell 
membranes bound with PEDF has identified an 80 kDa protein. It has 
also been found that PEDF binding leads to activation of NF- B, a 
transcription factor important in the activation of anti-apoptotic genes, 
and that it can modify the phosphorylation of ERK1/2 (important in cell 
proliferation) in cerebellar cells. Evidence exists to show that the two 
functions of PEDF: neuroprotective and anti-angiogenic are located on 
two different regions of the molecule (Barnstable & Tombran-Tink, 
2004).  
 
Since most angiogenic diseases of the eye lead to neuronal damage as 
one of the mechanisms of visual loss, PEDF makes a good potential 
candidate for use in the treatment of ocular neovascular disorders. 
Recently, PEDF (Mori et al, 2002) and angiostatin (Lai et al, 2001) have 
been packaged into a viral vector and introduced into rat eyes as a 
treatment for laser-induced choroidal neovascularisation, and when 
given systemically to a mouse model of retinal neovascularisation, 
significant inhibition occurred (Stellmach et al, 2001). Strangely, some 
workers have demonstrated opposing effects of PEDF on endothelial 
cells, with low doses (90µg/ml) being inhibitory and high doses 
(360µg/ml) being stimulatory, with augmentation of choroidal 
neovascularisation (Apte et al, 2004). Hutchings et al in 2002 also 
demonstrated that the action of PEDF on endothelial cells also depends 
on their phenotype, with opposite effects being demonstrated 
depending on whether they are maintained in VEGF or not. Cells 
cultured without VEGF which were subsequently exposed to VEGF did 
not demonstrate proliferation or phosphorylation of ERK1/2 when PEDF 
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was added, while those cultured/maintained in the presence of VEGF 
demonstrated ERK1/2 activation and thereby cell proliferation when 
PEDF was added. The combination of VEGF and PEDF were therefore 
synergistic. Caution is therefore sounded by the authors in deciding on 
the dose being contemplated in viral vector studies as opposing effects 
may be seen to those desired.  
 
Thrombospondin 1  
 
Thrombospondin 1 is a cell attachment factor present in the alpha 
granules of platelets that is released during the blood clotting process. 
Its main functions include the enhancement of fibroblast cell adhesion, 
cancer cell adhesion and prevention of angiogenesis via CD36, the 
thrombospondin 1 receptor, on endothelial cells. In the eye, it is located 
EHWZHHQ%UXFK¶VPHPEUDQHDQG53(FHOOVDQGPD\SOD\DUROHLQ
inhibiting choroidal neoYDVFXODULVDWLRQIURPEUHDNLQJWKURXJK%UXFK¶V
membrane (Miyajima-Uchida et al, 2000) and in inhibiting retinal 
neovascularisation (Shafiee et al, 2000).  
 
Endothelial cell heterogeneity 
 
It is thought that all endothelial cells are derived from a common 
precursor, the embryonic mesoderm. During embryogenesis, 
endothelial precursor cells appear to be co-localised with 
haematopoietic cells and share a number of cell surface markers 
(CD34, CD31, CD39, VEGFR-2 and CXCR4) (Hasegawa et al, 2007; 
Zambidis et al 2005). The production of Hb-İVXJJHVWVWKDWWKH\VKDUHD
common precursor cell, the haemangioblast (Zambidis et al 2005). 
Although all endothelial cells share a common embryonic precursor, it 
has been known for many years that there is a wide diversity of 
endothelial cell phenotypes in both human and mammalian vascular 
systems (Thorin & Shreeve, 1998). This wide divergence in cell 
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phenotype may in part be secondary to genetic changes amongst the 
precursor cells but may also be due to local environmental effects on 
the developing endothelial cells. 
 
In the human, there are a number of fundamental functional differences 
between different organ vascular beds (Aird, 2003). Endothelial cells in 
the glomerulus and the inner choroid allow the passage of fluid and 
molecules across themselves via small pore-like structures within the 
cell called fenestrations, whilst brain and retinal endothelial cells 
maintain very firm inter-cellular junctions to preserve the blood-brain 
and blood retinal barriers respectively. The liver, spleen and bone 
marrow sinusoids are different again, being lined by discontinuous 
endothelium that allows cellular trafficking which is thought to be 
important in the development of the immune system. 
 
Many human diseases appear to be restricted to specific vascular beds. 
For instance, many systemic vasculitic disorders appear vessel-specific 
such as giant cell arteritis, polyarteritis nodosa and idiopathic retinal 
vasculitis. Tumours also appear to metastasise to selected vascular 
beds. Diabetes, however, preferentially affects the microvasculature of 
the retina, kidney and nerves causing extensive vessel closure and 
subsequent neovascularisation, while the choroid is only mildly affected 
by a micro-angiopathy that appears to produce few clinical findings 
apart from some capillary drop-out and leucocyte aggregation within the 
choriocapillaris microvasculature on histological examination (Cao et al, 
1998, Lutty et al, 1997). While the underlying mechanism of many of 
these processes remains uncertain, it is known that endothelial cells are 
species (Rhodin,1968; Graier et al, 1996), organ and vascular bed 
specific (Keegan et al 1982; Thorin & Shreeve, 1998). These 
differences may in part contribute to the disease site specificity.  
 
At light microscopic level, endothelial cells lining the microvasculature 
are generally flattened and elongated whereas those lining large 
vessels (aorta and iliac arteries) are polygonal (Cornhill et al, 1980). 
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:KLOHPXFKRIWKHHQGRWKHOLDOFHOOKHWHURJHQHLW\PD\EH³SUH-
prograPPHG´VXFKDVWKHGLIIHUHQFHVEHWZHHQDUWHULDODQGYHQRXV
endothelial cells (Adams et al, 1999), it is thought that the cellular 
microenvironment may also play a role (Aird et al, 1997). The particular 
characteristics of an individual cell will depend on factors such as the 
local extracellular matrix, local growth factors, interactions with 
neighbouring cells, including leukocytes, and local mechanical forces. 
Examples of this apparent influence of the local environment influencing 
endothelial cell phenotypes include an animal model (mouse) of 
atherosclerotic disease in which a segment of vein is inserted into the 
arterial circulation. On connecting the jugular vein to the carotid artery 
in mice, the venous endothelial cells change to an arterial phenotype 
and an expansion in smooth muscle cells in the vessel wall occurs 
(Kwei et al 2004). Similarly, a model of tumour induced angiogenesis, 
whereby mouse carcinoma cells are injected subcutaneously, induces 
blood vessel growth with endothelial cells with a skin phenotype. If the 
same tumour is implanted into the brain of the mouse, the new vessels 
are lined by endothelial cells with a brain phenotype (Roberts et al, 
1998). Other similar in vivo studies demonstrate that endothelial cells 
can take on host tissue characteristics after transplantation (Moyon et 
al, 2001; Aird et al, 1997), while removal of ECs from an in vivo to an in 
vitro environment can also change cell phenotype (Grau et al, 1996).  
 
The earliest events controlling the differentiation of mesoderm into 
endothelial cells remain uncertain. Experiments on zebra fish have 
shown that the arterial and venous phenotype of vascular precursor 
cells or angioblasts (expression of gridlock) is determined while they 
are still located in the lateral plate (very early stage of embryogenesis), 
implying a genetic component to endothelial heterogeneity (Zhong et al, 
2001). This finding is reinforced by the finding that in mice, cells 
destined to be arteriolar and venular ECs express ephrin B2 and the 
receptor EphB4 respectively before the establishment of a circulation 
(Adams et al, 1999). In the embryo, venous specification is regulated by 
the expression of a transcription factor, COUP-TFII, which suppresses 
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endothelial cell Notch signalling. This leads to a failure in the 
expression of ephrin-B2, one of the main arterial endothelial 
determinants. Failure to express ephrin-B2 allows the expression of 
Eph-B4 on the endothelial cell and the vessel takes on the 
characteristics of a vein, i.e. thin walled with a sparse muscular coat 
(You et al, 2005).  
 
The Ephrin family of receptor tyrosine kinases has at least 13 members, 
while their ligands, the ephrins are divided into two classes. Class A 
ephrins (ephrin A1-A5) are tethered to the cell membrane and the B 
class (ephrin B1-B3) which have a transmembrane domain and a small 
intracellular domain. It is now understood that Ephrin receptors are not 
specific in the ephrin subtypes that they bind and because both are cell 
membrane bound, cell±cell contact must be made for interaction to 
occur (Aitsebaomo et al, 2008). Activation is thought to be bi-
directional. While signal transduction via Ephrin receptors is thought to 
stimulate cell migration, axonal guidance and cell border formation, 
their precise role in bringing about venous and arterial phenotype 
differentiation is unknown. While the initial identity of ECs appears to be 
genetically determined, later, after angioblast migration, local factors 
such as VEGF gradients can also have an effect on arterio-venous 
phenotype (Le Bras et al, 2010). It is thought that high local expression 
of VEGF leads to the activation of members of the FOXC transcription 
factors which in turn lead to up-regulation of the notch family and an 
arteriolar phenotype. Experiments have also shown that physiological 
requirements and haemodynamic influences can alter phenotype. 
Transplantation of arteriole ECs into veins rapidly changes their 
phenotype to venular (Moyon et al, 2001). This may be due to local 
factors such as VEGF secreted by surrounding cells or it may be 
secondary to differences in flow/shear stress as the placement of 
venules within a section of high flow artery leads to a rapid change to 
an arteriolar phenotype. 
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Inter-organ differences 
 
Craig et al in 1998 showed that endothelial cells derived from the brain, 
lung, adipose tissue and aorta of sheep differed in terms of 
ultrastructure and surface molecule expression depending on the site of 
origin. Müller et al in 2002 also showed that surface expression of 
ICAM-1, VCAM and E-Selectin on cultured HUVEC and human 
pulmonary microvascular endothelial cells differed in both the un-
stimulated and stimulated states. 
 
There are numerous studies demonstrating differences in in vitro 
behaviour between ECs from different anatomical sites. Examples 
include: 
 
 Aortic ECs cultured on ECM derived from the lung start to express 
Lu-ECAM-1 (a lung specific adhesion molecule) whereas the cells 
develop fenestrations when cultured on ECM derived from kidney 
(Augustin et al, 1994).  
 
 Differences in the proliferative response of HUVEC and 
microvascular ECs to VEGF, FGF-2 and placental growth factor. 
Lang et al in 2001 and 2003 demonstrated that the kinetics of the 
proliferative response to VEGF and FGF were different for micro- 
and macrovascular ECs and that placental microvascular ECs 
responded to placental growth factor whereas HUVECs showed little 
response (Lang et al, 2001, Lang et al, 2003). These authors also 
compared the amount of vasoactive substances such as endothelin-
1, thromboxane, angiotensin II and prostacyclin released into the 
medium of HUVEC and placental ECs (microvascular) and found 
that the latter were more similar to dermal microvascular ECs than 
macrovascular ECs (Lang et al, 2003). 
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 Differences in E-selectin expression by human iris and retinal ECs 
(Silverman et al, 2005).Under unstimulated conditions, the gene 
expression as measured by gene array of matched iris and retinal 
ECs were very similar. After inflammatory stimulation by 
lipopolysaccharide (PLS) or TNF alpha, a marked difference in the 
expression of E-selectin was noted, with up-regulation in retinal 
compared with iris ECs.  
 
 Differences in prostaglandin secretion between HUVEC and retinal 
ECs at different glucose concentrations (Rymaszewski et al, 1992). 
The authors studied the synthesis of proteins such as 
prostaglandins and plasminogen activators under normo- and 
hyperglycaemic conditions. They found that hyperglycaemia 
stimulated PGE2 secretion by retinal microvascular ECs but not by 
HUVEC macrovascular ECs. They also found that hyperglycaemia 
stimulated the release of plasminogen activator in retinal ECs but 
not HUVECs. They suggest that these differences may be important 
for the underlying mechanisms of diabetic retinopathy.  
 
 Differences in the expression of CD34, CD31 and vWf by various 
macro- and microvascular EC s in culture (Müller et al, 2002). They 
found that vWf was strongly expressed by HUVECs but less so by 
pulmonary microvascular ECs (although they were still positive), 
while both types of EC strongly expressed CD31 and only weakly 
expressed CD34.  
 
 Differences in retinal and choroidal EC expression of angiopoietin 2 
and VEGF receptors under normoxic and hypoxic conditions (Brylla 
et al, 2003). The authors found that bovine choroidal ECs expressed 
significant levels of VEGF mRNA compared with bovine retinal ECS 
under both norm- and hypoxic conditions. They also found that Ang 
2 mRNA levels were significantly higher in bovine retinal ECs under 
both norm- and hypoxic conditions.  
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 Differences in adenosine receptor (important in vascular tone) 
expression between HUVEC and dermal microvascular ECs 
(Feoktistov et al, 2002). The authors found that HUVECs 
preferentially express A2A adenosine receptors, whereas dermal 
microvascular ECs express A2B receptors. An adenosine agonist 
increased expression of IL-8, VEGF and FGF-2 in dermal 
microvascular ECs but not HUVECs.  
 
 Differences in chemokine receptor (CXCR1-3) and PKC activation 
between HUVECs and dermal microvascular ECs (Mason et al 
1997; Salcedo et al, 2000). Using phorbol esters and more specific 
PKC activators, the authors demonstrated that activation of PKC in 
microvascular ECs led to Thy-1 up-regulation compared with 
HUVECs. They also showed that PKC activation in HUVEC led to 
up-regulation of E-selctin and VCAM-1 but not dermal microvascular 
ECS  
 
 Differences in the expression of CD36 between HUVECs and 
dermal microvascular ECs (Swerlick et al, 1992). CD36 is thought to 
be a cell surface receptor allowing malaria-infected red blood cells 
to gain access into endothelial cells. The authors found strong 
staining for CD36 in dermal microvascular ECs while HUVECs 
showed no reaction and may be important in certain diseases 
affecting blood vessels. .  
 
 Lack of expression of ABO blood group antigens by HUVECs but 
not by other endothelial FHOOV2¶'RQQHOOHWDO The authors 
studied the HUVECs from 45 different umbilical cords and were 
unable to detect ABO antigens on any of the isolated HUVECs. This 
was not due to an absence of the precursor, H substance, but was 
due to the absence of the enzyme needed to form the blood group 
antigens. The authors state that HUVECs are the only ECs to lack 
ABO blood group antigens. This may protect the cord from maternal 
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antibodies during growth of the foetus. They suggest that care 
should be taken when extrapolating results from HUVE cells to other 
adult endothelial cells. 
 
Intra-organ differences 
 
Within the same organ, it has also been shown that ECs from different 
vascular beds differ (Ghitescu & Robert, 2002). In 1968, Rhodin 
described ultrastructural differences in mammalian venous ECs that 
were dependent on whether they were located in veins, venules or 
venous capillaries (Rhodin, 1968). Müller et al have also shown that in 
the human lung, ECs from the large and small vessels differed in their 
staining for CD34, vWf and CD31 (Müller et al, 2002). They found that 
ECs in the pulmonary veins and arteries stained strongly for vWf and 
poorly for CD34, while capillary ECs stained strongly for CD34 but 
poorly for vWf. In 2002, Lang found differences in endothelial cells from 
within the same placenta (HUVEC and placental venous endothelial 
cells), noting that placental vein ECs responded to placental growth 
factor whereas HUVECs did not (Lang I et al, 2003). 
 
Perhaps most importantly, it has also been shown in vivo that ECs from 
larger vessels do not participate in neovascularisation (Klagsbrun and 
Folkman, 1990) and that VEGF receptors are reportedly inducible on 
venular and capillary ECs but not arterial ECs (Ferrara et al, 1992). This 
may explain why neovascularisation in adults appears to originate from 
post-capillary venules (Gimbrone et al, 1974; Grunt et al, 1986). This 
observation has recently been questioned however (Shin et al 2001). 
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Interspecies differences 
 
It has also been recognised for many years that endothelial cells 
derived from different species are heterogeneous in their phenotype 
and functional properties. Imegwu et al have described species 
differences in the growth of human and bovine aortic ECs in co-culture 
with smooth muscle cells (Imegwu et al, 2001), while Ram and Hiebert 
demonstrated differences in the response of porcine and bovine ECs to 
free radical damage (Ram & Hiebert, 2003). Graier et al also found a 
species difference in the endothelium-dependent relaxation of bovine 
and porcine coronary artery endothelial cells in the presence of L-Ng 
nitroarginine and indomethacin (Graier et al, 1996).  
 
It is amazing that much of our knowledge of vascular diseases is based 
on in vitro studies using macrovascular ECs derived from the human 
umbilical vein (HUVEC), the large scale isolation and culture of which 
was first described in 1973 by Jaffe (Jaffe et al, 1973). The main reason 
for the popularity of these cells is that of their wide availability and 
relative ease of culture. Unfortunately, human umbilical vein cells do not 
appear to be susceptible to most of the diseases requiring investigation 
and, in vitro, differ significantly from other endothelial cells in their 
response to important substances such as hyaluronic acid and 
cytokines (Lokeshwar & Selzer, 2000; Tan et al, 2004). The question 
needs to be asked as to whether or not HUVEC should be used in 
experiments investigating human organ selective vascular diseases.  
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Adult Vascular structure 
Arteries  
 
Arteries are usually considered to be high pressure vessels taking 
blood away from the heart towards the target tissue. They absorb part 
of the force of systole and help maintain blood flow during diastole. The 
walls of arteries are composed of three coats. The innermost layer, 
called the intima, consists of a layer of endothelial cells, the basement 
membrane and an internal elastic lamina. The middle layer, or media, 
consists of one or more layers of smooth muscle cells lying within a 
network of elastic and collagen fibres; the thickness of this network 
layer increasing with the size of the artery, being thickest in the aorta 
where it exceeds the thickness of the smooth muscle cells. Lastly, the 
adventitia is a thin layer of loosely arranged collagen and elastic fibres 
that wrap around the outside of the vessel. The adventitia is rich in 
lymphatics and nerves and links the vessel to the surrounding tissue 
(Gabella G, 1995). 
 
Arterioles 
 
Arterioles are small arteries that have proportionately more smooth 
muscle cells within their media (up to 6 layers in the retina) and thus act 
as resistance vessels, controlling the flow of blood within tissues. The 
smooth muscle cells are often well supplied by autonomic nerve fibres 
(not so in the retina) and respond to circulating vasoactive substances, 
to control vessel calibre. Smooth muscle contraction can completely 
obliterate the lumen of an arteriole, thereby reducing blood flow to the 
tissue to zero (Gabella G, 1995). 
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Capillaries 
 
Capillaries are thin walled vessels composed of an inner layer of 
endothelial cells forming a lumen (5-8µm) that is the approximate 
diameter of a red blood cell. Surrounding the endothelial cells are 
pericytes, embedded in a shared basement membrane. Pericytes are 
thought to be supporting cells, providing both strucWXUDODQG³FKHPLFDO´
support to the juxtaposed endothelial cells. Capillary structure varies 
depending on the tissue/organ that it serves. The endothelial lining may 
be continuous as in the retina and muscle; sinusoidal as found in the 
liver, adrenal medulla and spleen; or fenestrated as found in the renal 
glomerulus, endocrine glands and the choriocapillaris. Fenestrations 
are thought to be pores through which substances can transfer between 
the luminal side of the endothelial cell and the extracellular tissue. They 
are between 50 and 100µm in diameter and at their edges, the luminal 
and abluminal surfaces of the endothelial cell in contact. It is now 
known that fenestrations are not simple holes in the cell membrane but 
are covered by an electron-dense diaphragm. In continuous capillaries, 
where a marked barrier to diffusion exists (brain), apart from an 
absence of fenestrations, the endothelial cells exhibit strong 
intercellular junctions (zonula occludens) (Gabella G, 1995). 
 
Venules 
 
Venules are formed when at least two capillaries converge. Generally, 
they do not contain any muscle within their walls. Like capillaries, they 
are the site of solute transfer and importantly, leukocyte migration, 
particularly in lymph nodes. In adults, they are thought to be the site at 
which pathological neovascularisation takes place (Gabella G, 1995). 
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Veins 
 
Veins are thin-walled low pressure vessels acting as capacitance 
vessels returning blood to the heart. The intima of veins differs from that 
of arteries in having no internal elastic lamina. Within the media, the 
amount of smooth muscle fibres is significantly less, with relatively more 
collagen and elastic fibres. Certain veins, such as the maternal 
placental vein, the dural sinus veins of the brain and retinal veins, do 
not possess any muscular tissue. The adventitia of veins, like arteries, 
may contain autonomic nerves but these are less abundant. A 
significant difference between arteries and veins is the presence of 
valves in many of the latter. These act to prevent reflux of blood, 
effectively only allowing flow in one direction. Retinal venules do not 
contain valves (Gabella G, 1995). 
 
Arteries and veins 
 
After the formation of a primitive vascular plexus occurs, remodelling 
into a more complex network takes place along with the demarcation 
into arterial and venous territories. Arterial endothelial cells express 
Ephrin B2 whereas EphB4 is only expressed by veins. This expression 
continues down to ECs lining capillaries with a definite boundary 
forming between those cells nearer to arterioles and post capillary 
venules (Adams et al, 1999). 
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Section 2: Human ocular vascular structures 
 
The human eye 
 
Before describing the specialised vascular structures of the human eye, 
it is important to understand the basic anatomy of the eye. The eye ball 
or globe is made up of two modified spheres, fused together. The 
smaller modified sphere consists of the cornea; WKHFOHDU³ZLQGRZ´RQ
the front of eye, which allows in light and provides the majority of the 
focussing power of the eye. The larger, posterior sphere is composed of 
sclera, the tough, white outer coating of the eye. The globe has an 
anterior/posterior length of approximately 24mm. The basic structure of 
the eye is shown below. 
 
 
 
 
Fig 1.10. Cross section of a human eye showing its basic structural 
components (Courtesy of University of Utah) 
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The human eye consists of 3 distinct, concentric layers.  
 
1. The external layer is known as the corneoscleral envelope. This 
layer is tough and inelastic and is composed predominantly of type I 
collagen. Depending on their orientation, the collagen fibres either 
give rise to the opaque sclera or the transparent cornea.  
 
2. The middle layer is called the uvea. This layer is highly vascular. 
The anterior part of the uvea is composed of the iris, one of the main 
functions of which is to control the amount of light entering the eye. 
The iris is attached to and supported by another part of the uvea, 
which is known as the ciliary body. The main functions of this 
structure are to produce aqueous, a clear fluid that fills the anterior 
part of the eye, and secondly to control the shape of the lens. The 
third part of the uvea is the choroid. This is a vascular structure and 
provides nutrients and oxygen for the inner layer of the eye, the 
retina. The choroid is discussed in more detail later 
 
3. The retina is the photosensitive layer of the eye. It is a complex, 
multi-layered structure composed of neuronal cells and 
photoreceptors. The inner two thirds of the retina (that part nearest 
the vitreous) receives its oxygen and nutrients from the retinal 
vascular circulation. The outer one third of the retina is supplied 
from the underlying choroidal vasculature. The inside of the eye is 
not hollow, but is full of vitreous. This is composed of a mixture of 
collagens, glycoproteins and water and has the consistency of jelly 
(Sharma and Ehinger, 2003). 
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The structure of the retina 
 
Within the retina, there are two types of photoreceptors: rods and 
cones. Rods are a type of neural cell that convert photons of light into 
electrical signals, and are designed to work at low light levels e.g. at 
night and at dusk. They have no colour discrimination, only shades of 
grey from white to black. The other cells, called cones are designed to 
work in conditions of bright light (i.e. daylight) and can discriminate 
colour. There are three types of cone: red, green and blue which 
respond to colours/ wavelengths suggested by their individual names. 
 
By a process of phototransduction, light is converted via chemical 
reactions into electrical signals. This process takes place in the rods 
and cones and relies on a plentiful supply of vitamin A as one of the 
intermediaries, so that the necessary chemical reactions can take 
place. The resultant electrical signals are transmitted through the layers 
of the retina where they can be modified and amplified by bipolar cells, 
until they reach the surface of the retina (nearest the vitreous) From 
here, the signal is transmitted to the optic nerve by the axons of 
ganglion cells. Fig 1.11 overleaf demonstrates the basic ultrastructure 
of the retina (Courtesy of University of Newcastle). 
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Fig 1.11. The basic histological structure of the human extra macular 
retina  
 
Underneath the retina, a single layer of cells exists that interdigitates 
with the outer segments of the photoreceptors. These cells are called 
retinal pigment epithelial (RPE) cells. The RPE cells are critical for 
recycling of the visual pigments and chemicals necessary for the 
photoreceptors to function. The cells are pigmented (contain melanin) 
and are also important for clearing up the debris from degenerating 
photoreceptors, pumping fluid out of the retina, secretion of pro- and 
anti-angiogenic factors and for forming the outer blood-retina barrier 
(preventing flow of fluid out of choroidal vessels into the retina). Without 
the supportive role played by the RPE cells, retinal photoreceptors soon 
die. The RPE cells sit on a thick basement membrane called Bruchs 
PHPEUDQH%UXFK¶VPHPEUDQHLVFRPSRVHGof five layers, rich in 
collagen IV and is probably is derived from both the overlying RPE cells 
and the underlying choriocapillaris. It forms a water impermeable 
membrane between the vascular choroidal compartment and the 
overlying RPE and retina (Sharma and Ehinger, 2003). 
 
 
Ganglion cells 
 
 
Bipolar cells 
 
 
Photoreceptors 
 
RPE 
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$VLPSOLILHGFORVHXSGLDJUDPRIWKH53(%UXFK¶VPHPEUDQH/ 
Choriocapillaris orientation is shown in Fig 1.12.  Appreciation of this 
anatomical orientation is critical for the understanding of choroidal and 
retinal diseases.  
       
                                                                                                                      
    
Fig 1.12. Diagrammatic representation of the relationship of outer 
UHWLQDOVWUXFWXUHV%UXFK¶VPHPEUDQHDQGFKRURLG&RXUWHV\of the 
University of Utah). 
 
The macula 
 
While most of the retina has the structure outlined above, an area 
diametrically opposite the lens, at the posterior pole of the globe exists 
called the macula. It has an average diameter of 5-6mm and is the area 
where most of the light entering the eye is focussed. It is bordered by 
the upper and lower vascular arcades and the optic disc. Within the 
macula, there is a disproportionately high density of cones to aid colour 
discrimination and hyperacuity. In the centre of the macula is an area 
called the fovea where the only light sensitive cells are cones and this is 
the area of maximum visual sensitivity. Ultrastructurally, the fovea is 
thinner than the rest of the retina and is seen in cross section as a dip 
Photoreceptors 
RPE cells 
%UXFK¶V
membrane 
Choriocapillaris 
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(foveal pit). No retinal blood vessels exist in the fovea (thereby avoiding 
light scattering and aiding resolution of images). The cones in the fovea 
receive their oxygen supply by diffusion via the choroid (Sharma and 
Ehinger, 2003a) 
 
 
 
 
 
 
Fig 1.13. The ultra structure of the human macula and fovea (compare 
this with fig 1.11.). The only structures at the fovea are the fibres of the 
photoreceptors and the dendrites of the bipolar cells. Together these 
DUHNQRZQDV+HQOH¶VOD\HU. 
 
 
 
 
 
Fig 1.14. A representative Optical Coherence Tomography (OCT) scan 
through the macula and fovea of a real (normal) patient. The similarities 
with the histopathological specimen (fig 1.13) are obvious and this 
technique has revolutionised patient investigation and management of 
macular diseases (Courtesy of the Royal Victoria Infirmary, Newcastle 
upon Tyne).  
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As the main body of this thesis relates to endothelial cell heterogeneity 
within the human eye, there now follows a description of the different 
human ocular vascular beds. 
 
Retinal vascular structure 
 
The inner two thirds of the retina are supplied by a network of blood 
vessels that emanates from the central retinal artery at the optic nerve 
head. This artery is itself supplied by the ophthalmic artery which 
ultimately is a branch of the internal carotid artery (the main artery 
supplying the brain). The central retinal artery usually splits into four 
arterioles at the optic nerve head which then subdivide to supply each 
retinal quadrant via a network of capillaries. Each arteriole is also 
associated with a corresponding venule which carries deoxygenated 
blood back to the optic nerve head and into the central retinal vein. 
Because of the multiple sub divisions of each retinal vessel, each 
SHUVRQ¶VUHWLQDOYDVFXODWXUHis said to be unique and may provide a 
form of finger print (Cioffi et al, 2003). 
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Fig 1.15. shows a photograph of a typical retina demonstrating the 
closely associated arterioles and venules (Courtesy of the University of 
Newcastle).  
 
Retinal vascular development  
 
In humans, development of the retinal vasculature begins at around 
week 14 of gestation. It occurs by the process of vasculogenesis from 
precursors that express CD39 (Fruttiger M, 2002; McLeod et al, 2006). 
This cell surface molecule is otherwise known as ecto ADPase and is 
found on endothelial cells in all vascular beds. The molecule is 
responsible for controlling extracellular ADP concentration and platelet 
aggregation. These precursor cells also express VEGFR2 but not CD31 
or CD34 (McLeod et al 2006), both apparently ubiquitous endothelial 
markers found in mature endothelial-lined vessels. It is thought that the 
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retinal vascular precursor cells (angioblasts) may be attracted to the 
developing retina by stroma derived factor 1 (SDF 1) because the 
angioblasts also express CXCR4 (SDF 1 receptor). It is thought that the 
majority of CXCR4-positive precursor cells originate from within the 
inner retina rather than from distant sites such as bone marrow 
(McLeod et al 2006). Most mature endothelial cells do not appear to 
express CXCR4, implying that its main role is in guiding endothelial 
cells of developing vascular systems. Vasculogenesis begins around 
the optic nerve head by accumulation of angioblasts. They then 
aggregate into blood vessels that align themselves along the routes of 
retinal neurones and an astrocyte template towards the periphery 
(Dorrell & Friedlander, 2006). In the mouse model of the developing 
retinal vasculature, it is thought that as the periphery of the developing 
retina is relatively hypoxic, VEGF188 expression by the resident 
astrocytes and Muller cells acts as a stimulus to the developing 
vascular network which follows the concentration of VEGF188 (Stalmans 
et al, 2002; Carmeliet and Tessier-Lavigne, 2005)
.
 The heparin binding 
property of VEGF188 is thought to be important because in mice only 
expressing VEGF120, retinal vascular development is severely 
impaired (Stalmans et al, 2002). 
 
Retinal vascularisation is not often complete at birth. The retinal 
vasculature is composed of arterioles, venules and capillaries rather 
than arteries and veins. The lumen is greatest (100microns) near the 
disc, where the vessels have neither a continuous muscular coat nor an 
internal elastic lamina (Hayreh et al, 1989). Retinal blood vessels have 
no adrenergic vasomotor nerve supply to bring about changes in 
vascular tone (Steinle & Granger, 2003) and it is thought that changes 
in vascular calibre and tone are brought about by local mediators 
secreted, at least in part, by vascular endothelial cells. These factors 
are vasodilators, such as nitric oxide (NO) synthesised by endothelial 
nitric oxide synthetase (eNOS) (Bouloumié et al, 1999), adenosine and 
prostanoids, and vasoconstrictors such as endothelin 1 and  
angiotensin II.  
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Blood supply and drainage of the choroid and retina 
 
The globe is supplied by a branch of the internal carotid artery and is 
drained by the vortex veins which drain into the cavernous sinus as 
shown in figs 1.16. & 1.17 below.  
 
 
 
 
Fig 1.16. The arterial supply of the globe. The eye is supplied by a 
branch of the internal carotid artery, the ophthalmic artery. This then 
gives off various branches within the orbit, some of which are called 
short posterior ciliary arteries. These penetrate the back of the globe to 
supply segments of the choroid. The retina is supplied by branches of 
the central retinal artery which enters the globe within the optic nerve 
before radiating out over the inner retina. Other branches such as the 
long posterior ciliary arteries supply the front of the eye and the 
muscles attached to the eye which bring about movement of the globe 
(non-copyright image). 
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Fig 1.17 The venous drainage of the globe, including the choroid is via 
a variable number of vortex veins. These drain the choroid and then 
pass backwards through the scleral coat of the eye. They then pass 
back into the orbit and congregate in the cavernous sinus which lies 
beside the pituitary gland. The retina is drained via the central retinal 
vein, which passes back out of the eye within the optic nerve. Key: 1 = 
vortex ampullae within choroidal tissue, 2 = superior vortex vein, 3 = 
inferior vortex vein, 4 = central retinal vein (within optic nerve), 5= 
cavernous sinus (Courtesy of Medrounds Publishing). 
 
Choroidal vascular structure 
 
The choroid forms part of the uveal tract (choroid, ciliary body and iris) 
of the eye and lies between the outer sclera (white of the eye) and the 
inner layer composed of the retina and retinal pigment epithelium 
(RPE). Its main roles are to supply the photoreceptors with oxygen, to 
remove waste products from the basal surface of the RPE and to 
regulate temperature within the photoreceptors. It is approximately 100-
ȝPWKLFNGHSHQGLQJRQVLWHDQGLVFRPSRVHGDOPRVWHQWLUHO\RI
blood vessels with some supporting cells such as fibroblasts, 
macrophages, mast cells, melanocytes and pericytes which surround 
endothelial capillaries (Bron et al, 2001). 
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Fig 1.18. Haematoxylin/Eosin section of human choroid (macular) 
demonstrating the dense vascular network with vessels of decreasing 
lumen diameter the nearer they are to the RPE layer. The vessels 
furthest from the RPE represent the feeding arterioles and draining 
veins. Those nearest the RPE represent the fine network of the 
choriocapillaris. The cells and tissue between the vessels represent the 
supporting cells such as melanocytes, fibroblasts and pericytes 
together with collagens (with permission of Springer images). 
  
 
Classically, the choroid at the posterior pole has been subdivided into 
three OD\HUVWKHRXWHUOD\HURIODUJHYHVVHOV+DOOHU¶VOD\HUDPLGGOH
OD\HURIPHGLXPVL]HGYHVVHOV6DWWOHU¶VOD\er) and an internal layer 
DGMDFHQWWR%UXFK¶V0HPEUDQHFRPSRVHGRIFDSLOODU\YHVVHOV
(choriocapillaris) arranged in a lobular structure (Nuel, 1892; Bron et al, 
2001 Olver J, 1990) (see fig 1.9). The large vessels of the outer choroid 
are supplied by branches of the short posterior ciliary arteries which 
themselves are supplied by branches of the internal carotid artery (main 
vessels supplying the brain) (see fig 1.6). Drainage of the choroid is via 
the vortex veins which drain sectors of the choroid through the scleral 
coat of the eye and converge on the cavernous sinus (see fig 1.7). 
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The large vessels of the choroid (branches of the short posterior ciliary 
arteries) WKHQVXSSO\WKHVPDOOHUYHVVHOVRI6DWWOHU¶VOD\HUZKLFKWKHQ
sub divide to supply individual lobules of the choriocapillaris. Each 
choriocapillaris lobule is thought to be composed of a central feeding 
arteriole and a number of peripheral draining venules (see fig 1.9 and 
1.10). Each lobule is not isolated bXWIRUPVD³KRQH\FRPbinJQHWZRUN´
where blood is thought to transfer directly between lobules if required 
(fig 1.19).  
 
 
 
Fig 1.19. A 3-dimensional representation of the pattern of blood supply 
of choriocapillaris lobules. A = supplying arteriole, V = draining venule. 
It can be seen that each lobule is supplied by a central arteriole and 
drained by more than one venule at the edge of each arteriole (from 
von Graefes Arch Ophthalmol 1974 with permission). 
 
RPE cells 
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Fig 1.20. Scanning electron micrograph of a cast of human choroidal 
vasculature viewed from the scleral side, showing draining choroidal 
veins (v), arterioles (a) and the choriocapillaris (c) visible through the 
gaps between the large vessels (from Olver J, 1990 Eye, 4:262, with 
permission).  
 
   
 
Fig 1.21. Scanning electron micrograph of a cast of human 
choriocapillaris viewed from the retinal aspect. Remnants of the retinal 
vasculature are visible at the top and bottom of the image. The 
interconnecting nature of the structure of the choriocapillaris is seen. 
(from Olver J, 1990 Eye, 4:262, with permission). 
Retinal capillaries 
Choriocapillaris (note  
the close juxta-position 
of the retinal capillaries 
and the choriocapillaris 
once the RPE cells and 
%UXFK¶VPHPEUDQHKDYH 
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The endothelial cells of the choriocapillaris appear to send out 
SURFHVVHVWKDWSHQHWUDWHWKHRXWHUOHYHORI%UXFK¶VPHPEUDQH7KHVH
processes do not appear to be a harbinger of choroidal 
neovascularisation, but may stabilise the endothelial cell (Guymer et al, 
2004). The peripheral choroid is simpler in structure and is composed of 
the choriocapillaris and a deeper layer of large vessels (McLeod & 
Lutty, 1994). The choriocapillaris has a lobular structure and, unlike the 
retinal circulation, is not an end organ system. A significant difference 
between the choriocapillaris and most other capillary structures in the 
body is that the endothelial cells lining the choriocapillaris are 
fenestrated on the inner or retinal side of the vessels that face the RPE. 
This corresponds to the polarised expression of VEGF receptors on the 
HQGRWKHOLDOFHOOVIDFLQJ%UXFK¶VPHPEUDQH%ODDXZJHHUVHWDO
There is evidence to suggest that the fenestrations within the 
choriocapillaris are dependent upon factors secreted from the RPE, be 
they growth factors such as VEGF and FGF or extracellular matrix 
components. Evidence for this is provided by destroying the RPE either 
surgically (Hayashi et al, 1999), genetically (May et al, 1996) or 
chemically with sodium iodate (Korte et al, 1984); the underlying 
choriocapillaris degenerates, but not the deeper, large choroidal 
vessels. When the RPE recovers, new areas of choriocapillaris re-
establish themselves from the larger choroidal veins by migration of 
endothelial cells. A similar effect is seen in animals with genetic retinal 
degenerations where the RPE is primarily involved (RCS rats with 
hereditary retinal degeneration), although the effect on the 
choriocapillaris is obviously non-reversible (May et al, 1996). In this 
model, despite endothelial cell migration and proliferation, choroidal 
QHRYDVFXODUPHPEUDQHVGRQRWDSSHDUWRIRUPSHUKDSVGXHWR%UXFK¶V
membrane being intact (c.f. animals genetically programmed to over 
express VEGF in the RPE, which demonstrate a similar result). 
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The choroid is innervated by both sympathetic and parasympathetic 
neurones. Stimulation of the alpha adrenergic sympathetic nerves 
within the choroid leads to vasoconstriction and a fall in ocular blood 
volume (the choroid acts as a large capacitance vessel within the eye). 
Stimulation of the parasympathetic nerves causes choroidal 
vasodilatation. The arterioles demonstrate a high density of VIPergic 
neurones (vasodilator). It is also thought that some neurones may 
release nitric oxide (NO) which acts as a vasodilator for choroidal 
vessels (Bron et al, 1997a). The choriocapillaris has no innervation.  
 
In contrast to the retina, the choriocapillaris develops at around 6.5 
weeks gestation by a process of haemovasculogenesis (see earlier) 
(Hasegawa et al, 2007; Baba et al, 2009). It is also thought that some of 
the larger choroidal vessels form by the process of haemo-
vasculogenesis as well. However, the density of CD39-positive 
(angioblasts) and haemoglobin epsilon-positive (a haemo-
vasculogenesis marker) cells within the developing choroid at week 12 
was insufficient to produce the whole choroid (Hasegawa et al, 2007). 
Positive staining for proliferation markers at this stage suggests that 
angiogenesis is also taking place in the developing choroid. It should be 
noted that the choroid develops far earlier than the retina and both 
develop by different mechanisms i.e. haemovasculogenesis and 
vasculogenesis respectively (Hasegawa et al, 2007). This may explain 
some of the differences between the mature retinal and choroidal 
YDVFXODWXUH¶VSK\VLRORJLFDOIHDWXUHV, responses and susceptibility to 
disease (Saint-*HQLH]	'¶$PRUH$OOHQGHHWDO 
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Iris vasculature structure 
 
Traditionally, the vessels of the iris have been regarded as being thick 
and hyaline in appearance. The adventitia has an abundance of loose 
FRQQHFWLYHWLVVXHSHUKDSVWRDFFRPPRGDWHWKHFRQVWDQW³FRQFHUWLQD-
OLNH´PRYHPHQWVRIWKHLULVZKLFKFDXVHIUHTXHQWVWUDLJKWHQLQJDQG
wrinkling of the vessels. The arteries have a media of circular non-
striated smooth muscle and elastic fibres. The iris capillary endothelium 
is non-fenestrated and has a thick basal lamina, surrounded by 
pericytes (Bron et al, 1997a). An interesting feature of the iris 
vasculature is that exposure to histamine renders the vessels 
permeable to macromolecules, unlike the retinal vasculature which is 
insensitive (Ashton & Cunha-Vaz, 1965). 
 
Regulation of ocular blood flow 
 
Because the retina has the highest metabolic demand of any tissue and 
those requirements change between light and dark conditions (Buttery 
et al, 1991), rregulation of blood flow is therefore paramount and is 
required to maintain an adequate flow of blood in the face of variations 
in perfusion pressure. It is also paramount that any vessels supplying 
blood do so with minimal impact on the light reaching the 
photoreceptors and on the process occurring in the retina. Interestingly, 
the regulation of blood flow differs between the retina and choroid. 
Retinal blood flow increases in response to raised partial pressure of 
carbon dioxide (pCO2), while raised partial pressure of oxygen (pO2) 
causes vasoconstriction and hence reduced flow. Retinal flow is 
autoregulated, and under most conditions is not affected by perfusion 
pressure. Indeed, elevation of intraocular pressure to twice normal 
levels, resulting in a 36% reduction of perfusion pressure, does not alter 
retinal blood flow (Riva et al, 1981). The main regulator of blood flow is 
thought to be the vascular smooth muscle cells of the retinal arterioles. 
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The depolarisation of the smooth muscle cells can be affected by pCO2 
in the blood (high levels cause muscle relaxation and vasodilatation) 
(Alm and Bill 1972), pH (Hessellund et al, 2006), dark illumination 
conditions (retinal blood flow increases by 40% in dark conditions)( 
Feke et al, 1983), and nitric oxide (Buerk et al, 1996). In contrast to the 
retina, the control of choroidal blood flow is less well understood 
because of the difficulties in studying the choroidal circulation in detail. 
However, it is known that choroidal blood flow is increased by raised 
pCO2 but is unaffected by raised pO2. Choroidal blood flow, unlike 
retinal flow, is not autoregulated, relying on sympathetic (with both 
noradrenergic and neuropeptide fibres) (Bruun et al, 1984) and 
parasympathetic (cholinergic) nerves (Bill and Sperber, 1990). 
Therefore changes in perfusion pressure cause a proportionate change 
in choroidal blood flow. The regulation of iris blood flow is very poorly 
understood and little, if any research has been conducted on it.
  
Section 3: Angiogenic diseases affecting the eye  
 
Wet age related macular degeneration 
 
Age related macular degeneration (AMD) is a heterogeneous condition 
characterised by the deterioration of structure and function of a well 
defined area at the posterior part of the eye responsible for central and 
reading vision, i.e. the macula. The disease is the most common cause 
of irreversible visual loss in the elderly populations of the industrialised 
world (Klein et al, 1992; Mitchell et al, 1995; Vingerling et al, 1995).  
 
While the cause(s) of AMD are unknown, it is probably polygenic in 
nature, being affected by multiple genetic and environmental factors 
such as age, smoking, drusen formation and possession of certain 
genetic alleles (Hageman et al, 2005). This concept may help to explain 
the wide range of disease phenotypes. While increasing age is an 
undoubted risk factor, unfortunately this is not modifiable. However, 
smoking has been shown to increase the risk of AMD by between 3 and 
4 fold (Khan et al, 2006). Smoking cessation regimens therefore offer 
the prospect of dramatically reducing the incidence of severe visual loss 
secondary to AMD. While the finding of macular drusen (small yellow 
sub-retinal deposits) increases dramatically with advancing age, the 
possession of the large, soft subtype increases the risk of advanced 
AMD by between 5 and 10 fold (Bird et al, 1995) (see fig 1.23). In 
addition, the occurrence of advanced AMD (e.g.: a large macular scar 
secondary to wet AMD) in one eye means that there is a 50% risk of the 
fellow eye developing a similar lesion over 5 years.  
 
Histologically, the disease is seen to affect all of the major layers of 
tissue at the macula: the choroid, retinal pigment epithelium (RPE), 
%UXFK¶VPHPEUDQHDQGWKHUHWLQD7UDGLWLRQDOO\WKHGLVHDVHLVFODVVLILHG
LQWR³GU\´RUDWURSKLF and ³ZHW´RUQHRYDVFXODUIRUPs. The dry form of 
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the disease is characterised by slow, progressive atrophy of the 
macular retinal pigment epithelium and underlying choroid, leading to 
secondary retinal photoreceptor death. This form of the disease will not 
be discussed any further. 
 
The wet form of the disease is characterised by new blood vessel 
growth (angiogenesis) from the choriocapillaris and inner choroid 
(Sarks et al 1997) to form a choroidal neovascular membrane (CNV). 
*URZWKRFFXUVWKURXJKSK\VLFDOGHIHFWVLQ%UXFK¶VPHPEUDQHWRWKH
potential space underneath the retinal pigment epithelium (RPE) and 
retina (Kent & Sheridan, 2003; Campochiaro et al, 1999, Kijlstra et al, 
2005; Tezel, 2004; Coleman et al, 2008), stimulated by cytokines such 
as vascular endothelial growth factor (VEGF). These new vessels are 
associated with massive exudation of fluid and lipid, which 
subsequently leads to severe damage to the retinal photoreceptors and 
fibrosis. This form of the disease is often of rapid onset and progression 
and commonly leads to severe visual loss. A stylised representation of 
events is shown on below (fig 1.22). 
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Fig 1.22. A representation of the underlying steps involved in choroidal 
neovascularisation (courtesy of Netscape, www.Medscape.com). 
 
 
Most established or experimental treatments for AMD such as external 
beam radiotherapy, transpupillary thermotherapy and macular surgery 
aim to bring about closure of the CNV, but do not affect the underlying 
disease or pathophysiological processes involved. One reason for this 
is the paucity of knowledge regarding the main cellular key player, the 
macular inner choroidal endothelial cell. Investigators have studied the 
disease in vitro by studying the phenotype and growth characteristics of 
bovine choroidal endothelial cells (Liu & Li, 1993; Sakamoto et al, 
1995a; Sakamoto et al, 1995b; Morse & Sidikaro, 1990; Hoffman et al, 
1998; Liu et al, 1998; Wang et al, 2002; Zubilewicz et al, 2001a; 
Zubilewicz et al, 2001b ; McLaughlin & de Vries, 2001; Eter & Spitznas, 
2002) and heterogeneous mixtures of human choroidal (Penfold et al, 
2002; Geisen et al, 2005; Peterson et al, 2007; Sakamoto et al, 1995; 
Bargagna-Mohan et al, 2006) or macrovascular (umbilical vein) 
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endothelial cells (Shankar et al, 2008; Stahl et al, 2008). It is known, 
however, that endothelial cells from different species and anatomical 
sites vary markedly in their phenotype and growth characteristics (see 
previous sections). In order to increase understanding of this disease it 
would seem logical to develop a technique to isolate and study human 
macular inner choroidal endothelial cells in vitro. 
 
Epidemiology  
 
As current demographic changes are skewed towards a more elderly 
population, the number of people with AMD is likely to increase even 
further, with marked health economic implications. In the Beaver Dam 
Eye Study in the USA, the prevalence of advanced AMD increased 
from 0.1% at age 43 - 54 years to 7.1% among those aged 75 years or 
older (Klein et al, 1992). In a similar study conducted in Australia, 0 % 
people under the age of 55 had advanced AMD but this increased to 
18.5% in the age 85 and over subgroup (Mitchell et al, 1995). While 
similar large scale epidemiological studies of the prevalence of AMD 
have yet to be undertaken in the UK, it is estimated that there are 
currently 214,000 people visually impaired by the disease and this was 
expected to rise to 239,000 by 2011 (Owen et al, 2003). It is therefore 
obvious that AMD is currently a major health burden which is likely to 
increase substantially in the future due to changes in the demographics 
of the ageing population. While the cause of the disease is unknown, a 
number of risk factors have been determined as listed below. 
 
Established risk factors  Relative risk 
 
Age    - 
Smoking   3.6 
Large drusen   5.7 
Soft drusen   9.9 
Hypertension   1.2 
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Clinical features  
 
Early age-related macular degeneration is characterised by thickening 
DQGORVVRIWKHQRUPDODUFKLWHFWXUHRI%UXFK¶VPHPEUDQHDFFXPXODWLRQ
of lipofuscin within RPE cells and the formation of Drusen (convex 
shaped deposits of glycoprotein lipids and inflammation-related 
PROHFXOHVEHQHDWKWKH53(ZLWKLQ%UXFK¶VPHPEUDQHSUHGRPLQDQWO\
in the macular area. With time, the number of drusen may increase in 
QXPEHUDQGVL]HDQGWDNHRQ³VRIW´FKDUDFWHULVWLFV:KHQthis occurs in 
association with RPE hypo- and hyper-pigmentation, the risk of 
developing more advanced AMD is high (Klein et al, 2002).  
 
 
 
 
Fig 1.23. $FRORXUIXQGDOSKRWRJUDSKRIDSDWLHQW¶VULJKWH\H
demonstrating drusen (sub-RPE deposits of amorphous material that 
LQFUHDVHDSDWLHQW¶VULVNRIGHYHORSLQJ$0'FRXUWHV\RIWKH8QLYHUVLW\
of Nottingham) 
Drusen 
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Wet AMD is characterised by serous or haemorrhagic detachment of 
the RPE by growth of new blood vessels (choroidal neovascular 
membrane or CNV) (see fig 1.24 and 1.25). 
 
 
 
Fig 1.24. Colour fundal photograph of the left eye of a patient with wet 
AMD. It demonstrates a circular area of haemorrhage in the macula, 
which encompasses an area of cream and darker pigmentation. These 
findings would suggest leakage of blood and fluid under the macula. 
(Courtesy of the University of Nottingham) 
Area of  
haemorrhage 
and leakage 
within the macula 
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Fig 1.25. Fundal IOXRUHVFHLQDQJLRJUDPRIDSDWLHQW¶VULJKWH\H
demonstrating the leakage of fluorescent dye in the central macular 
area from growing blood vessels of the choroidal neovascular 
membrane (Courtesy of the University of Nottingham). 
 
 
If left untreated, there is eventual death of the overlying photoreceptors 
and fibrosis, with a significant drop in vision and disruption of the 
structure by end stage fibrosis. Ultrastructurally, aberrant new vessels 
are seen to grow from the inner choroidal vessels (predominantly the 
veins), usually at or near sites of increased deposition of debris within 
DQGDORQJVLGH%UXFK¶VPHPEUDQHGUXVHQWKURXJKEUHDNVLQWKH
overlying membrane, to occupy a position in the potential sub-RPE and 
sub-retinal spaces (Sarks et al, 1997; Killingsworth, 1995). Along with 
endothelial cell proliferation within the CNV, mural cells such as 
pericytes, fibroblasts and smooth muscle cells also proliferate and 
migrate alongside the ECs. Macrophages are also usually seen 
associated with the CNV and may in fact pre-date the angiogenic event 
(Oh et al, 1999; Grossniklaus & Green, 1998; Skeie & Mullins, 2009). In 
keeping with neovascularisation elsewhere in the body, the choroidal 
new vessels leak fluid due to a reduction in endothelial cell-cell 
adhesion. 
Choroidal 
neovascularisation 
within the macula, 
demonstrating 
leakage of dye 
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Pathophysiological mechanisms 
 
As mentioned previously, a number of environmental factors predispose 
to AMD. Recently, the analysis of drusen showed their composition to 
include many complement related proteins and the finding of a number 
of immune related genes that may be important in the pathogenesis of 
³W\SLFDO´$0' (Hageman et al, 2005, Klein et al, 2005; Edwards et al, 
2005; Haines et al, 2005; Gold et al, 2006) have led researchers to 
suggest that chronic inflammation is a major contributory factor in the 
pathogenesis of the disease. The most important gene found to be 
associated with AMD is that for complement factor H (CFH), with 
patients harbouring the Y402H mutation having a significantly increased 
risk (Hageman et al, 2005, Klein et al, 2005; Edwards et al, 2005; 
Haines et al, 2005). CFH is a component of the alternative complement 
pathway and is involved in the inhibition of activated complement 
species. Reduced inhibitory activity caused by the Y402H mutation may 
lead to uncontrolled complement activation, drusen formation and 
GDPDJHWR%UXFK¶VPHPEUDQHWKHUeby simulating the early stages of 
AMD. Recent studies have shown that patients with the Y402H 
haplotype have a 2.7 to 5.8 fold increased risk of AMD and that 
possession of the mutation may account for 50% of the total risk of 
AMD. Patients who are homozygous for the mutation have up to a 7.4 
fold increased risk of AMD (Hageman et al, 2005, Klein et al, 2005; 
Edwards et al, 2005; Haines et al, 2005). 
 
Mutations in other genes such as LOC387715 on chromosome 10q26 
(Rivera et al, 2005) and fibulin 5 (Stone et al, 2004) are also thought to 
confer a higher risk of developing choroidal neovascularisation. 
However, to date, the risk and possible pathophysiological mechanism 
is less well understood than that of CFH. During studies of the genetic 
risk related to CNV, changes in genes coding for complement cascade 
factor B (BF), complement factor 2 (C2) and Apo E were found to 
confer relative protection against AMD (Scholl et al, 2007).  
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Another gene thought to be associated with AMD is SERPING 1 (Ennis 
et al, 2008). 
 
Further evidence for immune and complement dysregulation in the 
pathogenesis of AMD is that drusen, which are thought to be central to 
the early events in the pathogenesis of AMD, contain many 
complement components and immune related substances. To date, it is 
the harbouring of mutations in genes such as CFH that confers the 
highest risk of AMD, implying that some form of immune system 
dysregulation plays a key role in AMD (Kijlstra et al, 2005; Nussenblatt 
& Ferris, 2007; Anderson et al 2002; Nussenblatt, 2009; Patel & Chan, 
2008). Further evidence is given by the finding that macrophages are 
found around AMD lesions (Skeie & Mullins, 2009). It is also known that 
activated macrophages secrete many chemokines (Grossniklaus et al, 
2002) that may in turn stimulate the production of VEGF (Oh et al, 
1999). Recently, a counter argument has been placed that the 
macrophages may in fact inhibit angiogenesis, perhaps via Interleukin 
10 (Apte et al, 2006). Interestingly, an observation in a patient given 
Infliximab, aQDQWLERG\WRWXPRXUQHFURVLVIDFWRUĮ71)ĮJLYHQWRWUHDW
diseases such as rheumatoid arthritis, caused regression of 
concomitant choroidal neovascularisation (Markomichelakis et al, 
2004). This effect is supported by evidence provided by the observation 
that in vitro71)ĮDSSHDUVWRXS-regulate the action of Tie2 and VEGF 
receptors (Hangai et al, 2006), again suggesting that immune related 
factors are playing a role in the stimulation of wet AMD.  
 
It has been found that VEGF on its own is not sufficient to cause 
choroidal neovascularisation. Over-expression of VEGF within the 
retina causes retinal neovascularisation but has no effect on the choroid 
(Okamoto et al, 1997). Over expression of VEGF by RPE cells did not 
cause the formation of a true choroidal neovascular membrane except 
ZKHQ%UXFK¶VPHPEUDQHwas breached by trauma (in the case of one 
study, by a needle used to insert the viral vector within the choroid) 
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(Oshima et al, 2004; Spilsbury et al, 2000; Schwesinger C, 2001). 
These models suggest that other factors in addition to raised VEGF 
levels in the choroid are required for wet AMD to occur. Such factors 
PD\LQFOXGHLDWURJHQLFRUVSRQWDQHRXVO\RFFXUULQJEUHDNVLQ%UXFK¶V
membrane. Many growth factors appear to be up-regulated in the area 
of the choroidal neovascular membrane. It is not known if this is a 
response to local hypoxia (HIF-1 stimulating VEGF which is classically 
up-regulated in hypoxia and FGF 2 which can be secreted by 
macrophages in states of hypoxia) (Ishibashi et al, 1995) or because of 
local secretion by other cells such as RPE cells or macrophages, 
stimulated by an unknown non hypoxic stimulus (chronic viral or 
bacterial infection?). Interestingly, another growth factor, FGF2, again 
appears to be insufficient to bring about choroidal neovascularisation 
alone. In a mouse laser model, targeted disruption of the FGF2 gene 
failed to inhibit development of CNV (Tobe et al, 1998). 
 
The role of growth factors in choroidal neovascularisation 
  
It is well documented that, in vitro, endothelial cells from many sites 
express certain receptors for growth factors such as vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF), 
SODWHOHWGHULYHGJURZWKIDFWRU3'*)WUDQVIRUPLQJJURZWKIDFWRUȕ
(TGF-ȕLQVXOLQOLNHgrowth factor-1 (IGF-1) (Liu et al, 1998; Spraul et 
al, 2002) and pigment epithelium derived factor (PEDF) (Cai et al, 
2006).   In addition, immunohistochemical studies of excised choroidal 
neovascular membranes have shown positive staining for VEGF 
(Kvanta et al, 1996; Kliffen et al, 1997), FGF (Reddy et al, 1995; Amin 
et al, 1994; Frank, 1996; Ogata et al, 1996), TGF-ß (Amin et al 1994), 
angiopoietin 2 (Otani et al, 1999), Tie 2 (Otani et al, 1999), CD 105 
endoglin (Grisanti et al, 2004) and PEDF (Matsuoka et al, 2004). Some 
of these cytokines have a stimulatory effect on human umbilical vein 
and bovine retinal and choriocapillaris endothelial cell proliferation, 
except TGF-ȕDQG3(')ZKLFKDSSHDUWREHLQKLELWRU\/HEULQHWDO
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2005; Cai et al, 2006; Renno et al, 2002). Some of these cytokines also 
appear to stimulate the migration of cells towards the source and up-
regulate the production of MMPs, the enzymes necessary for the 
degradation of basement membranes. The role of each of these 
cytokines in the pathogenesis of AMD in humans can, at best, only be 
extrapolated from work carried out on different species or from ECs 
from other sites, as discussed above.  
 
Animal Models 
 
Animal models can provide invaluable insights into the mechanisms 
and possible treatments of a wide range of diseases. It is not surprising, 
therefore, that researchers have attempted to study the mechanisms in 
AMD by using animal models either with genetically induced defects 
that replicate the human disease susceptibility genes, or by studying 
animals with phenotypes that appear similar to human AMD. The most 
commonly used animal in the study of AMD, the mouse, has a major 
drawback, however; LWGRHVQ¶WKDYHDPDFXOD Interestingly, none of the 
animal models to date appear to have abnormalities of angiogenesis. It 
appears that the mechanism of disease is an abnormal insult that leads 
to a normal angiogenenic response. This would be in agreement with 
the human disease in which no defects in angiogenesis, e.g. an over-
reaction to an angiogenic stimulus, have been found to date.  
 
Genetic mouse models of AMD 
 
CCR2/CCL2 deficiency: This model leads to the deposition of drusen, 
WKLFNHQLQJRI%UXFK¶VPHPEUDQHJHRJUDSKLFDWURSK\DQG&197KH
underlying genetic mechanism leads to reduced accumulation of 
mDFURSKDJHVZLWKLQWLVVXHVVXFKDVWKH53(%UXFK¶VFRPSOH[ZLWK
reduced clearance of the components that later go on to form drusen 
(Ambati et al, 2003). 
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Cx3cr1 deficiency: This mouse model is characterised by retinal 
degeneration and drusen-like deposits. The underlying mechanism is 
thought to involve microglial accumulation and damage to 
photoreceptors (Chan et al, 2008). 
 
CFH deficiency: Mice with null mutations for CFH demonstrate 
reduced vision and abnormal retinal electrophysiology, increased retinal 
autofluorescence and accumulation of C3 and outer photoreceptor 
disorganisation. Fundoscopic examination and the choroidal 
vasculature were normal however. This model is therefore not a 
representative model of human disease (Coffey et al, 2007). 
 
Apo E: Mutations in the mouse Apo E4 gene demonstrated many of the 
features of human AMD when fed a diet high in fat. This is contrary to 
informed epidemiological opinion which suggests a protective role for 
Apo E4 in AMD. It also highlights the potential role of diet in AMD 
pathogenesis (Malek et al, 2005).  
 
Bst: It is reported that Bst/+ mice spontaneously develop sub retinal 
neovascular membranes. The Bst gene is thought to be important in 
axonal migration, closure of the optic fissure and involution of the 
hyaloid system (Smith et al, 2000).  
 
VLDL receptor: The very low density lipoprotein (VLDL) receptor is 
widely expressed on heart and skeletal muscle, adipose tissue, smooth 
muscle cells and endothelial cells. It binds a number of ligands 
including apolipoprotein lipase, thrombospondin 1 and urokinase 
plasminogen activator. As well as its role in lipid metabolism, it may 
also play a role in angiogenesis inhibition. Mice lacking the VLDL 
receptor develop a type of wet AMD characterised by a retinal 
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angiomatous proliferation (RAP) (Jiang et al, 2009; Hu et al, 2008; 
Chen et al, 2007). This lesion is also found in some human cases of 
wet AMD.  
 
SOD1: It is hypothesised that a causative factor in the pathogenesis of 
wet AMD is oxidative stress on the macula caused by free radicals. 
Imamura et al demonstrated the formation of drusen, thickening of 
%UXFK¶VPHPEUDQHDQG&19LQPLFHZLWKDPXWDWLRQLQVXSHUR[LGH
dismutase (SOD1) (Imamura et al, 2006). 
 
Laser photocoagulation models of wet AMD 
 
Choroidal neovascularisation can be induced experimentally by rupture 
RI%UXFK¶VPHPEUDQHE\ODVHUSKRWRFRDJXODWLRQ7KLVWHFKQLTXHKDV
been conducted in a number of animals such as mice, rats and 
monkeys and provides an efficient and easily reproducible system for 
studying some of the underlying mechanisms and provides a useful 
model to test new agents in vivo to determine their effect on the 
inhibition of CNV growth (Archer & Gardiner, 1981). However, laser 
induced CNV do not have the relentless natural history as pathologic 
CNV in AMD The relevance of this model to human disease is unknown 
as there is probably a major inflammatory mechanism involved in this 
PRGHOEHFDXVHWKHODVHUGLVUXSWLRQRI%UXFK¶VPHPEUDQHFDXVHVPDMRU
tissue damage. To date, factors such as oestrogens (Tanemura et al, 
2004), ICAM 1 and CD44 (Shen et al, 1998), VEGF (Shen et al, 1998; 
Yi et al, 1997; Baffi et al, 2000), tissue factor (Bora et al, 2003), matrix 
PHWDOORSURWHLQDVHV.YDQWDHWDODQGĮȖ- integrin (Yasukawa et 
al, 2004) have all been found to play a role in the growth of these 
artificially induced neovascular membranes. However, their relevance 
to human disease remains unknown. 
 
 98 
While the initiating event or stimulus for the disease remains unknown, 
it is clear from immunohistochemical examination of excised choroidal 
neovascular membranes (CNV) from both humans and animals 
(Killingsworth et al, 1995; Sarks et al, 1997) that inner choroidal 
endothelial cells (ICECs) and their supporting pericytes are stimulated 
to proliferate by paracrine factors generated by juxtapositioned cells 
such as the retinal pigment epithelium (RPE) or macrophages. Upon 
stimulation, the ICEC cells degrade local basement membranes by 
production of matrix metalloproteinases (MMPs), in particular MMP2 
and 9 (Kvanta et al, 2000), migrate along cytokine concentration 
gradients and form tube-like structures that later mature into new blood 
vessels (angiogenesis).  
 
Treatment 
 
Data from the Macular Photocoagulation Study Group (MPSG) 
suggests that the natural history of wet AMD is bleak. For many years, 
the only treatment proven to be effective in arresting the progression of 
the CNV was laser photocoagulation. However, only a small proportion 
of patients within a specific disease subgroup have been shown to 
benefit from this treatment which is also associated with a high rate of 
disease recurrence (paradoxically often under the fovea) (Macular 
Photocoagulation Study Group, 1991; Macular Photocoagulation Study 
Group, 1994). A major advance in treatment, first described in 1999, 
was the use of Verteporfin photodynamic therapy (PDT). Verteporfin is 
a photosensitiser, injected intravenously, that is selectively taken up by 
WKHDEQRUPDO³JURZLQJ´YHVVHOVRIWKHZHW$0'OHVLRQ,UUDGLDWLRQRIWKH
lesion with a diode laser for 83 seconds leads to vessel thrombosis and 
lesion regression in many cases, while leaving the foveal/macular 
photoreceptors unaffected. A study using this treatment showed that 
after 24 months follow up, the proportion of patients with a particular 
subtype of wet AMD (predominantly classic) losing fewer than 15 letters 
on the visual acuity chart was 61% in those given treatment compared 
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with 46% for those given placebo (TAP Study Group, 2001). Since the 
occluded vasculature commonly re-canalised, patients required an 
average of 5.6 treatments in the 24 months of the study. The type of 
lesion treated in the above trial only constitutes approximately 20% of 
patients with wet AMD; however this treatment received National 
Institute of Clinical Excellence and Health (NICE) approval for lesions 
ZLWKDSUHGRPLQDQWO\³FODVVLF´DSSHDUDQFHRn fluorescein angiography. 
Verteporfin PDT appeared not to be as effective in the type of lesions 
that constituted the remaining 80% of cases (minimally classic and 
occult lesions). During the early years of the 21st century, most patients 
with wet AMD were therefore still effectively untreatable. 
 
Research by our colleagues in oncology has shown that tumours rely 
on the growth of new blood vessels for their survival and that those 
blood vessels require VEGF for their growth. This led to the use of a 
number of anti-VEGF agents in the treatment of solid tumours. Based 
on those agents, a number of anti-VEGF agents (antibodies and an 
aptamer) were initially tested in animal models (Krzystolik et al, 2002) 
and have subsequently been licensed for the intra-ocular treatment of 
ZHW$0'7KHILUVWOLFHQVHGGUXJZDVSHJDSWDQLE0DFXJHQ7KLVLV
an aptamer that binds one subtype of VEGF (VEGF165). It is given every 
6 weeks in the form of an intra-vitreal injection. Results from two large 
randomised placebo controlled trials involving around 1200 patients 
demonstrated visual stabilisation in approximately 70% of patients after 
receiving the drug for 2 years (VISION Clinical Trial Group, 2006). Very 
few patients were noted to have improved vision. Approximately 55% of 
those receiving placebo treatment demonstrated visual stability. 
Importantly, all wet AMD lesion types (classic and occult) appeared to 
respond to treatment. Although the drug appeared to be safe, there was 
a 1.3% incidence of potentially visually devastating intra-ocular infection 
(endophthalmitis).  
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More recently, a second agent, 5DQLEL]XPDE/XFHQWLVKDVEHHQ
licensed and approved by NICE. This is a fragment of a monoclonal 
antibody that binds and inhibits the action of all subtypes of VEGF and 
was initially shown to be effective in a laser-induced CNV model in 
monkeys (Krzstolik et al, 2002). It is given every 4 weeks by intra-vitreal 
injection. The results of a large multicentre placebo controlled 
randomised trial showed that at 12 months, 95% of patients receiving 
monthly treatment demonstrated stable vision compared with 62% of 
those receiving placebo (Brown et al, 2006; Rosenfeld et al, 2006). The 
latter result highlights the favourable natural history of the disease in 
some patients. In addition, 34% of those receiving active treatment 
demonstrated improved vision. These benefits persisted for up to 
PRQWKVRIFRQWLQXRXVWUHDWPHQW$VZLWK0DFXJHQWKHPDMRUULVN
of treatment was endophthalmitis.  
 
%HIRUH5DQLEL]XPDE/XFHQWLVUHFHLYHGLWVOLFHQVHPDQ\
ophthalmologists had begun to treat patients with intra-vitreal 
%HYDFL]XPDE$YDVWLQLQMHFWLRQV7KLVLVDQDQWL-VEGF monoclonal 
antibody, formulated for the intravenous treatment of bowel cancer 
(Vincenzi et al, 2009). On a dose for dose basis, it is much cheaper 
WKDQ5DQLEL]XPDE/XFHQWLVDQGPD\EHDVHIIHFWLYHEXWLWLVQRW
licensed for intra-RFXODUXVH$WSUHVHQWWKHUHIRUHRQO\/XFHQWLVLV
approved by NICE for the treatment of wet AMD. Pegaptanib 
0DFXJHQZDVQRWDSSURYHGIRUXVHLQWKH1+6E\1,&(although 
clinically effective as it was thought not to be cost-effective, and not as 
HIIHFWLYHDV5DQLEL]XPDE/XFHQWLV 
 
In vitro study of endothelial cells with relevance to AMD 
 
In an attempt to further our understanding of the complex processes 
that underlie the proliferation of these inner choroidal endothelial cells, 
investigators have studied, in vitro, the phenotype and growth 
characteristics of bovine choroidal and choriocapillaris endothelial cells 
(Liu & Li, 1993; Sakamoto et al, 1995a; Sakamoto et al, 1995b; Morse 
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& Sidikaro, 1990; Hoffman et al, 1998; Liu et al, 1998; Wang et al, 
2002; Zubilewicz et al, 2001a; Zubilewicz et al, 2001b; McLaughlin & 
Vries, 2001; Eter & Spitznas, 2002) and heterogeneous mixtures of 
human choroidal endothelial cells (Penfold et al, 2002; Geisen et al, 
2005; Peterson et al, 2007; Sakamoto et al,1995; Bargagna-Mohan et 
al, 2006) or macrovascular (HUVECs) (Shankar et al, 2008; Stahl et al, 
2008). 
 
It is well recognised, however, that endothelial cells from different 
species and anatomical sites vary widely in their phenotype and growth 
characteristics. For example, in the eye, retinal endothelial cells 
resemble those of the brain in having tight junctions but no 
fenestrations, whereas choroidal endothelial cells express 
fenestrations. It has also been shown ex vivo and in vitro that 
microvascular endothelial cells in the human lung predominantly 
express CD34, whereas lung macrovascular endothelial cells and 
HUVECs predominantly express vWf in preference to CD34 (Müller et 
al, 2002). This means that it may not be appropriate to extrapolate data 
from more general endothelial cell models to study human choroidal 
neovascularisation due to the discrete species differences and the 
unique, anatomical and microvascular environment of the inner 
choroidal endothelial cell (ICEC). It would therefore seem logical to 
study human inner choroidal endothelial cells in an attempt to further 
our understanding of the neovascular form of AMD.  
 
In vitro experiments using human choroidal endothelial cells  
 
To date, human inner choroidal endothelial cells have not been 
selectively isolated and studied. However, workers have developed 
techniques to isolate human choroidal endothelial cells (hCECs) and 
have conducted a number of studies on them. 
 
Sakamoto et al in 1995a published a method to isolate human CECs 
using a density gradient to separate choroidal fragments after 
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collagenase digestion. The growing human CECs were purified by 
cloning. Using this technique, cells of 95% purity were isolated. 
Subsequently, Fan et al in 2002 enhanced human CEC purification by 
utilising anti-CD31 coated paramagnetic beads. They used these cells 
in a co-culture system with RPE cells stimulated with IL-1 and 
separated by a semi-permeable membrane to identify disease 
mechanisms in choroidal neovascularisation (Fan W et al, 2002). 
Geisen et al (2005) demonstrated increased migration of hCECs across 
a membrane when exposed to RPE cell conditioned medium and, to a 
lesser extent, VEGF. Peterson et al in 2007 demonstrated that PI-3K 
and Akt were important in this process of hCEC migration across a 
similar membrane. Unusually, VEGF had no effect on cell proliferation 
in these experiments. This is a very unusual result as, to date, all 
endothelial cells appear to respond to VEGF. The reason for this 
atypical result may be due to later passage hCECs being used in their 
experiments. It is known that endothelial cells, on passaging, may 
undergo phenotypic change and thus may change their in vitro 
behaviour (Shima et al, 1995; Prasad et al, 2006). Penfold et al in 2002 
also used these cells to demonstrate down-regulation of cell surface 
ICAM 1 and MHC antigens with a type of steroid that has been shown 
to have a beneficial role in the treatment of wet AMD, thereby 
hypothesising a mechanism for its actions.  
 
Steinle et al in 2003 demonstrated that sympathetic denervation in 
animals led to blood vessel growth in both the retina and choroid, and 
increased levels of local nerve growth factor (NGF) levels. They 
hypothesised that NGF was responsible for this up-regulation of 
angiogenesis. Using isolated human retinal and choroidal endothelial 
cells, they showed a difference in response when the cells were 
exposed to NGF in vitro. Choroidal ECs appeared to respond by 
increasing proliferation and migration to NGF via ERK 1/2 and Akt, 
whereas retinal ECs did not respond. An important difference in ocular 
EC response to external factors was therefore found, reinforcing the 
heterogenic nature of ECs within a single organ. In a similar vein, 
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Steinle et al in 2005 also demonstrated that human CECs possess ß 
adrenoreceptors and that stimulation of the ß3 receptors again resulted 
in activation of ERK 1/2 and Akt and affected cell migration and 
invasion. The role of the sympathetic/ parasympathetic nervous 
systems in choroidal neovascularisation remains unknown, however.  
 
Diabetic retinopathy 
 
Diabetes mellitus currently affects 150 million people worldwide. This 
number is set to soar by 2025 to reach 300 million, partly because of 
the epidemic of obesity (King et al, 1998). The majority of patients have 
type 2 diabetes mellitus where there is resistance to the action of 
insulin, although it is initially produced in normal amounts. Most patients 
with this type of diabetes are over the age of 40 years at disease onset. 
A minority of patients have type 1 or insulin-dependent diabetes which 
is caused by a lack of insulin due to autoimmune destruction of the 
pancreatic  cells. Both types of diabetes are characterised by raised 
blood glucose levels. A major effect of the disease process is the 
damage caused to the macrovascular and microvascular circulations 
leading to diseases of large vessels such as stroke and heart attack, 
and microvascular disorders such as renal glomerular damage, 
peripheral neuropathy and retinal vascular complications. 
 
Epidemiological studies have shown that after 15 years, almost all 
patients with type 1 diabetes and around 50% with type 2 diabetes not 
receiving insulin treatment have some degree of diabetic retinopathy. 
After 20 years of diabetes, 5.6% of patients will have developed 
clinically significant macular oedema caused by break down of the inner 
blood retinal barrier. Also, 7.9% will develop sight threatening 
retinopathy which includes proliferative diabetic retinopathy (PDR) due 
to retinal angiogenesis and consequent vitreous haemorrhage and 
tractional retinal detachment (Klein et al, 1989). More specifically, PDR 
occurs in 50% of type 1 diabetics and 15% of type 2 patients who have 
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had the disease for 25 years (Klein et al, 1989), making diabetes the 
leading cause of blindness in people under 65 years of age.  
 
 
 
 
 
 
 
Fig 1.26. Proliferative diabetic retinopathy (neovascularisation of the 
retina (upper), and optic disc (lower)). (Courtesy of the University of 
Wisconsin photographic reading centre) 
Advanced retinal 
neovascuarisation 
Seen in a diabetic 
patient  
Advanced optic disc 
neovascuarisation 
seen in a diabetic 
patient  
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The exact mechanism or pathogenesis of diabetic retinopathy is 
uncertain but persistent hyperglycaemia eventually leads to 
microvascular damage to the retina. Possible mechanisms include 
increased flux of sugars through the polyol or hexosamine pathway with 
subsequent changes in endothelial cell redox potential. This leads to 
the accumulation of intracellular sorbitol and cell damage. Another 
possible important mechanism is excessive activation of the 
intracellular messenger diacylglycerol (DAG) with subsequent activation 
of protein kinase (PKC). Lesions include retinal capillary basement 
membrane thickening, pericyte and vascular smooth muscle cell drop 
out, capillary microaneurysms and capillary occlusion. Other 
mechanisms include alterations in blood rheology, accumulation of 
advanced glycation end products (AGES), free radicals and over-
activation of the renin-angiotensin system (Brownlee, 2001; Stitt et al, 
2005; Curtis et al, 2009). 
 
Whatever the mechanism, the resulting pathological retinal lesions are 
caused by progressive inner retinal ischaemia (secondary to 
microvascular occlusion) and the subsequent secretion of pro-
angiogenic growth factors such as VEGF (Campochiaro, 2000). The 
role of VEGF in the causation of proliferative diabetic retinopathy has 
been strongly implicated by the finding that repeated intravitreal 
injections of VEGF165 into cynomolgus monkeys produces many of the 
changes in the retinal vasculature that are seen in diabetes, such as 
venous dilatation and tortuosity, retinal ischaemia, capillary 
microaneurysmal dilatation and pre-retinal neovascularisation 
(Tolentino et al, 1996; Tolentino et al, 2002). It appears that IGF-1 may 
also play a role in proliferative diabetic retinopathy (Chantelau et al, 
1997; Smith et al, 1997; Smith et al, 1999). It was observed many years 
ago that hypophysectomy (removal of the pituitary gland in patients with 
acromegaly (who also had diabetic retinopathy) led to a resolution of 
the PDR (Wright, 1969). It is known that the main stimulus for IGF-1 is 
growth hormone (GH) produced by the pituitary. Secondly, improved 
diabetic control by increased levels of insulin leads to higher levels of 
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IGF 1 (Chantelau et al, 1997) and VEGF (Lu et al, 1999) in the blood. 
This may explain the commonly occurring worsening of retinopathy 
when blood sugar levels are dramatically improved. It has also been 
observed that cardiac events increase when sudden improvement in 
blood sugars occurs (ACCORDS Group, 2008). Systemic blockade of 
growth hormone by a GH antagonist also leads to improvement in 
diabetic retinopathy (Boehm et al, 2000). 
 
Current proven treatment for diabetic retinopathy involves laser 
photocoagulation to areas of macular oedema (in an effort to stimulate 
regression of oedema by unknown mechanisms) or the obliteration of 
areas of retinal ischaemia in an effort to down regulate the production of 
pro-angiogenic growth factors. As VEGF appears to play a role in both 
the breakdown of the inner blood retinal barrier (due to increased 
vascular permeability) and in the growth of new retinal blood vessels 
(by retinal angiogenesis), researchers have recently investigated the 
use of intravitreal injections of anti-VEGF antibodies. In clinical trials, 
these drugs (ranibizumab, bevacizumab and pegaptanib) appear to 
have a marked effect on the disease. However, they need to be given 
every 4 to 6 weeks by invasive intra- ocular injections in a similar 
fashion to the treatment of wet AMD, as mentioned earlier. Other 
targets for treatment include the interruption of intracellular signalling 
secondary to up-regulation of PKC activity and inhibition of IGF-1. 
 
It is known that hyperglycaemia leads to an increased synthesis of 
intracellular diacylglycerol (DAG) in endothelial cells which in turn leads 
to activation of protein kinase C (PKC) (Donnelly et al, 2004). The effect 
of increased PKC activation in endothelial cells is to bring about 
changes in vascular permeability and blood flow and to modify the 
formation and response to growth factors such as VEGF. The role of 
PKC in the pathogenesis was therefore thought to be important and has 
been the subject of much research (Donnelly et al, 2004). There are at 
least 12 isoforms of PKC with different tissue expression profiles 
(Moriarty et al, 2000). It emerged that hyperglycaemia leads to a 
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proportionately larger increase in the isoforms PKC I and PKC II in 
endothelial cells. Because PKC is widely found in different cells, 
treatment strategies using non-specific PKC inhibition were likely to 
lead to widespread tissue dysfunction and toxicity. In 1996, a more 
selective PKC inhibitor ( I and II ) became available and was used in a 
number of diabetic clinical trials The new drug, called LY-333531 
(Ruboxistaurin) was found to inhibit the increase in retinal blood flow 
and reduce macular oedema in diabetic patients (Frank, 2002). In one 
clinical randomised trial, the drug reduced moderate visual loss by 40% 
in those given the drug (cf. placebo). There was also a significant 
reduction in progression of diabetic macular oedema and the 
requirement of macular laser treatment (Aiello et al 2006). In a second 
study, the drug appeared to have no effect on the progression of 
diabetic retinopathy, a disappointing outcome. This study, however, 
again demonstrated a significant reduction in moderate visual loss 
(PKC-DRS study group, 2005). Although the preliminary results for the 
effects of this drug on diabetic eye disease appear encouraging, the 
drug has yet to be licensed for this use and the FDA in the USA has 
required further data in the form of further clinical trials before making a 
decision on its use.  
 
Retinopathy of prematurity 
 
Retinopathy of prematurity (ROP) is a proliferative retinopathy seen in 
³DWULVN´QHZERUQLQIDQWVDQGUHPDLQVDOHDGLQJFDXVHRIFKLOGKRRG
blindness. It was first recognised in 1942 when a link between 
proliferative retinopathy and neonatal oxygen supplementation was 
described. Over the next 20 years, as the rate of oxygen 
supplementation reduced, so did the incidence of ROP. During the 
¶VDQG¶VLWVLQFLGHQFHLQFUHDVHGDJDLQGXHWRDGYDQFHVLQ
neonatal care in which lower birth weight children survived. The risk of 
developing abnormal retinal neovascularisation or ROP appears to be 
inversely related to birth weight and gestation. During normal 
 108 
development of the retina, vessels migrate from the optic disc to the 
periphery of the eye, starting at week 16. Interruption of this process by 
premature birth leads to areas of avascular peripheral retina being 
present after birth. If the baby is given high concentrations of inspired 
oxygen (necessary due to under-developed lungs) this leads to 
inhibition of normal retinal vascular development by suppressing 
capillary development and causing vascular obliteration at the interface 
between normal and avascular retina. If the oxygen tension is then 
reduced, the areas of avascular retina become hypoxic and secrete 
growth factors such as VEGF. This in turn leads to uncoordinated 
retinal neovascularisation at the junctional zone.  
 
 
 
 
The recognition and treatment of ROP involves regular examination of 
³DWULVN´H\HVIRUWKHWHOOWDOHVLJQVRIUHWLQDOQHRYDVFXODULVDWLRQIRUPLQJ
a ridge at the junctional zone. This would lead to treatment to ablate the 
areas of avascular retina by laser or cryotherapy. Failure of treatment 
may lead to retinal detachment by fibrovascular membranes and 
vitreous haemorrhage, both leading to poor visual outcome.  
 
Fig 1.27. Fundus 
photograph of a 
SUHPDWXUHEDE\¶VOHIW
eye, demonstrating a 
ridge of 
neovascuarisation in 
the peripheral area of 
the retina. Also note the 
dilated and tortuous 
retinal vessels, 
indicating marked 
retinal ischaemia 
(courtesy of the 
University of Texas) 
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Much understanding of this disease has come from an animal model in 
which one week old mice are exposed to 75% oxygen for 5 days and 
then are returned to room air. Neovascularisation occurred between 
post natal days 17 and 21, at the junction between vascularised and 
avascular retina in the mid periphery. In contrast to the human disease, 
this murine model develops vasoconstriction and ischaemia around the 
disc at the posterior pole with sparing of the peripheral vessels (in the 
human disease, the opposite distribution of vascular closure occurs). 
This distribution is thought to be because of continued perfusion of the 
murine peripheral retina by remnants of the central hyaloid vessels. The 
retinal ischaemia induced by the vascular closure causes a reflex over-
expression of VEGF which in turn leads to abnormal retinal 
neovascularisation or angiogenesis (Smith et al, 1994). Nowadays, the 
use of lower levels of oxygen supplementation would be thought to 
have led to a marked reduction in the incidence of ROP if the oxygen 
hypothesis is the unifying hypothesis, but in reality this has not 
happened. Slidsborg et al in 2008 found that the incidence of ROP 
doubled in Denmark between 1996 to 2000 and 2001 to 2005, while in 
Canada, Schiatriti et al in 2008 found an increase between the periods 
1992 to 1996 and 1997 to 2001. Conventional treatment of ROP 
involves the ablation of the ischaemic peripheral retina in the hope of 
reducing the risk of ultimate retinal detachment. Recently, intravitreal 
injection of anti-VEGF agents such as bevacizumab (Avastin) has been 
used experimentally in an attempt to reduce or abolish the 
neovascularisation (Mintz-Hittner et al, 2011). While the treatment was 
very successful in treating neovascularisation around the optic disc and 
macula, it was unsuccessful for disease in the more peripheral retina. 
This would imply that peripheral disease is not VEGF driven or that 
other mechanisms are responsible for this stage of disease. Some 
workers suspect that other factors apart from VEGF may be important 
in disease pathogenesis and progression. It has been hypothesised that 
IGF 1 may play a role because its secretion correlates with birth weight 
and gestational age (Hellström et al, 2002; Hellström et al, 2003). In 
addition, IGF-1 levels drop in the neonatal period as the main sources 
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to the infant, the placenta and the amniotic fluid, are lost. Recent 
studies have shown that IGF-1 is important for retinal vascular 
development and is an endothelial survival factor (Modanlou et al, 
2006; Lofqvist et al, 2009; Hellström et al, 2002) and if IGF-1 levels rise 
quickly after birth, normal development occurs. It has also been shown 
that in the presence of low IGF-1 levels, VEGF is insufficient to allow 
retinal vascular development. It is thought that when IGF-1 levels are 
low, retinal vessels fail to develop, allowing the retina to become 
hypoxic and VEGF to accumulate. With the normal increase in IGF 1 
with age a threshold is reached that allows VEGF to trigger the massive 
increase in retinal angiogenesis, implying that IGF 1 is required for 
maximal VEGF action. It has now been hypothesised that a blood test 
to measure IGF 1 levels may predict those babies at risk of ROP and 
that IGF 1 supplementation may restore normal retinal vasculature 
development in such infants (Hellström et al, 2001). 
 
Iris neovascularisation 
 
Very few disorders appear to specifically affect the iris vasculature with 
the exception of anterior uveitis, an autoimmune inflammatory condition 
that targets cells within the iris and the ciliary body. In this condition, 
leukocytes are attracted to the iris vasculature and pass through gaps 
between the endothelial cells to reach the tissue interstitium. The 
underlying pathogenesis of this condition and the target antigens are 
largely unknown.  
 
Occlusion and subsequent ischaemia of the iris vasculature in 
conditions such as herpetic uveitis and acute angle closure glaucoma 
rarely, if ever, give rise to iris neovascularisation. This is perhaps 
because the level of VEGF stimulated by the occlusion is too low or it is 
rapidly removed from the anterior segment of the eye by the rapid flow 
of aqueous. Iris neovascularisation tends to occur in the presence of 
retinal ischaemia caused by diseases such as diabetes mellitus or by 
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retinal vascular occlusions such as central retinal vein occlusion. Both 
of these conditions are thought to generate large amounts of VEGF that 
diffuse into the anterior chamber and hence come into contact with the 
iris vasculature. Iris neovascularisation can occur in the absence of 
retinal neovascularisation. The reason for this is unknown but may 
include the rapid diffusion of VEGF away from the retina towards the 
anterior segment and the potential production of pro-angiogenic 
substances to which the iris but not the retina responds. In a primate 
model of central retinal vein occlusion with iris neovascularisation, 
levels of retinal VEGF and VEGF mRNA are significantly raised, while 
intra-ocular injection of VEGF is sufficient to cause iris new vessel 
growth (Miller et al, 1994). This effect can be neutralised by injection of 
anti-VEGF antibodies (Adamis et al, 1996). Iris neovascularisation 
usually starts at the pupil margin (perhaps due to the flow of VEGF from 
the posterior segment) and grows across the iris to the drainage angle 
and the trabecular meshwork. Angiogenesis in the drainage angle 
impedes the outflow of aqueous and (rubeotic) glaucoma ensues. 
Histopathological examination reveals that the new vessels arise from 
pre-existing capillaries, are thin walled and interestingly are fenestrated. 
Normal iris capillaries are not fenestrated (Bron et al, 1997a).  
 
Conclusion 
 
It is now widely accepted that endothelial cells derived from different 
species, vascular organs and from within different vascular beds, 
display phenotypical, biochemical and genetic heterogeneity. It follows 
that the extrapolation of results from non human ocular or HUVEC cells 
may not provide reliable data applicable to human eye disease. Any 
meaningful insight into the pathogenesis and selective treatment of the 
diseases mentioned previously would therefore probably only be gained 
by conducting in vitro studies using early passage microvascular 
endothelial cells derived from the particular site(s) affected by specific 
diseases because within the ocular vascular beds themselves, many 
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diseases appear site specific. This work therefore aims to develop 
techniques to isolate human ocular vascular endothelial cells, in 
particular, those from the inner macular choroid, as these are thought to 
be crucial to the pathogenesis of the common blinding condition, wet 
AMD. This work also aims to explore their heterogeneity by comparing 
their differential gene expression with endothelial cells from other sites, 
both within the human choroid and at other sites within the eye. I also 
aim to determine the effects of various growth factors on the macular 
choroidal endothelial cells in an attempt to more fully understand some 
of the important mechanisms that may contribute to wet AMD and that 
may perhaps lead to new targets for disease treatment.  
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The Isolation of Ocular 
Microvascular Endothelial Cells 
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Introduction 
 
Previous investigators have utilised a variety of techniques to isolate 
vascular endothelial cells from a diverse range of human tissues and 
organs. These include the bone marrow (Rafii et al, 1994; Masek & 
Sweetenham, 1994), myometrium (Gargett et al, 2000), placenta (Dye 
et al, 2001), stomach (Hull et al, 1996), saphenous vein (Scoumanne et 
al, 2002), retinal capillaries (*LWOLQDQG'¶$PRUHSu et al, 1992) 
and iris (Silverman et al, 2001). Early techniques relied on enzyme 
digestion of the tissue, followed by selective scraping of contaminating 
cells in culture, followed by preferential growth of endothelial cells in 
selective media containing a range of agents such as brain extract, 
retinal extract or heparin. Later, enzyme tissue digestion was first 
followed by density gradiHQWVHSDUDWLRQDQGWKHQ³VZHHSLQJ´RIFXOWXUHG
cells. However, more modern techniques rely on cell isolation by 
endothelial specific/selective antibodies attached to paramagnetic 
EHDGVVXFKDVWKH³'\QDEHDG´(QGRWKHOLDODQWLJHQVXVHGLQFOXGH
CD31 (PECAM1) and lectins such as Ulex europaeus agglutinin 1 
(UEA-1). The manufacturer states that binding of CD31 paramagnetic 
beads has no effect on cell properties or stimulation; however, Tiwari et 
al in 2003 stated that CD31 coated beads may have an effect on cell 
proliferation when used in high concentrations (higher than the 
manufacturers recommendation). A method is described below for the 
reliable isolation of ocular microvascular endothelial cells from human 
eyes that may then be used for subsequent analysis. 
 
Methods 
 
Human posterior segments were obtained from UK Transplant within 72 
hours of death. The corneas had previously been removed for 
transplantation and the posterior segments were stored at 4°C in sterile 
normal saline if consent for their use in research had been obtained. 
Donors were free of any known ocular disease or systemic infection. 
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The project had the approval of the Manchester eye bank and the local 
research ethics committee (Nottingham 2 LREC ) (Nottingham 
Q1060301). 
 
Isolation of human choroidal endothelial cells  
 
Human eyes were dissected on sterile Petri dishes on an open 
laboratory bench using a binocular dissecting microscope 
(approximately x10 magnification). It was intended to perform the 
procedure in a laminar flow hood but this would not accept the 
dissecting microscope. It was subsequently found that the rate of 
culture infection using the bench dissection was very low, justifying this 
approach. Dissection was conducted using disposable equipment or 
instruments sterilized in 100% alcohol. 
 
The iris was removed and was stored in isolation medium consisting of 
Minimum Essential Medium (MEM) (Invitrogen Ltd, Paisley, UK) 
FRQWDLQLQJȝJPODPSKRWHURFLQ%ȝJPOVWUHSWRP\FLQȝJPO
NDQDP\FLQDQGȝJPOSHQLFLOOLQIRUXSWRminutes at room 
temperature. Four relieving-incisions were made in the sclera, and the 
posterior segment was flat mounted. The vitreous was removed and 
discarded and the neuroretina was teased from the underlying choroid 
and stored in isolation medium consisting of Minimum Essential 
0HGLXP0(0,QYLWURJHQ/WG3DLVOH\8.FRQWDLQLQJȝJPO
DPSKRWHURFLQ%ȝJPOVWUHSWRP\FLQȝJPONDQDP\FLQDQG
ȝJPOSHQLFLOOLQ. The overlying retinal pigment epithelium (RPE) was 
removed by gentle brushing with a sterile spatula and irrigated with 
sterile phosphate buffered saline (PBS) and discarded. The full 
thickness choroidal sample could now be separated from the sclera 
with toothed forceps. The bridging vortex veins were cut with sterile 
scissors, as were the adhesions around the optic disc.  
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The choroidal samples from each pair of eyes were combined and 
washed 3 times in isolation medium (composition described above) and 
cut into 1-2mm pieces. The pieces were incubated in collagenase I 
(0.1%) in MEM for 60 minutes at 37°C with frequent agitation. After 60 
minutes, the collagenase was neutralised with MEM and 10% foetal calf 
serum (Invitrogen Ltd, Paisley, UK). The mixture was filtered through a 
sterile 40µm filter (Millipore Ltd, Watford, UK) and the eluate was 
centrifuged at 75g and washed 3 times in isolation medium. The cells 
were re-suspended in 1 ml of PBS/ 0.1% BSA and were incubated with 
25µl of anti-CD31 coated D\QDEHDGVIRUPLQXWHVDW&'\QDO
Ltd, Wirral, UK). After binding of the Dynabeads, the complexes were 
washed 4 times in PBS/ 0.1% BSA using a magnetic particle 
concentrator (Dynal Ltd, Wirral, UK). The endothelial-bead complexes 
were re-suspended in Endothelial Growth Medium (EGM2-MV with 
hydrocortisone omitted) (Cambrex Biosciences, Wokingham, Berks, 
UK) and seeded onto either 30mm fibronectin-coated culture dishes 
(Beckton Dickinson, Oxford, UK) or into 25cm2 fibronectin-coated flasks 
(Beckton Dickinson, Oxford, UK), depending on the experiment the 
cells were required for. After overnight incubation at 37ºC in a 
humidified atmosphere of 5% CO2, fresh endothelial growth medium 
was added. After 5-7 days, large areas of confluent cells were present 
and were removed for experiments with 0.025% trypsin and 0.01% 
EDTA in sterile PBS, after which the cells were washed 3 times with 
sterile PBS. All reagents were from Sigma-Aldrich, Poole, Dorset, UK 
unless otherwise specified. 
 
Isolation of human iris endothelial cells  
 
During the dissection of human donor eyes, the irides were removed 
and placed into isolation medium as mentioned previously. The irides 
were removed from the isolation medium and placed onto a sterile petri 
dish. The posterior aspect of the iris was brushed with a sterile spatula 
to remove the pigmented epithelium. The irises were then cut up into 
tiny pieces and washed in isolation medium as described above (for the 
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choroidal endothelial cells). The tissue was then treated exactly as 
detailed above to isolate the iris microvascular endothelial cells.  
 
Isolation of human retinal endothelial cells  
 
During the dissection of human donor eyes, the retina was removed 
and placed into isolation medium as mentioned previously. The retinal 
samples were transferred onto a sterile petri dish and cut into tiny 
pieces. The sample was then transferred back into isolation medium 
and processed as detailed previously to isolate the choroidal 
microvascular endothelial cells.  
Human umbilical vein endothelial cells (HUVEC) 
 
Fresh un-passaged HUVEC cells were purchased from PromoCell 
GmbH, Heidelberg, Germany. On arrival, the cells were thawed and re-
suspended in endothelial growth medium (EGM2-MV with 
hydrocortisone omitted, Cambrex Biosciences, Wokingham, Berks, UK) 
and washed 3 times. The cells were purified using Dynabeads and then 
seeded onto fibronectin-coated 35mm culture dishes (Beckton 
Dickinson, Oxford, UK) and incubated at 37 C in a humidified 
atmosphere of 5% CO2 as previously described.  
Endothelial cell characterisation 
 
Prior to use in subsequent experiments, a small sample of trypsinised 
cells, suspended in EGM-2MV, was placed onto sterile glass cover slips 
(VWR Ltd, Poole, UK) coated with 1% gelatin (Sigma) (cover slips were 
immersed in 1% gelatin in sterile PBS for 30 mins at 37°C, then washed 
gently in sterile PBS and dried in a laminar flow hood). After allowing 3 
hours for cells to attach, they were fixed in ice cold methanol at -20°C 
for 20 minutes. A standard two-stage immunofluoresence technique 
was applied using primary antibodies to CD31 (murine IgG1) (Dako, 
Cambridgeshire, UK) at a dilution of 1:20 and vWf (rabbit 
immunoglobulin fraction) (Dako) at a dilution of 1:200. The primary 
antibodies were left in contact with the cells for 60 minutes before 
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washing 4 times with sterile PBS. The secondary antibodies used were: 
rabbit anti-PRXVH)DE¶IUDJPHQWIOXRUHVFHLQLVRWKLRF\DQDWH),7&
conjugated (Dako) at a dilution of 1:20 when used to visualise the anti-
CD31 primary antibody; and swine anti-UDEELW)DE¶IUDJPHQW),7&
conjugate (Dako) at a dilution of 1:20 to visualise the anti-vWf primary 
antibody. The secondary antibodies were left in contact with the cells 
for 60 minutes before washing 4 times with sterile PBS. The slides were 
then mounted in glycerol containing 2.5% 1-4 diazabicyclo[2,2,2] octane 
(DABCO) (Sigma ±Aldrich) and observed by confocal fluorescence 
microscopy (Leica TCS0D, Leica, Milton Keynes, UK). A non-specific 
anti-rat epitope murine IgG1 antibody was used as a negative control 
primary antibody for the CD31 (mouse) antibody) and FITC labelled 
non-specific swine anti-rabbit immunoglobulin fraction  (DAKO) as a 
negative control for the vWf  antibody . Negative controls for the 
secondary antibody (only possible for anti-CD31 as anti-vWf was a 
labelled primary antibody)  was performed by replacing the secondary 
antibody with PBS  In assessing the identity and purity of the 
endothelial cells, at least 500 nucleated cells were counted after 
staining with each antibody. For some of the identification experiments, 
the cell nuclei were also stained with propidium iodide (500nM for 60 
seconds) to aid cell detection.  
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Results 
 
After isolation, HUVEC, choroidal, iris and retinal endothelial cells all 
grew with a typical cobblestone morphology (figs. 2.1-2.4). By randomly 
counting at least 500 cells, at least 99.5 % of each cell type 
demonstrated positive expression of CD31 (fig. 2.5) and vWf (fig. 2.8), 
thereby confirming their identity as endothelial cells. Negative control 
samples for both CD31 (primary and secondary antibody) and vWf 
(primary antibody) failed to show any significant staining, thereby 
confirming the positive results for the primary antibodies. Each 25cm2 
flask used to grow each sample provided up to 200,000 endothelial 
cells of extremely high purity for use in subsequent experiments.  
        
 
 
 
Fig. 2.1. Phase contrast photomicrograph of primary cultures of human 
umbilical cells (HUVEC) demonstrating a typical cobblestone 
appearance. The dark clumps are adherent Dynabeads (20x original 
magnification) 
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Fig. 2.2. Phase contrast photomicrograph of primary cultures of human 
choroidal endothelial cells demonstrating a typical cobblestone 
appearance. The dark clumps are adherent Dynabeads (20x original 
magnification). 
 
 
 
 
Fig. 2.3. Phase contrast photomicrograph of primary cultures of human 
retinal endothelial cells demonstrating a typical cobblestone 
appearance. The dark clumps are adherent Dynabeads (20x original 
magnification). 
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Fig. 2.4. Phase contrast photomicrograph of primary cultures of human 
iris endothelial cells demonstrating a typical cobblestone appearance. 
The dark clumps are adherent Dynabeads (20x original magnification). 
 
 
 
 
Fig. 2.5a. Immunofluorescent photomicrograph of human retinal (left) 
and choroidal (right) endothelial cells stained for CD31 (63x original 
magnification). Note the predominance of staining at edges of cells, the 
area where the density of the cell adhesion molecule CD 31 is known to 
be highest. 
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Fig. 2.5b. Immunofluorescent photomicrograph of human iris (left) and 
umbilical vein (right) endothelial cells stained for CD31 (63x original 
magnification). Note the predominance of staining at edges of cells, the 
area where the density of the cell adhesion molecule CD 31 is known to 
highest. Also note that the nuclei have been stained red with propidium 
iodide to aid detection. 
 
 
 
 
 
Fig. 2.6a. Immunofluorescent photomicrograph of human retinal (left) 
and choroidal (right) endothelial cells stained with a non-specific anti-rat 
epitope murine IgG1 antibody as a negative control of the anti-CD31 
primary antibody (63x original magnification).Note the absence of any 
staining of cells. Some non-specific fluorescence from precipitation of 
secondary antibody can be seen. 
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Fig. 2.6b. Immunofluorescent photomicrograph of human iris (left) and 
umbilical vein (right) endothelial cells stained with a non-specific anti-rat 
epitope murine IgG1 antibody as a negative control of the anti-CD31 
primary antibody (63x original magnification).Note the absence of any 
staining of cells. Some non-specific fluorescence from precipitation of 
secondary antibody can be seen. Also note that the nuclei have been 
stained red with propidium iodide to aid detection. 
 
 
 
 
 
Fig. 2.7. Immunofluorescent photomicrograph of human retinal (left) 
and choroidal (right) endothelial cells stained with anti-CD31 and the 
secondary antibody replaced with PBS (63x original magnification).Note 
the absence of any specific staining of cells. Some very faint 
background fluorescence from the cells can be seen. 
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Fig. 2.8a. Immunofluorescent photomicrograph of human retinal (left) 
and choroidal (right) endothelial cells stained for vWf (63x original 
magnification). Note the predominance of staining within granules in the 
cell cytoplasm. While many microvascular ECs are stated not to have 
electron dense Weibel-Palade bodies, the traditional site of vWf 
storage, it is now known that vWf can also be stored in alternative intra-
cellular vesicles. Analysis of gene expression data from chapter 3 
reveals that both choroidal and retinal ECs show a significant 
expression of vWf.  
 
 
 
 
Fig. 2.8b. Immunofluorescent photomicrograph of human iris (left) and 
umbilical vein (right) endothelial cells stained for vWf (63x original 
magnification). Note the predominance of cytoplasmic granular staining 
consistent with the known location of vWf within ECs. Nuclei are stained 
red with propidium iodide to aim cell localisation. 
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Fig. 2.9a. Immunofluorescent photomicrograph of human retinal (left) 
and choroidal (right) endothelial cells stained with a FITC labelled non-
specific swine anti-rabbit immunoglobulin fraction as a negative control 
of the anti-vWf primary antibody. Note the absence of any staining of 
cells. Some very faint fluorescence from non specific binding can be 
seen as well as the natural fluorescence of Dynabeads (green circles) 
 
 
 
 
Fig. 2.9b. Immunofluorescent photomicrograph of human iris (left) and 
HUVEC (right) endothelial cells stained with a FITC labelled non-
specific swine anti-rabbit immunoglobulin fraction as a negative control 
of the anti-vWf primary antibody. Note, the nuclei are stained red with 
propidium iodide to aid cell localisation.  
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Discussion  
 
The work described in this chapter demonstrates that it has been 
possible to reliably isolate microvascular endothelial cells from the 
choroid, iris, and retina. Interestingly, to the naked eye, they appear 
similar with typical cobblestone appearances. Visual inspection also 
failed to show any evidence of Weibel-Palade bodies, often present in 
macrovascular ECs. These bodies are thought to be the site of vWf 
storage before release at the cell surface where it plays a role in blood 
coagulation. It can be seen in Fig 2.8 that numerous points of vWf 
staining are present in the choroidal EC cytoplasm. While these cells 
are thought to lack traditional WP bodies, they may store vWf in 
vesicles that lack the typical electron dense appearance on electron 
microscopy. It will be shown later that iris, retinal and choroidal ECs all 
express significant levels of vWf at a gene level when examined by 
gene microarray analysis, thereby confirming this immunohistochemical 
result. 
 
The origin and purity of the cells was confirmed and they could 
therefore be used in any subsequent experiments. The purity of cells 
matches that from other studies and the reliability of the isolation 
procedure means that matched iris, retinal and choroidal ECs can be 
isolated and cultured from the same patients. This will be a major 
advantage in forthcoming experiments, particularly those utilising gene 
expression techniques, as it removes much of the variability between 
samples due to differences in gene expression between different 
donors e.g. GXHWRWKHLUDJHRUJHQHWLF³PDNHXS´7KHWHFKQLTXHDOVR
allowed sufficient cells from each donor to be cultured. Approximately 
200,000 un-passaged endothelial cells could be cultured from a flask 
seeded with isolated ECs within 5-7 days. As will be seen later, this is 
enough to perform the experiments necessary to examine both gene 
expression profiles and to examine their in-vitro behaviour. 
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Introduction 
 
Intraocular angiogenesis causes a number of common blinding 
conditions including wet age-related macular degeneration, proliferative 
diabetic retinopathy, retinopathy of prematurity and rubeotic glaucoma. 
The pathogenesis of these disorders is centred upon choroidal, retinal 
and iris microvascular endothelial cells respectively. Ocular vascular 
disorders also appear to demonstrate a preference for different 
microvascular beds and sometimes particular locations within a 
microvascular bed, e.g. diabetes preferentially affecting the retinal 
vasculature and age related macular degeneration affecting the 
choroidal circulation. 
 
Investigators have attempted to increase the understanding of these 
disorders by studying non-ocular human endothelial cells derived from 
sites such as the umbilical vein (HUVEC) because of their availability in 
large numbers and their relative ease of culture. The conclusions drawn 
from studies using these cells have then been extrapolated to human 
angiogenic eye diseases. Stahl et al used the proliferation of HUVECs 
to study the effect of rapamycin on the production of VEGF by RPE 
cells in co-culture, thereby hypothesising that this drug may have a 
significant role in the treatment of choroidal neovascularisation (Stahl et 
al, 2008). Sakamoto et al used human RPE cells, transfected with 
retroviral vectors in culture with HUVECs, as a model for human ocular 
angiogenic diseases (Sakamoto et al, 1998), while Kumar (Kumar et al, 
2008) also used a co-culture system, this time, of aortic endothelial 
cells with retinal cells in the investigation of growth factors thought to 
important in human ocular angiogenic diseases. Sengutpa et al used 
human lung microvascular ECs to study the effect of stromal-derived 
factor and extrapolated the results to the study of choroidal 
neovascularisation (Sengupta et al, 2010), while Hamilton used a co-
culture system of HUVE cells and RPE cells, both grown on amniotic 
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membrane in oUGHUWRPLPLFWKHFKRULRFDSLOODULV%UXFK¶V
membrane/RPE complex found in human eyes (Hamilton et al, 2007).  
 
This in vitro system was hypothesised to be a model to investigate the 
mechanisms of wet AMD. Shankar et al recently used HUVECs to 
determine the importance of PI3K/AKT pathways in angiogenesis, 
applying the results to a range of conditions such as proliferative 
diabetic retinopathy and choroidal neovascularisation (Shankar S, 
2008), while Yang et al used HUVECs and RPE conditioned medium to 
study the pathogenesis of choroidal neovascularisation (Yang et al, 
1993). Lastly, Kim et al recently used HUVECs to study the effects of 
heptanomide (an inhibitor of histone deacetylase) (Kim et al, 2009) and 
deguelin (Kim et al, 2008) as models for the potential treatment of wet 
AMD. Because HUVECs are termed macrovascular ECs and are 
derived from a specialised tissue, it is uncertain if they are 
representative of ocular microvascular ECs in general and therefore 
may not be appropriate for investigation of the mechanisms of ocular 
angiogenic diseases.  
 
HUVECs have also been utilised in the investigation of angiogenic 
diseases elsewhere in the body. By association, other groups feel that 
these macrovascular cells offer results that can be applied locally to the 
blood vessels of the individual tissues of interest. These include 
melanoma-associated neovascularisation (Boyd et al, 2002; 
Mangiameli et al, 2007), brain glioblastomas (Chen et al, 2009; Martina 
et al, 2009), kidney (Ho et al, 2008) and the bone marrow (Cenni et al, 
2009). It has been discussed previously in chapter 1, however, that in 
vitro responses of HUVEC cells often differ from those of microvascular 
origin, such as retinal and dermal ECs, thereby emphasising the degree 
of scepticism needed when interpreting the results of experiments using 
HUVECs. 
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In order to use endothelial cells that are phenotypically closer to those 
found in the human choroid, other workers have used ocular cells from 
non-human sources. Examples include the use of bovine choroidal ECs 
in the investigation of cell signalling pathways (VEGF, PLC Ca2+and 
MAPK) thought to be important in choroidal angiogenesis. Bullard et al 
used bovine retinal ECs to investigate the importance of MAPK in 
retinal neovascularisation (Bullard et al, 2003), while Brylla et al used 
both bovine retinal and choroidal ECs to investigate the effect of 
hypoxia on angiogenesis (Brylla et al, 2003). The results of these 
experiments were thought to be applicable to retinal and choroidal 
neovascularisation in humans, but while the use of site-specific ECs is 
important, it is not known how close these bovine cells are 
phenotypically and genotypically to their human counterparts and how 
much inter species heterogeneity exists in important intracellular 
signalling pathways. 
 
As detailed previously in chapter 1, it is now widely accepted that 
endothelial cells derived from different vascular organs and from within 
different vascular beds within those organs display phenotypic, 
biochemical and genetic heterogeneity. Any definitive insight into the 
pathogenesis and selective treatment of human angiogenic eye 
diseases is therefore likely to be gained only by conducting studies 
using microvascular endothelial cells derived from the particular ocular 
site(s) affected by the disease. Recently, Smith et al studied the 
expression of 8500 genes of human retinal and choroidal endothelial 
cells using DNA microarrays (Smith et al, 2007). They demonstrated 
distinct differences in expression profiles between the two cell types, 
particularly in those genes thought to be important in the immune 
response and leukocyte trafficking. This may explain why the retina 
appears to be susceptible to certain inflammatory diseases such as that 
caused by toxoplasmosis (Smith et al, 2004). Recently, Chi et al used 
DNA microarrays to explore the diversity of human ECs from different 
blood vessels (no ocular ECs were examined) (Chi et al, 2003). They 
found distinct differences in gene expression between macro- and 
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microvascular endothelial cells and between microvascular ECs from 
different vascular beds.  
 
The aim of this section of work was to take the previously isolated, 
unpassaged, proliferating human umbilical vein cells and matched 
retinal, choroidal and iris endothelial cells and determine the degree of 
heterogeneity between the macrovascular and ocular microvascular 
ECs by microarray gene expression profiling. The difference in gene 
expression profiles was also determined between groups of different 
matched ocular microvascular ECs. Because of the previously stated 
interest in ocular angiogenic mechanisms, particular attention was paid 
to differences in those genes involved in vascular cell signalling. 
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Methods  
 
Three sets of matched, un-passaged human choroidal, retinal and iris 
endothelial cells and HUVECs from 3 different donors were cultured to 
approximately 80% confluence on fibronectin-coated 35mm culture 
plates as described previously. The age and sex of the donors were: 
47yrs male, 58yrs male and 63yrs female. The times from death to 
endothelial cell isolation were 49, 48 and 52 hours respectively.  
RNA extraction 
 
Total RNA was extracted from primary cultures of un-passaged 
endothelial cells when they had reached approximately 80% 
confluence, using the Qiagen RNeasy Minikit (Qiagen, Crawley, UK). 
This method has the advantage that RNA molecules of greater than 
200 bases are enriched, but smaller RNA molecules (tRNAs and 
rRNAs) are selectively excluded. 
 
To each culture plate was added 350µl of Buffer R/7ZLWKȕ-
mercaptoethanol added); this lead to almost instant lysis of the cells 
with release of RNA. The lysate was immediately pipetted into a 
microcentrifuge tube and vortexed for 60 seconds to ensure 
homogenisation. To the homogenised lysate was added an equal 
volume (350µl) of 70% ethanol and mixed well by pipetting. Each lysate 
was then added to the top of individual RNeasy columns and 
centrifuged at >8000g for 15 seconds. The flow-through was discarded 
and 700µl of Buffer RW1 was added to each column and again was 
centrifuged at >8000g for 15 seconds. The flow-through was again 
discarded. Next, 500µl of Buffer RPE was added to the column and 
centrifuged as before. Again, the flow-through was discarded. This step 
was repeated as previously, but the tube was centrifuged for 2 minutes 
to dry the RNeasy silica gel membrane in the column. To elute the 
RNA, 50µl of RNase-free water was added to the column and 
centrifuged at >8000g for 1 minute over a clean collection tube.  
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The RNA concentration was measured in each sample using a 
Nanodrop ND-1000 spectrophotometer before the eluate was 
transferred into microcentrifuge tubes and stored at -80°C until used for 
subsequent analysis. It was found that approximately 5 g of total RNA 
was obtained from each 35mm culture plate.  
 
Microarray analysis 
 
The previously stored RNA was thawed and the RNA concentration re-
checked using the Nanodrop ND-1000 spectrophotometer. The RNA 
integrity and quality was assessed using an Agilent 2100 Bioanalyser 
and RNA 6000 Nano kit (Agilent Technologies). Briefly, 1µl aliquots of 
each RNA sample were taken from the stock samples and diluted, if 
necessary, to give a concentration of less than 500ng/µl and then 
stored on ice. The stock sample was immediately returned to the -80°C 
freezer. Prior to use, the Agilent 2100 bioanalyser electrode was 
FOHDQHGZLWK51DVH]DSE\IROORZLQJWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV
Next, preparation was made for the chip priming station. A new syringe 
was inserted into the station and 550µl of gel matrix was centrifuged 
through a spin filter for 10 minutes at 1500g. To a 65µl aliquot of filtered 
gel was added 1µl of well mixed dye concentrate. After mixing, the gel-
dye mixture was centrifuged for 10 minutes at 13000g. A new RNA 
6000 nanochip was inserted into the chip priming station and 9µl of the 
gel-G\HPL[ZDVSLSHWWHGLQWRZHOO³*´. Next, the chip priming station 
was activated and the plunger was released exactly 30 seconds after 
activation. The plunger was then pulled back to the 1ml position. The 
chip priming station was then opened and 9µl of gel-dye mix was 
SLSHWWHGLQWRDOOZHOOVPDUNHG³*´ 
 
Next, 5µl of the Nano marker was pipetted into the ladder well and the 
12 samples wells. Any unused wells had an extra 1µl of marker added 
so that the volume in all the wells was the same. Next, 1µl of heat-
denatured RNA ladder solution was pipetted into the ladder well.  
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All of the labelled test samples were then heat-denatured at 70°C for 2 
minutes using a heat block and 1µl aliquots of each sample were 
pipetted into the relevant sample well. The chip was then vortex mixed 
for 1 minute in an IKA vortexer at 2400rpm. The chip was then loaded 
onto the Agilent 2100 Bioanalyser, the lid closed and the run started 
(takes 25 minutes). The Agilent 2100 expert software was used to 
analyse the electropherogram. First, the ladder data was viewed to 
assess the function of the chip. If this was satisfactory each individual 
sample was viewed to check for the presence of 2 distinct peaks 
(rRNA) and a normal distribution curve representing mRNA (see 
example below). 
 
 
An Agilant electrophoretogram of biotinylated cRNA probes for 
microarray analysis 
 
 
The Affymetrix microarray chips require the use of biotinylated cRNA 
probes to be generated from the total RNA samples. Briefly, cDNA is 
synthesised form the total RNA using reverse transcriptase. The cDNA 
then undergoes second strand synthesis using DNA polymerase and 
clean up. The dsDNA is then amplified by PCR, to become a template 
for in vitro transcription with RNA polymerase to produce cRNA. This is 
then labelled with biotin for microarray analysis. During the last stage, 
amplification of the original RNA template occurs.  
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First strand cDNA synthesis 
 
First strand cDNA synthesis was conducted using the Roche Applied 
Sciences Microarray Target Amplification Kit. Total RNA samples (1µg) 
from samples that had passed Agilent quality control were pipetted into 
0.5 ml microfuge tubes and 2µl of T7 oligo Target Amplification 
Sequence (TAS) primer added. Nuclease-free water was added to bring 
the final volume up to 10.5µl. After mixing, the samples were incubated 
for 10 minutes at 70°C in a thermal cycler. To each sample was then 
added 4µl of reverse transcriptase buffer, 2µl of dNTP mix, 2µl of 
dithiothreitol (DTT), and 1.5 µl of reverse transcriptase enzyme mix. 
This mixture was then incubated at 42°C for 1 hour. The samples were 
then incubated for 5 minutes at 95°C to denature RNA/DNA hybrids. 
After this, the samples (cDNA) were briefly centrifuged and placed on 
ice.  
 
Second strand cDNA synthesis 
 
Second strand cDNA synthesis was conducted by adding the following 
to the cDNA samples: 13.5 µl of nuclease free water, 5µl of Target 
Amplification Sequence (TAS) ± (dN) 10 primer, 5µl of Klenow reaction 
buffer, 2.5µl of dNTP mix, 4µl of Klenow enzyme (DNA polymerase). 
After mixing, the samples were incubated for 30 minutes at 37 °C.  
 
Double stranded cDNA purification 
 
The ds-cDNA was then purified using a Roche Microarray Target 
Purification Kit (Roche). This relies on the binding of nucleic acids to a 
glass fibre fleece (in filter cartridge) in the presence of ethanol. The filter 
is then subjected to a number of rapid wash/spin steps to inactivate and 
wash out RNases and other enzymes. The nucleic acids are then 
eluted by a low salt solution. Briefly, 1.25 µl of carrier RNA and 50µl of 
nuclease-free water are added to each sample. Next, 400µl of cDNA 
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ELQGLQJEXIIHUZLWKȕ-mercaptoethanol added) and 200µl of ethanol 
were added to the ds-cDNA samples, mixed and pipetted onto the 
centre of a cDNA filter cartridge placed in a wash tube. This was 
centrifuged at 6000g for 15 seconds and the eluate discarded. Five 
hundred microlitres of cDNA wash buffer was added to the top of the 
cartridge and centrifuged again, as described previously. A further 
300µl of wash buffer were added and the cartridge centrifuged at 
13000g for 1 minute. The cartridge was then placed into an elution tube 
and 50µl of elution buffer B added to the centre of the cartridge. This 
was left at room temperature for 1 minute, and then centrifuged at 
6000g for 90 seconds. The eluate was placed on ice.  
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cDNA amplification by PCR 
 
To 12.5µl of purified cDNA were added: 1µl of TAS primer, 2µl of dNTP 
mix, 73µl of nuclease free water, 10µl of expand PCR buffer and 1.5µl 
of expand enzyme mix. The mixture was run on a thermocycler for 27 
cycles. The resulting amplified cDNA was purified again using the 
protocol as described previously. The concentration of DNA was 
measured using the Nanodrop ND-1000 spectrophotometer. The 
samples were placed on ice for further use.  
 
Synthesis of cRNA 
 
To synthesise cRNA from the purified ds-cDNA, the Roche Microarray 
Target RNA Target Synthesis Kit was used (Roche Applied Sciences). 
Briefly, 200ng of ds-cDNA were mixed with: 4µl of NTP mix, 2.5µl of 
biotin 16-UTP, 2µl of DTT, 2µl of transcription buffer, 3 µl transcription 
enzyme blend and the required amount of nuclease-free water to make 
the entire volume up to 20µl. The mixture was incubated at 37°C for 3 
hours. The final RNA concentration was measured and individual 
samples were subjected to bioanalysis (Agilent 2100 Bioanalyser RNA 
6000 nanoassay) using the protocol described previously to ensure 
good transcription. The labelled cRNA samples were then fragmented 
by mixing 20µg (in 32µl) of target cRNA with 8µl of Ambion 
fragmentation buffer and incubating them at 94°C for 35 minutes.  
 
Microarray hybridisation 
 
The arrays used in this experiment were Affymetrix GeneChip ® 
Human Genome U133 Plus 2.0 arrays (Affymetrix, High Wycombe, 
Bucks, UK). This array offers complete coverage of the human genome 
plus 6500 additional genes. In reality this offers the potential for 
analysis of 47,000 different transcripts. The following hybridisation 
cocktail was prepared for each sample: 15µg of fragmented cRNA, 5µl 
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of control oligonucleotide B2, 15µl of 20X eukaryotic hybridisation 
controls, 3µl of Herring sperm DNA, 3µl of acetylated bovine serum 
albumin, 30µl of DMSO, 150µl 2X hybridisation buffer and sufficient 
RNase-free water to make a final volume of 300µl. The cocktails were 
heated to 99°C for 5 minutes then to 45° C for 5 minutes. The arrays 
were removed from their packaging and filled with 1X hybridisation 
buffer. The arrays were then incubated for 10 minutes at 45°C while 
rotating. The buffer solution was removed from the arrays and replaced 
with 200µl of hybridisation cocktail which was then incubated for 16 
hours at 45°C while rotating at 45-60 rpm.  
 
After hybridisation, the cocktails were removed and stored at -80°C in 
case they were needed later. The Fluidics Station (Affymetrix Fluidics 
Station 450) required for staining and washing the arrays is prepared as 
are the SAPE (Strepavidin r-phycoerythrin conjugate) and biotinylated 
anti-streptavidin antibody solutions.  Each individual array is washed 
and stained and stored in the dark to await reading by array scanner 
(Affymetrix Scanner 3000). The GCOS software (Affymetrix) was used 
to monitor scanning and to convert the raw image files into cell intensity 
ILOHVµ&(/¶ 
 
Data Analysis 
 
Affymetrix CEL files were imported into GeneSpring GX 11.0.1 and 
processed with the MAS5 algorithm to generate PMA flags. Probesets 
were excluded from further analysis if there was not a Present or 
Marginal flag in 100% of the samples in one of the four cell groups. 
Affymetrix control probesets were also excluded to leave a probeset list 
for subsequent analysis. Data were then normalised with GC-RMA to 
provide expression values. To identify differentially expressed genes 
between cell groups, ANOVA was performed on this probeset list with 
Tukey-HSD post-hoc testing and Benjamini-Hochberg false discovery 
rate control. A difference in expression between probesets with a 
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corrected p-value of <0.05 and a fold change of greater than 2 were 
considered to be statistically significant. Data were exported directly 
from GeneSpring 11.0.1. to Ingenuity Pathway Analysis for these 
probesets. Heatmaps were drawn using dChip (Harvard University, 
Boston, USA) (Li and Wong 2001). Pie charts showing the breakdown 
of up regulated probesets with regard to biological processes were 
constructed using Panther microarray data analysis software 
(www.panther.org). 
 
Canonical pathways analysis identified the pathways from the Ingenuity 
Pathways Analysis library of canonical pathways that were most 
significant to the data set. Molecules from the data set that met the cut 
RIIFULWHULDDQGZHUHDVVRFLDWHGZLWKDFDQRQLFDOSDWKZD\LQ,QJHQXLW\¶V
Knowledge Base were considered for the analysis. The significance of 
the association between the data set and the canonical pathway was 
measured in two ways: 
 
1) A ratio of the number of molecules from the data set that map to the 
pathway divided by the total number of molecules that map to the 
canonical pathway is displayed. 
 
2) )LVKHU¶VH[DFWWHVWZDVXVHGWRFDOFXODWHDS-value determining the 
probability that the association between the genes in the dataset 
and the canonical pathway is explained by chance alone. 
  
Real time PCR 
 
Expression data from the microarray experiments were validated by 
TaqMan real time PCR (ABI). This meWKRGH[SORLWVWKH¶QXFOHDVH
activity of DNA polymerase to cleave a TaqMan probe during the PCR 
UHDFWLRQ7KH7DT0DQSUREHFRQWDLQVDUHSRUWHUG\HDWWKH¶HQGRIWKH
SUREHDQGDTXHQFKHUDWWKH¶HQG'XULQJWKHUHDFWLRQFOHDYDJHRI
the probe separates the reporter and quencher dye which results in 
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increased fluorescence of the reporter. Accumulation of the PCR 
product is detected by monitoring the increase in fluorescence of the 
reporter dye. Nine transcripts were chosen that demonstrated at least a 
2-fold differential expression between ECs from various sources on 
microarray analysis and that were thought to be relevant to a range of 
endothelial cellular functions. The chosen transcripts were: Angiopoietin 
2, Keratin 18, CD44, CD73 (5 nucleotidase ecto), MAPK 3, Integrin 3, 
Laminin 2, Decay Accelerating Factor and Carboxypeptidase E. For 
analysis, cDNA from each of the matched donor samples was 
generated from total RNA using the Superscript III first strand synthesis 
system (Invitrogen). Fifty nanograms of RNA from each sample to be 
assayed were mixed with 1µl of primer and 1µl of dNTP and made up to 
10µl with RNase free water. The mixture was incubated at 65°C for 5 
minutes then cooled on ice. To each cooled sample, 10µl of synthesis 
mix was added (composed of 10X RT buffer, MgCl2, DTT, RNaseOUT 
and Superscript III reverse transcriptase). The mixture was incubated at 
25°C for 10 minutes followed by 50 minutes at 50°C. The reaction was 
terminated by heating the mixtures at 85°C for 5 minutes. After adding 
1µl of RNase H and incubating for 20 minutes at 37°C, the samples 
were stored at -20°C unless they were to be used immediately for 
further analysis. The resulting cDNA was subjected to real time PCR 
UHDFWLRQXVLQJWKHPDQXIDFWXUHU¶V7DT0DQ8QLYHUVDO0Dstermix Kit 
protocol. Into each well of a 96 well MicroAmp Optical reaction plate, 
1µl of cDNA (concentration between 1-100ng/µl) and 19µl of reaction 
mixture were mixed together. The reaction mixture consisted of the 
TaqMan probe for the gene of interest or the house keeper gene, 
nuclease free water and the PCR mastermix. Three replicates were run 
for each gene of interest. Control samples, consisting of either water or 
a pooled cDNA mix were used. The 96 well plates were loaded onto the 
ABI PRISM 7000 sequence detection system and run for 45 cycles. The 
expression of hypoxanthine-guanine phosphoribosyltransferase (HPRT) 
was chosen for normalisation. Analysis of the relative gene expression 
data was performed using the Ct method.  
 203 
 
This is represented as follows:  
 
In the TaqMan system, signal (fluorescence) increases with time in 
direct proportion to the number of starting molecules (mRNA). The 
accumulation of reaction product (or signal) increases in a sigmoid 
fashion. The crossing point or threshold (Ct) occurs at the point 
threshold at which fluorescence can be detected and the Ct is inversely 
proportional to the initial concentration of the target in the sample. The 
Ct is usually expressed as a cycle number and can automatically 
measured by the instrument. The Ct for each target gene can be 
compared to a house keeper gene for comparative or fold-change 
analysis.  
 
The calculation of fold change from a Ct value is as follows: 
 
Ct  (gene of interest) ± &WKRXVHNHHSLQJJHQH ǻ&W 
 
ǻ&WVDPSOHRILQWHUHst i.e. choroid gene) -  ǻ&WFRPSDUDWRUVDPSOH
LH+89(& ǻǻ&W 
 
Fold change = 2- ǻǻ&W 
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Results  
Confirmation of human endothelial cell identity 
 
Samples of cells from all locations displayed homogenous cobblestone 
morphology with no evidence of cell contamination. Greater than 99.5% 
of the endothelial cells from each site demonstrated staining for factor 
VIII and CD31 prior to their use in the aforementioned experiments, 
confirming their purity and identity as endothelial cells.  
 
Overview of gene expression patterns 
 
Between 1.5 and 3.4 µg of total RNA were isolated from each 35mm 
plate. Biotinylated cRNA probes were hybridised to Affymetrix 
GeneChip ® Human Genome U133 Plus 2.0 arrays containing 47000 
transcripts, of which 38500 were well characterised human genes. A 
total of 26312 probe sets passed quality control testing during analysis. 
 
Gene expression patterns of proliferating HUVEC vs ocular 
microvascular endothelial cells 
 
When HUVE cells were compared to ocular microvascular cells, 802 
probesets demonstrated a significant difference. Within this total, 383 
probesets were found to be up-regulated in HUVECs and 419 down-
regulated. The probesets for up-regulated genes in HUVECs were 
enriched with genes important in embryonic development such as the 
homeobox genes HOX B7, B5, A2, A4, A9 and D8, neuroregulin 1 and 
osteonectin. Probe sets for ocular microvascular endothelial cells 
appeared to be enriched in genes important in MHC class I (A ± C, F 
and G) and II (alpha and beta chains), immune responses (Interleukin 6 
receptor, CXCL 12  and FAS), signal transduction (EGF receptor, G 
protein receptors, phospholipase C ) and cell response to stimulus 
(TIMP3, collagen types I and III, laminin beta). Tables 3.1 and 3.2 
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indicate the 100 most highly expressed probesets in HUVECs and 
ocular MVECs respectively. 
 
Comparison of HUVECs with different ocular microvascular endothelial 
cells demonstrated a difference of 2146 probesets (8.9% of probesets 
that passed quality control) when HUVECs were compared with 
choroidal ECs (1100 up- and 1046 down-regulated), 1801 probesets 
(6.8%) when HUVE cells were compared with retinal ECs (797 up- and 
1004 down- regulated) and 2325 probesets (8.8%) when HUVE cells 
were compared with iris ECs (1205 up- and 1120 down-regulated). The 
raw data is available at 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=nfcplwewowqowp
k&acc=GSE20986. 
 
 
Fig 3.1,shows the heatmap of differential gene expression for those 
probesets reaching statistical significance. It can be seen that ECs from 
choroid and iris share similar gene expression profiles, whereas 
HUVEC and retinal ECs have distinct identities. The positions of 
important, differentially expressed genes are indicated at the side.  
 
Examination of fig 3.2a and b pie charts shows that HUVE cells 
demonstrate a greater proportion of up-regulated genes for 
developmental processes (12% vs 8 %) and metabolic processes (27% 
vs 16%) compared with ocular MVECs, while ocular MVEC 
demonstrated a greater proportion of probesets up-regulated for 
immune function (9% vs 5%) and cell adhesion (5% vs 2%) compared 
with HUVECs. 
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    HUVEC           Iris             Choroid          Retina 
 
 
Fig 3.1 Heatmap of ascending differential probeset expression reaching 
statistical significance with reference to HUVEC and different human 
ocular microvascular endothelial cells. Upregulated probesets are 
shown in red, downregulated in blue. A total of 2146 different probesets 
are represented. The positions of selected  probesets thought to be 
important in endothelial cell biology are shown.  
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Table 3.1 One hundred most highly expressed probesets in HUVECs 
compared with ocular microvascular endothelial cells  
 
Gene Title  
 
Fold 
Change 
 
homeobox A9 384.0  
homeobox A9 244.0  
regulator of G-protein signalling 5 201.0  
homeobox B7 163.0  
homeobox B7 145.0  
interleukin 1 receptor-like 1 131.0  
regulator of G-protein signalling 5 128.0  
aldehyde dehydrogenase 1 family, member A2 123.0  
cyclin A1 99.0  
regulator of G-protein signalling 5 92.0  
regulator of G-protein signalling 5 86.0  
gamma-aminobutyric acid (GABA) B receptor, 2 80.0  
ST2 protein 76.0  
serpin peptidase inhibitor, clade D (heparin cofactor), 
member 1 76.0 
 
chromosome 4 open reading frame 49 66.0  
homeobox A5 60.0  
hypothetical gene supported by BC013438 48.0  
T cell receptor beta constant 1 /// T cell receptor beta 
constant 2 48.0 
 
growth factor receptor-bound protein 14 35.0  
G protein-coupled receptor 37 (endothelin receptor type 
B-like) 33.0 
 
sparc/osteonectin, cwcv and kazal-like domains 
proteoglycan (testican) 1 32.0 
 
kelch-like 13 (Drosophila) 32.0  
gamma-aminobutyric acid (GABA) B receptor, 2 32.0  
GATA binding protein 3 32.0  
family with sequence similarity 101, member A 32.0  
WD repeat domain 69 30.0  
EPH receptor B2 29.0  
erythrocyte membrane protein band 4.1-like 3 29.0  
homeobox A7 27.0  
heparanase 27.0  
fermitin family homolog 3 (Drosophila) 26.0  
ALX homeobox 1 26.0  
EPH receptor B2 25.0  
TRAF2 and NCK interacting kinase 25.0  
ST2 protein 24.0  
prickle homolog 1 (Drosophila) 24.0  
erythrocyte membrane protein band 4.1-like 3 24.0  
placenta-specific 8 23.0  
gamma-aminobutyric acid (GABA) B receptor, 2 23.0  
homeobox B3 23.0  
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Gene Title  
 
Fold 
Change 
 
collectin sub-family member 12 22.0  
gamma-aminobutyric acid (GABA) B receptor, 2 22.0  
homeobox A10 21.0  
BMX non-receptor tyrosine kinase 21.0  
erythrocyte membrane protein band 4.1-like 3 20.0  
globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 20.0  
TRAF2 and NCK interacting kinase 19.3  
TRAF2 and NCK interacting kinase 18.5  
insulin-like growth factor 2 mRNA binding protein 1 18.4  
G protein-coupled receptor 143 17.4  
EPH receptor B2 17.1  
chromosome 6 open reading frame 142 17.0  
phosphatidic acid phosphatase type 2 domain 
containing 1A 16.7 
 
neuroligin 1 16.4  
caspase recruitment domain family, member 11 16.3  
T cell receptor beta constant 1 15.9  
fibrillin 2 15.7  
neuregulin 1 15.4  
fibronectin type III and SPRY domain containing 1 15.0  
insulin-like growth factor 2 mRNA binding protein 1 15.0  
neuronatin 14.8  
transmembrane protein 163 14.5  
Full length insert cDNA clone YW19A06 13.8  
E2F transcription factor 8 13.8  
thiosulfate sulfurtransferase KAT, putative /// KAT protein 13.7  
transmembrane protein 163 13.3  
homeobox A3 13.0  
paraneoplastic antigen MA2 12.9  
protein tyrosine phosphatase, non-receptor type 22 
(lymphoid) 12.6 
 
solute carrier family 47, member 1 12.4  
prickle homolog 1 (Drosophila) 12.2  
keratin 80 12.1  
protein tyrosine phosphatase, non-receptor type 22 
(lymphoid) 12.0 
 
homeobox D1 11.8  
mal, T-cell differentiation protein 2 11.7  
follistatin-like 5 11.5  
hypothetical LOC401022 11.1  
G protein-coupled receptor, family C, group 5, member A 11.0  
tumor necrosis factor (ligand) superfamily, member 15 10.8  
galanin prepropeptide 10.2  
EPH receptor B2 10.2  
glucosaminyl (N-acetyl) transferase 1, core 2 (beta-1,6-N-
acetylglucosaminyltransferase) 10.1 
 
Prickle homolog 1 (Drosophila) (PRICKLE1), mRNA 10.1  
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Gene Title  
 
Fold 
Change 
 
GATA binding protein 3 9.7  
heparanase 9.7  
homeobox B2 9.1  
protocadherin 7 9.1  
neuregulin 1 9.0  
family with sequence similarity 174, member B 8.6  
runt-related transcription factor 1; translocated to, 1 
(cyclin D-related) 8.5 
 
TAF7-like RNA polymerase II,  8.5  
PRP31 pre-mRNA processing factor 31 homolog (S. 
cerevisiae) 8.3 
 
stearoyl-CoA desaturase (delta-9-desaturase) 8.3  
FERM domain containing 5 8.2  
keratin 15 8.1  
homeobox B8 8.1  
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Table 3.2 One hundred most highly expressed probesets in ocular 
microvascular endothelial cells compared with HUVE cells 
 
Gene Title 
 
Fold 
change 
 
collagen, type I, alpha 1 736.0  
major histocompatibility complex, class II, DR beta 1  451.0  
collagen, type I, alpha 1 422.0  
deoxyribonuclease I-like 3 381.0  
collagen, type III, alpha 1 222.0  
periostin, osteoblast specific factor 212.0  
major histocompatibility complex, class II, DR beta 1  202.0  
collagen, type VI, alpha 3 182.0  
collagen, type I, alpha 2 181.0  
cytochrome P450, family 1, subfamily B, polypeptide 1 171.0  
collagen, type I, alpha 2 162.0  
collagen, type III, alpha 1 156.0  
cytochrome P450, family 1, subfamily B, polypeptide 1 156.0  
major histocompatibility complex, class II, DP beta 1 149.0  
major histocompatibility complex, class II, DP alpha 1 145.0  
major histocompatibility complex, class II, DR beta 1  91.0  
chemokine (C-X-C motif) ligand 12 (stromal cell-derived 
factor 1) 90.0 
 
paired related homeobox 1 90.0  
alpha-2-macroglobulin 85.0  
interleukin 13 receptor, alpha 2 80.0  
ATP-binding cassette, sub-family B (MDR/TAP), member 1 77.0  
selenoprotein P, plasma, 1 71.0  
desmoplakin 70.0  
TIMP metallopeptidase inhibitor 3 66.0  
transgelin 66.0  
MHC class II HLA-DRB3 mRNA (HLA-DRB3*01012 allele) 61.0  
Rho GTPase activating protein 25 58.0  
chemokine (C-X-C motif) ligand 12 (stromal cell-derived 
factor 1) 54.0 
 
SH3 and cysteine rich domain 53.0  
major histocompatibility complex, class II, DP alpha 1 47.0  
aggrecan 47.0  
insulin-like growth factor binding protein 5 45.0  
collagen, type XV, alpha 1 44.0  
TIMP metallopeptidase inhibitor 3 42.0  
hydroxysteroid (17-beta) dehydrogenase 2 42.0  
doublecortin-like kinase 1 41.0  
periostin, osteoblast specific factor 40.0  
cytochrome P450, family 1, subfamily B, polypeptide 1 40.0  
synaptopodin 2 38.0  
acyl-CoA synthetase long-chain family member 5 38,0  
Thy-1 cell surface antigen 37.0  
kynureninase (L-kynurenine hydrolase) 35.0  
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Gene Title 
 
Fold 
change 
 
Rho GTPase activating protein 25 34.0  
hypothetical protein FLJ22662 34.0  
suppressor of cytokine signaling 2 33.0  
aggrecan 32.0  
sushi domain containing 2 31.0  
tumor necrosis factor receptor superfamily, member 11b 31.0  
GTPase, IMAP family member 5 27.0  
filamin A interacting protein 1 27.0  
carbonic anhydrase XII 26.0  
tenascin C 26.0  
crystallin, alpha B 26.0  
transgelin 25.0  
acyl-CoA synthetase long-chain family member 5 25.0  
lymphocyte cytosolic protein 1 (L-plastin) 25.0  
insulin-like growth factor binding protein 3 25.0  
versican 24.0  
aggrecan 24.0  
lymphocyte cytosolic protein 2 (SH2 domain containing 
leukocyte protein of 76kDa) 23.0 
 
Ras protein-specific guanine nucleotide-releasing factor 2 23.0  
family with sequence similarity 46, member A 23.0  
hyaluronan synthase 2 23.0  
guanine nucleotide binding protein (G protein), alpha 14 22.0  
GTPase, IMAP family member 5 22.0  
gremlin 1, cysteine knot superfamily, homolog (Xenopus 
laevis) 22.0 
 
fibroblast activation protein, alpha 22.0  
mannose receptor, C type 1 /// mannose receptor, C type 
1-like 1 20.0 
 
CDNA clone IMAGE:4826696 20.0  
phosphotriesterase related 20.0  
syndecan 2 20.0  
dipeptidyl-peptidase 4 20.0  
G protein-coupled receptor 116 19.6  
syndecan 2 19.5  
chromosome 10 open reading frame 128 19.2  
G protein-coupled receptor, family C, group 5, member B 19.0  
sprouty homolog 1, antagonist of FGF signaling 
(Drosophila) 19.0 
 
fibroblast growth factor 13 18.3  
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 4 18.1 
 
snail homolog 2 (Drosophila) 18.0  
NLR family, CARD domain containing 3 17.7  
zinc finger protein 415 17.0  
CD248 molecule, endosialin 17.0  
cysteine-rich protein 1 (intestinal) 16.8  
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Gene Title 
 
Fold 
change 
 
ependymin related protein 1 (zebrafish) 16.8  
versican 16.8  
carbonic anhydrase II 16.4  
actin, alpha 2, smooth muscle, aorta 16.3  
lymphocyte cytosolic protein 2 (SH2 domain containing 
leukocyte protein of 76kDa) 16.2 
 
suppressor of cytokine signaling 2 16.1  
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Fig 3.2a. Pie chart of significantly upregulated genes grouped by 
biological processes in proliferating HUVECs compared with 
proliferating ocular microvascular endothelial cells  
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Fig 3.2b. Pie chart of significantly upregulated genes grouped by 
biological processes in proliferating ocular microvascular endothelial 
cells compared with proliferating HUVECs. 
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Proliferating human choroidal versus retinal vascular endothelial 
cells 
 
Comparison of human choroidal endothelial cells with human retinal 
endothelial cells demonstrated a difference of 2217 probe sets (8.4% of 
probesets that passed quality control). Of this total, 1078 were up-
regulated in choroidal ECs and 1139 were up-regulated in retinal ECs. 
Using Ingenuity Pathway Analysis software, differences between retinal 
and choroidal ECs were shown in the expression of genes involved in a 
wide range of biological processes such as cell cycle, DNA replication, 
cell morphology, vascular cell-to-cell interactions, cell movement and 
gene expression. Because of the enormity of the gene expression data 
sets, it is not possible to show it in its entirety in this thesis. Tables 3.4 
and 3.5 show the top 100 differentially expressed genes for each EC 
subtype. The complete data set (raw and post analysis) can be 
obtained from the University of Nottingham, Division of Ophthalmology 
and Visual Sciences academic secretary. The raw data is also available 
at 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=nfcplwewowqowp
k&acc=GSE20986. 
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Table 3.3. Differential expression of probe sets involved in cell signalling between matched human choroidal and retinal 
 endothelial cells 
 
Signalling 
Pathway Affy ID 
Gene 
Symbol Gene Name 
Fold 
Change 
Direction of regulation 
(retina vs choroid) 
IGF-1 
signalling 201163_s_at IGFBP7 Insulin like growth factor binding protein 7 4.1 Up 
 204686_at IRS1 Insulin receptor substrate 1 6.4 Up 
 225330_at IGF1R Insulin like growth factor 1 receptor 3.0 Up 
VEGF 
signalling 218488_at EIF2B3 
Eukaryotic translation initiation factor 2B, 
subunit 3 2.7 Down 
 212351_at EIF2B5 Eukaryotic translation initiation factor 2B, 
subunit 5 2.0 Down 
 200989_at HIF1A Hypoxia inducible factor 1 alpha subunit 2.2 Up 
 208351_s_at MAPK1 Mitogen-activated protein kinase 1 2.1 Down 
 
1553694_a_
at PIK3C2A Phosphoinositide 3 kinase class 2 alpha 7.9 Down 
 210512_s_at VEGFA Vascular endothelial growth factor A 8.7 Up 
TOR 210949_s_at EIF3C  Eukaryotic translation initiation factor 3 (subunit C)  2.7 Down 
 211937_at EIF4B Eukaryotic translation initiation factor 4B 2.0 Down 
 208624_s_at EIF4G1 Eukaryotic translation initiation factor 4 gamma 4.6 Down 
 217 
Signalling 
Pathway Affy ID 
Gene 
Symbol Gene Name 
Fold 
Change 
Direction of regulation 
(retina vs choroid) 
 200989_at HIF1A Hypoxia inducible factor 1 alpha subunit 2.2 Up 
 204686_at IRS1 Insulin receptor substrate 1 6.4 Up 
 226312_at RICTOR RPTOR independent companion of mTOR 2.9 Up 
 211578_s_at RPS6KB1 Ribosomal protein S6 kinase (70kDa) 7.1 Down 
PI3K/AKT 211968_s_at HSP90AA1 Heat shock protein alpha, class A 3.0 Down 
 1557910_at HSP90AB1 Heat shock protein alpha, class B 4.4 Down 
 201474_s_at ITGA3 Integrin alpha 3 (CD49C) 4.4 Up 
 
1552610_a_
at JAK1 Janus kinase 1 4.7 Down 
 212240_s_at PIK3R1 Phosphoinositide 3 kinase subunit 1  2.2 Down 
PI3K/AKT 207749_s_a PPP2R3A Protein phosphatase 2 subunit B 2.2 Down 
ERK/MAPK 201474_s_at ITGA3 Integrin alpha 3 (CD49C) 4.4 Up 
 201841_s_at HSPB1 Heat shock protein 1 (27kDa) 3.3 Up 
 208351_s_at MAPK1 Mitogen-activated protein kinase 1 2.1 Down 
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Signalling 
Pathway Affy ID 
Gene 
Symbol Gene Name 
Fold 
Change 
Direction of regulation 
(retina vs choroid) 
ERK/MAPK 1553694_a_
at PIK3C2A Phosphoinositide-3-kinase, class 2, alpha 7.9 Down 
 209785_s_at PLA2G4C Phospholipase A2, (group IVC) 3.2 Up 
 207821_s_at PTK2 PTK2 protein tyrosine kinase 2 2.4 Down 
 201213_at PPP1R7 Protein phosphatase 1, subunit 7 2.5 Down 
 204284_at PPP1R3C Protein phosphatase 1, subunit 3C 3.4 Up 
T Cell 
Receptor 215092_s_at NFAT5 Nuclear factor of activated T-cells 5 6.7 Down 
 201502_s_at NFKBIA Nuclear factor of kappa light polypeptide alpha 3.4 Up 
 205263_at BCL10 B-cell CLL/lymphoma 10 3.4 Up 
Interferon 209417_s_at IFI35 Interferon-induced protein 35 2.3 Up 
 214022_s_at IFITM1 Interferon induced transmembrane protein 1 6.3 Up 
 201642_at IFNGR2 Interferon gamma receptor 2 2.9 Up 
IL4 203233_at IL4R interleukin 4 receptor 2.6 Up 
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Signalling 
Pathway Affy ID 
Gene 
Symbol Gene Name 
Fold 
Change 
Direction of regulation 
(retina vs choroid) 
Wnt 213425_at WNT5A Wingless type family 5.2 up 
 210220_at FZD2 Frizzeled homologue 2 10.3 up 
 200816_s_at PAFAH1B Platelet Activating Factor Acetaldehyde 2.0 up 
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Fig 3.3 shows the heatmap of differential gene expression for all 
probesets reaching statistical significance. It can be seen that there is a 
wide disparity between retinal and choroidal ECs. The positioning of 
some of the important, differentially expressed genes is indicated at the 
side. 
 
Figure 3.4a and 3.4b pie charts demonstrate a greater proportion of up-
regulated probesets for cell communication processes in retinal ECs 
(13% vs 8%) when compared with choroidal ECs. All other biological 
process subsets demonstrated similar proportions of expression in both 
retinal and choroidal ECs.  
 
Canonical pathway analysis revealed collections of probe sets from a 
number of signalling pathways that were differentially expressed 
including: ERK/MAPK, mTOR, VEGF, insulin like growth factor 1 (IGF 
1), PI3K/AKT, T cell receptor, and IL4 signalling pathways (Table 3.3). 
Interestingly, this shows that proliferating retinal ECs demonstrate up-
regulation of components of IGF 1 signalling such as IGF binding 
protein 7 and IGF receptor compared with choroidal ECs. Retinal ECs 
also demonstrate up-regulation of HIF 1alpha, VEGF and some 
immune related signalling pathways compared with choroidal ECs.  
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Fig 3.3 Heatmap of ascending differential probeset expression reaching 
statistical significance with reference to human retinal and choroidal 
microvascular endothelial cells. Up-regulated probesets are shown in 
red, down-regulated in blue. A total of 2217 different probesets are 
represented. The positions of selected probesets thought to be 
important in endothelial cell biology are shown.  
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Fig 3.4a. Pie chart of significantly up-regulated genes grouped by 
biological processes in proliferating human choroidal endothelial cells 
compared with proliferating human retinal endothelial cells  
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Fig 3.4b. Pie chart of significantly upregulated genes grouped by 
biological processes in proliferating human retinal endothelial cells 
compared with proliferating human choroidal endothelia cells 
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Table 3.4 One hundred most highly expressed probesets in human 
choroidal microvascular endothelial cells compared with human retinal 
endothelial cells 
 
Gene Title 
 
Fold 
Change 
 
histone 1, H1c 9.4  
phosphatase and actin regulator 2 8.2  
cyclin E2 6.9  
Rho-related BTB domain containing 3 6.6  
WD repeat domain 4 6.5  
epithelial membrane protein 1 6.1  
dipeptidylpeptidase 4 (CD26, adenosine deaminase 
complexing protein  5.9 
 
NIMA  5.8  
cyclin-dependent kinase 2 5.8  
TAO kinase 1 5.8  
plasminogen activator, urokinase /// plasminogen activator, 
urokinase 5.5 
 
retinoblastoma 1 (including osteosarcoma) 5.5  
HECT domain containing 1 5.5  
jumonji domain containing 1C 5.4  
KIAA0372 5.3  
squalene epoxidase 5.2  
protein tyrosine phosphatase, non-receptor type 12 5.1  
suppressor of Ty 16 homolog (S. cerevisiae) 5.0  
BUB1 budding uninhibited by benzimidazoles 1 homolog 
(yeast) 4.9 
 
muscleblind-like 2 (Drosophila) 4.9  
chromosome X open reading frame 53 4.9  
SLD5 homolog /// SLD5 homolog 4.8  
proline-rich nuclear receptor coactivator 2 4.8  
thymopoietin 4.8  
PTPRF interacting protein, binding protein 1 (liprin beta 1) 4.8  
zinc finger protein 146 4.6  
PRP4 pre-mRNA processing factor 4  4.5  
DEAH (Asp-Glu-Ala-His) box polypeptide 9 4.5  
huntingtin interacting protein B 4.5  
nuclear factor I/B 4.5  
phosphoinositide-3-kinase, class 2, alpha polypeptide 4.4  
ATPase family, AAA domain containing 2 4.4  
transcription factor Dp-1 4.4  
dystonin 4.4  
c-Mpl binding protein 4.3  
FERM domain containing 4A 4.3  
cell division cycle associated 2 4.2  
translocase of inner mitochondrial membrane 44 homolog 
(yeast) 4.1 
 
G protein-coupled receptor kinase 5 4.1  
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Gene Title 
 
Fold 
Change 
 
protein BAP28 4.1  
hypothetical protein FLJ12735 4.1  
UDP-glucose ceramide glucosyltransferase-like 1 4.1  
met proto-oncogene (hepatocyte growth factor receptor) 4.0  
DnaJ (Hsp40) homolog, subfamily C, member 13 4.0  
A kinase (PRKA) anchor protein 1 4.0  
septin 10 3.9  
RAB6A, member RAS oncogene family 3.9  
G elongation factor, mitochondrial 1 3.8  
RAS and EF hand domain containing 3.8  
RAS and EF hand domain containing 3.8  
muted homolog (mouse) 3.8  
matrin 3 3.7  
MLF1 interacting protein 3.7  
lamin B1 3.7  
chromodomain protein, Y-like 2 3.7  
dUTP pyrophosphatase 3.7  
diaphanous homolog 2 (Drosophila) 3.7  
sperm specific antigen 2 3.7  
RAD21 homolog (S. pombe) 3.7  
zinc finger RNA binding protein 3.7  
tetratricopeptide repeat domain 3 3.6  
M-phase phosphoprotein 9 3.6  
vav 3 oncogene 3.6  
DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 3.6  
cell division cycle 27 3.5  
translocated promoter region (to activated MET oncogene) 3.5  
cell division cycle 2, G1 to S and G2 to M 3.5  
guanine nucleotide binding protein-like 3 (nucleolar)-like 3.5  
arrestin, beta 1 3.5  
zinc finger RNA binding protein 3.5  
replication factor C (activator 1) 2, 40kDa 3.5  
nucleolar and spindle associated protein 1 3.4  
c-Mpl binding protein 3.4  
erythrocyte membrane protein band 4.1-like 3 3.4  
cell division cycle 2, G1 to S and G2 to M 3.4  
F-box protein 5 3.4  
chromosome 6 open reading frame 106 3.3  
ankyrin repeat domain 11 3.3  
hydroxyacyl-Coenzyme A dehydrogenase 3.3  
Zwilch 3.3  
chondroitin sulfate proteoglycan 6 3.3  
pericentriolar material 1 3.3  
amyloid beta (A4) precursor protein  3.3  
chromosome condensation 1 3.3  
cell division cycle associated 7 /// cell division cycle 
associated 7 3.2 
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Gene Title 
 
Fold 
Change 
 
ATPase family, AAA domain containing 2 3.2  
thymidine kinase 1, soluble 3.2  
NACHT, leucine rich repeat and PYD (pyrin domain) 
containing 1 3.2 
 
MCM4 minichromosome maintenance deficient 4 (S. 
cerevisiae) 3.2 
 
DEP domain containing 1 3.2  
hypothetical protein FLJ12973 3.2  
erythrocyte membrane protein band 4.1-like 3 3.2  
nucleoporin 35kDa 3.2  
ets variant gene 4 (E1A enhancer binding protein, E1AF) 3.2  
transforming, acidic coiled-coil containing protein 1 3.2  
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Table 3.5 One hundred most highly expressed probesets in human 
retinal microvascular endothelial cells compared with human choroidal 
endothelial cells 
 
Gene Title 
 
Fold 
Change 
 
hepatocyte growth factor (hepapoietin A; scatter factor) 17.2  
gremlin 1 homolog, cysteine knot superfamily (Xenopus 
laevis) 13.2 
 
collagen, type I, alpha 1 11.3  
neuronal PAS domain protein 2 7.2  
response gene to complement 32 7.2  
Tissue factor pathway inhibitor 2 6.4  
stanniocalcin 2 6.1  
hypothetical gene supported by BC009447 5.8  
aldehyde dehydrogenase 1 family, member L2 5.6  
collagen, type VI, alpha 1 5.2  
lectin, galactoside-binding, soluble, 3 binding protein 5.0  
vascular endothelial growth factor 5.0  
Notch homolog 3 (Drosophila) 4.9  
melanophilin 4.6  
Tropomyosin 4 4.3  
selenoprotein M 4.2  
pecanex-like 2 (Drosophila) 4.2  
adrenomedullin 4.2  
limitrin 4.1  
Hypothetical protein LOC149478 4.1  
interferon regulatory factor 7 4.0  
Full length insert cDNA YI37C01 3.9  
agrin 3.9  
Prickle-like 1 (Drosophila) 3.7  
CDNA FLJ41321 fis, clone BRAMY2045299 3.7  
pleckstrin and Sec7 domain containing 3 3.5  
agrin 3.5  
Full length insert cDNA YI37C01 3.4  
E2F transcription factor 5, p130-binding 3.4  
platelet derived growth factor C 3.4  
gb:AA805633  3.3  
transmembrane anchor protein 1 3.3  
integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 
receptor) 3.3 
 
MRNA (clone ICRFp507I1077) 0.2  
family with sequence similarity 14, member A 3.2  
DNA-damage-inducible transcript 4 3.2  
UDP-glucose ceramide glucosyltransferase 3.1  
B-cell translocation gene 1, anti-proliferative 3.1  
nephronophthisis 3 (adolescent) 3.1  
tissue inhibitor of metalloproteinase 2 3.1  
follistatin 3.1  
 228 
Gene Title 
 
Fold 
Change 
 
zinc and ring finger 1 3.1  
RNA binding protein with multiple splicing 3.0  
protein phosphatase 1, regulatory (inhibitor) subunit 14B 3.0  
Full length insert cDNA YH99G08 3.0  
ras homolog gene family, member B 3.0  
CDNA FLJ11397 fis, clone HEMBA1000622 3.0  
Sine oculis homeobox homolog 1 (Drosophila) 3.0  
phosphoinositide-3-kinase, class 2, beta polypeptide 2.9  
complement component 1, r subcomponent-like 2.9  
yippee-like 2 (Drosophila) 2.9  
discoidin domain receptor family, member 1 2.9  
Homo sapiens, clone IMAGE:5259272, mRNA 2.9  
ADP-ribosylation factor-like 7 2.8  
hypothetical protein MGC18216 2.8  
Gene 33/Mig-6 (MIG-6) 2.8  
ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog, 
yeast) 2.8 
 
gb:N51405  2.8  
Similar to lymphocyte-specific protein 1 2.8  
cathepsin C 2.0  
glycine receptor, beta 2.8  
SNRPN upstream reading frame 2.8  
LOC439987 2.8  
estrogen-related receptor alpha 2.7  
beta-site APP-cleaving enzyme 2 2.7  
sin3-associated polypeptide, 30kDa 2.7  
pleckstrin homology domain containing, family C (with 
FERM domain)  2.7 
 
nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor 2.7 
 
Hypothetical protein LOC201895 2.7  
regulator of G-protein signalling 10 2.7  
CDNA clone IMAGE:4797120, partial cds 2.7  
LOC440309 2.6  
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
retention receptor 3 2.6 
 
retinol dehydrogenase 11 (all-trans and 9-cis) 2.6  
PRKC, apoptosis, WT1, regulator 2.6  
ADP-ribosylation factor-like 7 2.6  
methionine sulfoxide reductase B2 2.6  
uronyl-2-sulfotransferase 2.5  
aspartate beta-hydroxylase 2.5  
heat shock 27kDa protein 1 2.5  
microfibrillar-associated protein 2 2.5  
Transcribed locus 2.5  
SAR1a gene homolog 1 (S. cerevisiae) 2.5  
Hypothetical protein BC001096 2.0  
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Gene Title 
 
Fold 
Change 
 
synaptosomal-associated protein, 29kDa 2.5  
insulin-like growth factor binding protein 7 2.4  
Homo sapiens, clone IMAGE:5261213, mRNA 2.4  
Dickkopf homolog 3 (Xenopus laevis) 2.3  
Zinc finger protein 302 2.3  
zinc finger protein 326 2.4  
kinesin family member 22 2.4  
erythrocyte membrane protein band 4.1-like 3 2.4  
methylthioadenosine phosphorylase 2.5  
chromosome 22 open reading frame 18 2.5  
histone 1, H4c 2.5  
G-2 and S-phase expressed 1 2.8  
Protein phosphatase 1F (PP2C domain containing) 2.6  
BAT2 domain containing 1 2.6  
KIAA1641 2.6  
THO complex 3 2.6  
interleukin enhancer binding factor 3, 90kDa 2.7  
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Proliferating human choroidal versus iris vascular endothelial 
cells 
 
Comparison of human choroidal endothelial cells with human iris 
endothelial cells demonstrated a difference of 138 probe sets (0.33% of 
probesets that passed quality control). Of this total, 81 were up-
regulated in choroidal ECs and 57 were up-regulated in iris ECs. This 
study demonstrated a striking homogeneity of gene expression 
between choroidal and iris tissues which may not be surprising 
considering that types of endothelial cells are derived from different 
sites within the uveal tract. Differences in the expression of a small 
number of genes such as thrombospondin 1, synaptopodin 2, CD74, 
Carboxypeptidase and IL8 were noted. Canonical pathway analysis 
failed to reveal any pathways that were significantly represented. A 
representative heat map is shown in fig 3.5 and a complete list of 
differentially expressed probesets reaching statistical significance in 
choroidal and iris ECs are shown in tables 3.6 and 3.7 respectively. 
Although the relative numbers of differentially up-regulated genes were 
small, fig 3.6a and 3.6b pie charts demonstrate a greater proportion of 
up-regulated probesets for cell development in iris ECs (13% vs 8%) 
when compared with choroidal ECs. Choroidal ECs demonstrated a 
greater proportion of up-regulated genes for cell metabolism (28% vs 
13%) All other biological process subsets demonstrated similar 
proportions of expression in both iris and choroidal ECs. 
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Fig 3.5 Heatmap of ascending differential probeset expression reaching 
statistical significance with reference to human iris and choroidal 
microvascular endothelial cells. Up-regulated probesets are shown in 
red, down-regulated in blue. A total of 138 different probesets are 
represented. The positions of selected probesets thought to be 
important in endothelial cell biology are shown.  
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Fig 3.6a. Pie chart of significantly up-regulated genes grouped by 
biological processes in proliferating human iris endothelial cells 
compared with proliferating human choroidal endothelial cells 
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Fig 3.6b. Pie chart of significantly up-regulated genes grouped by 
biological processes in proliferating human choroidal endothelial cells 
compared with proliferating human iris endothelial cells 
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Table 3.6. All probesets reaching differential expression of 2.0 or 
greater in human choroidal microvascular endothelial cells compared 
with human iris endothelial cells. 
  
Gene Title 
 
Fold 
Change 
 
thrombospondin, type I, domain containing 2 6.0     
sushi domain containing 2 4.8  
synaptopodin 2 4.3  
aggrecan 1 (chondroitin sulfate proteoglycan 1, 4.0  
aggrecan 1 (chondroitin sulfate proteoglycan 1, 4.0  
CD74 antigen  3.9  
gb:AB020690.1  3.8  
hypothetical protein FLJ22662 3.7  
erythrocyte membrane protein band 4.1-like 3 3.5  
collagen, type VI, alpha 3 3.4  
gb:AI733234  3.3  
erythrocyte membrane protein band 4.1-like 3 3.2  
succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp)  3.2 
 
aggrecan 1 (chondroitin sulfate proteoglycan 1,  3.2  
insulin-like growth factor binding protein 5 3.2  
Protease, serine, 12 (neurotrypsin, motopsin) 3.1  
transmembrane protein 46 3.1  
carboxypeptidase E 3.1  
erythrocyte membrane protein band 4.1-like 3 3.1  
interleukin 8 3.0  
carboxypeptidase E 3.0  
FERM domain containing 3 2.9  
steroid sensitive gene 1 2.9  
leucine rich repeat containing 15 2.8  
GTP binding protein over-expressed in skeletal muscle 2.8  
ABI gene family, member 3 (NESH) binding protein 2.8  
crystallin, alpha B 2.8  
keratin 19 2.8  
transketolase (Wernicke-Korsakoff syndrome) 2.8  
KIAA1913 2.7  
phosphatase and actin regulator 3 2.7  
early growth response 1 2.6  
periostin, osteoblast specific factor 2.6  
inhibitor of DNA binding 1, dominant negative helix-loop-
helix protein 2.6 
 
chemokine (C-X-C motif) ligand 12 (stromal cell-derived 
factor 1) 2.6 
 
GLI pathogenesis-related 1 (glioma) 2.6  
Inhibin, beta A (activin A, activin AB alpha polypeptide) 2.5  
AE binding protein 1 2.5  
periostin, osteoblast specific factor 2.5  
inhibin, beta A (activin A, activin AB alpha polypeptide) 2.4  
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Gene Title 
 
Fold 
Change 
 
UDP-glucose ceramide glucosyltransferase-like 2 2.4  
lipopolysaccharide-induced TNF factor 2.4  
lipase, endothelial 2.3  
prostaglandin-endoperoxide synthase 1  2.3  
CDNA clone IMAGE:4079668, partial cds 2.3  
GLI pathogenesis-related 1 (glioma) 2.3  
syndecan 2 (heparan sulfate proteoglycan 1, cell surface-
associated 2.3 
 
Hypothetical protein LOC123722 2.3  
Transcribed locus 2.3  
GAJ protein 2.3  
mitochondrial ribosomal protein L43 2.3  
Noggin 2.3  
transgelin 2.3  
syndecan 2 (heparan sulfate proteoglycan 1, cell surface-
associated 2.3 
 
platelet-derived growth factor alpha polypeptide 2.2  
Cadherin 11, type 2, OB-cadherin (osteoblast) 2.2  
brain expressed X-linked 2 /// brain expressed X-linked 2 2.2  
tenascin C (hexabrachion) 2.2  
syndecan 2 (heparan sulfate proteoglycan 1, cell surface-
associated,  2.2 
 
desmoplakin 2.1  
ankyrin repeat domain 1 (cardiac muscle) 2.1  
zinc finger protein 643 2.1  
GLI pathogenesis-related 1 (glioma) 2.1  
KIAA0830 protein 2.1  
trefoil factor 3 (intestinal) 2.1  
Homo sapiens, clone IMAGE:5285282, mRNA 2.1  
deleted in lymphocytic leukaemia, 2 /// BCMS upstream 
neighbor-like 2.1 
 
deleted in lymphocytic leukemia, 2 /// BCMS upstream 
neighbor-like 2.1 
 
prostaglandin-endoperoxide synthase 1  2.1  
nucleophosmin/nucleoplasmin, 3 2.1  
Rap guanine nucleotide exchange factor (GEF) 1 2.1  
hypothetical protein LOC144997 2.1  
solute carrier family 38, member 5 2.1  
cytochrome P450, family 1, subfamily B, polypeptide 1 2.1  
cytochrome b5 reductase b5R.2 2.0  
follistatin 2.0  
heme oxygenase (decycling) 1 2.0  
neuron navigator 3 2.0  
chromosome 20 open reading frame 35 2.0  
prostaglandin-endoperoxide synthase 1  2.0  
hypothetical protein LOC286505 2.0  
ST3 beta-galactoside alpha-2,3-sialyltransferase 6 2.0  
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Table 3.7. All probesets reaching diiferential expression of 2.0 or 
greater in human iris microvascular endothelial cells compared with 
human choroidal endothelial cells. 
  
Gene Title 
 
Fold 
Change 
 
cardiomyopathy associated 3 4.2  
popeye domain containing 3 3.8  
Protocadherin 9 3.8  
delta-notch-like EGF repeat-containing transmembrane 3.7  
synaptotagmin I 3.6  
extracellular link domain containing 1 3.6  
CD69 antigen (p60, early T-cell activation antigen) 3.2  
interferon-induced protein with tetratricopeptide repeats 1  3.2  
family with sequence similarity 38, member B 3.1  
extracellular link domain containing 1 2.9  
protein tyrosine phosphatase, non-receptor type 22 
(lymphoid) 2.9 
 
synaptotagmin I  2.9  
interferon-induced protein 44-like 2.8  
Homo sapiens, clone IMAGE:5312689, mRNA 2.8  
myxovirus (influenza virus) resistance 1, interferon-
inducible protein p78 2.7 
 
solute carrier family 6, member 15 2.7  
aldo-keto reductase family 1, member C3  2.7  
LOC440156 2.7  
protein tyrosine phosphatase, non-receptor type 22 
(lymphoid) 2.6 
 
KIAA1598 2.6  
family with sequence similarity 38, member B 2.6  
zinc finger protein 317 2.5  
lanosterol synthase (2,3-oxidosqualene-lanosterol 
cyclase) 2.5 
 
aldo-keto reductase family 1, member C2  2.5  
nitric oxide synthase trafficker 2.4  
filamin A interacting protein 1 2.4  
neurofilament 3 (150kDa medium) 2.4  
myosin VB 2.4  
calmegin 2.3  
Tissue factor pathway inhibitor 2 2.3  
filamin-binding LIM protein-1 2.3  
collagen, type XXI, alpha 1 /// collagen, type XXI, alpha 1 2.3  
tissue factor pathway inhibitor 2 2.3  
BMX non-receptor tyrosine kinase 2.2  
Zinc finger-like 2.2  
paternally expressed 10 2.2  
aldo-keto reductase family 1, member C1  2.2  
CD34 antigen 2.2  
protocadherin 9 2.3  
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Gene Title 
 
Fold 
Change 
 
zona pellucida glycoprotein 3  2.2  
chromosome 10 open reading frame 10 2.2  
aldo-keto reductase family 1, member C1  2.2  
Homo sapiens, clone IMAGE:5261213, mRNA 2.2  
KIAA0711 gene product 2.1  
KIAA0960 protein 2.1  
chemokine (C-C motif) ligand 2 2.1  
LOC132671 2.1  
hypothetical gene supported by BC009447 2.1  
Homo sapiens, clone IMAGE:5261213, mRNA 2.1  
filamin A interacting protein 1 2.1  
p53 target zinc finger protein 2.1  
gremlin 1 homolog, cysteine knot superfamily (Xenopus 
laevis) 2.0 
 
cyclin A1 2.0  
lanosterol synthase (2,3-oxidosqualene-lanosterol 
cyclase) 2.0 
 
protocadherin 19 2.0  
 
 
Proliferating human retinal versus iris vascular endothelial cells 
 
Comparison of human retinal endothelial cells with human iris 
endothelial cells demonstrated a difference of 2041 probe sets (7.8% of 
probesets that passed quality control). Of this total, 880 were up-
regulated in retinal ECs and 1161 were up-regulated in iris ECs. Using 
Ingenuity Pathway Analysis software, differences between retinal and 
iris ECs were shown in the expression of genes involved in a wide 
range of biological processes such as RNA post-translational 
modification, cell signalling, DNA replication and gene expression. As 
described previously, there were close similarities between iris and 
choroidal ECs, meaning that many of the genes differentially expressed 
between iris and retinal ECs were the same as those differentially 
expressed between choroidal and retinal ECs. However, canonical 
pathway analysis revealed a small number of differences in interferon, 
IL 22 and TGF  signalling pathways (table 3.8). A representative heat 
map is shown in Fig 3.7 and a list of the top 100 differentially expressed 
probesets reaching statistical significance in retinal and iris ECs are 
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shown in tables 3.9 and 3.10 respectively. Figs 3.8a and 3.8b pie charts 
demonstrate a greater proportion of up-regulated probesets for cell 
development in iris ECs compared with retinal ECs (19 vs 5%). 
However, all other biological process subsets demonstrated similar 
proportions of up-regulation of expression in both iris and ECs. As can 
be seen from the detailed analysis of differences in gene expression, 
the pie chart is not a good representation of the more subtle differences 
in gene expression.  
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Table 3.8. Differential expression of probe sets involved in cell signalling between matched human iris and retinal endothelial cells 
 
 
 
Signalling  
Pathway 
 
Affy ID Gene Symbol Gene Name 
Fold  
Change 
Direction of 
regulation (retina 
vs Iris) 
IL 22 
 
209575_at IL10RB Interleukin 10 receptor, beta 2.0 Up 
 212046_x_at MAPK3 Mitogen-activated protein kinase 3 2.1 Up 
 208992_s_at STAT3 Signal transducer and activator of 
transcription 3 2.1 
Up 
Interferon 
 
229450_at IFIT3 Interferon-induced protein with 
tetratricopeptide repeats 3 9.0 
Up 
 217863_at PIAS1 Protein inhibitor of activated STAT, 1 2.1 Up 
TGF Beta 
 
228121_at TGFB2 TGF-beta2 7.8 Down 
 207334_s_at TGFBR2 TGF-betaII receptor 2.5 Up 
 212666_at SMURF1 SMAD protein ligase 2.1 Down 
 212046_x_at MAPK 3 Mitogen-activated protein kinase 3 2.1 Up 
 210511_s_at INHBA Inhibin beta A  14.6 Down 
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Urokinase 
 
 
Nuclear factor B 
Histone cluster 1 
PRP31 
IFIT3 
TAO kinase 
 
 
Spectrin 1 
TLR 4 
 
 
 
IL10 receptor 
MAPK3 
 
    Iris                     Retina 
Fig 3.7 Heatmap of ascending differential probeset expression reaching 
 statistical significance with reference to human retinal and iris micro- 
vascular endothelial cells. Upregulated probesets are shown in red, 
downregulated in blue. A total of 2041 different probesets are represented. 
The positions of selected probesets thought to be important in endothelial 
cell biology are shown.  
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 Fig 3.8a. Pie chart of significantly up-regulated genes grouped by 
biological processes in proliferating human iris endothelial cells 
compared with proliferating human retinal endothelial cells 
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Fig 3.8b. Pie chart of significantly up-regulated genes grouped by 
biological processes in proliferating human retinal endothelial cells 
compared with proliferating human iris endothelial cells 
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Table 3.9. One hundred most highly expressed probesets in human 
retinal   microvascular endothelial cells compared with human iris 
endothelial cells. 
 
Gene Title 
 
Fold 
Change 
 
plasminogen activator, urokinase 20.1  
Rho-related BTB domain containing 3 17.5  
phosphatase and actin regulator 2 17.0  
protein tyrosine phosphatase, non-receptor type 22 
(lymphoid) 16.7 
 
SCY1-like 2 (S. cerevisiae) 15.4  
protein tyrosine phosphatase, non-receptor type 22 
(lymphoid) 15.0 
 
dipeptidyl-peptidase 4 14.8  
nuclear factor I/B 14.5  
tetratricopeptide repeat domain 37 14.1  
dipeptidyl-peptidase 4 13.9  
fusion (involved in t(12;16) in malignant liposarcoma) 12.8  
histone cluster 1,  12.1  
PRP31 pre-mRNA processing factor 31 homolog (S. 
cerevisiae) 12.0 
 
TAO kinase 1 11.6  
squalene epoxidase 11.4  
histone cluster 1, H1c 11.3  
PRP4 pre-mRNA processing factor 4 homolog B (yeast) 11.0  
zinc finger protein 480 10.7  
HECT domain containing 1 10.6  
epithelial cell transforming sequence 2 oncogene 10.5  
zinc finger protein 146 10.2  
dystonin 10.0  
jumonji domain containing 1C 9.9  
G elongation factor, mitochondrial 1 9.9  
G protein-coupled receptor kinase 5 9.4  
epithelial membrane protein 1 9.3  
vacuolar protein sorting 13 homolog C (S. cerevisiae) 9.3  
IFIT3 9.3  
cyclin E2 9.1  
nucleoporin 43kDa 9.1  
thymopoietin 8.9  
replication factor C (activator 1) 3, 38kDa 8.9  
cyclin K 8.8  
nuclear factor of activated T-cells 5, tonicity-responsive 8.7  
ADAM metallopeptidase domain 15 8.6  
M-phase phosphoprotein 9 8.5  
septin 10 8.5  
baculoviral IAP repeat-containing 5 8.4  
family with sequence similarity 115, member A  8.4  
mannosidase, alpha, class 1A, member 1 8.3  
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Gene Title 
 
Fold 
Change 
 
spectrin, beta, non-erythrocytic 1 8.3  
serum deprivation response (phosphatidylserine binding 
protein) 8.3 
 
phosphoinositide-3-kinase, class 2, alpha polypeptide 8.3  
cell division cycle associated 2 8.0  
NIMA (never in mitosis gene a)-related kinase 2 7.9  
neural precursor cell expressed, developmentally down-
regulated 1 7.8 
 
toll-like receptor 4 7.8  
matrin 3 7.7  
RNA binding motif protein 22 7.7  
Rho-guanine nucleotide exchange factor 7.7  
ubiquitin specific peptidase 34 7.7  
ribonucleotide reductase M1 7.7  
SET domain containing 2 7.6  
polo-like kinase 4 (Drosophila) 7.6  
thrombospondin 1 7.6  
BRCA1/BRCA2-containing complex, subunit 3 7.6  
twinfilin, actin-binding protein, homolog 1 (Drosophila) 7.4  
PCTAIRE protein kinase 2 7.4  
cancer susceptibility candidate 5 7.3  
sperm associated antigen 9 7.3  
AHNAK nucleoprotein 7.3  
ribosomal protein S6 kinase, 70kDa, polypeptide 1 7.2  
Nipped-B homolog (Drosophila) 7.1  
RAS and EF-hand domain containing 7.7  
catenin (cadherin-associated protein), alpha 1, 102kDa 7.1  
FERM domain containing 4A 7.9  
muted homolog (mouse) 7.0  
Meis homeobox 1 7.0  
kelch repeat and BTB (POZ) domain containing 11 7.0  
transcription factor Dp-1 7.0  
protein tyrosine phosphatase, non-receptor type 12 6.9  
hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-
Coenzyme A 6.9 
 
RAS and EF-hand domain containing 6.9  
Ewing sarcoma breakpoint region 1  6.9  
KIAA1826 6.8  
phosphoinositide-3-kinase, class 2, alpha polypeptide 6.8  
RAB38, member RAS oncogene family 6.7  
Fanconi anemia, complementation group M 6.7  
Senataxin 6.7  
arrestin, beta 1 6.7  
FGFR1 oncogene partner 2 6.7  
muscleblind-like 2 (Drosophila) 6.6  
kinesin family member 22 6.6  
budding uninhibited by benzimidazoles 1 homolog (yeast) 6.6  
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Gene Title 
 
Fold 
Change 
 
NLR family, pyrin domain containing 1 6.5  
suppressor of Ty 16 homolog (S. cerevisiae) 6.5  
PTPRF interacting protein, binding protein 1 (liprin beta 
1) 6.5 
 
folate hydrolase (prostate-specific membrane antigen) 1 6.5  
sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted 6.3 
 
ADAM metallopeptidase with thrombospondin type 1 
motif, 9 6.3 
 
HECT, UBA and WWE domain containing 1 6.3  
asp (abnormal spindle) homolog, microcephaly 
associated (Drosophila) 6.7 
 
zinc finger E-box binding homeobox 1 6.3  
sulfatase 2 6.3  
DENN/MADD domain containing 3 6.2  
nidogen 1 6.2  
prion protein 6.2  
UEV and lactate/malate dehyrogenase domains 6.2  
pericentriolar material 1 6.1  
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Table 3.10. One hundred most highly expressed probesets in human 
iris microvascular endothelial cells compared with human retinal 
endothelial cells. 
Gene Title 
 
Fold 
Change 
 
wnt 5A 36.4  
collagen, type I, alpha 1 34.1  
interferon, alpha-inducible protein 6 33.8  
pleckstrin homology-like domain, family A, member 2 28.8  
ADAM metallopeptidase with thrombospondin type 1 
motif, 12, 26.0 
 
transmembrane protein 45A 25.7  
gremlin 1, cysteine knot superfamily, homolog (Xenopus 
laevis) 24.1 
 
Zic family member 2 (odd-paired homolog, Drosophila) 23.6  
thrombospondin 2 22.2  
CCAAT/enhancer binding protein (C/EBP), beta 21.6  
endothelin receptor type A 21.6  
gremlin 1, cysteine knot superfamily, homolog (Xenopus 
laevis) 19.8 
 
reticulon 1 19.8  
cytoglobin 18.9  
collagen, type VI, alpha 1 18.8  
crystallin, alpha B 18.6  
GATA binding protein 6 18.5  
brain-derived neurotrophic factor 18.3  
potassium voltage-gated channel, Isk-related family, 
member 4 17.9 
 
lysyl oxidase-like 1 17.4  
follistatin 17.3  
dermatan sulfate epimerase-like 16.9  
glutamyl aminopeptidase (aminopeptidase A) 16.3  
coagulation factor II (thrombin) receptor-like 1 16.2  
amphiregulin  16.1  
nexilin (F actin binding protein) 15.9  
inhibin, beta A 15.0  
cAMP responsive element binding protein 3-like 1 14.8  
collagen, type VI, alpha 3 14.6  
scinderin 14.6  
EF-hand domain family, member D1 14.5  
Full length insert cDNA clone ZA02A01 14.5  
chemokine (C-X-C motif) ligand 10 14.4  
vascular endothelial growth factor A 14.3  
follistatin 14.2  
lectin, galactoside-binding, soluble, 3 binding protein 14.2  
frizzled homolog 2 (Drosophila) 14.2  
regeneration associated muscle protease 14.2  
inhibitor of DNA binding 4, dominant negative helix-loop-
helix protein 13.8 
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Gene Title 
 
Fold 
Change 
 
reticulon 1 13.5  
stanniocalcin 2 13.5  
solute carrier organic anion transporter family, member 
2B1 13.5 
 
collagen, type I, alpha 1 13.5  
collagen, type XII, alpha 1 13.4  
wingless-type MMTV integration site family, member 5A 13.2  
platelet-derived growth factor receptor, beta polypeptide 13.2  
adrenergic, beta-1-, receptor 13.1  
proline rich 16 13.0  
dystrophin 13.0  
fibroblast growth factor 1 (acidic) 12.9  
insulin receptor substrate 1 12.9  
procollagen C-endopeptidase enhancer 12.6  
cadherin 6, type 2, K-cadherin (fetal kidney) 12.5  
hyaluronan synthase 2 12.5  
chemokine (C-X-C motif) ligand 11 12.2  
TP53 regulating kinase 12.1  
ubiquitin associated and SH3 domain containing, B 12.1  
CHD2 11.7  
prostaglandin-endoperoxide synthase 2  11.4  
chromosome 1 open reading frame 64 11.4  
frizzled homolog 7 (Drosophila) 11.2  
mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase,  11.2 
 
interferon induced transmembrane protein 1 (9-27) 11.1  
hexokinase 2 10.9  
forkhead box D1 10.7  
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 2-like 10.6 
 
chromosome 1 open reading frame 85 10.6  
family with sequence similarity 91, member A2  10.5  
jun D proto-oncogene 10.4  
chromosome 21 open reading frame 7 10.4  
PDZ domain containing ring finger 3 10.2  
similar to lymphocyte-specific protein 1 10.2  
platelet-derived growth factor alpha polypeptide 9.9  
collagen, type V, alpha 3 9.8  
neuronal PAS domain protein 2 9.8  
hypothetical LOC387763 9.7  
chromosome 11 open reading frame 70 9.6  
solute carrier family 16, member 6 (monocarboxylic acid 
transporter 7) 9.4 
 
ring finger protein 182 9.3  
interferon-induced protein with tetratricopeptide repeats 3 9.3  
spondin 2, extracellular matrix protein 9.2  
alpha-kinase 2 9.2  
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Gene Title 
 
Fold 
Change 
 
pleckstrin and Sec7 domain containing 3 9.2  
synaptotagmin XI 9.1  
hepatocyte growth factor (hepapoietin A; scatter factor) 9.0  
CKLF-like MARVEL transmembrane domain containing 8 9.0  
integrin, alpha 7 8.9  
EPH receptor A4 8.8  
interferon-induced protein with tetratricopeptide repeats 1 8.6  
carboxypeptidase A3 (mast cell) 8.6  
fibroblast growth factor 5 8.5  
vestigial like 3 (Drosophila) 8.5  
translation initiation factor eIF-2B subunit 
alpha/beta/delta-like protein 8.5 
 
SIX homeobox 1 8.5  
neuronal PAS domain protein 2 8.5  
cystatin SN 8.4  
prostate transmembrane protein, androgen induced 1 8.4  
collagen, type V, alpha 3 8.4  
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Real time PCR 
 
Real time PCR was used to validate the differences in gene expression 
between HUVEC, iris, retinal and choroidal endothelial cells. Nine 
transcripts were chosen that demonstrated at least a 2-fold differential 
expression between ECs from various sources on microarray analysis 
and that were thought to be relevant to a range of endothelial cellular 
functions. The chosen transcripts were: Angiopoietin 2, Keratin 18, 
CD44, CD73 (5 nucleotidase ecto), MAPKK 3, Integrin 3, Laminin 2, 
Decay Accelerating Factor and Carboxypeptidase M. Fig 3.9 
demonstrates examples of real time PCR curves of selected probesets 
in HUVEC and ocular endothelial cells while table 3.11 shows an 
example of the output from the ABI PRISM 7000 sequence detection 
system and demonstrates the reproducibility of the triplicates for each 
cell type and also shows the figures used in the calculation of the fold 
FKDQJHXVLQJWKHǻ&7PHWKRG. 
 
Table 3.12demonstrates that the differences in expression between the 
microarray and real time PCR techniques were similar for 8 out of the 9 
transcripts evaluated, with only those results from the decay 
accelerating factor showing a discrepancy. Overall, these results 
confirm the overall reliability of the results obtained by the Affymetrix 
microarray technique.  
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Fig 3.9 demonstrates examples of real time PCR dissociation curves of 
selected probesets in HUVEC and ocular endothelial cells. The Y axis 
depicts the fluorescence of the reporter signal normalised to a 
reference signal (Rn) while the X axis depicts the cycle number. Each 
probeset under investigation is represented by all 3 curves of the 
sample triplicate and also includes a probeset for the reference 
housekeeping gene - hypoxanthine-guanine phosphoribosyltransferase 
(HPRT). Also represented are the curves of the No Template Control 
(NTC) (sterile water). Fig 3.9a, demonstrates the dissociation curves for 
a series of 10 fold dilutions for an Angiopoietin 2 reference sample 
while Fig 3.9b shows the calculated standard curve derived from Fig 
3.9a, demonstrating its linearity of the range tested.  
Ct is the crossing point or threshold at which fluorescence can be 
detected and log C0 is the log of the relative standard concentration 
(chosen to correspond to the expected relative concentration of 
probeset in the samples).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.9a    Fig 3.9b 
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Fig 3.9c demonstrates the QPCR dissociation curves (triplicates) for 
Angiopoietin 2 expression in HUVEC and human choroidal endothelial 
cells. The reference housekeeping gene is HPRT.  
The No Template Controls are also included 
 
 
Ang2 in choroidal 
ECs 
Ang2 in 
HUVEC 
HPRT in choroidal 
ECs and HUVEC 
NTC for 
HPRT 
NTC for Ang2 
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Fig 3.9d demonstrates the QPCR dissociation curves (triplicates) for 
Keratin 18 expression in HUVEC and human retinal endothelial cells. 
The reference housekeeping gene is HPRT.  
The No Template Controls are also included.  
Keratin 18 in HUVEC 
Keratin 18 
in retinal 
ECs 
HPRT in retinal ECs 
and HUVEC 
 
NTC for HPRT 
NTC for Keratin 
18 
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Fig 3.9e demonstrates the QPCR dissociation curves (triplicates) for 
CD44 expression in HUVEC, retinal and iris human endothelial cells. 
The reference housekeeping gene is HPRT.  
The No Template Controls are also included. Note that the dissociation 
curves for HUVEC and retinal ECs are almost identical whereas iris 
ECs shifted to the right (reflecting lower expression of CD44 mRNA). 
CD44 in HUVEC and 
retinal ECs 
CD 44 in iris 
ECs 
HPRT in HUVEC, 
retinal and iris ECs 
 
NTC for CD44 
NTC for 
HPRT 
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Table 3.11. A table showing an example of the output of the ABI PRISM 7000 sequence detection system for Angiopoietin 2  QPCR 
for human iris, retinal, choroidal ECs and HUVEC demonstrating the Ct, average Ct, difference in Ct between the target and 
reference (HPRT). The last column on the right shows the final fold change expression of Ang2 in individual ocular EC type 
compared with the HUVEC reference. (See table 3.12 for the complete set of results. 
 
 
Well Detector Ct (Ang 2) Average Ct 
  
Ct  (HPRT) Av Ct DCt Av DCt DDCt Fold Change 
IRIS A1 ab ANG2 24.8  eh HPRT1 Unknown 27.56       
1 A2 ab ANG2 24.59  eh HPRT1 Unknown 27.37       
 A3 ab ANG2 25.05 24.81 eh HPRT1 Unknown 27.31 27.41 -2.6     
IRIS B1 ab ANG2 24.62  eh HPRT1 Unknown 27.83       
2 B2 ab ANG2 25.58  eh HPRT1 Unknown 27.98       
 B3 ab ANG2 24.61 24.93 eh HPRT1 Unknown 27.99 27.93 -3     
IRIS C1 ab ANG2 24.32  eh HPRT1 Unknown 27.82       
3 C2 ab ANG2 24.38  eh HPRT1 Unknown 28.03       
 C3 ab ANG2 24.57 24.42 eh HPRT1 Unknown 27.81 27.89 -3.47 -3.02 -3.25 9.5  
CHOROID D1 ab ANG2 25  eh HPRT1 Unknown 27.08       
4 D2 ab ANG2 25.29  eh HPRT1 Unknown 27.18       
 D3 ab ANG2 25.11 25.13 eh HPRT1 Unknown 27.28 27.18 -2.05     
CHOROID E1 ab ANG2 25.07  eh HPRT1 Unknown 27.05       
5 E2 ab ANG2 25.07  eh HPRT1 Unknown 26.91       
 E3 ab ANG2 25.02 25.05 eh HPRT1 Unknown 27.01 26.99 -1.94     
CHOROID F1 ab ANG2 25.21  eh HPRT1 Unknown 28.42       
6 F2 ab ANG2 25.46  eh HPRT1 Unknown 28.42       
 F3 ab ANG2 25.95 25.54 eh HPRT1 Unknown 28.58 28.47 -2.93 -2.31 -2.54 5.9  
HUVEC G1 ab ANG2 28.23  eh HPRT1 Unknown 27.9       
7 G2 ab ANG2 28.15  eh HPRT1 Unknown 27.62       
 G3 ab ANG2 28.09 28.16 eh HPRT1 Unknown 27.51 27.68 0.48     
HUVEC H1 ab ANG2 27.42  eh HPRT1 Unknown 27.65       
8 H2 ab ANG2 27.73  eh HPRT1 Unknown 27.63       
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Well Detector Ct (Ang 2) Average Ct 
  
Ct  (HPRT) Av Ct DCt Av DCt DDCt Fold Change 
 H3 ab ANG2 27.88 27.68 eh HPRT1 Unknown 27.86 27.71 -0.03     
HUVEC A7 ab ANG2 27.36  eh HPRT1 Unknown 27.18       
9 A8 ab ANG2 27.35  eh HPRT1 Unknown 27.16       
 A9 ab ANG2 27.56 27.42 eh HPRT1 Unknown 27.18 27.17 0.25 0.23 reference   
RETINA B7 ab ANG2 24.39  eh HPRT1 Unknown 28.95       
11 B8 ab ANG2 24.55  eh HPRT1 Unknown 28.75       
 B9 ab ANG2 24.62 24.52 eh HPRT1 Unknown 28.64 28.78 -4.26     
RETINA C7 ab ANG2 23.21  eh HPRT1 Unknown 27.02       
12 C8 ab ANG2 23.32  eh HPRT1 Unknown 27.19       
 C9 ab ANG2 23.15 23.22 eh HPRT1 Unknown 26.93 27.05 -3.83     
RETINA D7 ab ANG2 25.9  eh HPRT1 Unknown 29.53       
20 D8 ab ANG2 26.05  eh HPRT1 Unknown 29       
 D9 ab ANG2 25.78 25.91 eh HPRT1 Unknown 29.16 29.23 -3.32 -3.8 -4.03 16.3  
 
         
    
 
         
    
 A10 ab ANG2 Undetermined NTC          
 A11 ab ANG2 Undetermined NTC          
 B10 eh HPRT1 Undetermined NTC          
 B11 eh HPRT1 Undetermined  NTC          
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Table 3.12. Differences in gene expression of selected genes for HUVEC, iris, choroidal and retinal endothelial cells according to 
microarray (MA) and Real time-PCR (RT-PCR) 
 
 
 
  Difference in gene expression  (fold change) 
Gene transcript Affy ID HUVEC Iris Choroid Retina 
  MA RT-PCR MA RT-PCR MA RT-PCR MA RT-PCR 
Angiopoietin 2 205572_at 0 0 9.2 9.5 7.6 5.9 10.7 16.3 
Keratin 18 201596_x_at 0 0 -4.7 -4.2 -4.1 -3.4 -4.7 -2.7 
CD44 204489_s_at 0 0 -4.9 -3.5 -4.8 -5.7 <2.0 0.9 
CD73  203939_at 0 0 3.9 4.5 3.8 3.0 4.1 4.5 
MAPKK 3 201474_s_at 0 0 2.8 3.1 2.3 3.4 4.6 5.3 
Integrin  3 201474_s_at 0 0 <2.0 1.6 <2.0 1.4 5.6 4.6 
Laminin 2 216264_s_at 0 0 2.9 2.5 2.4 1.4 3.4 2.9 
Decay Accelerating 
Factor (CD55)  201926_s_at 0 0 2.9 1.4 4.0 1.2 <2.0 2.1 
Carboxypeptidase M 235706_at 0 0 - 4.4 -5.3 <2.0 -2.5 <2.0 -1.3 
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Discussion 
 
The well described morphological, biochemical, phenotypical and 
molecular heterogeneity of endothelial cells raises the question as to 
whether conclusions drawn from studies using animal or human 
macrovascular endothelial cells such as HUVECs can be applied to 
different angiogenic diseases causing blindness in humans, such as 
wet AMD, proliferative diabetic retinopathy, rubeotic glaucoma and 
retinopathy of prematurity. Despite their anatomical juxtaposition, the 
diseases appear to be selective for different ocular vascular beds so 
any reliable and meaningful insight into their pathophysiological 
mechanisms and the development of potentially selective treatments 
would most likely only be gained by conducting studies using 
microvascular endothelial cells derived from the particular intra-ocular 
site(s) affected by the condition. 
  
There is a paucity of information as to whether different human ocular 
microvascular endothelial cells demonstrate similarities in the 
intracellular mechanisms involved in angiogenesis. Previously, workers 
have shown a difference between human retinal endothelial and 
HUVEC cell secretory functions (prostaglandin I2, and E2) and their 
responses to high glucose concentrations in an attempt to understand 
the underlying mechanisms of proliferative diabetic retinopathy 
(Rymaszewski et al, 1992). In the investigation of the mechanisms of 
inflammatory eye disease, Silverman et al in 2005 showed differences 
in E-Selectin expression using nylon-based gene array by matched 
human iris and retinal microvascular endothelial cells after stimulation 
with inflammatory agents (LPS and TNF ). Similarly, Smith et al in 
2007 used gene expression profiling to examine differences between 
matched retinal and choroidal endothelial cells as a means to determine 
underlying mechanisms of posterior ocular inflammatory diseases. They 
found an 8.9% difference in transcripts between retinal and choroidal 
ECs after stimulation with toxoplasma tachyzoites. Many of the 
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transcripts related to genes important in inflammatory processes, 
leukocyte trafficking and mediators of immune responses (ICAM 1, E 
Selectin, chemokines and VCAM 1), suggesting that the retinal 
vasculature is susceptible to inflammatory processes.  
 
The present study had two main objectives. The first was to compare 
the gene expression profiles of human umbilical vein ECs with a 
number of different ocular microvascular endothelial cells to determine 
whether HUVECs are representative cells to use in ocular vascular 
research. Secondly, the gene expression profiles, particularly those of 
canonical cell signalling pathways of matched human choroidal, retinal 
and iris endothelial cells were compared to determine whether any 
differences in canonical pathway expression could be identified that 
could provide insights into our understanding of site-specific 
mechanisms of ocular angiogenic diseases and perhaps identify areas 
for future targeted therapies. 
 
In this study, 3% of probesets were differentially expressed between 
HUVECs and ocular microvascular cells, with 1.4% of probesets being 
found to be up-regulated in HUVECs. While there was a wide range of 
different genes that were up-regulated, there was an enrichment of 
genes involved in embryonic development such as the homeobox 
genes. Interestingly, Murthi et al in 2007 found a differential expression 
of homeobox genes between HUVE and placental microvascular 
endothelial cells, with HLX1 (thought to be important in the 
development of B cells) being down-regulated in HUVECs (Murthi et al, 
2007). This finding is not surprising as the umbilical vein and its 
endothelial lining is of foetal origin and forms part of the foetoplacental 
unit and is a high flow vessel with a thick wall containing elastin and 
PXVFOHILEUHVVXUURXQGHGE\:KDUWRQ¶VMHOO\FDUU\LQg oxygenated 
blood from the placenta to the foetus. It is therefore intrinsically involved 
in embryonic development. Homeobox (HOX) genes encode a range of 
transcription factors, found in clusters named A,B,C and D on four 
different chromosomes and their expression is spatially and temporally 
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UHJXODWHGGXULQJHPEU\RQLFGHYHORSPHQW8QGHUWKLVDSSOLFDQW¶V
guidance, workers in the same laboratory have recently detected 
expression of HOX B7 and A9 protein in HUVECs by Western blotting, 
whereas no expression was detected in human retinal or choroidal ECs. 
Other up-regulated genes included those involved in encoding proteins 
involved in ECM interactions such as MMP 2, heparinase and fibrillin 2, 
and cytoskeletal proteins such as cytokeratin 18. These genes may be 
important given the growth and remodelling of the thick walled umbilical 
vein required during gestation. Specifically, fibrillins have been shown 
to be important in the attachment of endothelial cells to the elastin 
found in the ECM on the abluminal side of vessels, thereby aiding the 
anchoring of cells to underlying structures (Weber et al, 2002). 
Interestingly, some cytokeratins, which are intermediate filaments 
usually found in epithelial cells, have been found to be up-regulated in 
breast cancer by oestrogens via an oestrogen-response element close 
to the cytokeratin gene on chromosome 17 (Choi et al, 2000). Its up-
regulation in HUVECs may therefore reflect its origin from an oestrogen 
rich environment. HUVECs also appear to express a distinct pattern of 
cell membrane components involved in cell signalling, such as the 
hepatocyte growth factor receptor (c-met). Hepatocyte growth factor 
(HGF) is a pro-angiogenic factor found in the placenta and is thought to 
be important in placental and foetal development, although its precise 
role is unknown (Dash et al, 2005). HGF receptors on HUVE cells may 
therefore be important in the vascular development of placental tissues. 
Similarly, ephrin B2 (the transmembrane ligand for the EphB4 receptor) 
was found to be up-regulated in HUVECs by other workers (Kim et al, 
2002) and is one of a group of receptor tyrosine kinases found in 
abundance in placental tissue (Goldman-Wohl et al, 2004). They are 
thought to play a role in embryonal vascular and neuronal development 
and endothelial cell migration. Specifically, the ephrin B2 
transmembrane ligand is found in abundance in the placenta, 
VXJJHVWLQJWKDWWKHUHFHSWRU¶VSUHVHQFHRQ+89(Cs is important and 
may play a role in vascular development of the foetoplacental unit 
(Chennakesava et al, 2006). It is interesting to note that ephrin B2 is 
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usually thought to be an arterial-specific marker. Its presence on 
HUVECs is surprising until one recognises that the umbilical vein 
carries highly oxygenated (arterial) blood from the placenta to the 
foetus and that some think of HUVECs as a specific subtype of arterial 
ECs (T Gardiner, personal communication).  
 
Approximately 1.6% of probesets were found to be up-regulated in 
ocular microvascular ECs compared to HUVECs, and again, while this 
included a diverse range of different genes, there were specific groups 
which were enriched. These include genes involved in immune 
responses (MHC class I and II and interleukin receptors), signal 
transduction and the cellular responses to stimuli. These differences 
may be explained by the different roles of HUVEC and ocular 
microvascular ECs. The ocular microvasculature is thought to be 
important as a barrier to blood borne pathogens where immune cells 
such as macrophages and lymphocytes, must interact with ECs to 
traverse this endothelial barrier to enter extravascular tissues. Immune 
mechanisms are also thought to be important in the pathogenesis of 
both diabetic retinopathy and wet AMD.  
 
Given that the microvasculature is always undergoing remodelling and 
is the site of physiological angiogenesis, it is not surprising that a 
number genes involved in cell signalling (G proteins and phospholipase 
C) and interactions with the microenvironment such as those involved 
with the endothelial cell basement membrane (TIMP 3, collagens I and 
III) are differentially up-UHJXODWHG8QGHUWKLVDSSOLFDQW¶VJXLGDQFH
workers in the same laboratory have recently detected expression of 
collagen 1 alpha1 sub unit protein in ocular MVECs by Western blotting, 
whereas no expression was detected in HUVECs, thereby adding 
weight to microarray findings. TIMP 3 is thought to modify breakdown of 
the extracellular matrix and type IV and VI collagen alpha chains, both 
of which are components of cellular basement membranes. A gene 
differentially expressed in ocular MVECs is angiopoietin 2, which is 
thought to modulate vascular stability and remodelling by the 
 261 
antagonism of Tie 2 receptors and Sprouty which, in turn, is thought to 
modify the sprouting of growing vessels by interacting with receptor 
tyrosine kinases which have been stimulated by angiogenic growth 
factors such as VEGF (Cabrita & Christofori, 2008). 
 
 
Proliferating ocular MVEC also appear to possess distinct intracellular 
signalling pathways not utilised significantly by HUVECs. These include 
pathways utilising components such as MAPKK 3, and PLC alpha 2. 
The significance of these alternative pathway components is currently 
unknown but they may provide selective targets for future interventions 
in modulating cellular function. Ocular microvascular endothelial cells 
also demonstrate up-regulation of a range of genes encoding cell 
surface proteins involved in the action of cytokines, cell adhesion and 
binding to the extracellular matrix. As the microvascular environment 
may be a site of inflammation, the up-regulation of cell surface proteins 
involved in leukocyte trafficking such as the mannose receptor 1 and 
versican may also be important in understanding ocular inflammatory 
diseases. The mannose receptor has recently been found on dermal 
MVEC but not HUVEC, reinforcing the significance of the current 
findings (Groger et al, 2000). All of these findings suggest that ocular 
MVECs are actively involved in communicating and remodelling their 
local surroundings and are distinctly different from macrovascular 
HUVE cells. This was suggested over 20 years ago by Klagsbrun and 
Folkman who observed that angiogenesis occurs in the 
microvasculature or capillaries, not in large vessels (Klagsbrun and 
Folkman, 1990). In vitro studies have subsequently shown that 
microvascular endothelial cells have a higher angiogenic potential than 
macrovascular ECs, either by their increased expression of matrix 
metalloproteinases (Jackson and Nguyen, 1997), their response to 
tumour angiogenesis factor (Keegan et al, 1982), IGF-1 (King et al, 
1985) or VEGF (Bian et al, 2006). 
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This dichotomy in differential gene expression suggests that HUVECs 
are probably not a suitable substitute for ocular ECs in the study of the 
underlying mechanisms of ocular vascular diseases. 
  
When matched, proliferating human retinal and choroidal endothelial 
cells were compared; we found that 8.4% of probesets were 
differentially expressed. Because of the importance of angiogenesis in 
a number of common blinding diseases, it was decided to concentrate 
on those genes important in the angiogenic response, in particular 
those of canonical signalling pathways,  
 
The selective treatment of diseases relies on the identification of 
unique, or at least significantly different, attributes in the affected site 
compared with their surroundings. Finding significant differences 
between human retinal and choroidal ECs would therefore be 
advantageous for the selective treatment of either predominantly retinal 
or choroidal neovascular disorders, while at the same time leaving 
juxtaposed ECs intact.  
 
The current study shows that retinal ECs demonstrate selective up-
regulation of some components of the wnt-5 signalling pathway such as 
a frizzled homolog and WNT5a. This is a poorly understood pathway 
that may regulate cell proliferation, apoptosis and branching 
morphogenesis (Masckauchán et al, 2006; Masckauchán et al, 2005). 
The importance of this pathway to human retinal vasculogenesis has 
recently been described (Parmalee & Kitajewski, 2008). Human retinal 
ECs also demonstrated up-regulated gene expression of a wide range 
of growth factors such as VEGF, PDGF-C, PDGF-B chain and IL-32. 
This would imply a local paracrine function for retinal ECs either by 
stimulating surrounding endothelial cells or by stimulating their 
surrounding pericytes which are known to be dependent upon PDGF for 
their maintenance (Jo et al, 2006). It is now known that there is 
extensive communication between ECs and pericytes and each cell 
type relies on the other for many of its functions and perhaps even 
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survival. Pericytes are embedded within the basement membrane of 
endothelial cells and direct communication may occur via peg-socket 
junctions which contain gap junctions (Cuevas et al, 1984). What this 
communication consists of is currently unknown. As mentioned 
previously, endothelial cells secrete PDGF-B which is thought to 
promote proliferation and recruitment of pericytes to newly formed 
vessels. Knockout models show that if this fails to occur, then vascular 
dysfunction ensues with endothelial hyperplasia and the formation of 
abnormal endothelial junctions and leads to perinatal death (Hellstrom 
et al, 2001). It is also thought that TGF-ȕLVVHFUHWHGE\HQGRWKHOLDO
cells and plays a role in the differentiation of vascular mural cells such 
as pericytes. It is also thought to act in an autocrine fashion acting via 
endoglin (a type of TGF receptor) to affect endothelial cell differentiation 
and proliferation. Finally, there is evidence to suggest that Tie 2-
Angiopoietin 1 (Ang-1) interactions are important in EC-pericyte 
communication. Tie-2 is highly expressed on endothelial cells and its 
ligand, Ang 1 is expressed by pericytes. Knockout models show that 
this interaction is essential for vessel maturation and stability (Suri et al, 
1996). 
  
Retinal ECs also demonstrate significant expression of growth factor 
receptors and binding proteins such as the insulin and IGF-2 receptors; 
stromal-cell-derived-factor receptor (CXCR4); IGF binding proteins 2 
and 7; and the interferon gamma and IL-4 receptors. These findings 
may be important in clinical practice as retinal neovascularisation seen 
in diabetes appears in part to be related to diabetic control and insulin 
and IGF levels (Meyer-Schwickerath et al, 1993; Grant et al, 1986). 
This hypothesis is given additional weight because, when under the 
guidance of the applicant, workers in Nottingham have recently 
demonstrated in a functional assay, that IGF 1 stimulates the 
proliferation of human retinal ECs to a similar degree to VEGF (similar 
to the findings of Grant et al, 1993a and 1993b), whereas IGF-1 has 
little effect on matched human choroidal ECs (see later chapter). Other 
workers have also shown an inhibitory effect on retinal 
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neovascularisation by agents that block growth hormone or by removal 
RIWKHSDWLHQW¶VSLWXLWDU\JODQGWKHUHE\GRZQ-regulating circulating IGF 
1 levels) (Sharp et al, 1987; Merimee et al, 1970; Wright et al, 1969; 
Palii et al, 2007). Interestingly, our laboratory found that equimolar 
concentrations of IGF-1 and VEGF appeared to have synergistic effects 
on the proliferation of human RECs whereas human CECs did not 
demonstrate any additional effect above that of VEGF alone. This effect 
on human RECs may be explained by the findings of Smith et al in 
1999, when her group looked at the effects of VEGF and IGF-1 on 
bovine RECs and found evidence of interactions between the intra 
cellular signalling pathways for each growth factor, and suggested that 
IGF 1 is required for maximal neovascularisation to be induced by 
VEGF. Finally, in vitro studies on bovine retinal endothelial cells have 
demonstrated a significant effect of IGF-1 on cell survival and 
proliferation (Castellon et al, 2002). IGF-1 is also strongly implicated in 
the pathogenesis of retinopathy of prematurity (ROP), such that 
researchers are suggesting manipulation of IGF-1 levels soon after birth 
as a treatment for this condition.  
 
It is interesting that the proliferation of human CECs does not appear to 
be dependent on IGF (Browning et al, 2007) and in vivo, choroidal 
neovascularisation does not appear to respond to agents that inhibit 
IGF (Papadaki et al, 2003), despite a positive effect in an animal model 
(Bezerra et al, 2005). In contrast, this work has shown that choroidal 
ECs demonstrate up-regulated expression of the FGF receptor 1. This 
is important for binding a number of FGF sub-types which have been 
shown to be important for the development of the choroidal vasculature 
(Rousseau et al, 2003). Choroidal ECs also appear to differentially 
express genes involved in intra-cellular signalling such as G-protein-
coupled receptor kinase, MAPK 1 and G-protein-coupled receptor 89. 
This would imply that compared to retinal ECs, proliferating choroidal 
ECs may be utilising slightly different intra-cellular signalling pathways. 
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In this study the retinal and choroidal endothelial cells were proliferating 
under exactly the same conditions, but there were consistent variations 
in the expression of genes in a number of ubiquitous endothelial cell 
signalling pathways such as the PI3K/ AKT, ERK/MAPK and mTOR 
pathways. While both retinal and choroidal endothelial cells appear to 
utilise all of these pathways, many of the differentially expressed probe 
sets of the PI3K/AKT pathway were up-regulated in choroidal ECs, 
suggesting that this is a potentially more important pathway for these 
cells and perhaps a potential target for inhibitory compounds. 
Examination of the ERK/MAPK signalling pathways also showed that 
choroidal ECs demonstrated up-regulation of MAPK 1. At present, the 
significance of these findings is uncertain but again, it may offer a more 
selective method of inhibiting retinal or choroidal angiogenesis. This 
author and co-workers have recently found that the potency of the 
VEGF 121 and 165 isoforms was greater when used to stimulate 
proliferation of human retinal endothelial cells compared with matched 
human choroidal endothelial cells (Stewart et al, 2011). This suggests 
that components of canonical pathways differentially up-regulated in 
retinal ECs such as the wnt pathway (WNT5A and Frizzled homologue) 
and the ERK/MAPK pathway (Integrin alpha 3 and phospholipase A2 
may account for the increased proliferation and may be important 
drivers for angiogenesis in the retina. This is an area that requires 
further research as, to date, little is known about the fine details of cell 
signalling pathways activated in proliferating human choroidal, retinal 
and iris endothelial cells. Limited data from work on bovine choroidal 
endothelial cells, stimulated by VEGF, showed activation of MAPK/ERK 
via 3/&Ȗ (Zubilewicz et al, 2001) However, these are very common 
stimulatory pathways for many different types of cells and so the results 
are not unsurprising. Again, this is an area where further comparative 
work is required.  
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Another specialised feature of the retinal vasculature ECs is the 
formation of the inner blood retinal barrier (similar to the blood brain 
barrier). Unlike the choroidal vasculature, which allows small molecules 
to extravasate from the vascular compartment via fenestrations in 
choriocapillaris endothelial cells, the retinal vasculature possesses very 
tight cell junctions between adjacent endothelial cells in order to stop 
small molecules and cells extravasating unless very specific situations 
exist. The integrity of this endothelial barrier function is dependent on 
tight junctions (TJ), composed of molecules such as ZO-1, occludin, 
cadherins and claudins. The subtypes of TJ molecules found in human 
retinal ECS are poorly understood. However, Luo et al have recently 
described some of the molecules found in the murine retinal 
vasculature. They found that claudins 1,2 and 5 appear to be prominent 
in retinal ECs whereas claudins 3,4,12,22 and 23 were not detected. In 
our experiments, compared with human choroidal ECs, it was found 
that in a similar fashion to Luo et al, human retinal ECs preferentially 
expressed Claudin 5 (4.2 fold expression), ZO-1 (2.7 fold expression). 
Unlike Lou et al however, we also found that Claudin 12 was up-
regulated (2.4 fold). In 1998, Russ et al demonstrated that human 
retinal ECs expressed Cadherin 5 (VE Cadherin), suggesting that it was 
EC specific. In our experiments we did not find it to be preferentially 
expressed by retinal ECs (it being expressed to the same extent by 
both retinal and choroidal ECs). We did find however, that the retinal 
ECs preferentially expressed Cadherin 2. (2.9 fold expression). This is 
more usually associated with neuronal tissue, hence its other name N-
Cadherin and is a new finding. Our results otherwise agree with those 
published for murine retinal ECs.  
 
Both retinal and choroidal ECs demonstrate up-regulated expression of 
genes involved in collagen and integrin synthesis. Retinal ECs show 
up-regulated expression of the alpha chains of collagens XII, VI, V, IV 
(alpha 1) and III, while choroidal ECs express collagen IV alpha 3 
chains. This would suggest that the basement membranes of retinal 
and choroidal ECs may be different. 
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Our results also confirm the findings of others that retinal endothelial 
cells preferentially express genes involved in immune functions (up-
regulation of signalling pathways involved in the interferon and 
interleukin 2 and 4 receptors). There is evidence to suggest that 
proliferative diabetic retinopathy is a pro-inflammatory condition with 
lymphocyte infiltration of blood vessels early in the disease (Joussen et 
al, 2001; Grisanti et al, 1994). There are also elevated levels of 
inflammatory cytokines such as IL 6 and IL 12 and chemokines CXCL8, 
CCL2, 4 and 5 in the vitreous of such patients in addition to VEGF 
(Banerjee et al, 2007; Wakabayashi et al, 2010). Interestingly, 
Interferon was not detected in the vitreous samples of these patients 
with retinal neovascularisation which may be of significance as 
interferon is thought to be anti-angiogenic. 
  
Another striking finding from this study was the similarity between 
choroidal and iris endothelial cells. The iris and choroid are considered 
to be different parts of the same tissue, the uveal tract, although the 
vascular systems in which they belong have entirely different roles. 
Previous workers looking at the characteristics and role of the iris 
vasculature in anterior uveitis have shown that human iris ECs 
constitutively express genes involved in the immune response such as 
Toll-like receptor 4, ICAM-1 and 2, and demonstrate up-regulation of E-
Selectin after LPS stimulation (Silverman et al, 2001; Brito et al, 2004). 
To our knowledge, however, no comparison has been made with 
matched choroidal ECs. However, Hageman et al in 1991 did show that 
choroidal ECs stained positive for carbonic anhydrase IV whereas the 
iris vasculature did not. In our study, we did not find a significant 
difference between the expression of any carbonic anhydrase 
isoenzyme probesets in these two cell types. The small number of 
differentially expressed probe sets did not show any significant 
aggregation into known canonical signalling pathways. The down-
regulation of genes for SMAD 9, Serpine 1 and hyaluronan synthase 
suggests that iris ECs interact slightly differently with their surroundings, 
particularly with respect to the turnover of extracellular matrix and the 
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level of inhibition of local tissue plasminogen activation and fibrinolysis 
compared with choroidal ECs. Interestingly, SMAD proteins are 
intracellular signalling molecules, activated by Bone Morphogenetic 
Protein (BMP) receptors. These in turn are activated by members of the 
TGF-beta superfamily (such as BMPs). SMAD 9 has been found to date 
to be expressed in the heart, lung brain and liver. No ocular expression 
has been reported (to date). Specific mutations in SMAD 9, leading to a 
loss in function, have been found in a number of cases of primary 
pulmonary hypertension (Nasim et al, 2011). This disorder is 
characterised by the abnormal plexiform growth of endothelial cells 
which in turn leads to resistance to flow. It appears that a lack of SMAD 
9 leads to the abnormal growth of blood vessels. It is also known that 
Bone Morphogenetic Protein 4 is important for ocular development via 
the stimulation of SMADs and has also been found to inhibit choroidal 
angiogenesis in an animal model (Xu et al, 2012). Again, SMADs 
(including SMAD 9) appear to be acting as an indirect anti-angiogenic 
factor. Down regulation of SMAD 9 in our experiments would therefore 
suggest a lack of receptor activation by BMPs in iris ECs which in turn 
may indirectly be pro-angiogenic. This is an area where future work 
could be considered. 
 
We found no significant difference in the expression of genes involved 
in inflammation or immune function as alluded to by other workers. This 
may be due to a lack of specific stimulation by factors such as LPS. 
 
Because of the marked similarity between iris and choroidal endothelial 
cells, most of the differences noted between retinal and iris ECs were 
similar to those seen between retinal and choroidal ECs. There were a 
few notable exceptions, however, such as in the expression of 
probesets associated with genes involved in immune or inflammatory 
signalling pathways. It was shown that proliferating retinal endothelial 
cells showed up-regulated expression of genes involved in interferon 
and IL22 signalling compared to iris ECs. This finding adds further 
weight to the findings of Silverman et al (2005) who found differences in 
 269 
E-selectin expression using a nylon-based gene array by matched 
human iris and retinal microvascular endothelial cells after stimulation 
with inflammatory agents (LPS and TNF ). They found that retinal ECs 
consistently expressed higher levels of E-selectin mRNA (and protein) 
after stimulation, compared with matched iris ECs. Similarly, Smith et al 
(2007) used gene expression profiling to examine differences between 
matched retinal and choroidal endothelial cells as a means to determine 
underlying mechanisms of posterior ocular inflammatory diseases. They 
found an 8.9% difference in transcripts between retinal and choroidal 
ECs after stimulation with toxoplasma tachyzoites. Many of the 
transcripts up-regulated in retinal ECs related to genes important in 
inflammatory processes, leukocyte trafficking and mediators of immune 
responses (ICAM 1, E selectin, chemokines and VCAM 1). These 
findings underlie the fact that retinal endothelial cells are probably 
important in immune function and/or leukocyte trafficking within the 
retina and may explain why the retinal vasculature may be preferentially 
susceptible to inflammatory disorders. 
 
The present study has a number of strengths over previous studies. 
Firstly, the use of purified, unpassaged cells means that the in vitro 
gene expression profiles are as close as possible to the in vivo 
proliferative state. It is known that endothelial cell phenotype changes 
quickly in vitro (Miebach et al, 2006; Kalashnik et al, 2000; Shima et al, 
1995) so it would not be unexpected for human ocular vascular 
endothelial cell gene expression profiles to change in a similar manner. 
Secondly, the ocular endothelial cells were matched from the same 
donors, thereby reducing the effect of inter-individual gene expression 
differences in this study and thirdly, the microarray expression results 
were validated by RT-PCR (and later by protein expression and 
functional studies). While the isolation of endothelial cells from 
FU\RVHFWLRQVZRXOGKDYHDOORZHGWKH³WUXH´in vivo gene expression to 
be measured, the isolation of cells by techniques such as laser capture 
is hampered by its small sample size, contamination by non-endothelial 
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cells and possible post mortem changes in RNA quality. Such a 
technique also has the disadvantage that the profile of proliferating cells 
(important in the study of pathological angiogenesis) cannot be easily 
measured, as most endothelial cells in vivo are in a quiescent state.  
 
A criticism of this study is that the expression levels of probesets and 
the differences between endothelial cells simply reflect different rates of 
proliferation and cell growth between cells. In answering this criticism, it 
should be remembered that the cells were matched for donor, growth 
conditions and confluency. Although not measured directly, all cells 
reached sub-confluence (approx 80%) at approximately the same times 
(5-7 days) as described in chapter 2. Any small differences in the rate 
of growth of cells and therefore reaching the required level of 
confluence would be unlikely to account for the 10 fold differences in 
gene expression between iris/choroid and iris/retina. A further feature 
designed to eliminate low level fluctuation in the differences in gene 
expression is by only accepting differential expression if all 3 samples 
for each cell type demonstrate significant results. 
 
In conclusion, this study has demonstrated a significant difference in 
gene expression between proliferating HUVEC and ocular 
microvascular ECs. This suggests that extrapolation of in vitro results 
derived from HUVECs to the investigation of ocular diseases should be 
avoided. Microvascular ECs derived from different sites within human 
eyes also demonstrated heterogeneity in gene expression. These 
results may provide insight into different ocular vascular disorders and 
allow development of new, targeted treatment strategies.   
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Introduction  
 
The choroid forms part of the uveal tract within the eye and lies 
between the outer sclera (white of the eye) and the inner layer 
composed of the retina, and the retinal pigment epithelium (RPE). It is 
approximately 100-ȝPWKLFNGHSHQGLQJRQWKHSDUWLFXODUVLWHLQWKH
eye, and is composed almost entirely of blood vessels with some 
supporting cells such as fibroblasts and melanocytes. As previously 
described, the choroid has historically been sub-divided into 3 layers: 
WKHRXWHUOD\HURIODUJHYHVVHOV+DOOHU¶VOD\HUDPLGGOHOD\HURI
PHGLXPVL]HGYHVVHOV6DWWOHU¶VOD\HUDQGDQLQWHUQDOOD\HUDGMDFHQWWR
%UXFK¶V0HPEUDQHFRPSRVHGRIFDSLOODU\YHVVHOVFKRULRFDSLOODULV  
 
 
 
 
Fig 4.1. A haematoxylin and Eosin stained section of human choroid 
and RPE demonstrating the different calibres of the choroidal 
vasculature (with permission of Springer images)  
 
The choroid derives its blood supply from the short posterior ciliary 
arteries, which are themselves a branch of the ophthalmic artery. This 
means that the choroid has a very rich blood supply which is effectively 
derived from a branch of the internal carotid artery (the main function of 
which is to supply the brain). The choriocapillaris has a honeycomb 
structure of numerous inter-communicating channels which serve to 
supply oxygen and nutrients to the overlying RPE cells and 
photoreceptors. While it appears as a diffuse interconnecting sheet on 
Sclera 
Large outer choroidal  
arterioles and 
YHQXOHV+DOOHU¶V
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6DWWOHU¶VOD\HU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electron microscopy (see chapter 1), in reality, it has a lobular structure, 
with each lobule being supplied by a central arteriole and drained by a 
SHULSKHUDOOREXODUYHQXOH7KHPDLQ³PDVV´RIWKHFKRURLGLVPDde up of 
sequential subdivisions of the supplying and draining veins which 
ensure a rich blood supply to the choriocapillaris (see below). It is 
thought that the choriocapillaris is important in certain eye disorders as 
they appear to occur selectively within this vascular bed e.g. wet AMD 
and certain inflammatory choriocapillopathies such as MEWDS 
(multiple evanescent white dot syndrome). This suggests that the 
FKRULRFDSLOODULVLV³GLIIHUHQW´IURPWKHUHVWRIWKHFKRURLGDOYDVFXODWXUH 
 
 
 
Fig 4.2. Scanning electron micrograph of a cast of human choroidal 
vasculature viewed from the scleral side showing draining choroidal 
veins (v), arterioles (a) and the choriocapillaris (c) visible through the 
gaps between the large vessels (from Olver J, 1990 Eye, 4:262, with 
permission).  
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Fig 4.3.  Scanning electron micrograph of a cast of human choroidal 
vasculature viewed from the side showing the large and medium sized 
FKRURLGDOYHVVHOV+DOOHU¶VDQG6DWWOHU¶VOD\HUVDQGWKHFKRULRFDSLOODULV
visible at the top of the image (From Olver J, 1990 Eye, 4:262, with 
permission).  
 
The endothelial cells lining the choriocapillaris have an unusual 
property when compared with the other choroidal, ocular and most 
other endothelial cells (both micro- and macro-vascular); they are 
IHQHVWUDWHGRQWKHVLGHIDFLQJ%UXFK¶VPHPEUDQHDQGWKH53(FHOOV 
Fenestrations are round or oval transcellular holes through the thinnest 
parts of the endothelial cell cytoplasm. They are found in areas where a 
high rate of partially selective exchange of components between the 
intra and extravascular compartments is required. This exchange is 
usually limited to water and small solutes with passage of larger 
components such as lipids and proteins being inhibited. The 
fenestrations within the choriocapillaris therefore allow the rapid transfer 
RIQXWULHQWVWKURXJK%UXFK¶VPHPEUane and the RPE, into the highly 
metabolically active photoreceptors. To date, three types of 
fenestrations have been described (Satchell and Braet, 2009):  
 
Type 1 fenestrations are 60-70 µm in diameter and are covered by a 
thin diaphragm. The glycoprotein - plasmalemmal vesicle associated 
protein, 1 (PLVAP-1), is thought to be a major component of this 
diaphragm. Each fenestration is surrounded by a cytoskeletal lattice. 
Type I fenestrations are found in the endothelia of endocrine glands, 
Choriocapillaris 
 
 
 
 
 
Large and medium 
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gastrointestinal mucosa and renal tubular capillaries. It is thought that 
the fenestrations found in the human choriocapillaris may be type I by 
virtue of the expression of PLVAP in gene array experiments (see later) 
and the possession of a diaphragm.  
 
 
 
 
Fig 4.4. An electron micrograph of a renal glomerular endothelial cell 
membrane demonstrating diaphragmed fenestrations (with permission 
of Springer images)  
 
 
Type II fenestrations are found in discontinuous endothelia such as that 
found in the spleen, liver and bone marrow. These fenestrations are 
wider (up to 200µm diameter) and do not have diaphragms or express 
PLVAP.  
 
Type III fenestrations are found in the endothelium of renal glomeruli. 
They are of a similar size to type I, but like type II, do not express 
PLVAP or have diaphragms.  
 
While possession of fenestrations is thought to be an endothelial 
specific marker, of use in the confirmation of EC lineage, the in vitro 
study of fenestrations is somewhat limited by their paucity of expression 
in many ECs derived from vascular beds known to be fenestrated in 
Extracellular compartment 
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vivo. The expression of fenestrations also appears to be lost by 
prolonged culture and sub-culture. Experiments are therefore best 
carried out on fresh tissue or unpassaged cells (Satchell and Braet, 
2009). Interestingly, fenestrations can also be induced in vitro in ECs 
that do not normally express them. This appears to be easier to perform 
in microvascular than macrovascular ECs (Esser et al, 1998) and is 
thought to be dependent on VEGF. Indeed, endothelial cells that are 
not normally fenestrated such as those found in the cremaster muscle 
and skin, can be induced to form them by the application of VEGF 
(Roberts & Palade, 1995). In the eye, VEGF secreted by the RPE is 
thought to be important for maintaining the state of fenestration of the 
choriocapillaris ECs as inhibition of intraocular VEGF by bevacizumab 
(an anti-VEGF antibody) leads to a reduction of choriocapillaris 
fenestration density (Peters et al, 2007).  
 
To better understand the angiogenic mechanisms important in the 
development of wet AMD, the leading cause of blindness in those over 
65, it would be advantageous to study the behaviour of endothelial cells 
derived from the site where the disease occurs, that is within the inner 
choroid of the human macula. This requirement has been reinforced by 
the previous finding in chapter 3 of significant heterogeneity in different 
human ocular endothelial cells. What is not known is whether this 
heterogeneity exists within the choroid at sites known to be predisposed 
to angiogenic disease (wet AMD). 
 
The isolation of ECs from the choriocapillaris/inner choroid has 
previously proved difficult. To date, workers have either used complete 
choroidal enzyme digests which contain all ECs, or have attempted 
selective enzyme separation of the choriocapillaris away from the 
underlying tissue (Liu & Li, 1993). This latter technique was conducted 
in bovine eyes which have a tapetal membrane underlying the 
choriocapillaris, making isolation simpler than in humans. Selective 
isolation in humans is also hampered by the increased susceptibility of 
the choroidal tissues to trypsin/collagenase digestion. This makes 
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selective isolation extremely difficult to achieve reliably and 
consistently.  
 
A new technique is therefore required to separate the 
choriocapillaris/inner choroid from the underlying structures. 
Interestingly, it has been known for over 100 years that the human 
choroid is made up of a lamellar structure. In 1892, Nuel described a 
natural cleavage plane between the layers of Haller (inner choroid) and 
Sattler (outer choroid) (Nuel, 1892), while in 1912, Saltzmann noted 
that dissection of the choroid was achieved most easily by teasing apart 
the layers from the outside (Saltzmann 1912). In order to exploit this 
phenomenon, two different techniques were tried to reliably separate 
the layers so that viable ECs could be extracted from the two layers of 
tissue. The first technique was the use of a Vibratome, which aimed to 
section the different horizontal layers of adult human choroid. The 
second technique was an attempt to isolate the desired ECs by manual 
dissection and cell isolation using paramagnetic beads coated with 
endothelial selective antibodies after enzyme digestion of the choroid.  
 
After isolation using the latter technique, the macular inner choroidal 
ECs were characterised in terms of their antigen expression 
(determined by selective binding of fluorescent labelled antibodies), 
their ability to form capillary-like tubes in a 3D collagen rich matrix and 
the presence of fenestrations. After isolation and characterisation, the 
isolated human inner choroidal endothelial cells could then be used in 
experiments to aid our understanding of the mechanisms of inner 
choroidal neovascularisation.  
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Methods  
 
Vibratome sectioning 
 
The vibratome (Campden Instruments, Loughborough, UK) is a 
vibrating keratome that enables the sectioning of living tissues into 
sheets for further physiological experimentation. Living tissue is held 
within gelatine blocks which is then subject to vibratome sectioning. It 
has been used successfully to produce functioning sections of the brain 
(Snyder et al, 2001) and the outer retina (Tezel & Kaplan, 1998; Kaplan 
et al, 1997; Silverman & Hughes, 1989; Ghosh et al, 1999) which have 
then been used for subsequent intraocular transplantation. Since retina 
is of a similar thickness to choroid, it was felt that this technique may be 
able to produce viable sheets of inner choroid. 
 
Gelatin blocks (10%) (Sigma Alrich, UK) were cast in silver foil and 
cooled at 4ºC to allow solidification. Flat sections of choroid, 
approximately 8mm in diameter, were removed from globe flat mounts 
using an 8mm biopsy punch and layered onto the gelatin block. The 
choroid was then covered with liquid gelatin (10%) and again allowed to 
solidify at 4ºC. The gelatin block was then mounted onto the vibratome 
chuck with superglue and sectioning at various thicknesses (20-50µm) 
was attempted. Despite varying the gelatin concentration and varying 
the thickness of the cut section, it was not possible for the blade to 
enter the choroid to produce a flat sheet of tissue. On all attempts, the 
blade either passed over the choroid sheet, pressing it further into the 
gelatin, or simply lifted the whole section out of the gelatin. The reason 
for this may be that choroid is composed of a dense network of blood 
vessels held together in a fibrous network which impedes the easy 
passage of the vibratome blade. This technique was therefore 
abandoned. 
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Manual dissection 
 
Human posterior segments were dissected as described in chapter 2 
and the vitreous gel removed in order to give access to the posterior 
segment. A full thickness macular sample, centred on the fovea, 
consisting of choroidal and scleral tissue was removed with an 8mm 
sterile punch and transferred to a petri dish. The macula was identified 
by the presence of yellow macular pigment. The choroid was then 
gently teased from the attached sclera and turned upside down with the 
outer choroid facing upwards. With the use of a dissecting microscope 
(x10 magnification) and fine forceps, a natural cleavage plane was 
found that allowed the outer choroidal vessels, along with adherent 
pigmented fibrous tissue, to be peeled off, leaving the relatively non-
pigmented inner choroidal vessels and choriocapiOODULV%UXFK¶V
membrane complex. The tissue samples (inner and outer choroid) were 
washed 3 times in isolation medium and the vascular endothelial cells 
were isolated by the method described previously using anti CD31 
coated paramagnetic beads (Chapter 2). Matched endothelial cells from 
the inner and outer macular choroid and peripheral inner choroid were 
routinely isolated and cultured for further experiments using this 
technique (described in detail in Chapter 2). 
 
Because of their importance in the pathogenesis of wet age-related 
macular degeneration, human macular inner choroidal endothelial cells 
were chosen for further characterisation with a view to further 
experiments into macular inner choroidal endothelial cell proliferation. 
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Human inner choroidal endothelial cell characterisation 
 
Immunohistochemistry  
 
A small sample of trypsinised cells, suspended in EGM-2MV, was 
placed onto sterile glass cover slips (VWR Ltd, Poole, UK) coated with 
1% gelatin (Sigma) (cover slips were immersed in 1% gelatin in sterile 
PBS for 30 mins at 37°C, then washed gently in sterile PBS and dried 
in a laminar flow hood). After allowing 3 hours for cells to attach, they 
were fixed in ice cold methanol at -20°C for 20 minutes. A standard two 
stage immunofluoresence technique was applied using the primary 
antibodies listed below in table 4.1. The primary antibodies were left in 
contact with the cells for 60 minutes before washing 4 times with sterile 
PBS. The secondary antibodies used were: rabbit anti-PRXVH)DE¶
fragment fluorescein isothiocyanate (FITC) conjugated (Dako) at a 
dilution of 1:20 when used to visualise all primary antibodies except 
swine anti-UDEELW)DE¶IUDJPHQW),7&FRQMXJDWH'DNRDWDGLOXWLRQ
of 1:20 which was used to visualise the anti-vWf primary antibody. The 
secondary antibodies were left in contact with the cells for 60 minutes 
before washing 4 times with sterile PBS. The slides were then mounted 
in glycerol containing 2.5% 1-4 diazabicyclo[2,2,2] octane (DABCO) 
(Sigma ±Aldrich) and observed by confocal fluorescence microscopy 
(Leica TCS0D, Leica, Milton Keynes, UK). Negative primary antibody 
controls were conducted by replacing the primary antibody with either a 
non-specific anti-rat epitope murine IgG1 antibody, rabbit 
immunoglobulin fraction or PBS. Additional negative controls were 
conducted using the appropriate primary and secondary antibodies on 
human RPE cells. In assessing the identity and purity of the endothelial 
cells, at least 500 nucleated cells were counted after staining with each 
antibody. 
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It was felt important to characterise any contamination from other cells 
found within the choroidal stroma (fibroblasts and RPE cells), therefore 
hXPDQ53(FHOOVDQG7HQRQ¶VFDSVXOHILEUREODVWVZHUHXVHGDV
controls and staining of samples for ĮSMA (for RPE cells) and fibroblast 
surface protein (for fibroblasts) was conducted. E-Selectin expression 
on endothelial cells was examined after exposure to TNF-ĮSJPO
for 1 hour.  
 
 
Table 4.1. Primary antibodies used in the study of human inner 
choroidal endothelial cells 
 
Epitope Class Dilution Source 
CD31 murine 
IgG1 
1:20 Dako 
vWf rabbit Ig 
fract 
1:200 Dako 
VEGFR1 murine 
IgG1 
1:100 Sigma-Aldrich 
VEGFR2 murine 
IgG1 
1:800 Sigma-Aldrich 
Į60$ murine 
IgG1 
1:50 Dako 
Fibroblast Surface 
Protein 
murine 
IgG1 
1:200 Dako 
E-Selectin murine 
IgG1 
1:20 Serotec 
Negative control murine 
IgG1 
1:20 Dako 
Negative control  Rabbit Ig 
fraction 
1:200 Dako 
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Transmission electron microscopy 
 
A sample of inner choroidal macular endothelial cells was grown to near 
confluence on 35mm fibronectin coated culture plates (Becton 
Dickinson, Oxford, UK) as previously described. The cells were then 
fixed in situ by immersion in 2.5% glutaraldehyde (in 0.1M cacodylate 
buffer, pH 7.4) for 16-24 hours and processed for transmission electron 
microscopy (TEM). The fixed cells, still attached to the plastic culture 
plate, were cut into 1mm thick slices and washed with cacodylate 
buffer, followed by secondary fixation in 1% osmium tetroxide for 1 
hour. The attached cells were then dehydrated in ascending 
concentrations of ethanol, followed by infiltration and embedding in 
Epon resin before polymerization at 60°C for 16 hours. Suitable areas 
for TEM were selected from 0.5µm toluidine blue stained sections. After 
they were trimmed, 80nm sections were cut and mounted on copper 
grids before double staining with uranyl acetate and lead citrate. A 
transmission electron microscope (model 1010; JEOL, Welwyn Garden 
City, UK) was used to observe the prepared sections.  
The transverse sections of macular inner choroidal endothelial cells 
were examined specifically for fenestrations and in vitro tube formation 
 
An important property that appears to be limited to vascular endothelial 
cells is their ability to coalesce into capillary-like tubes in a basement 
membrane matrix such as Matrigel (BD Biosciences, Oxford, UK). This 
property can therefore be utilized to identify isolated cells as originating 
from an endothelial lineage. Matrigel is a solubilised basement 
membrane preparation extracted from the Engelbreth-Holm-Swarm 
mouse sarcoma. This is a tumour rich in extracellular matrix proteins 
such as laminin, collagen IV, heparin sulphate, entactin and nidogen. It 
also contains TGF-beta, fibroblast growth factor and tissue 
plasminogen activator. The product has the property of rapidly forming 
a gel at 22-35°C and should therefore be used as close as possible to 
4°C until ready to gel, at which point it is brought up to room 
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temperature. During use, the product should be keep on ice, and used 
with cooled pipette tips, plates and tubes. 
 
In this experiment, a 1:1 mixture of chilled Matrigel and endothelial 
growth medium (EGM2-MV) was dispensed into pre-chilled wells of a 
cooled 96 well plate. The mixture was allowed to solidify at 37°C for 30 
minutes before macular inner choroidal endothelial cells, suspended in 
endothelial growth medium (EGM2-MV) were seeded at a density of 4.8 
x 104 per well. The wells were observed hourly for the formation of 
tubes. For transmission electron microscopy, the growth medium was 
removed and replaced by 2.5% glutaraldehyde (in 0.1M cacodylate 
buffer, pH 7.4) for 16-24 hours at 37°C. The fixed Matrigel was then 
gently removed from the well and processed as described previously.  
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Results 
 
Human posterior segments from 6 different donors were used. The 
ages of the donors (years) and the lengths of time from death to 
endothelial cell isolation (hours) were 45 (52), 76 (42), 70 (43), 37 (60), 
83 (60) and 56 (60).  
Toludine blue staining of sections of human choroid 
 
After manual dissection of samples of full thickness choroid, light 
microscopy showed the samples to comprise of %UXFK¶VPHPEUDQH
along with adherent choriocapillaris and inner choroidal vessels. The 
large outer choroidal vessels were reliably and reproducibly removed. 
Examples of the pre and post dissection toluidine stained choroid are 
shown in 4.5a and 4.5b respectively.  
 
 
 
Fig. 4.5a. Histological section of human sub-macular choroid stained 
with toluidine blue before removal of the outer choroidal vessels 
VKRZLQJWKHGDUNEOXHVWDLQLQJRI%UXFK¶VPHPEUDQHZLWKWKH
underlying fine complex of the choriocapillaris and the larger calibre 
middle and outer choroidal vessels. The nuclei of the supporting 
choroidal fibroblasts and melanocytes can also be seen (all arrowed.) 
Bruch¶s membrane/choriocapillaris  
Mid/outer choroidal vessels 
Fibroblasts and melanocytes 
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Fig. 4.5b. Histological section of human sub-macular choroid stained 
with toluidine after removal of the outer choroidal vessels. The residual 
%UXFK¶VPHPEUDQHchoriocapillaris and inner choroidal vessels can be 
seen. Note the absence of large outer choroidal vessels. 
 
 
Immunohistochemistry 
 
 
The isolates of macular inner choroidal endothelial cells stained positive 
for CD31, vWf, VEGFR1, VEGFR2 and E-Selection after stimulation 
with TNF . They did not stain with mouse anti-rat negative control, 
Smooth muscle actin or fibroblast surface protein. Selected 
photographs of macular inner choroidal ECs along with the appropriate 
negative controls are shown in figures 4.6-4.21. As important as the fact 
that the cells stained positive or negative for a certain antigen, is an 
understanding of the distribution of the stained antigen and whether the 
findings are compatible with the knowledge of this protein within 
endothelial cells.  
 
The macular inner choroidal ECs stained positive for vWf in a granular 
pattern within the cell cytoplasm. On transmission electron microscopy, 
no Weibel-Palade bodies were seen. The cells also stained positive for 
%UXFK¶VPHPEUDQHFKRULRFDSLOODULV 
5HPQDQWVRIPLGGOH³IHHGHU´ 
arterioles and veins 
 297 
CD31 (PECAM), with staining heaviest at endothelial cell-cell junctions 
while VEGF receptors 1 and 2 stained positively across the entire cell, 
with strong staining particularly around the nucleus (this may represent 
staining within the Golgi, where proteins are modified after synthesis). 
The cells were also positive for E-Selectin after stimulation with TNF 
alpha (the RPE cell control did not show similar up-regulation). The 
most intense staining was seen around the nucleus, perhaps because 
of the abrupt up-regulation of protein synthesis and modification within 
the Golgi.  The ECs did not demonstrate significant binding of alpha 
smooth muscle actin (a marker of RPE cells) or fibroblast surface 
protein (a marker of fibroblasts)+XPDQ53(FHOOVDQG7HQRQ¶VFDSVXOH
fibroblasts stained positive for alpha smooth muscle actin and fibroblast 
surface protein respectively.  
 
 
Matrigel tube formation 
 
Human macular inner choroidal ECs formed capillary-like tubes within 3 
hours of suspension (Fig 4.22). By 6 hours the tubes had begun to 
break up. Control Tenon¶V capsule fibroblasts did not show any 
evidence of tube formation. When samples of cells were cultured in 
Matrigel plugs and processed for transmission EM, numerous lumina 
were detected when tubes were cut in cross section. In some instances, 
at least 3 different cells were seen to make up the tube wall (Fig 4.23) 
and were joined by junctional complexes. This suggests that the tubes 
were formed by an active process on the part of the cells and had not 
simply occurred by random cell aggregation. 
 
Fenestrations  
 
Cells were cultured on gelatine coated plastic cover slips in growth 
medium. They were then fixed and examined by TEM. At no point were 
electron dense Weibel-Palade bodies found. Scattered throughout the 
cells, particularly at points where they were at their thinnest were 
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diaphragmed fenestrations (Fig 4.24). These were seen as gaps within 
the cell membranes joined by electron dense lines (the diaphragm). 
Compared to published pictures of fenestrations in freeze fractured 
ECs, the fenestrations in our cells were much less abundant.  
 
 
 
 
Fig 4.6. Macular inner choroidal endothelial cells stained for vWf 
(primary antibody - rabbit polyclonal anti-vWf, secondary antibody - 
swine anti-rabbit  )DE¶IUDJPHQW),7&FRQMXJDWH). This demonstrates 
cells staining positive in a granular pattern consistent with the known 
localisation of vWf being within cytoplasmic granules. 
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Fig 4.7. Macular inner choroidal endothelial cells negative control, 
stained with rabbit Ig fraction (primary antibody and secondary antibody 
- swine anti-UDEELW)DE¶IUDJPHQW),7&FRQMXJDWH). Compared with 
Fig 4.2 (vWf), there is an absence of granular staining within the 
cytoplasm indicating that Fig 4.6 (vWf) shows a true positive result 
There is non-specific staining of cell nuclei. 
 
 
 
Fig 4.8. Macular inner choroidal endothelial cells stained for CD31. 
There is a ring of increased staining around the nuclei, perhaps 
indicating the site of CD31 synthesis. However, maximal staining is 
located at the cell surface, particularly at points of cell contact. This 
would be compatible with the known role of CD31 in being an 
endothelial cell surface adhesion molecule. 
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Fig 4.4. Macular inner choroidal endothelial cells stained for CD105 ( 
 
 
 
 
 
 
Fig 4.10. Macular inner choroidal endothelial cells stained for VEGF 
receptor 1. There is homogeneous staining throughout the cell, 
consistent with the VEGF receptor being abundant on the cell surface. 
In addition, there appears to be increased staining around the nuclei, 
perhaps because of the site of protein synthesis and modification. The 
cell on the left also demonstrates autofluorescence of bound 
Dynabeads.  
Fig 4.9. Human RPE cells stained for CD31 (negative control). 
There is a very faint non specific staining of the cells but no 
paranuclear or cell surface staining. 
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Fig 4.11. Human RPE cells stained for VEGF R1 (negative control). 
There is a very faint non-specific staining of the cells, but no consistent 
staining across the cell surface.  
 
 
 
 
Fig 4.12. Macular inner choroidal endothelial cells stained for VEGF 
receptor 2 (VEGFR2). There is homogeneous staining throughout the 
cell, consistent with the VEGF receptor being abundant on the cell 
surface. In addition, there appears to be increased staining around the 
nuclei, perhaps because of the site of protein synthesis. This would be 
consistent with the known distribution of VEGF R2 being abundant 
across the cell surface.  
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Fig 4.13. Human RPE cells stained for VEGF R2 (negative control). 
There is a very faint non specific staining of the cells, but no consistent 
staining across the cell surface. 
 
 
 
Fig 4.14. Macular inner choroidal endothelial cells stained for E-Selectin 
(unstimulated). There is a faint non-specific, generalised staining of the 
cells, perhaps due to background production of E-Selectin by the cells. 
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Fig 4.15. Macular inner choroidal endothelial cells stained for E-Selectin 
(1 hour post TNF-ĮVWLPXODWLRQ. There is increased staining in a 
granular fashion around the cell nuclei. This may represent the site of 
E-Selectin protein synthesis or modification e.g. the Golgi apparatus.  
 
 
 
Fig 4.16. Human RPE cells stained for E-Selectin (1 hour post TNF-Į
stimulation). This is non specific cell staining and possible secondary 
antibody precipitation, but no evidence of granular paranuclear staining 
as seen in corresponding endothelial cells. 
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Fig 4.17. Macular inner choroidal endothelial cells stained with mouse 
anti-rat isotype negative control. There is evidence of faint cell staining 
and secondary antibody FITC precipitation but no significant or distinct 
pattern of staining. 
 
 
 
 
Fig 4.18 Macular inner choroidal endothelial cells stained for alpha-
smooth muscle actin (Į-SMA). The cells demonstrate no discernable 
staining. The faint fluorescence is more likely to be due to non specific 
secondary antibody precipitation.  
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Fig 4.19+XPDQ53(FHOOVWDLQHGIRUĮ-smooth muscle actin. There is 
strong staining indicating that RPE cells express ĮSMA. This can be 
used as a marker for cell contamination. 
 
 
 
 
Fig 4.20. Macular inner choroidal endothelial cells stained for Fibroblast 
surface protein. There is faint and grainy staining across the whole cell 
which may be non-specific. 
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Fig 4.21+XPDQ7HQRQ¶VFDSVXOHILEUREODVWVVWDLQHGIRUILEUREODVW
surface protein. In comparison with the endothelial cell above, staining 
is much stronger and homogeneous. This marker can be used as a 
measure of fibroblast contamination in cell preparations. 
 
 
 
 
Fig. 4.22. Macular inner choroidal endothelial cells seeded onto 
Matrigel forming capillary-like structures within 3 hours of seeding. 
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Fig. 4.23. Transmission electron microscopy of macular inner choroidal 
endothelial cells showed that the tube-like structures possessed a 
lumen, and each lumen was surrounded by up to 3 cells joined by 
junctional complexes (inset). 
 
 
 
 
Fig. 4.24. Macular inner choroidal endothelial cell fenestrations 
(arrowed) were found scattered throughout the cell on T.E.M. The 
fenestrations had obvious diaphragms suggesting that they were type I 
fenestrations. The dark homogeneous structure is the gelatin coated 
plastic cover slip used to culture the cells on. 
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Discussion 
 
There are certain diseases that appear to selectively affect the human 
choriocapillaris and inner choroid. The reason for this is currently 
unknown. They include wet age-related macular degeneration (Sarks et 
al, 1997) and the primary inflammatory choriocapillopathies such as 
multiple evanescent white dot syndrome (MEWDS) and acute multi-
focal posterior placoid pigment epitheliopathy (AMPPPE) (Cimino et al, 
2000). In these latter disorders, because of their rarity and the fact that 
they tend to affect otherwise young healthy patients, histological 
evidence is lacking of choriocapillaris involvement. However, analysis of 
data from indocyanine green angiography points to the inner 
choroid/choriocapillaris as the site of disease (Cimono et al, 2000, 
Bouchenaki et al, 2002). In all of these disorders, devastating visual 
loss can occur and current treatment modalities may not be particularly 
effective. It is important, therefore to increase our understanding of the 
underlying pathogenesis of these diseases. As the site of disease lies 
within the inner choroidal vasculature, the endothelial cells lining these 
vessels would be obvious candidates for further study.  
 
A major obstacle in trying to correlate endothelial cells with site specific 
pathological processes is endothelial cell heterogeneity. It has been 
shown that endothelial cells derived from large vessels (macrovascular 
ECs) and smaller vessels (microvascular ECs) from different tissues 
have distinct and characteristic gene expression profiles Chi et al, 
2003). Endothelial cell heterogeneity has even been described within 
the same organ such as the lung (Müller et al, 2002, Ghitescu et al 
2002) and the placenta (Lang et al, 2003). These factors and the 
previously discussed differences in the functional differences in EC 
derived from different vascular beds suggest that it is probably 
necessary to use site-specific endothelial cells when studying vascular 
or angiogenic diseases. This means that it would be useful to describe 
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a method for the successful and reproducible isolation of human 
macular inner choroidal endothelial cells  
 
While others have described methods for the isolation of human 
choroidal endothelial cells that contain a mixture of inner and outer 
choroidal endothelial cells (Sakamoto et al 1995, Penfold et al, 2002), 
until now, no method has been described to isolate human macular 
inner choroidal endothelial cells alone. In 1993, Liu and Li described a 
technique to isolate choriocapillaris endothelial cells in bovine eyes. 
This method took advantage of the differences in structure of the 
choriocapillaris ± %UXFK¶VPHPEUDQHFRPSOH[ to that of the larger 
choroidal vessels. The method entailed cutting the choroid up into tiny 
pieces with scissors and digesting the fragments with trypsin. This is 
designed to dissolve away the large outer choroidal vessels leaving the 
%UXFK¶V-choriocapillaris complex intact. The resulting fragments were 
then washed and the free floating choriocapillaris fragments were 
manually picked out and further digested with collagenase to release 
individual cells. The cells were then plated and grown in endothelial 
selective medium. This method has a number of drawbacks in relation 
to the isolation of the human equivalent cells. Firstly, bovine eyes are 
NQRZQWRKDYHDPXFKILUPHU%UXFK¶VPHPEUDQHZKLFKPHDQVWKDWWKLV
method is more likely to leave the Bruch¶V± choriocapillaris complex 
intact after enzyme digestion. Secondly, the resultant plated cells would 
have contained a rich mixture of contaminating cells (fibroblasts) which 
can easily overgrow the cultures. When attempted with human tissue, 
we failed to produce the necessary cleavage plane, suggesting a 
stronger bond between the choriocapillaris and the outer choroid in 
humans, 
 
The aim of this chapter was to determine a new technique for the 
reliable isolation of human macular inner choroidal ECs. Initially, a 
manual technique using a Vibratome was attempted. In the past, this 
machine had been used to cut viable sheets of neuronal tissue 
including retina for use in functional experiments. It was thought that a 
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similar technique could be applied to the human choroid. Despite 
numerous attempts, it was found that the tissue was too firm for the 
blade to cut reliable sections. In addition, due to the prolonged time 
taken in attempting to cut the tissue and the severe conditions the cells 
were exposed to while undergoing sectioning (extreme cold necessary 
to solidify the gelatine and potential tissue drying), this technique was 
abandoned.  
 
A different, solution-based approach was taken and in this chapter is 
described a successful technique for the isolation of human macular 
inner choroidal ECs that utilises an observation made around 100 years 
ago. In 1892, Nuel described a natural cleavage plane within the human 
choroid between the layers of Haller (inner choroid) and Sattler (outer 
choroid). In 1912 Salzmann noted that dissection of the choroid was 
easiest when the layers were teased apart from the outside. With the 
aid of a dissecting microscope and a microdissection technique, it was 
easy to peel the large outer choroidal vessels from the underlying inner 
choroid/choriocapillaris complex, hence the adoption of the manual 
dissection technique. The individual outer choroidal vessels or the inner 
choroidal complex could then be finely cut into pieces and the tissues 
gently dissolved in collagenase. In order to increase the purity of cells 
isolated and therefore to improve the reliability of any downstream 
experiments, the use of anti-CD31 coated paramagnetic beads 
replaced the older manual sweeping techniques mentioned previously 
or the use of endothelial-specific culture medium (which may also 
support other cells such as fibroblasts). CD 31, otherwise known as 
PECAM-1 is reported to be a pan-endothelial marker in mature, human 
endothelial cells (manufacturer¶VOLWHUDWXUH. The anti-CD31 
paramagnetic bead technique is reported to produce cultures with a 
purity in excess of 99%. 
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The isolated, unpassaged cells were found to stain strongly for CD31, 
vWf, VEGF receptors 1 and 2. The cells were also shown to express E-
Selectin (CD62E), an inducible endothelial-leukocyte adhesion 
molecule, after stimulation with TNF- , a feature that may be unique to 
endothelial cells (Bevilacua et al, 1987). The isolated cells were 
negative for alpha smooth muscle actin and fibroblast surface protein. 
The finding of positive staining for vWf is an interesting finding as it was 
originally thought that only macrovascular ECs contained vWf within 
electron dense Weibel-Palade (WP) bodies (Jaffe et al, 1973; Wagner 
and Matthews, 1975). These bodies are seen on electron microscopy, 
as electron dense and contain a defined cytoskeleton. Electron 
microscopy of human inner choroidal ECs did not reveal any WP 
bodies. However, vWf staining on immunohistochemistry was granular 
in pattern within the cell cytoplasm, similar to the known distribution of 
WP bodies. It may be that in these cells, vWf is contained within 
different intracellular structures when compared to macrovascular ECs. 
Interestingly, review of the raw microarray data for macular inner 
choroidal ECs (see chapter 5) reveals significantly up-regulated gene 
expression for vWf (as it was for all choroidal ECs and retinal ECs). 
 
The isolation of human macular inner choroidal ECs is further validated 
by an absence of contamination from RPE cells (negative for -smooth 
muscle actin) and fibroblasts (negative for fibroblast surface protein). In 
this study, the isolated cells also formed fenestrations when grown on 
fibronectin and formed capillary-like tubes when cultured in Matrigel. 
The lumen of these tubes was surrounded by two or more cells joined 
by junctional complexes, suggesting that these cells had not simply 
aggregated together randomly. Again, the formation of fenestrations 
and formation of tubes in culture are thought to be specific to 
endothelial cells.  
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Considering that the choriocapillaris is heavily fenestrated in vivo, I was 
surprised to find that fenestrations were not found in abundance in this 
in vitro model. This discrepancy in in vivo and in vitro rates of 
fenestrations has previously been found in fenestrated kidney ECs 
(Satchell and Braet 2009). Reasons for this include methods used in 
tissue preparation, reduced levels of VEGF within the milieu around the 
ECs (VEGF is thought to be critical for fenestration formation and 
maintenance, (Peters et al 2007, Esser et al, 1998) or dysregulation of 
proteins such as PVLAP, known to be important in the assembly of 
fenestrations. For the purposes of this experiment, no additional VEGF 
was added to the Matrigel and so may be important as it shows that 
these cells still express fenestrations under basal conditions, showing 
that the cells are still reflecting their in vivo phenotype even when 
subjected to in vitro conditions. The fenestrations observed had obvious 
diaphragms thereby suggesting that they are type I fenestrations Their 
ability to form tubes with junctional complexes also shows that they 
retain their endothelial phenotype and this observation could be used 
subsequently as an assay of endothelial cell function.  
 
In summary, a method has been developed to isolate and culture 
human inner choroidal endothelial cells. During early passages these 
cells possess the morphological characteristics of vascular endothelial 
cells; they form fenestrations and capillary tube-like structures and 
express a number of surface markers consistent with their endothelial 
cell origin. These cells may therefore be useful in studying the 
pathophysiological mechanisms of choroidal neovascularisation. This 
technique is also applicable to the isolation of macular outer choroidal 
endothelial cells if required.  
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Introduction 
 
The posterior segment of the eye is topographically arranged to provide 
different functions. Its most widely recognised feature is the variable 
topographical distribution of rods and cones across the retina which 
provides predominantly photopic (bright light and colour) and scotopic 
(low light level and black/white) functions. The area known as the 
macula has the highest density of photoreceptors (rods and cones), 
with the central foveal area containing only cones. Although the macula 
only occupies 1.4% of the retinal area, it contains 8.4% of all retinal 
cones, 3.4% of rods and 60% of retinal ganglion cells (Curcio et al, 
1990). Not surprisingly, comparison of gene expression between the 
macular and peripheral retina has found that a number of genes are 
preferentially expressed in the macula. Many of these differences were 
of axonal origin and included neurofilament 3, brain specific alpha 
tubulin and light neurofilament (Sharon et al, 2002). Their differential 
expression probably reflects the increased density of ganglion cells in 
the macula. The same study found cone-specific genes such as cone 
alpha transducin, cGMP phosphodiesterase and cone opsins to be 
more abundant in the macula, but the differences did not reach 
statistical significance. In contrast, genes up-regulated in the retinal 
periphery included rod-specific genes such as rhodopsin, transducin 
and recoverin and non-specific genes such as transferrin (involved in 
iron transport) and DOPA decarboxylase. While the topographical 
differences in retinal gene expression can be explained by well 
documented and understood functions, topographical differences in the 
distribution in other cells within the posterior segment are less well 
understood.  
 
Several studies have investigated the variation in RPE gene expression 
across the posterior segment. It is known that at the light and electron 
microscope level, RPE cells differ in appearance between those found 
in the macula and those in the periphery. For example, macular RPE 
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cells are more columnar and contain more melanin than those in the 
periphery (Ishibashi et al, 2004). In 2001, Bron stated that at the fovea, 
each RPE cell measures 12-18µm in width and is 10-14µm in height, 
while in the periphery they are flatter and are up to 60µm in width (Bron 
et al, 1997b). However, with increasing age, macular RPE cells become 
taller and thinner, whilst in the periphery it is vice versa (Watzke et al, 
1993). In addition, with increasing age, RPE cells at the macula 
become less pigmented while those in the periphery become more so. 
At a gene expression level, Ishibashi et al demonstrated a difference in 
the expression of a number of genes between peripheral and macular 
RPE cells prepared by laser microdissection of human eyes (Ishibashi 
et al, 2004). They identified 11 genes that showed differential 
expression, each showing reduced expression in the macular area, 
including: aldehyde dehydrogenase 6, sialic acid synthase, protein 
kinase C and glutathione S-transferase. Van Soest, using a similar 
laser capture dissection technique, found 438 genes that were 
differentially expressed (1-5% of the transcriptome), with 33 showing at 
least a 4-fold change. There was enrichment of extracellular matrix 
genes such as collagen types I, II and VI, laminin, TIMP 2 and 
thrombospondin 4, all being up-regulated in peripheral RPE cells (van 
Soest et al, 2007). When the van Soest study was compared with the 
previous study (Ishibashi et al, 2004), only the results for aldehyde 
dehydrogenase and c-kit were found to be comparable. Reasons for 
this wide discrepancy between the results of the two studies include 
sample contamination by photoreceptors (Bowes Rickman et al, 2006), 
age of the donors and the type of microarray used. The authors of the 
studies suggest that the up-regulation of genes involved in ECM may 
UHSUHVHQWDUROHIRUWKH53(LQ%UXFK¶VPHPEUDQHWXUQRYHU8S-
regulation of the aforementioned genes may also contribute to the 
topographical differences found in the composition and physical 
SURSHUWLHVRI%UXFK¶VPHPEUDQHSDUWRIWKHEDVHPHQWPHPEUDQHRIWKH
RPE (Chong et al, 2005; Ramrattan et al, 1994; Okubo et al, 1999; Guo 
et al, 1999). This may in turn lead to disease susceptibility of the 
macula to conditions such as age-related macular degeneration. 
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Little is known about the topographical changes within the human 
choroid. It has been subdivided into three layers: the outer layer of large 
YHVVHOV+DOOHU¶VOD\HUDPLGGOHOD\HURIPHGLXPVL]HG vessels 
6DWWOHU¶VOD\HUDQGDQLQWHUQDOOD\HUDGMDFHQWWR%UXFK¶V0HPEUDQH
composed of capillary vessels (choriocapillaris), as discussed 
previously. The choriocapillaris at the macula is supplied by a higher 
density of pre-capillary arterioles than that found in the periphery, while 
the peripheral choroid is simpler in structure with the meshwork of the 
choriocapillaris being much wider than that found in the macular area. 
In 2006, Mullins et al described differences in the distribution of ICAM 1 
across the choriocapillaris and retina, with labelling being stronger in 
the macular area. They suggested that this may play a role in increased 
leukocyte trafficking in the macula (Mullins et al, 2006). In 2007, 
Radeke studied the gene expression of macular and peripheral 
RPE/choroidal samples and found differences in a number of genes 
that may have relevance to wet AMD. These include an RPE cell 
growth factor (TFP12) and a number of inflammation-related genes 
such as CXCL14, CCL19 and CCL26 (Radeke et al, 2007). 
Unfortunately, it is not known if these gene differences were solely 
derived from the RPE or choroid as the samples tested were a mixture 
of both tissues. 
 
As mentioned previously, choroidal neovascularisation in wet age-
related macular degeneration begins within the inner choroid and is 
almost always within the macular area. Given the fact that the 
WRSRJUDSK\RISKRWRUHFHSWRUV53(DQG%UXFK¶VPHPEUDQHLVGLIIHUHQW
at the macula compared to elsewhere in the eye, it is important to 
establish whether the choroidal endothelial cells in the sub-macular 
area are different to those in the periphery, possibly making them more 
susceptible to certain diseases. It is known that the choroidal 
vasculature is formed by a process of haemovasculogenesis 
(Hasegawa et al, 2007). In theory, all choroidal endothelial cells are 
derived from the same precursor, meaning any differences are probably 
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due to the local microenvironment that the ECs find themselves in, i.e. 
WKHVXUURXQGLQJ³GLIIHUHQW´%UXFK¶VPHPEUDQHSKRWRUHFHSWRUs or RPE 
cells. Any differences might also render them differentially responsive to 
treatment, because selective treatment of disease relies on the 
identification of unique, or at least significantly different, attributes in the 
affected site compared with its surroundings.  
 
The aim of this section was to compare the gene expression profiles of 
matched human sub-macular inner and outer choroidal endothelial cells 
and matched human sub-macular and peripheral inner choroidal 
endothelial cells using the gene microarray technique described 
previously. An additional aim was to determine whether there were, in 
fact, specific gene expression profiles that were unique to cells within 
different areas of the human choroid that may help to explain the 
topographical selectivity of choroidal disease and perhaps lead to the 
development of site-specific treatments. 
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Methods  
 
The technique for the isolation of human macular inner choroidal 
endothelial cells has previously been described in Chapter 4. During 
dissection of the human choroid, matched 6mm diameter samples of 
peripheral inner choroid (peripheral area nasal to the optic disc) and 
macular outer choroidal tissue were collected and treated in the same 
manner as described for the macular inner choroidal samples.  
 
Briefly, matched human macular inner and outer and peripheral inner 
choroidal endothelial cells were isolated from anonymised, paired 
human globes, enucleated within 24 hours of death and free of any 
known ocular disease. The globes were obtained from UK Transplant 
after removal of corneas for transplantation. The research had the 
approval of the local research ethics committee (Nottingham 
Q1060301). The matched choroidal endothelial cells from the different 
locations underwent identical isolation procedures using anti CD31 
coated Dynabeads (Dynal Ltd, Wirral, UK), were seeded onto 
fibronectin-coated 35mm culture dishes (Beckton Dickinson, Oxford, 
UK) and incubated at 37 C in Endothelial Growth Medium (EGM2-MV 
with hydrocortisone omitted, Cambrex Biosciences, Wokingham, Berks, 
UK) in a humidified atmosphere of 5% CO2.  
 
Confirmation of EC purity 
 
The identity and purity of cells used in the microarray assays was 
confirmed prior to RNA extraction by staining for Factor VIII and CD31 
as described in Chapter 4.  
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RNA extraction 
 
Total RNA was extracted from primary cultures of un-passaged 
endothelial cells when they had reached approximately 80% 
confluence, using the Qiagen RNeasy Minikit (Qiagen, Crawley, UK) as 
described in chapter 3. As before, the isolated RNA was transferred into 
microcentrifuge tubes and stored at -80°C until used for subsequent 
analysis. It was found that approximately 1±3 g of total RNA was 
obtained from each 35mm culture plate.  
 
Microarray analysis 
 
The previously stored RNA was processed through the different stages 
of microarray analysis using Affymetrix GeneChip ® Human Genome 
U133 Plus 2.0 arrays (Affymetrix, High Wycombe, Bucks, UK) as 
described in chapter 3. 
 
Data Analysis 
 
Affymetrix CEL files were imported into GeneSpring GX 11.0.1 and 
processed with the MAS5 algorithm to generate PMA flags. Probesets 
were excluded from further analysis if there was not a Present or 
Marginal flag in 100% of the samples in one of the four cell groups. 
Affymetrix control probesets were also excluded, leaving a probeset list 
for subsequent analysis. Data was then normalised with GC-RMA to 
provide expression values. To identify differentially expressed genes 
between cell groups, ANOVA was performed on this probeset list with 
Tukey-HSD post-hoc testing and Benjamini-Hochberg false discovery 
rate control. A difference in expression between probesets with a 
corrected p-value of <0.05 and a fold-change of greater than 2 were 
considered to be statistically significant. Data was exported directly 
from GeneSpring 11.0.1. to Ingenuity Pathway Analysis for these 
probesets. Biological functions analysis identified areas of the Ingenuity 
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Functional Analysis library of biological functions that were most 
significant to the data set. Molecules from the data set that met the cut 
off criteria and were associated with an area of biological function in 
,QJHQXLW\¶V.QRZOHGJH%DVHZHUHFRQVLGHUHGIRUWKHDQDO\VLV The 
significance of the association between the data set and the biological 
function was measured in two ways:  
 
1) A ratio of the number of molecules from the data set that map to the 
area, divided by the total number of molecules that map to the 
functional area is displayed.  
 
2) )LVKHU¶VH[DFWWHVWZDVXVHGWRFDOFXODWHDS-value determining the 
probability that the association between the genes in the dataset 
and the functional area is explained by chance alone. 
 
QPCR 
 
The method for QPCR confirmation of microarray probeset expression 
results has been described previously (Chapter 3).  
 
 
 324 
Results  
 
Nine matched, un-passaged EC samples, representing 3 different intra-
choroidal locations from three different donors were propagated under 
identical conditions. The 3 choroidal areas represented by the matched 
samples were: macular inner choroidal ECs, macular outer choroidal 
ECs and peripheral inner choroidal ECs (peripheral area nasal to the 
optic disc). The age, sex and time from death to the cells being placed 
in culture were as follows: 58, male, 28 hours; 42, male, 43 hours; 62, 
female, 36 hours. All eyes were free of ocular disease, in particular the 
macula, on examination with the dissecting microscope. 
 
Samples of cells from all locations displayed homogeneous 
cobblestone morphology with no evidence of cell contamination. 
Greater than 99.5% of the endothelial cells from each site 
demonstrated staining for factor CD31 prior to their use in the 
aforementioned experiments, confirming their purity and identity as 
endothelial cells.  
 
Overview of gene expression patterns 
 
Between 1.5 and 3.4 µg of total RNA were isolated from each 35mm 
plate. Biotinylated cRNA probes were hybridised to Affymetrix 
GeneChip ® Human Genome U133 Plus 2.0 arrays containing 47000 
transcripts, of which 38500 were well characterised human genes. A 
total of 23636 probe sets passed quality control testing during analysis. 
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Proliferating human macular inner choroidal endothelial cells 
(ECs) versus peripheral inner choroidal ECs 
 
Comparison of matched, un-passaged proliferating human macular 
inner choroidal endothelial cells (ECs) with peripheral inner choroidal 
ECs demonstrated a small difference of 35 probe sets (0.15% of 
probesets that passed quality control) Of this total, 19 were up-
regulated in macular inner choroidal ECs and 16 were up-regulated in 
peripheral inner choroidal ECs. This study demonstrated a striking 
homogeneity of gene expression between inner choroidal ECs derived 
from the macula and periphery. Differences in the expression of a small 
number of genes such as Annexin 10, collagen type XVI and mannose 
receptor C were noted. Canonical pathway analysis failed to reveal any 
pathways that were significantly represented. A complete list of 
differentially expressed probesets reaching statistical significance is 
shown in tables 5.1 and 5.2. 
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Table 5.1. All probesets reaching differential expression of 2.0 or 
greater in human macular inner choroidal endothelial cells compared 
with matching peripheral inner choroidal ECs. 
 
  
GENE TITLE 
 
Fold 
Change 
 
mesoderm specific transcript homolog  2.5  
Rho GTPase activating protein 23 3.8  
serine (or cysteine) proteinase inhibitor, clade B 2.9  
lymphocyte cytosolic protein 1 (L-plastin) 2.2  
sema domain, immunoglobulin domain (Ig),(semaphorin) 2.1  
eukaryotic translation initiation factor 1A, Y 2.3  
annexin A10 4.3  
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked 2.4  
plasmalemma vesicle associated protein 2.2  
solute carrier family 6, member 15 2.1  
ring finger protein 128 2.7  
keratin associated protein 2-1  2.1  
SH3-domain GRB2-like 2 2.1  
interleukin 13 receptor, alpha 2 2.3  
ribosomal protein S4,  2.2  
tetraspanin 7 2.5  
solute carrier family 4, sodium bicarbonate cotransporter, 
member 4 2.2 
 
collagen, type XVI, alpha 1 2.1  
UDP-N-acetyl-alpha-D-galactosamine:polypeptide  2.2  
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Table 5.2. All probesets reaching differential expression of 2.0 or 
greater in human peripheral inner choroidal endothelial cells compared 
with macular inner choroidal ECs 
 
 
GENE TITLE 
Fold 
Change 
trefoil factor 3 (intestinal) 3.1  
Meis1, 2.7  
mannose receptor, C type 1  2.2  
pregnancy specific beta-1-glycoprotein 5 2.3  
fatty acid binding protein 4, adipocyte 2.1  
pregnancy specific beta-1-glycoprotein 1 2.1  
extracellular link domain containing 1 2.7  
ATP-binding cassette, sub-family G  2.1  
extracellular link domain containing 1 2.3  
pregnancy specific beta-1-glycoprotein 9 2.1  
zinc finger protein 659 2.1  
coronin, actin binding protein, 1B 2.1  
churchill domain containing 1 2.9  
tumor-associated calcium signal transducer 2 2.1  
periplakin 2.2  
heat shock 70kDa protein 6 (HSP70B') 2.8  
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Proliferating human macular inner choroidal ECs versus macular 
outer choroidal ECs 
 
Comparison of matched, un-passaged proliferating human macular 
inner choroidal endothelial cells (ECs) with macular outer choroidal 
endothelial cells revealed 302 probesets that were differentially 
expressed between the two cell types (1.3%). Of the 302 differentially 
expressed probesets, 96 were up-regulated in macular inner choroidal 
ECs, and 193 were up-regulated in macular outer choroidal ECs. Probe 
sets for a diverse range of functions including nervous system 
development (Brain Derived Neurotrophic factor, Neurofilament light 
and medium polypeptides), cell signalling (MAPK 11, Apelin receptor, 
Parvin beta, diacylglycerol kinase and MAPK binding protein 1 and 
WNT5A), cellular growth and proliferation (VEGF, HGF, CXCL12, TGF 
Beta1 and MMP10), immune response (MHC class II alpha and HLA 
DR B1 and CD200) and cell morphology (Keratin 19, Collagen 11 alpha 
subunit and Collagen 15 alpha subunit and PLVAP) were found to be 
differentially expressed. Lists of the most highly expressed probesets 
reaching statistical significance are shown in tables 5.3, 5.4 and 5.5. 
The difference in probeset expression with regards to groupings of 
biological processes is represented by pie charts in Figs 5.1a and 5.1b. 
This showed a similar distribution in biological processes. However, 
macular ICECs demonstrated a slightly greater proportion of probesets 
involved in cell adhesion, organisation and development  
 
Fig 5.2 demonstrates a heat map of the differential probeset expression 
reaching statistical significance with reference to human macular inner 
and outer choroidal microvascular endothelial cells. Selected genes 
thought to be important in endothelial cell biology are shown on the 
right of the heat map.  
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Table 5.3 All probesets reaching differential expression of 2.0 or greater 
in human macular inner choroidal ECs compared with macular outer 
choroidal ECs. 
 
GENE TITLE 
 
Fold 
Change 
 
insulin-like growth factor binding protein 3 11.5  
neurofilament, medium polypeptide 10.4  
brain-derived neurotrophic factor 8.9  
platelet-derived growth factor receptor, alpha polypeptide 8.8  
keratin 19 7.3  
pleckstrin homology-like domain, family A, member 2 7.1  
solute carrier family 6  6.6  
popeye domain containing 3 5.9  
olfactomedin-like 3 5.6  
SIX homeobox 2 5.5  
neurofilament, light polypeptide 5.2  
mesoderm specific transcript homolog (mouse) 5.1  
mannosyl (alpha-1,3-)-glycoprotein beta-1,4- 4.9  
vascular endothelial growth factor A 4.7  
brain expressed, X-linked 1 4.7  
lysophosphatidic acid receptor 1 4.4  
collagen, type XI, alpha 1 4.4  
pleckstrin and Sec7 domain containing 3 4.3  
carbonic anhydrase XII 4.3  
procollagen C-endopeptidase enhancer 2 4.2  
ABI family, member 3 (NESH) binding protein 4.2  
PNMA-like 1 4.1  
tissue factor pathway inhibitor 2 3.9  
glycine receptor, beta 3.9  
wingless-type MMTV integration site family, member 5A 3.9  
carbonic anhydrase XII 3.9  
forkhead box F2 3.7  
MSTP150 3.8  
glycine receptor, beta 3.7  
TP53 regulating kinase 3.6  
calmegin 3.6  
carbonic anhydrase XII 3.6  
ectonucleotide pyrophosphatase/phosphodiesterase 2 3.5  
hepatocyte growth factor (hepapoietin A; scatter factor) 3.4  
protein phosphatase 1, regulatory (inhibitor) subunit 14B 3.4  
golgi autoantigen, golgin subfamily a, 8A 3.4  
lymphoid-restricted membrane protein 3.4  
sulfatase 1 3.4  
secretogranin II (chromogranin C) 3.4  
poliovirus receptor-related 3 3.4  
folate receptor 1 (adult) 3.4  
transforming growth factor, beta receptor 1 3.3  
tissue factor pathway inhibitor 2 3.3  
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GENE TITLE 
 
Fold 
Change 
 
emopamil binding protein-like 3.3  
aldehyde dehydrogenase 1 family, member A3 3.3  
interferon-induced protein with tetratricopeptide repeats 1 3.2  
tumor necrosis factor (ligand) superfamily, member 15 3.1  
mitogen-activated protein kinase kinase kinase kinase 4 3.1  
chromosome 9 open reading frame 40 3.1  
neuropilin (NRP) and tolloid (TLL)-like 2 3.1  
family with sequence similarity 13, member B 3.1  
aspartyl-tRNA synthetase 3.1  
paternally expressed 10 3.1  
versican 3.1  
phosphoglycolate phosphatase 2.9  
prostaglandin-endoperoxide synthase 2 2.9  
retinol dehydrogenase 14 (all-trans/9-cis/11-cis) 2.9  
carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 2.9  
proline rich 16 2.9  
aryl hydrocarbon receptor 2.9  
glycoprotein (transmembrane) nmb 2.9  
chromosome 13 open reading frame 15 2.9  
B-cell translocation gene 1, anti-proliferative 2.9  
phosphatidic acid phosphatase type 2B 2.8  
TAF10 RNA polymerase II, TATA box binding protein 2.8  
serpin peptidase inhibitor, clade E  2.8  
COMM domain containing 2 2.8  
transducer of ERBB2, 1 2.8  
aldo-keto reductase family 1, member C1  2.8  
DnaJ (Hsp40) homolog, subfamily C, member 1 2.8  
nebulette 2.8  
UDP-N-acetyl-alpha-D-galactosamine: 2.8  
histone cluster 1, H2ac 2.8  
BAT2 domain containing 1 2.7  
lymphoid-restricted membrane protein 2.7  
pleiomorphic adenoma gene-like 1 2.7  
chromosome 1 open reading frame 63 2.7  
insulin-like growth factor binding protein 2, 36kDa 2.7  
glioma tumor suppressor candidate region gene 2 2.6  
kinectin 1 (kinesin receptor) 2.6  
phospholipid scramblase 4 2.6  
brain protein I3 2.6  
zinc finger E-box binding homeobox 2 2.6  
hairy and enhancer of split 1, (Drosophila) 2.6  
Cbp/p300-interacting transactivator 2.6  
Nedd4 family interacting protein 2 2.6  
splicing factor, arginine/serine-rich 18 2.5  
endothelin receptor type B 2.5  
solute carrier family 25, member 37 2.5  
Mdm2 p53 binding protein homolog (mouse) 2.5  
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GENE TITLE 
 
Fold 
Change 
 
chondroitin sulfate N-acetylgalactosaminyltransferase 2 2.5  
zinc finger protein 623 2.4  
plasmalemma vesicle associated protein 2.4  
O-linked N-acetylglucosamine (GlcNAc) transferase  2.4  
transmembrane protein with EGF-like domain 2.4  
phosphoserine phosphatase 2.3  
mitogen-activated protein kinase kinase kinase 2 2.3  
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Table 5.4 Top one hundred probesets reaching differential expression 
of 2.0 or greater in human macular outer choroidal ECs compared with 
macular inner choroidal ECs. 
 
Gene Title 
 
Fold 
Change 
 
histone cluster 1, H3b 14.7  
LSM4 homolog, U6  10.2  
translocase of inner mitochondrial membrane 44 homolog 
(yeast) 8.9 
 
chromosome 6 open reading frame 108 8.4  
fascin homolog 1, actin-bundling protein  7.9  
FXYD domain containing ion transport regulator 6 7.9  
leucine rich repeat containing 15 7.6  
translocase of inner mitochondrial membrane 44 homolog 
(yeast) 7.2 
 
kinesin light chain 1 6.9  
cyclin K 6.5  
polypyrimidine tract binding protein 1 6.1  
valyl-tRNA synthetase 6.1  
apelin receptor 5.4  
fascin homolog 1, actin-bundling protein  5.4  
mitogen-activated protein kinase kinase 2 5.1  
cleft lip and palate associated transmembrane protein 1 5.1  
histone cluster 1, H2bf 4.6  
transforming growth factor beta 1 induced transcript 1 4.5  
deoxyribonuclease I-like 3 4.5  
RAN binding protein 3 4.5  
histone deacetylase 5 4.4  
cysteine-rich protein 2 4.2  
cell division cycle 34 homolog (S. cerevisiae) 4.1  
dicarbonyl/L-xylulose reductase 4.1  
collagen, type XV, alpha 1 3.9  
coronin, actin binding protein, 1B 3.9  
mannose receptor, C type 1  3.9  
DEAD (Asp-Glu-Ala-Asp) box polypeptide 54 3.9  
sema domain, transmembrane domain (TM), 3.9  
coronin, actin binding protein, 1B 3.8  
GINS complex subunit 4 (Sld5 homolog) 3.7  
guanine nucleotide binding protein-like 3 (nucleolar)-like 3.7  
protein kinase C and casein kinase substrate in neurons 
2 3.6 
 
thimet oligopeptidase 1 3.6  
major histocompatibility complex, class II, DR beta 1  3.6  
zinc finger protein 688 3.6  
histone cluster 1, H1b 3.6  
SH3KBP1 binding protein 1 3.6  
cleft lip and palate associated transmembrane protein 1 3.5  
major histocompatibility complex, class II, DR beta 1  3.5  
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Gene Title 
 
Fold 
Change 
 
MAD1 mitotic arrest deficient-like 1 (yeast) 3.4  
exosome component 4 3.4  
YKT6 v-SNARE homolog (S. cerevisiae) 3.4  
zinc finger CCCH-type containing 7B 3.4  
ATPase type 13A2 3.3  
similar to RABEP2 protein  3.3  
hepatoma-derived growth factor-related protein 2 3.3  
matrix metallopeptidase 10 (stromelysin 2) 3.2  
mitogen-activated protein kinase kinase 2 3.2  
endoglin 3.2  
F-box and WD repeat domain containing 5 3.2  
carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 3.2  
lipase, endothelial 3.2  
spectrin repeat containing, nuclear envelope 2 3.2  
kinesin light chain 1 3.1  
homer homolog 3 (Drosophila) 3.1  
hypothetical protein LOC286434 3.1  
exosome component 4 3.1  
glucocorticoid receptor DNA binding factor 1 3.1  
chromosome 21 open reading frame 45 3.1  
cytochrome P450, family 1, subfamily B, polypeptide 1 3.1  
peter pan homolog (Drosophila) 3.1  
cytochrome P450, family 1, subfamily B, polypeptide 1 3.1  
cyclin D1 3.1  
nasal embryonic LHRH factor 3.1  
zinc finger protein 160 3.1  
3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 
(soluble) 3.1 
 
small optic lobes homolog (Drosophila) 3.1  
splicing factor, arginine/serine-rich 8  3.1  
Wolf-Hirschhorn syndrome candidate 1 3.1  
dedicator of cytokinesis 6 2.9  
lysosomal multispanning membrane protein 5 2.9  
ankyrin repeat domain 1 (cardiac muscle) 2.9  
ring finger protein 125 2.9  
sorbitol dehydrogenase 2.9  
sparc/osteonectin,  2.9  
Hypothetical protein LOC100129502 2.9  
hypothetical protein LOC100132181 2.9  
EH-domain containing 1 2.9  
hepatocyte growth factor-regulated tyrosine kinase 
substrate 2.9 
 
thrombospondin 1 2.9  
Meis homeobox 2 2.9  
mitogen-activated protein kinase 11 2.8  
trefoil factor 3 (intestinal) 2.8  
IMP (inosine monophosphate) dehydrogenase 1 2.8  
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Gene Title 
 
Fold 
Change 
 
ribosomal RNA processing 7 homolog A (S. cerevisiae) 2.8  
major histocompatibility complex, class II, DR beta 1  2.8  
macrophage erythroblast attacher 2.8  
chromosome 7 open reading frame 50 2.8  
LSM7 homolog, U6 small nuclear RNA associated  2.8  
limb bud and heart development homolog (mouse) 2.8  
activin A receptor type II-like 1 2.8  
ATG4 autophagy related 4 homolog B (S. cerevisiae) 2.8  
guanine nucleotide binding protein (G protein), alpha 11  2.8  
major histocompatibility complex, class II, DP alpha 1 2.8  
mitogen-activated protein kinase binding protein 1 2.7  
major histocompatibility complex, class II, DP beta 1 2.7  
translocase of inner mitochondrial membrane 8  2.7  
CXCL12 2.4  
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Fig 5.1a. Pie chart of significantly up-regulated genes grouped by 
biological processes in proliferating human macular inner choroidal 
endothelial cells compared with proliferating human macular outer 
endothelial cells 
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Fig 5.1b. Pie chart of significantly up-regulated genes grouped by 
biological processes in proliferating human retinal endothelial cells 
compared with proliferating human iris endothelial cells 
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Fig 5.2 Heatmap of the differential probeset expression reaching 
statistical significance with reference to human macular inner and outer 
choroidal microvascular endothelial cells. Up-regulated probesets are 
shown in red, down-regulated in blue. A total of 302 different probesets 
are represented. The positions of selected probesets thought to be 
important in endothelial cell biology are shown.  
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Table 5.5. Comparison of selected probesets up-regulated in human macular inner and outer choroidal endothelial cells 
 
 
PROBESET    UP-REGULATED IN MACULAR     UP-REGULATED IN MACULAR  
    INNER CECS (FOLD CHANGE)    OUTER CECS (FOLD CHANGE) 
 
Nervous system development Brain derived neurotrophic factor (BDNF) (8.8) 
     Neurofilament  light polypeptide (NEFL) (5.2) 
     Neurofilament medium polypeptide (NEFM) (10.4)  
 
Cell signalling   WNT5A (3.9)       Apelin receptor (5.4) 
             MAPK 11 (2.8) 
             MAPK binding protein 1 (2.7) 
             DAG kinase zeta (2.3) 
             Parvin beta (2.6) 
 
Cell morphology   Collagen XI alpha subunit (4.4)    Collagen XV alpha subunit (4.0)  
     Keratin 19 (7.3) 
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PROBESET    UP-REGULATED IN MACULAR     UP-REGULATED IN MACULAR  
    INNER CECS (FOLD CHANGE)    OUTER CECS (FOLD CHANGE) 
 
Immune function           HLA DR B1 (2.7) 
             MHC class II alpha (2.8) 
             CD200 (2.3) 
 
Cellular growth and proliferation  VEGF (4.7)       MMP 10 (3.2)    
     Hepatocyte growth factor (HGF) (3.4)   CXCL 12 (stromal cell derived factor) (2.4) 
     PDGF receptor alpha (8.8) 
     TGF beta receptor 1 (3.3)     TGF beta 1 (4.5)    
  
 
Misc     Plasmalemmal vesicle associated protein-1   Endothelial lipase (3.2)   
     (PLVAP) (2.5) 
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Real time PCR 
 
Real time PCR was used to validate the differences in gene expression 
between proliferating human macular inner and outer choroidal 
endothelial cells and also human macular inner and peripheral inner 
choroidal ECs. Five transcripts were chosen that demonstrated at least 
a 2-fold differential expression between the endothelial cells on 
microarray analysis and were thought to be relevant to a range of 
different endothelial cellular functions. The chosen transcripts were: 
Keratin 19, Brain derived neurotrophic factor, CXCL 12 , Annexin 10 
and MAPK 11. The differences in expression between the microarray 
and real time PCR techniques were similar for all 5 transcripts 
evaluated (Table 5.6 and 5.7). Fig 5.3 demonstrates examples of real 
time PCR dissociation curves for Keratin 19 in peripheral inner 
choroidal ECs, macular inner and macular outer choroidal ECs. 
 
These results confirm the overall reliability of the results obtained by the 
Affymetrix microarray technique. 
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Fig 5.3 Examples of the real time PCR dissociation curves for Keratin 
19 in peripheral inner choroidal ECs, macular inner and macular outer 
choroidal ECs. The Y axis depicts the fluorescence of the reporter 
signal normalised to a reference signal (Rn,) while the X axis depicts 
the cycle number. The probeset under investigation is represented by 
all 3 curves of the sample triplicate and also includes a probeset for the 
reference housekeeping gene, hypoxanthine-guanine 
phosphoribosyltransferase (HPRT). Also represented are the curves of 
the No Template Control (NTC) (sterile water). 
Fig 5.3a, demonstrates the dissociation curves for a series of 10 fold 
dilutions for Keratin 19 reference sample while Fig 5.3b shows the 
calculated standard curve derived from Fig 5.3a demonstrating its 
linearity of the range tested.  
Ct is the crossing point or threshold at which fluorescence can be 
detected and log C0 is the log of the relative standard concentration 
(chosen to correspond to the expected relative concentration of 
probeset in the samples).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3a Fig 5.3b 
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Fig 5.3c demonstrates the QPCR dissociation curves (triplicates) for 
Keratin 19expression in peripheral inner choroidal ECs, macular inner 
and macular outer choroidal ECs.  The reference housekeeping gene is 
HPRT. The No Template Controls are also included. 
Keratin 19 in 
peripheral inner 
CECs and 
macular outer 
CECs 
NTC for Keratin 19 
HPRT 
in ECs 
NTC for 
 HPRT 
Keratin 19 in macular 
inner CECs 
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Table 5.6. Differences in gene expression of selected genes for 
proliferating human macular inner and outer choroidal endothelial cells 
according to microarray (MA) and Real time-PCR (RT-PCR) 
 
 
 
Difference in gene expression 
  (fold change) 
Gene 
transcript Affy ID 
Fold change in gene expression 
relative to human macular inner 
CECs 
  Microarray RT-PCR 
Keratin 19 201650_at 7.3 10.5 
Brain derived 
Neurotrophic 
factor 
206382_s_at 8.9 7.2 
CXCL 12 203666_at -2.4 -3.6 
MAPK 11 
 
206040_s_at -2.8 -3.3 
 
 
 
Table 5.7. Differences in gene expression of a selected gene for 
proliferating human macular inner and peripheral inner choroidal 
endothelial cells according to microarray (MA) and Real time-PCR (RT-
PCR) 
 
 
 
Difference in gene expression 
(fold change) 
Gene 
transcript Affy ID 
Fold change in gene expression 
relative to human macular inner 
CECs 
  Microarray RT-PCR 
Annexin 10 210143_at 4.3 3.2 
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Discussion 
 
One of the mysteries for those investigating and treating diseases of the 
ocular posterior segment is why different disorders demonstrate 
exquisite topographic selectivity for the choroidal vascular bed. Another 
is the quest for treatments that are selective for the cells involved in the 
pathological process but which leave normal, juxtaposed cells 
unaffected ± the so called magic bullet. In the case of wet AMD, this 
would involve a treatment that specifically targets the proliferating 
endothelial cells of the inner choroid of the macula. Choroidal 
neovascularisation associated with wet age-related macular 
degeneration appears to have a predilection for the macular area of the 
posterior pole, unless some other secondary event has affected another 
DUHDRIWKHSRVWHULRUVHJPHQWHJGDPDJHWR%UXFK¶VPHPEUDQe in the 
extra-macular area by inflammation or trauma. Interestingly, in an 
animal model of wet AMD, using focal laser treatment, application of 
identical burns to the extra-macular areas was relatively ineffective at 
stimulating a CNV compared with those placed in the macula, 
suggesting a predilection of the macula for choroidal neovascularisation 
(Shen et al, 2004).  
 
Disease predilection for different layers of the choroid at similar 
locations is exemplified by punctate inner choroidopathy (PIC) and 
multiple evanescent white dot syndrome (MEWDS) which are 
inflammatory diseases that appear to preferentially affect the inner 
choroid (Cimono et al, 2000, Bouchenaki et al, 2002), while central 
serous chorioretinopathy is an idiopathic vasculopathy that also 
appears to involve the inner choroidal vasculature (based on the results 
of indocyanine green angiography ) (Piccolino et al, 1995; Guyer et al, 
1994).  
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For many years, workers have attempted to determine why the human 
macula is predisposed to age-related macular degeneration, the leading 
cause of blindness in those over 65years of age. There are a number of 
theories including: increased free radical production at the macula 
FDXVHGE\WKHH\H¶VLQKHUHQWIRFXVLQJRIXOWUDYLROHWRUYLVLEOHOLJKWDW
this location; a localised immune response at the macula causing 
VHFRQGDU\DQJLRJHQLFHYHQWVORFDOGLIIHUHQFHVLQ%UXFK¶VPHPEUDQH
structure; local differences in the RPE; and local differences in the 
choroid.  
 
The first of these theories is plausible as it is known that visible light 
generates the production of free radicals which in turn can bring about 
local tissue damage which, in theory, could predispose to wet AMD. 
There is animal and epidemiological evidence to suggest that short 
wave length light (blue/UV) can damage the retina and may increase 
the risk of AMD (Cruickshanks et al, 2001; Tomany et al 2004; Grimm 
et al, 2001; Hafezi et al, 1997). However, the majority of large scale 
epidemiological studies have failed to demonstrate an association 
(Delcourt et al, 2001; Darzins et al 1997; AREDS Report 19, 2005; 
McCarty et al, 2001). The lack of a strong association, despite years of 
work in this area, probably means that the effect, if true, does not 
account for the majority of the cases and therefore is unlikely to be the 
major factor in the macular location of the condition.  
 
Chong et al (2005) have shown that the thickness of the elastic layer of 
%UXFK¶VPHPEUDQHLQWKHPDFXODUDUHDLVXSWRWLPHVWKLQQHUDQGXS
to 5 times less abundant than in the periphery. The integrity of the 
elastic layer was also significantly lower in eyes with some degree of 
AMD. They suggest that for these reasons, the macula is predisposed 
to AMD, perhaps making the in-growth of choroidal blood vessels 
WKURXJK%UXFK¶VPHPEUDQHHasier. 
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The evidence for a local, macular-centred immune response is based 
on the findings of a predilection for drusen (particularly the soft variety, 
associated with increased risk of AMD) to form in the macular area 
(Midena et al, 1994; Abdelsalam et al, 1999) and the recent discovery 
of drusen containing elements of the immune response such as those 
involved in the complement cascade. On ultra structural analysis, cells 
such as macrophages appear to be localised to areas containing 
drusen, and local proGXFWLRQRI³DFWLYH´LPPXQHPHGLDWRUVKDVDOVR
been found near to these cells. The localisation of the immune 
response to the macula is therefore probably based on the 
topographical distribution of drusen. The reason for their predilection at 
the macula is unknown but it may be due to the higher metabolic 
turnover of cells in this area (cones, and RPE cells) and therefore 
increased waste product formation and accumulation at the macula. 
More interestingly, it may also be due to the different architectural 
patterns within the vasculature of the choriocapillaris of the macula 
compared with peripheral areas (Lengyel et al, 2004), making drusen 
deposition between choroidal capillaries more likely in this location. 
 
As mentioned previously, workers have studied both the morphological 
and gene expression differences in human RPE cell topography in an 
attempt to explain the difference in disease site specificity. However, 
very little is known regarding differences in gene expression between 
peripheral and macular choroidal endothelial cells. To date, only one 
study using microarrays has been conducted and this demonstrated a 
difference in 76 probesets between macular and peripheral 
choroid/RPE complexes. Of significance was a number of inflammation 
related genes such as CXCL14, CCL19 and CCL26 that were 
significantly up-regulated in the macula (Radeke et al, 2007). 
Unfortunately, the samples tested were a homogenate of choroid and 
RPE so any differences could not be ascribed solely to the choroid. 
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In order to expand our knowledge of the potential endothelial cell 
diversity within the human choroid, this study compared the differential 
gene expression of matched human macular and peripheral inner 
choroidal cells and macular inner and outer choroidal endothelial cells. 
It would not be surprising if there was heterogeneity within the 
endothelial cells of the choroid because the inner and outer choroid 
subserve different functions, with the inner choroid functioning to 
nourish the outer retina and the RPE layer via its fenestrated 
endothelium while the outer choroid functions to deliver and regulate 
blood flow to the inner choroid.  
 
This study failed to demonstrate any significant difference in gene 
expression between matched human macular and peripheral 
endothelial cells. This confirms that despite the macular and peripheral 
choriocapillaris having different ultra-structural appearances, the lining 
endothelium appears to exhibit the same gene expression. This would 
suggest that the propensity of the macula to suffer choroidal 
neovascularisation is not due to topographical differences in the 
endothelial cells. This would also imply that any treatment designed to 
target the inner choroidal endothelial cell is just as likely to affect the 
peripheral cells as it is the macula, with the potential for widespread 
side effects inside the eye.  
 
Significant differences, however, were found between matched inner 
and outer macular choroidal endothelial cells with around 300 (1.3%) 
probesets showing a significant difference. While no major differences 
in canonical pathways were discovered and many of the probesets 
remain unclassified, differences in functional areas such as nervous 
system development, cell signalling, immune functions and cell 
morphology were represented. In general, inner choroidal ECs 
demonstrated up-regulation of probesets involved in nervous system 
development (brain derived neurotrophic factor and neurofilaments), 
growth factors (VEGF, HGF, PDGF), plasmalemmal vesicle associated 
protein-1 (PLVAP), collagen XI and keratin 19 while macular outer 
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choroidal ECs demonstrated up-regulation of probesets involved in 
immune function (HLA DR B1, MHC class II alpha and CD200), some 
cell signalling components (DAG, MAPK11 and apelin) and other 
growth factors (TGF beta and stromal cell derived factor) and collagen 
XV. These differences are likely to be related to their different functions 
within the choroidal vascular unit. A hypothesis to explain many of 
these differences relies on the assumption that the inner macular CECs 
are the true microvascular ECs where physiological and pathological 
angiogenesis takes place, whereas the outer macular ECs are lining a 
W\SHRI³PDFURYDVFXODUYHVVHO´ZKRVHIXQFWLRQLVWRVXSSO\DQGUHJXODWH
the supply of blood, including white cells and nutrients, to the 
choriocapillaris/inner choroid. This would explain why a wide variety of 
growth factor genes are found to be up-regulated in inner CECs 
(angiogenesis related ). By contrast, up-regulation of immune function 
genes by the RXWHUFKRURLGDO³PDFURYDVFXODU´(&V may control the 
passage of lymphocytes and macrophages into the inner choroid. It has 
also been shown that a fragment of collagen XV forms an endostatin, 
an anti-angiogenic factor thought to be important in inhibition of both 
physiological and pathological angiogenesis (Sasaki et al, 2002). The 
finding of the up-regulation of the gene coding collagen XV in outer 
choroid ECs may explain the absence of pathological angiogenesis in 
this area. 
 
Perhaps one of the most important probesets found to be differentially 
expressed is that of plasmalemmal vesicle associated protein-1 
(PVLAP). This was found to be up-regulated in macular inner CECs. 
PVLAP is a major structural protein known to be associated with 
fenestrations. The macular inner choroidal ECs are known to be 
fenestrated, whilst the outer choroidal ECs are not, and this is one of 
the major features differentiating inner choroidal ECs from other ocular 
endothelial cells. Interestingly, however, not all fenestrated ECs have 
been shown to express PLVAP, with those of the liver and the 
glomerulus being negative (Satchell & Braet, 2009).  
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Brain derived neurotrophic factor (BDNF) is a member of a group of 
proteins called neurotrophins which promote the growth, survival and 
differentiation of neurones in the central and peripheral nervous system. 
Within the eye, it is known that it is secreted by RPE cells, 
photoreceptors and Muller cells and has been shown experimentally to 
prevent ischaemic ganglion cell death and to protect photoreceptors 
from light induced toxicity (Kano et al, 2002). Recently, BDNF has been 
found to be secreted by vascular endothelial cells and may be 
responsible for the levels of the growth factor detected in serum. 
However, its role outside the central and peripheral nervous system 
remains unknown (Nakahashi et al, 2000). In the current work, BDNF 
was found to be up-regulated 5-fold in macular inner choroidal ECs 
compared with matched outer macular ECs. There are a number of 
hypotheses as to why this should be. It may be involved in the 
maintenance and function of neurones found within the choroid which 
are involved in regulation of choriocapillaris blood flow or it may pass 
DFURVV%UXFK¶VPHPEUDQHDQGthe RPE and be involved in outer 
photoreceptor function.  
 
Interestingly, inner and outer macular choroidal ECs appear to 
demonstrate preferential up-regulation of collagen types XI and XV 
respectively. Collagens are components of cell basement membranes 
and this difference in collagen expression suggests discrete 
requirements for these structures within the different layers of the 
choroid. Collagen XI is a fibrillar collagen, mutations in which have been 
IRXQGLQ6WLFNOHU¶VV\QGURPHDFRQGLWLRQDVVRFLDWHGZLWKP\RSLDDQG
abnormalities of the vitreous, retina and posterior segment. Collagen 
XV is a non-fibrillar type of collagen which is found in some endothelial 
cell basement membranes and is thought to facilitate its binding to 
surrounding connective tissue (Amenta et al, 2005). There also appear 
to be subtle differences in the expression of a number of components 
involved in cell signalling activation. Inner macular ECs demonstrated 
up-regulation of the WNT5 pathway, which may be involved in 
angiogenesis. This is a poorly understood pathway that may regulate 
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cell proliferation, apoptosis and branching morphogenesis 
(Masckauchán et al, 2006; Masckauchán et al, 2005). In contrast, outer 
macular choroidal ECs demonstrated up-regulation of a range of 
probesets including apelin, MAPK11 and diacyl-glycerol kinase zeta. 
These peptides are members of a large family of peptides involved in 
the transduction of cell signalling from cell surface receptors to the 
nucleus, stimulating cell proliferation. Apelin and its receptor have been 
found on a variety of endothelial cells (including those in the eye) and 
activation leads to vasodilatation, proliferation, vasculogenesis and in 
vitro tube formation (Kasai et al, 2004). These findings would suggest 
that there are subtle differences in the intracellular signalling cascades 
of proliferating inner and outer choroidal ECs. This finding may be 
utilised to enable a more selective inhibition of inner choroidal 
endothelial cell function.  
 
Activation of cell signalling pathways usually requires binding and 
stimulation of cell surface receptors by ligands (often growth factors, if 
stimulation of cell proliferation is occurring). Macular inner and outer 
CECs demonstrated a different pattern of growth factor expression. 
Stimulation of vascular endothelial cells is usually via growth factors 
secreted by other cell types such as RPE cells and macrophages which 
are known to secrete VEGF. The role of similar growth factors 
expressed by endothelial cells themselves suggests either local 
paracrine stimulation, perhaps to maintain cell phenotype, or the 
stimulation of different types of juxtaposed cells such as pericytes or 
stromal cells. Macular inner choroidal cells demonstrated up-regulation 
of VEGF and hepatocyte growth factor (HGF). It would be interesting to 
hypothesise that VEGF secretion is required to maintain the specialised 
phenotype of endothelial cells within the choriocapillaris (fenestrations). 
It is known that RPE cells also secrete VEGF which is thought to be 
important in maintaining choriocapillaris fenestrations.  
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Hepatocyte growth factor is another potent endothelial mitogen 
secreted by cells of mesenchymal origin including vascular endothelial 
cells and macrophages. It has a structure very similar to plasminogen, 
contains a heparin binding domain and is secreted by cells in an 
inactive form (Grierson et al, 2000). It relies on the action of serine 
proteases for activation and activates cells via the c-met receptor 
(present predominantly on cells of epithelial lineage but includes 
vascular endothelial cells). In the eye, it is thought to play a role in 
corneal development and maintenance of normal corneal structure and 
in the maintenance of trabecular meshwork structure (Grierson et al, 
2000). In the posterior segment, the RPE demonstrates a high level of 
expression of the c-met receptor and this may be necessary for its 
normal function and secondarily, for photoreceptor health. In vitro 
studies have revealed that HGF protects confluent cultures of RPE cells 
against apoptosis (Jin et al, 2005), promotes RPE cell proliferation and 
migration (Miura et al, 2003) and also leads to disassembly of tight and 
adherens junctions (Jin et al, 2002). Hepatocyte growth factor therefore 
appears to bring about the same effects on RPE cells as does VEGF on 
vascular endothelial cells.  
 
There is controversy as to whether RPE cells also secrete HGF, as this 
would indicate a local paracrine loop (He et al, 1998). However, HGF is 
known to be required for the maintenance of the RPE barrier function 
with local over-expression being linked with retinal detachment (Jin et 
al, 2002; Jin et al, 2004). Elevated levels are also found in the vitreous 
of diabetics and it has been shown to be a potent angiogenic growth 
factor (greater than VEGF) and may therefore play a role in proliferative 
diabetic retinopathy (Nishimura et al, 1999).  
 
While there is a large body of evidence regarding the effect of HGF in 
retinal neovascularisation, its role in choroidal homeostasis and 
neovascularisation is less well understood. In a rat laser model of 
choroidal neovascularisation, HGF was found to be up-regulated early 
on in the angiogenic process within the choroid (Hu et al, 2009). 
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7RWKHDXWKRU¶VNQRZOHGJHQRVWXGLHVRQ+*)LQKXPDQH\HVHLWKHU
normal or those with CNV, have been conducted. This study 
demonstrated that proliferating human macular inner choroidal 
endothelial cells preferentially express HGF compared with outer 
choroidal ECs. There are a number of possible reasons for this. Based 
on the findings from other parts of the eye (RPE), the expression may 
be part of a paracrine loop required for either the normal functioning of 
endothelial cells or as an amplification factor for CECs already 
proliferating (review of raw microarray data shows that the cells also 
demonstrate background expression of the c-met receptor). However, 
this does not explain why juxtaposed proliferating outer choroidal ECs 
do not demonstrate a similar phenomenon. Another reason could be 
the local (paracrine) secretion of HGF to affect non-endothelial cells 
such as RPE cells which are known to require HGF for normal cell ± 
cell interactions. These findings may imply that local targeting of HGF in 
the treatment of choroidal neovascularisation may have inadvertent 
deleterious effects on the posterior segment of the eye.  
 
In contrast, macular outer choroidal ECs demonstrated up-regulation of 
probesets for the growth factors CXCL12 (stromal cell derived factor) 
and TGF-Beta 1. Stromal cell derived factor (SDF-1) is a known 
mitogen for endothelial cells It is also involved in the attraction of 
endothelial progenitor cells to areas of neovascularisation and has been 
found on histological examination of excised choroidal neovascular 
membranes. Its differential expression by outer macular CECs was 
previously unknown. However, Bhutto et al (2006) recently 
demonstrated expression of SDF-1 and its receptor within the choroidal 
stroma (as well as the RPE) and suggested that they may be involved 
in the recruitment of leukocytes and other inflammatory cells to the 
choroidal stroma as well of endothelial progenitor cells during local 
wound healing responses i.e. angiogenesis (Bhutto et al, 2006). 
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In summary, this particular part of the study has demonstrated small 
subtle differences between matched human macular inner and outer 
choroidal endothelial cells. No significant topographical differences 
were found between macular and peripheral inner choroidal endothelial 
cells. This is in contrast to other studies which have shown 
topographical differences in the structure, function or gene expression 
RIUHWLQDODQG53(FHOOVDQGLQ%UXFK¶VPHPErane. Interestingly, when 
one reviews the results of previous studies which examined the gene 
expression differences between macular and peripheral tissue using a 
combination of RPE/choroidal tissue (Radeke et al, 2007; Bowes 
Rickman et al, 2006), none of the gene differences found in their 
studies were represented in this present study. This suggests that most 
of the variation described was probably due to variability within the RPE 
cells. It is further suggested that the non-significant topographical 
variability within proliferating inner choroidal endothelial cells is 
probably not the cause of the site specific selectivity of wet AMD to the 
macula, and that this phenomenon is more likely, as previously stated, 
to be due to topographical differences in other ocular cell types or to 
selective exposure of the macular to a disease causing agent.  
 
Variability was noted, however, in the gene expression of matched 
macular inner and outer choroidal ECs. This differential gene 
expression would suggest subtle differences in the roles and 
microenvironments of the two cell types commensurate with the 
different structures and functions of the inner and outer choroid. These 
observed differences may assist us in understanding some of the 
underlying mechanisms of choroidal neovascularisation and provide 
potential routes for selective intervention to treat the disease. 
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Chapter 6 
 
 
 
 
The effects of growth factors on the 
proliferation and in-vitro 
angiogenesis of human macular 
inner choroidal endothelial cells 
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Introduction 
 
While wet AMD remains the leading cause of blindness in people over 
65 years, the underlying pathophysiological mechanisms responsible 
for disease initiation and progression remain largely unknown. Current 
opinion suggests that there is an angiogenic response by inner 
choroidal endothelial cells to a range of cytokines and growth factors, 
driven by a local adverse stimulus. An electron microscopic study by 
Killingsworth in 1995 of eyes with early choroidal neovascularisation 
demonstrated endothelial sprouts continuous with intra-choroidal 
YHVVHOVSHQHWUDWLQJ%UXFK¶VPHPEUDQH7KH\ZHUHDOVRVKRZQWR
VSUHDGEHWZHHQWKHLQQHUOD\HUVRI%UXFK¶V membrane in the space 
normally occupied by drusen. The authors described two phases to the 
growth of vessels - an early intra-FKRURLGDOSKDVHZKLFKZDVRID³ORZ
WXUQRYHU´W\SHDQGDODWHUVXE-RPE neovascular phase characterised 
by marked endothelial celOSUROLIHUDWLRQWHUPHGDV³KLJKWXUQRYHU´
Interestingly, Guymer et al in 2004 described cellular processes from 
FKRURLGDOFDSLOODU\HQGRWKHOLDOFHOOVWKDWSHQHWUDWH%UXFK¶VPHPEUDQH
but are not associated with choroidal neovascular membrane formation 
(Guymer et al, 2004). These processes are thought to stabilise the 
endothelial cell and to play a structural role in the maintenance of the 
choriocapillaris. It is not known what factors are important in the 
differentiation of the endothelial cell processes from physiological to 
pathological states.  
 
Immunohistochemical examination of surgically excised human 
choroidal neovascularisation (CNV) and animal models of laser induced 
CNV implicate several growth factors in the pathogenesis of CNV. 
Examination of CNV induced in rats by krypton laser photocoagulation 
has consistently revealed up-regulation of vascular endothelial growth 
factor (Wada et al, 1999; Yi et al, 1997; Shen et al, 1998) and fibroblast 
growth factor 2 (Ogata et al, 1996; Frank et al, 1997) by RPE cells, 
fibroblasts and macrophages within the CNV. Studies conducted on 
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human CNV secondary to AMD and presumed ocular histoplasmosis 
syndrome have shown increased expression of VEGF (Grossniklaus et 
al, 2002; Frank et al 1996; Kliffen et al, 1997; Kvanta et al, 1996), FGF2 
(Frank et al, 1996; Amin et al, 1994; Reddy et al, 1995),  Insulin- like 
growth factor 1 (IGF-1) (Rosenthal R et al, 2004; Lambooij et al, 2003), 
Platelet derived growth factor (PDGF) (Kliffen et al, 1997), connective 
tissue growth factor (CTGF) (Watanbe et al, 2005; He et al, 2003), 
Placental growth factor (PlGF) (Rakic et al, 2003), and Interleukin-ȕ
(IL-ȕ=RXHWDO 
 
Further evidence for the role of growth factors in the pathogenesis of 
CNV is supported by the findings that inhibition of VEGF (Kwak et al, 
2000), FGF2 (Tobe et al, 1998), IGF-1 (Bezerra et al, 2005), PDGF (Jo 
et al, 2006) and IL-
fluorescein leakage in animal models. Recent human studies have 
reported beneficial effects of intra-ocular VEGF inhibition on visual 
acuity in patients with sub-foveal CNV, further implicating a role for this 
growth factor in AMD (Rosenfeld et al, 2006). However, evidence from 
studies of retinal neovascularisation (Watnabe et al, 2005; Dills et al, 
1991, Freyberger et al, 2000), in which IGF 1 may play a role, and the 
observation that inhibition of VEGF does not completely abrogate CNV 
growth and/or leakage in all cases (Williams & Fekrat, 2006; Gragoudas 
et all, 2004) makes it likely that other growth factors are also important 
in choroidal neovascularisation. 
 
In vitro studies using bovine choroidal endothelial cells have shown pro-
angiogenic effects for VEGF, FGF2, IGF-1 and PDGF (Sakamoto et al, 
1995; Wang et al, 2002; Liu et al, 1998). However, as mentioned 
previously, it is well recognised that there is a marked heterogeneity 
amongst endothelial cells from different species and sites, making it 
difficult to extrapolate these results to human inner macular choroidal 
disease i.e. wet AMD. It has been previously shown in Chapters 3 and 
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5 that even within the eye, there is heterogeneity in vascular endothelial 
cells, even within the layers of the choroid. In this chapter, the in vitro 
proliferative and angiogenic effects of a range of candidate growth 
factors on human macular inner choroidal endothelial cells was 
undertaken in order to increase our understanding of the underlying 
mechanisms of human choroidal neovascularisation. This research is 
unique in that, for the first time, it reports the effects of the 
aforementioned factors on human macular inner choroidal endothelial 
cells (ICECs). 
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Methods 
 
Isolation of human macular inner choroidal endothelial cells 
 
The isolation of these cells has been described previously (Chapter 4). 
 
Cell Proliferation assays 
Manual Cell counting 
 
Twenty thousand first passage human macular ICECs in EGM2-MV 
were added to each gelatin (0.1%) coated 35mm cell culture dish, 
marked with 2mm grids (Nunc, Rochester, NY, USA). The number of 
culture dishes used allowed testing of each factor at each concentration 
in triplicate sets. Cells were incubated at 37°C in a humidified 
atmosphere of 5% CO2 for 24 hours to allow cell attachment. The 
medium was then removed and the cells washed 3 times with sterile 
PBS. The PBS was then replaced with serum-reduced medium (EGM-
2), supplemented with Gentamicin (5µg/ml), Amphoterocin B (2.5µg/ml) 
and 0.5% foetal calf serum heat inactivated for 4 hours at 56ºC. After 
18 hours, the medium was replaced with 2 ml of serum-reduced 
medium containing selected growth factors (VEGF165, FGF2, IGF1, 
PDGF-AA, PDGF-BB and IL-ȕDOOIURPR and D systems, Abingdon, 
UK at 300 and 900pmol/l). Attached cells within 14 squares of each 
plate were counted 3 times at baseline and 48 hours after addition of 
growth factor or serum-reduced medium. Cell proliferation (%) was 
calculated by the mean increase in cell number relative to baseline.  For 
each growth factor investigated, all tests were carried out in triplicate, 
on human macular ICECs derived from the same donor and repeated 
on a total of four separate donors.   
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WST-1 assay 
 
Human macular ICEC proliferation in the presence of different growth 
factors was also assessed using the WST-1 assay (Roche, Lewes, UK). 
This is one of a range of rapid, non-radioactive, liquid based assays for 
assessing cell proliferation by the measurement of metabolic activity. 
The assays utilise the property of viable and proliferating cells cleaving 
a tetrazolium salt to formazan by mitochondrial respiratory chain 
enzymes. This brings about a colour change in the tetrazolium 
compound that can be measured by a spectrophotometer. The assay is 
based on the assumption that the more functioning mitochondria that 
are present, the more intense the colour change that can be measured. 
Over a specified range of viable or proliferating cells, this colour change 
is linear. The most common tetrazolium salt used is MTT [3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. However it 
suffers from the disadvantage that the formazan dye produced from 
MTT is extremely water insoluble, so an additional extraction step is 
needed before quantification. Instead, WST-1 utilizes a tetrazolium salt 
[2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-terazolium] 
which produces a water soluble formazan, which makes the assay 
much easier and user friendly. The change in the structure of the 
tetrazolium salt is shown below 
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In the assay, two thousand five hundred (2500) first passage ICECs, 
suspended in EGM2-MV, were added to each well of a fibronectin 
coated 96 well plate (Beckton Dickinson, Oxford, UK) and incubated at 
37ºC in a humidified atmosphere of 5% CO2 for 24 hours to allow cell 
attachment. The medium was then removed and the cells washed 3 
times with PBS and replaced with serum-reduced medium (EGM-2) 
supplemented with antibiotics and 0.5% heat inactivated serum as 
described above. After 18 hours, the medium in selected wells was 
replaced with 150µl of serum reduced medium containing growth 
factors: VEGF165, FGF2, IGF1, PDGF-AA, PDGF-BB and IL-ȕDOOIURP
R & D systems, Abingdon, UK, at a concentration of 1000 pmol/l. 
Further alterations in growth factor concentrations were then obtained 
by a double dilution technique across the plate. The cells were 
incubated in the presence of the growth factors for 48 hours, after which 
WST-1 was added to each well and incubated for 4 hours at 37ºC and 
then the absorbance of each well was recorded at 450nm and 650nm 
using a Thermamax microplate reader (Molecular Devices, Wokingham, 
UK) aFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV&HOOSUROLIHUDWLRQZDV
expressed as a percentage increase relative to controls i.e. cells 
exposed to serum reduced medium without any growth factor added. 
Each growth factor concentration was examined in triplicate as stated 
above and the mean values were used in the data analysis. 
 
In vitro Angiogenesis Assay 
 
The three dimensional in vitro angiogenesis assay used in this work 
was a modification of that previously described by Stitt et al in 2005. 
Briefly, chilled first passage human macular ICECs in EGM2, 
supplemented with 1.5% heat inactivated foetal calf serum, was mixed 
with Matrigel (Beckton Dickinson, Oxford, UK) chilled to 4ºC in a ratio of 
1:2 to give a final 0.5% foetal calf serum containing ICECs at a 
concentration of 1x107/ml. Aliquots of the mixture (4µl) were pipetted 
into the base of the wells of a flat bottom 96 well plate using cooled 
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pipette tips. The spots of Matrigel mixture were allowed to polymerise at 
37ºC in a humidified atmosphere of 5% CO2  for 1 hour, after which 
200µl of  serum (0.5%) reduced EGM2 was gently added to each well 
and incubated at 37ºC in a humidified atmosphere of 5% CO2  for 24 
hours. At this stage, ICECs were seen to form a network of tubes within 
and up to the edge of the Matrigel spot. The medium was gently 
aspirated and the plate allowed to stand at room temperature in a 
laminar flow hood for 5 minutes. Fifteen microlitres of a 1:2 mixture of 
serum (0.5%) reduced EGM2 and chilled Matrigel (4ºC), each 
supplemented with the same selected growth factors (VEGF165, FGF2, 
IGF-1, PDGF-AA, PDGF-BB and IL-ȕDWDILQDOFRQFHQWUDWLRQRI
1000pmol/l), was carefully pipetted around the edge of the spot to give 
a duplex culture as previously described (Stitt et al, 2005). After 
polymerisation at 37ºC for 1 hour, 200µl of serum (0.5%) reduced 
EGM2 were added to each well. After 48 hours, each spot was 
observed by phase contrast microscope. As previously described by 
Stitt et al, a dark line was seen to demarcate the interface between the 
primary and secondary Matrigel layers. The numbers of endothelial 
sprouts that were seen to cross the demarcation line were counted 
around the circumference of each primary Matrigel spot (see Fig 6.1). 
For each growth factor, the mean number of sprouts counted in 10 
wells was compared with the mean number of sprouts counted in 
control wells exposed to serum reduced (0.5%) EGM2 without any 
added growth factors.  
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Fig. 6.1. Phase contrast micrograph demonstrating the invasion of 
preformed microvessels into the secondary Matrigel layer (dark lines 
represent the demarcation of the two layers of Matrigel). 
 
 
Statistics 
 
The results are presented as the mean of at least 3 separate 
experiments ± standard error of the mean (SEM). Differences between 
growth factors and a serum reduced control were analysed by a 
6WXGHQW¶s t test. Significance was defined as p< 0.05. 
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Results 
 
Human macular ICEC Proliferation 
 
Prior to undertaking the cell proliferation assays, it was shown that 
 
first 
passage human macular ICECs survived without undergoing significant 
proliferation or phenotype change when maintained for 48 hours in 
EGM-2 supplemented with 0.5% foetal calf serum, heat inactivated for 4 
hours. This provided a baseline against which the effects of various 
growth factors on endothelial cell proliferation and in-vitro angiogenesis 
could be determined (Fig 6.2). 
 
Change in human macular ICEC proliferation with different 
concentrations of foetal calf serum
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Fig 6.2. Mean proliferation of macular inner choroidal endothelial cells 
measured using cell counting in the presence of different 
concentrations of heat inactivated foetal calf serum (error bars indicate 
± SEM, n=3.)  
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Two different techniques were used to determine cell proliferation. The 
manual cell counting technique allowed determination of absolute cell 
numbers in response to stimulation with growth factors and monitoring 
of cell phenotype over time. The other technique was the WST-1 
colorimetric assay, which measures cellular mitochondrial activity that 
can be used as an indicator of cell viability and/or proliferation.  
 
Manual Cell Counting 
 
The mean of 3 experiments carried out in triplicate are summarised in 
Fig. 6.3 (growth factor concentration of 300pmol/l) and Fig. 6.4 (growth 
factor concentration of 900 pmol/l). Both VEGF165 and FGF2 showed a 
significant increase in proliferation at both concentrations examined. At           
300 pmol/l, VEGF165 and FGF2 increased mean proliferation (± SEM) 
by 40 ± 8% (p=0.004) and 42 ± 4% (p=0.002) respectively, compared 
with control serum reduced medium. At 900pmol/l, VEGF165 and FGF2 
increased mean proliferation (± SEM) by 140 ± 13 % and 107 ± 13 % 
respectively (p<0.0004 for both). Equimolar combinations of VEGF165 
and FGF2 at 300 and 900 pmol/l increased proliferation (± SEM) by 71 
± 10% and 217 ± 52% respectively (effects approximately additive). 
There was no significant effect of IGF-1, PDGF-AA, PDGF-BB or IL-ȕ
on hICEC proliferation at either 300 or 900 pmol/l concentrations. 
Equimolar combinations of VEGF165 with any of the other factors, 
namely IGF-1, PDGF-AA, PDGF-BB and IL-ȕDWSPROOGLGQRW
show a significant increase in proliferation over VEGF165 alone. 
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Proliferation of human macular ICECs in the presence of growth 
factors (300pmol/l)
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Fig 6.3. Mean proliferation of human macular inner choroidal 
endothelial cells measured by manual cell counting in the presence of 
various growth factors at 300 pmol/l (± SEM, n=3) 
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Proliferation of hCECs with growth factors (900pmol/l)
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Fig 6.4. Mean proliferation of human macular inner choroidal 
endothelial cells measured by manual cell counting in the presence of 
various growth factors at 900 pmol/l (± SEM, n=3) 
 
WST-1 assay 
 
The growth curves representing the mean of 3 different experiments for 
each growth factor are shown in Fig. 6.5. This shows a significant dose-
response effect for VEGF165 (p=0.0002) and FGF2 (p=0.02) between 
7.8 and 1000pmol/l. At 1000pmol/l, an equimolar combination of VEGF 
and FGF2 increased proliferation (± SEM) from 126 ± 9% and 114 ± 
23% respectively for the individual growth factors to 193 ± 62% for the 
combination. There was no significant dose response effect for IGF-1 
(p=0.20), PDGF-AA (p=0.53), PDGF-BB (p=0.88) or IL-ȕS 
between 7.8 and 1000pmol/l. 
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Proliferation of human macular ICECs in the presence of growth 
factors
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Fig 6.5. Growth curves for human macular inner choroidal endothelial 
cells measured using the WST-1 assay in the presence of different 
growth factors. (Error bars indicate ± SEM, n=3)  
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In vitro Angiogenesis Assay 
 
The mean percentage increase in tubes crossing the junction between 
the primary and secondary Matrigel layers is shown in Fig 6.6  
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Fig 6.6. Mean increase in tube formation compared with control as a 
measurement of angiogenesis using 3D double layer Matrigel assay for 
various growth factors (± SEM, n=3) 
 
 
Compared with controls (EBM-2 supplemented with 0.5% FCS), there 
was a significant increase in tube formation (± SEM) for VEGF165 and 
FGF2 at 1000pmol/l by 161± 50 % (p=0.003) and 139 ± 46% (p=0.003) 
respectively. Equimolar combinations of VEGF165 and FGF2 at 
1000pmol/l increased tube formation (± SEM) by 240 ± 28%. There was 
no significant increase in tube formation compared with EBM-2 
supplemented with 0.5% FCS for IGF-1 (p=0.21), PDGF-BB (p=0.36), 
PDGF-AA (p = 0.41) or IL-ȕS  
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Discussion 
 
A number of different growth factors have been found to be associated 
with CNV tissue removed from human eyes. However, knowledge of 
their individual roles in disease pathogenesis remains incomplete. Many 
growth factors have been found to be pro-angiogenic in in vivo animal 
models of CNV and in in vitro experiments utilising animal choroidal 
ECs or human non-choroidal ECs. It is accepted though, that ECs are 
extremely heterogeneous in nature and may show varying responses to 
a range of potential mitogens (Thorin & Shreeve, 1998; Rhodin 1968; 
Graier et al, 1996; Imegwu et al, 2001; Ram & Hiebert, 2003; Craig et 
al, 1998). To overcome these potential problems in the investigation of 
the effect of various growth factors in the pathogenesis of choroidal 
neovascularisation, we have utilised human macular inner choroidal 
endothelial cells in this work. In addition, all ICECs were used at first 
passage to reduce potential problems associated with phenotypic 
change which is known to occur in cultured ECs (Augustin-Voss et al, 
1993, Fenyves et al, 1993). With multiple passages these cells may 
lose their differentiated characteristics which they had in vivo, and may 
be prone to genetic instability. The modified angiogenesis assay used 
in this work has previously been shown to be an accurate model of the 
concurrent processes involved in angiogenesis: cell proliferation, BM 
digestion, migration and tube formation (Stitt et al, 2005). This makes it 
ideal in the investigation of the factors underlying abnormal choroidal 
angiogenesis.  
 
This work has shown that both VEGF and FGF2 individually stimulate 
human ICEC proliferation and angiogenic tube formation with similar 
potency. This finding is significant because while it is known that the 
biological effects of VEGF are largely restricted to ECs, the role of 
FGF2 on CNV pathogenesis has been largely unexplored and remains 
controversial (Rosenthal et al, 2005; Tobe et al, 1998). Fibroblast 
growth factor is known to have mitogenic effects on fibroblasts, 
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chondrocytes, smooth muscle cells and melanocytes in addition to ECs 
(Burgess & Macaig, 1989). The FGF2 subtype is known to be present in 
CNV (as discussed previously) and may therefore also promote effects 
in cells other than ECs in the formation and propagation of CNV. As 
mentioned in chapter 1, there is still debate as to whether FGF exerts 
its pro-angiogenenic effect on endothelial cells by its own effect on the 
cellular proliferative mechanism via FGF receptors and intracellular 
signalling cascades or via up-regulation of the effect of VEGF. Evidence 
exists for both hypotheses as it is known that specific pro-angiogenic 
pathways are activated when FGF binds to its receptor (FGFR1) (Cross 
and Claesson-Welsh) and FGF has also been shown to up-regulate 
VEGF and VEGF receptor expression on ECs (Murakami and Simons, 
2008; Murakami et al 2011; Seghezzi et al, 1998). This is an area 
where future research would be beneficial. 
 
When hICECs were exposed to equimolar concentrations of VEGF and 
FGF2, the effect of the growth factors was additive even within the 
plateau phase of proliferation of the individual growth factors. This 
suggests that the growth factors may, at least in part, be acting via 
different activation pathways, an important factor for future development 
of anti-angiogenic therapies. This hypothesis is given weight by studies 
on bovine adrenal ECs which demonstrated synergistic effects of VEGF 
and FGF2 (Goto et al,1993; Pepper et al, 1992) and on bovine CECs 
and HUVECs, which showed activation of the intracellular MAPK 
pathway by VEGF and FGF2 by different mechanisms (Mc Laughlin et 
al, 2001; Zubilewitz et al, 2001). While little work has previously been 
conducted on the mechanism of FGF2 stimulation of hCEC, it has 
recently been found that these proliferating cells preferentially express 
mRNA for the FGF Receptor 1 compared with retinal endothelial cells 
(see Chapter 3), again implicating a direct role for FGF-2 in hCEC 
biology. 
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It is known that most of the pro-angiogenic actions of FGF 2 are 
mediated via the receptor tyrosine kinase, FGFR-1. There are at least 
three other FGF receptors (FGFR2-4) which are present on a variety of 
different cells, implying a degree of system redundancy as suggested 
by embryological studies (Cross and Claesson-Welsh, 2001). Activation 
of the receptor requires dimerisation of two receptors which is followed 
by autophosphorylation of specific tyrosine residues (Klint and 
Claesson-Welsh, 1999). The specific sites of phosphorylation have 
been found to bind molecules such as Crk which leads to MAPK 
activation, and PLC-Ȗ. Receptor activation is known to lead to activation 
of a number of intracellular signalling cascades including the Ras 
pathway, Src receptor kinases, PI3K and the PLC pathway (see Fig 6.7 
for a diagrammatic representation). 
 379 
 
 
Fig 6.7. An overview of FGFR-1 signalling. As mentioned above, 
activation leads to the autophosphorylation of several sites of the 
intracellular molecule which leads to activation of different signalling 
cascades. The end result appears to be up-regulation of MAPK which is 
able to enter the nucleus to modify gene expression i.e. cell proliferation 
and protection from apoptosis. (Reproduced by permission of Elsevier) 
 
 
In contrast, VEGF-A exerts its pro-angiogenic effects on vascular 
endothelial cells via two distinct receptors, VEGFR-1 and VEGFR-2. 
The receptors consist of an extracellular portion composed of seven Ig 
like domains, a transmembrane domain and an intracellular kinase 
domain. While VEGFR-1 is a weak tyrosine kinase, but with a ten fold 
higher affinity for VEGF than R-2, it is VEGFR-2 that is thought to 
important in angiogenic responses. Binding of VEGF-A to its R-2 
receptor activates a number of signalling cascades. Lke FGFR-1, PLCȖ
is activated and leads to up-regulation of MAPK. In addition, PKC, Akt 
and PI3K are also activated. These cascades are not dissimilar to the 
action of FGF (see Fig 6.8 below). 
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Fig 6.8. An overview of VEGFR-1 and VEGFR-2 signalling. Ligand 
binding results in receptor dimerisation and the phosphorylation of 
specific intracellular tyrosine residues. Only the downstream pathways 
for VEGFR-2 are shown as it is this receptor that is thought to be 
important for endothelial cell proliferation. In a similar fashion to FGFR-
1 activation, MAPK is activated and this can then bring about changes 
in gene expression within the nucleus. (Reproduced by permission of 
Elsevier) 
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Despite the similarities, researchers have attempted to detect 
differences in the signalling cascades brought about by the actions of 
VEGF and FGF. In the chick allantoic membrane, FGF 2 mediated 
angiogenesis was blocked following treatment with a specific MEK 
inhibitor (thereby reducing MAPK production) (Eliceiri et al, 1998). The 
same group also demonstrated that the induction of a mouse knockout 
of Src tyrosine kinase inhibited VEGF but not FGF induced 
angiogenesis (Eliceiri et al, 1999). As can be seen from the above 
diagrams, Src is to be found on both cytokine activated pathways. In 
2001, Zubilewicz et al demonstrated that FGF 2 induces a marked 
increase in MEK activity in bovine choroidal EC whereas VEGF did not. 
7KLVVWXG\XWLOLVHG³VSHFLILF´LQKLELWRUVRILQWUDFHOOXODUPHVVHQJHUVto 
dissect out important pathways. It is now widely accepted that these 
inhibitors may not be as specific as once thought and other methods 
such as proteomics would be more reliable. An example of a once 
widely used inhibitor is apigenin. It is used as a specific inhibitor of 
MAPK generation, but can also inhibit Protein Kinase 2 (CK2), nitric 
oxide synthase-2 (NOS2), Hypoxia-inducible factor 1 alpha (HIF-Į
lipoxygenase and cyclooxygenase-2 (COX-2) (information from Santa 
Cruz Biotechnology, Ca, USA). This means that any results derived 
from its use are probably a gross over simplification of the true 
pathways and interactions involved. 
 
When one considers the questions surrounding whether FGF and 
VEGF act separately on the stimulation of angiogenesis in endothelial 
cells and how the intracellular signalling cascades differ it would be 
interesting to study the effect of anti-VEGF antibodies on the 
proliferation of CECs when stimulated with FGF and FGF/VEGF 
combinations. The continued controversy as to whether FGF acts as a 
pro-angiogenic factor in its own right or acts via effects on VEGF or its 
receptor is an area where future research is necessary and may lead to 
future improved treatments for ocular angiogenenic diseases.  
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The author and co-workers have recently published a study 
demonstrating the comparative effects of VEGF isoforms on the 
proliferation of first passage human choroidal ECs and human retinal 
ECs using the methods described above (Stewart et al, 2011). It was 
found that both VEGF121 and VEGF165 were equally potent in 
stimulating both retinal and choroidal ECs. In addition, retinal ECs 
demonstrated a higher proliferation than choroidal ECs with equimolar 
concentrations of both VEGF isoforms. This suggests that retinal and 
choroidal ECs differ in their response to growth factors (VEGF isoforms) 
and again validates the results of the gene expression experiments, 
suggesting significant differences in gene expression (and thereby, 
possible functional differences) between retinal and choroidal ECs. It 
would also be interesting to compare the effects of FGF and VEGF/FGF 
combinations on matched retinal and choroidal endothelial cells as this 
may give information regarding the possible differential pathogenesis 
and treatment of retinal and choroidal diseases  
Other factors such as PDGF-AA, PDGF-BB, IGF-1 or IL-ȕSUHVHQWLQ
excised human CNV tissue did not show significant effects on human 
ICEC proliferation or angiogenic tube formation in this study. These 
results are in contradiction to the results found by workers utilising 
endothelial cells derived from non-human choroidal and animal models 
as a surrogate to the study of human choroidal disease. While we found 
no effect of IL-ȕRQK&(&V=RXHWDOLQIRXQGWKDWLQKLELWLRQRI
the effects of IL-1 on HUVEC cells significantly inhibited cell 
proliferation. Risau et al (1992) found PDGF-BB and to a lesser extent 
PDGF-AA to be pro-angiogenic in a chick chorioallantoic membrane 
model and to stimulate chemotaxis of rat brain ECs. Importantly, the 
preparations of PDGF were derived from recombinant yeast expression 
systems, so would be unlikely to be contaminated with VEGF. 
Interestingly, it has recently been suggested that PDGF is important in 
CNV pathogenesis due to its effect on pericyte recruitment and 
stabilisation, with absence of PDGF causing regression of new vessels 
due to loss of supporting pericytes. Agents targeting the intracellular 
 383 
effects of PDGF have therefore been proposed as a new treatment for 
CNV. Similarly, whilst a role for IGF-1 in retinal angiogenesis is 
established (Sharp, 1987; Smith et al, 1999, Hellstrom et al, 2001), its 
effect on the pathogenesis of CNV is controversial and appears to be 
dependent on species and/or site under investigation. We found no 
effect of IGF-1 on the proliferation and angiogenic tube formation of 
human ICECs. Spraul et al (2002) recently found that IGF-1 stimulated 
the proliferation of bovine CECs with a similar potency to VEGF, while 
Grant et al (1993) and Castellon et al (2002) independently found a 
stimulatory effect of recombinant IGF-1 on human and bovine retinal 
endothelial cells respectively, suggesting a direct pro-angiogenic effect 
for IGF-1 in diabetic retinopathy. This differential effect of IGF-1 on 
different ECs may explain the lack of significant benefit for lanreotide, a 
potential IGF-1 inhibitor, on the outcome of patients with CNV 
secondary to AMD (Papadaki et al, 2003). Any effect of IGF-1 on the 
pathogenesis of CNV may, therefore, be due to indirect effects on other 
pro-angiogenic cells and pathways.  
 
The author and co-workers recently published a study in which the 
effect of IGF-1 on unpassaged choroidal and retinal ECs was compared 
(Browning et al, 2012). This work showed that compared to choroidal 
ECs, which failed to demonstrate any proliferative response to IGF-1, 
retinal ECs showed a marked response which also demonstrated an 
additive response when used in the presence of VEGF. This work 
supports the gene expression experiments in chapter 3 which found 
that proliferating retinal ECs preferentially expressed various 
components of the IGF-1 activation pathways. This has implications for 
the pathogenesis and future treatments of proliferative diabetic 
retinopathy. Based on one of the conclusions of the gene expression 
studies in Chapter 5, it would be interesting to study the effect of Brain 
Derived Neurotrophic Factor (BDNF) on ICECs.  
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The potential drawback of this work is that the study of the hICECs took 
place in an environment far removed from their natural environment and 
the cells may behave differently in vitro to their in vivo state. To try and 
abrogate this effect, only cells of first passage that formed the typical 
cobblestone morphology in culture on fibronectin plates were used, so 
that the cells used were as near to the in vivo state as possible. 
However, as hICEC do not naturally exist in isolation in vivo, some of 
the factors tested may be able to influence hICEC indirectly via their 
effects on other neighbouring cells.  
 
On the other hand, the culture conditions used in this study allowed 
assessment of individual growth factors without the confounding effects 
of other factors and other cell types. The biological effect of single 
growth factors on the hICECs could therefore be tested in isolation.  
 
In summary, this study has found that VEGF and FGF2 stimulate hCEC 
proliferation and angiogenic tube formation in isolation and produce an 
additive effect when used in combination. Other growth factors such as 
IGF-1, PDGF-AA or BB and IL-ȕGRQRWKDYHDGLUHFWin vitro 
stimulatory effect on hCECs. It is, however, possible that other 
cytokines, including PDGF-AA or BB, IGF-1 and IL-ȕPD\SURGXFH
an effect by stimulation of other cell types involved in CNV formation. 
Such effects will require further investigation using co-cultures of 
different cell types. These results suggest that in addition to VEGF, 
FGF2 could be a potential therapeutic target for the development of 
new agents to treat angiogenic diseases such as CNV in humans 
(Hagedorn et al, 2001).  
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Other than glaucoma, angiogenic driven diseases such as proliferative 
diabetic retinopathy (PDR), wet age-related macular degeneration and 
retinopathy of prematurity (ROP) remain the most common blinding 
disorders in the developed world. Unfortunately, many of the underlying 
mechanisms or causes of these diseases remain unknown and 
definitive treatment is not usually possible. Treatment modalities 
therefore rely on tissue destruction in the case of PDR and ROP or on 
the inhibition of a ubiquitous growth factor (VEGF) in wet AMD. More 
selective treatment of these conditions would reduce the collateral 
damage at the site of disease and allow the treatment to be more 
specific. To allow this more selective treatment to be developed, an 
increase in the knowledge of site specific differences in tissues is 
required. In the case of angiogenic diseases, this requires increased 
knowledge of endothelial cells, particularly those undergoing 
proliferation in the target tissue of interest.  
 
It has been known for many years that endothelial cells are 
heterogeneous in nature, even within a single organ such as the lung. 
It would not be surprising therefore, to speculate that endothelial cells 
within the eye may differ, even though their different vascular beds may 
only be separated by a factor of microns. Evidence for this 
heterogeneity is gleaned from the fact that different diseases appear to 
affect different ocular vascular beds with marked selectivity, e.g. retinal 
vasculitis and diabetes selectively affecting the retinal vasculature and 
wet AMD and inflammatory choriocapillopathies affecting the choroidal 
vasculature. 
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For many years, researchers have used HUVECs to study angiogenic 
processes in normal and pathological states and applied the 
conclusions to both ocular and non-ocular disorders. A major drawback 
of this approach is that HUVECs are specialised cells found in a 
microenvironment not encountered anywhere else in the body and are 
therefore likely to demonstrate unique responses. The usefulness of 
any conclusions derived from these cells in the understanding of 
diseases such as wet AMD and proliferative retinopathy must therefore 
be questioned. As alluded to previously, there is ample evidence in the 
literature demonstrating that HUVECs differ in many aspects in terms of 
their responses to external stimuli compared with other endothelial 
cells.  
 
In this work, it has been shown that at the level of gene expression, 
HUVECs are indeed different. They demonstrate significant differences 
in the expression of at least 800 genes, across many functional groups, 
when compared with ocular microvascular endothelial cells. 
Examination of the results obtained from HUVECs revealed that 
numerous genes involved in embryonic development were up-
regulated. This included numerous homeobox transcription factors 
which have been shown to be crucial to the development of many 
embryological structures and processes. Reasons for this difference 
may include the fact that the umbilical vein has the feature of being 
derived embryologically from the developing foetus. Another reason 
may be that in vivo, angiogenesis tends to occur at the microvascular 
level of the vascular tree, not in large capacitance vessels (such as the 
umbilical vein). These findings would seem to confirm earlier opinions, 
which suggest that HUVECs are different from other endothelial cells, 
and would lead one to suggest that these cells should not be used for 
the investigation of complex angiogenic disorders of specialised organs 
such as the eye. If one is not to use HUVECs in the investigation of 
human ocular disease, then the question arises as to which cells should 
be used in in vitro models.  
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Investigation of the gene expression patterns of human ocular 
endothelial cells revealed that there were significant differences 
between proliferating human retinal and choroidal endothelial cells. 
This study revealed that approximately 8% of tested genes showed a 
significant difference in expression. As the current research is 
particularly focused on angiogenic processes and diseases, genes 
thought to be involved in cell signalling pathways and which could be 
important in cell proliferation were specifically studied. This study found 
that there were a number of genes encoding proteins of signalling 
pathways that were differentially expressed between retinal and 
choroidal endothelial cells. As previously stated, diabetes is the leading 
cause of blindness in people of working age. From this work, it appears 
that as well as VEGF playing an important role in the progression and 
treatment of diabetic retinopathy, IGF-1 also appears to be important. 
This finding is backed by numerous clinical studies in which IGF1 is 
manipulated or measured in diabetic subjects. There is also evidence 
from myself and co-workers that IGF-1 brings about proliferation of 
human retinal endothelial cells but not human choroidal ECs (Stewart et 
al, 2011). In addition, the findings from this work have implications for 
the pathogenesis of ROP, in which the developing retinal vasculature 
appears to show differential responses to IGF-1 and may be involved in 
the disease pathogenesis.  
 
Interestingly, comparison of choroidal and iris endothelial cells 
demonstrated very few significant differences. The reason for this is 
unknown but may be related to the fact that both the iris and the choroid 
are part of the same ocular structure ± the uveal tract. They may 
therefore be part of the same embryological precursor.  
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The research presented in this thesis has a number of advantages 
compared to previous or similar studies:  
 
1. The work is conducted on human tissue. Some previous work has 
been conducted on bovine tissue. 
 
2. The endothelial cells are matched in terms of the donor, thereby 
reducing any variability due to donor differences. 
 
3. The cells are unpassaged. This avoids any differences in gene 
expression being due to changes related to passage drift.  
 
4. All cells were isolated and grown under exactly the same conditions, 
thereby avoiding any differences in gene expression being due to 
external factors. 
 
These rigorous culture and examination conditions allow one to directly 
compare gene expression and makes any significant differences more 
meaningful. Also, by studying proliferating cells, cell processes such as 
signalling pathways important in angiogenesis may be studied. Other 
work, particularly on ocular RPE cells has been conducted using laser 
capture microdissection prior to microarray analysis. Unfortunately, this 
would be unlikely to be suitable for this work, as very few endothelial 
cells are undergoing proliferation in the normal eye. Secondly, this 
technique is prone to contamination with other adjacent cells.  
 
In this project, cell purity was maximised by the use of paramagnetic 
bead separation prior to culture. One drawback of this work is that in all 
three types of ocular endothelial cells, no separation of venules, 
arterioles or capillaries was possible. This means that homogeneous 
mixtures of cells from each anatomical site were used. At present, the 
limits of microdissection prevent the isolation of individual retinal 
venules and arterioles to reliably provide enough cells to culture for 
further analysis. The use of laser capture dissection would provide a 
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suitable method of isolating samples of the individual vessels (if they 
could be reliably identified). The previous comments regarding 
contamination and the quiescent state of the isolated cells mean, 
however, that the technique in its present state is unlikely to provide 
additional information than that achieved by the methodology in this 
project.  
 
A major question that needs to be considered is the origin of the 
diversity of endothelial cells. Is this diversity due to nature i.e. genetic, 
or to nurture i.e. the effect of the local environment on the cell? The 
earliest events controlling the differentiation of mesoderm into 
endothelial cells remain uncertain. Experiments on zebra fish have 
shown that the arterial and venous phenotype of vascular precursor 
cells or angioblasts (expression of gridlock) is determined while they 
are still located in the lateral plate (very early stage of embryogenesis), 
implying a genetic component to endothelial heterogeneity (Zhong et al, 
2001). This finding is reinforced by the finding that in mice, cells 
destined to be arteriolar and venular ECs express ephrin B2 and EphB4 
respectively before the onset of a circulation (Adams et al, 1999).  
 
While the initial identity of ECs appears to be genetically determined 
later, after angioblast migration, local factors such as VEGF gradients 
can also have an effect on arterio-venous phenotype (Le Bras et al, 
2010). It is thought that high local expression of VEGF leads to the 
activation of members of the FOXC transcription factors which in turn 
leads to up-regulation of notch family and an arteriolar phenotype. 
Experiments have also shown that physiological requirements and 
haemodynamic influences can alter phenotype. Transplantation of 
arteriole ECs into veins rapidly changes their phenotype to venular 
(Moyon et al, 2001). This may be due to local factors such as VEGF 
secreted by surrounding cells or it may be secondary to differences in 
flow/shear stress as the placement of venules within a section of high 
flow artery leads to a rapid change to an arteriolar phenotype.  
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Less is known about the variability of EC phenotype between/within 
organs. It is not known if angioblasts migrate to these different areas or 
arise de novo. Cells arising de novo at different sites could obviously 
demonstrate variable gene expression patterns as they arise in isolation 
from other endothelial cells. However, it is probable that local factors 
such as differences in extracellular matrix and cytokines also play a 
significant part in local cell differentiation. For example, within the brain, 
the endothelium is highly specialised with avid tight junctions and is 
non-fenestrated. The cells form the crucial blood-brain barrier. It is 
thought that juxtaposed cells such as pericytes, astrocytes and 
neurones are crucial for this EC tight junction formation and thereby the 
formation of the blood-brain barrier (Hawkins and Davis, 2005; Lee et 
al, 2003). 
 
It has recently been suggested that the conventional concept of a 
particular transcription factor binding to the promoter sequence of a 
gene in order to regulate its transcription does not fully explain some 
features of endothelial cell gene expression. For instance, how does the 
endothelial cell environment exert chronic effects on gene expression 
over weeks or years or when the cell divides and how is this information 
regarding the environmental effects transmitted to daughter cells? 
Epigenetics is the term used to try to explain these findings and refers 
to chromatin based effects on the modification of gene expression. 
Three distinct mechanisms have been described: DNA methylation, 
histone post-translational modifications and RNA based mechanisms, 
all of which modify the structure and accessibility of DNA to 
transcription factors (Yan et al, 2010). 
 
DNA methylation refers to the addition of a methyl group on DNA 
cytosine and has the effect of reducing promoter transcription (Meissner 
et al, 2008) by steric interference of the binding of transcription factors 
to specific DNA sequences. This mechanism has been described as 
one method responsible for the modification of HIF-1 alpha gene 
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packaged by wrapping around histone proteins, forming nucleosomes. 
Histone proteins can be modified post-translationally by mechanisms 
such as acetylation which can affect DNA transcription. These 
modifications can therefore encode regulatory information for cells that 
reproducibly affect DNA expression and may be passed onto daughter 
cells. Finally, it has been found that small lengths of RNA (less than 200 
nucleotides) can affect DNA expression. These short lengths are called 
non-coding RNA and many have been found associated with the 
human genome. How can the environment affect these epigenetic 
processes? It has been found that shear stress on endothelial cells can 
modify the histones around which DNA is wrapped (Illi et al, 2003). 
Shear stress can therefore affect gene expression, particularly at sites 
of turbulence. This is thought to play a role in the pathogenesis of 
atherosclerosis, which is characterised by focal pathological changes 
within blood vessel walls. 
  
It has been shown that endothelial cells of the choroid, iris and retina 
are all derived from embryonic mesoderm, while supporting pericytes 
are derived from the neural crest (Gage et al, 2005). Following on from 
this is the finding that choroidal blood vessels develop by a process of 
haemovasculogenesis while those of the retina develop by 
vasculogenesis. The endothelial cells of both the retinal and choroidal 
vessels themselves are ultimately thought to be derived from CD39 
positive angioblasts. What is not known is whether all these angioblasts 
are the same i.e. from a common precursor which should therefore 
demonstrate early identical gene expression patterns. 
 
The difference in the gene expression patterns of matched mature 
human retinal and choroidal endothelial cells may therefore be due in 
part to this difference in origin (although all are ultimately derived from 
mesoderm).  
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The alternative argument is that cues from the local environment 
around the identical angioblasts/endothelial cells cause them to 
diversify and differentiate to suit their environment (Janzer and Raff, 
1987). Examples include brain and retinal endothelial cells which 
require strong tight junctions to provide the inner retinal and blood brain 
barrier or adrenal and inner choroidal endothelial cells which are 
fenestrated to facilitate passage of fluid and ions across the 
endothelium. Early experiments using endoderm-derived cells such as 
cells of developing lung have shown that local cues stimulate the 
formation and development of angioblasts that go on to form part of the 
pulmonary vasculature (which is known to be heterogeneous). In 
contrast, ectoderm-derived cells do not have this effect. This is an 
example, therefore, of the cell environment influencing angioblast 
behaviour (probably at the level of the gene).  
 
Further evidence for the effect of the environment on ECs include the 
finding that HUVECs exposed to TGFȕJURZDVDUDSLGO\GLYLGLQJ
monolayer if cultured on collagen I coated plates, but as tubes when 
cultured within a 360 degree matrix containing collagen I. Many of the 
interactions of ECs with their environment are thought to be facilitated 
by integrins, which are a family of cell surface molecules found on 
endothelial cells. It is known that the subtypes of these receptors 
change as the EC develops, thereby suggesting that changes in the 
development and maturation of the cell are at least in part related to the 
microenvironment.  
 
It has previously been mentioned that fibroblast growth factor 2 (FGF2) 
is important for vascular development. However, the effect of VEGF 
appears to be more dramatic and visual. Culture of mammary gland 
endothelial cells (Esser et al, 1998) and the in vivo exposure of ECs 
within muscle and skin (Roberts & Palade, 1995) (none of which are 
normally fenestrated) to VEGF stimulated the formation of 
fenestrations. This may explain why the retinal pigment epithelium 
secretes VEGF (and other factors) from its basal surface, across 
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%UXFK¶VPHPEUDQH± to maintain fenestrations and cell survival within 
the inner choroid (Liu et al, 1997). Interestingly, large vessel endothelial 
cells such as HUVECs can also be stimulated to form fenestrations by 
exposing them to phorbol ester (Lombardi et al, 1987). Phorbol ester is 
a tumour promoter which activates intracellular signal transduction 
cascades via protein kinase C and is commonly used in research to 
stimulate the cancerous transformation of cells. This finding shows that 
even cells which in vivo have no reason to develop fenestrae maintain 
the capacity to do so. Gregory Roberts & Palade in 1997 and 1998 
found that implantation of tumours containing growing blood vessels 
took on the phenotype of the tissue the tumour was implanted into (skin 
and brain), providing further evidence that the local environment 
influences the phenotype of endothelial cells. Similarly, in a mouse 
model in which a section of vein was interposed into the arterial 
circulation, the venous segment soon took on arterial characteristics 
such as an increase in smooth muscle cells with the vessel wall and the 
endothelial cells took on arterial characteristics (Kwei et al, 2004). 
There is substantive proof therefore that the parenchyma can determine 
the phenotype endothelial cells.  
 
Focussing on the choroidal neovascularisation involved in wet age-
related macular degeneration, one could hypothesise that the 
phenotype of proliferating endothelial cells at the site of disease leads 
to this devastating angiogenic process which is so frequently located at 
the macula, an area only a few mm in diameter. Are the unique gene 
expression profiles previously demonstrated in different proliferating 
ocular endothelial cells occurring at different sites within the human 
FKRURLG",IVRGRHVWKLV³ORFDO´JHQHH[SUHVVLRQSURILOHDOVRSURYLGHDQ\
clues to future site selective potential treatments? This work has shown 
that there is no significant difference in gene expression profiles 
between macular and peripheral human inner choroidal ECs. This result 
would suggest that the susceptibility of the macula to wet AMD is not 
due to a fundamental difference in the endothelial cells within the inner 
choroid. Other reasons could include the previously noted differences in 
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PDFXODU53(FHOOVRU%UXFK¶VPHPEUDQH7KLVZRXOGDOVRLPSO\WKDW
DQ\³PDJLFEXOOHW´WUHDWPHQWZRXOGLQWKHRU\KDYHDQHIIHFWRQ
peripheral inner CECs as well, giving rise to potential collateral damage 
and side effects.  
 
When macular inner and outer CECs are compared, however, some 
interesting differences are found, perhaps giving insight into the 
different physiological roles of the blood vessels of the two layers of the 
choroid: the inner as a fenestrated layer supplying the outer retina with 
oxygen and nutrients and the outer choroid as a layer of larger vessels 
supplying the inner choroid with a regulated blood supply.  
 
Inner choroidal ECs demonstrated up-regulation of probesets involved 
in nervous system development, in particular brain derived neurotrophic 
factor and certain growth factors such as VEGF and HGF. These may 
act in a local paracrine fashion to maintain local tissue phenotype 
(maintenance of photoreceptor integrity and RPE polarity) or to provide 
a local amplification loop to cell proliferation. It was also found that 
plasmalemmal vesicle associated protein-1 (PLVAP) which is a 
component of fenestrations, was up-regulated in inner macular 
endothelial cells (but not outer macular ECs or retinal and iris ECs) 
[from review of raw microarray data]), confirming the importance of 
fenestrations to the inner choroidal ECs. In contrast, macular outer 
choroidal ECs demonstrated up-regulation of probesets involved in 
immune function, certain cell signalling components and interestingly, 
different growth factors (TGF-beta and stromal cell derived factor).  
 
It has been demonstrated that human macular inner choroidal ECs 
have a unique gene expression profile but the next question to be 
answered is how these cells behave in a microenvironment that aims to 
mimic wet AMD. While all endothelial cells have been shown to respond 
positively to VEGF, there are widely reported differences in ECs¶ 
responses to other growth factors. Excised choroidal neovascular 
membranes from humans have been found to contain a wide range of 
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growth factors, some of which have been found to lead to variable 
responses with other ECs. Newly isolated and characterised human 
macular inner choroidal endothelial cells were used to determine their in 
vitro responses to a range of growth factors using an in vitro 
angiogenesis assay. The main aim of this experiment was to determine 
which growth factors may be important in wet AMD and to perhaps 
provide other therapeutic targets apart from VEGF for the treatment of 
the disease. Interestingly, it was found that FGF2 had a similar positive 
effect on cell proliferation and capillary tube formation and growth to 
VEGF. This would appear to be a new exciting target for disease 
treatment. Unfortunately, to date, no drug has been devised to 
specifically target this growth factor and which could be injected into the 
human eye. Other factors such as PDGF and IGF-1 appear not to have 
any direct effect on these ECs. As such, their role in wet AMD must be 
questioned unless they are acting in a secondary role upon other 
undetermined cell types (such as the proposed role of PDGF in the 
maintenance of vascular pericytes).  
 
This work has a number of advantages over previous work conducted 
on different endothelial cells or other ocular cells in an attempt to 
understand human ocular diseases. The first advantage is that the cells 
are isolated from human eyes and in particular, from the areas of the 
eye affected by various angiogenic diseases. Secondly, unlike 
techniques using laser capture dissection, contamination from 
surrounding cells is minimised by using a method to extract endothelial 
cells using paramagnetic beads. This allows a large number of living 
cells to be isolated for further investigation, such as microarray or in 
vitro proliferation studies. Another disadvantage of laser capture 
dissection studies, particularly in studies such as this, which aims to 
investigate proliferating cells, is that most of the cells isolated are in a 
quiescent state and are only available in small numbers. Thirdly, cells 
used in this study were unpassaged. Many studies using endothelial 
cells, not just those from humans, rely on cells that have undergone 
multiple passages in an attempt to provide enough cells for large scale 
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assays. Unfortunately, it is widely accepted that endothelial cells 
undergo phenotypic changes after multiple passages, thereby making 
any results derived from these cells questionable. This makes any 
conclusions derived from my studies more applicable to human 
disease. In experiments described in this project where cell gene 
expression was studied, the cells were from matched donors and were 
cultured under exactly the same conditions, therefore abrogating any 
differences in gene expression due to differential culture conditions or 
because of differences between donors. 
 
The main disadvantage of this work is that the endothelial cells are 
UHPRYHGIURPWKHLU³QRUPDO´VXUURXQGLQJVEDVHPHQWPHPEUDQH
SHULF\WHVHWFZKLFKPD\KDYHDQHIIHFWRQDFHOO¶Vin vitro performance. 
In an attempt to circumvent this, in many of the experiments, conditions 
were made as close as possible to their natural surroundings by using 
specialised endothelial growth medium and collagen coated plates (an 
attempt to re-create cell basement membranes). A counter argument in 
support of studying of cells in isolation is that there is no possibility of 
their being affected by other cells or extraneous factors. This allows a 
strict control of the cell environment to occur with small manipulations 
possible to the experimental conditions, therefore allowing minute 
changes in cell behaviour to be studied.  
 
In summary, this research work has developed new techniques to 
isolate ocular endothelial cells from different vascular beds within the 
human eye and from different levels within the same vascular bed. The 
study has also demonstrated that HUVECs are not suitable surrogates 
to be used in the study of human ocular diseases because there are 
significant gene expression differences between them and ocular 
microvascular endothelial cells which may affect their in vitro behaviour. 
Within the eye, endothelial cells from different vascular beds show 
heterogeneity at a gene expression level which may go some way to 
explaining why different ocular beds appear to be affected by different 
disorders and respond to different treatments. 
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A major advantage of this study is that it has allowed one to study 
endothelial cells from within the human macular inner choroid (the site 
at which AMD occurs), revealing a unique gene expression profile 
which may be important in deriving new treatments for wet AMD. 
Secondly, it has demonstrated that FGF2 may be an important growth 
factor in the pathogenesis of choroidal neovascularisation and therefore 
may be a new candidate for therapeutic intervention. It has, 
furthermore, demonstrated why manipulating IGF may be important in 
retinal vascular disease, but not in choroidal vascular disease. 
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